sumatriptan has been researched along with Abdominal Migraine in 1213 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Results from The Spectrum Study suggested that early treatment of migraine attacks with sumatriptan 50-mg tablets while the pain is mild might enhance pain-free response and reduce headache recurrence." | 10.19 | Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. ( Cady, RK; Crisp, A; Jones, M; Lipton, RB; McNeal, S; Metz, A; O'Quinn, S; Putnam, DG; Sheftell, F, 2000) |
| "Longitudinal nausea trajectories differed for AVP-825 and oral sumatriptan in the Overall Nausea model (Model 1) and TEN model (Model 2), but were more comparable across treatments for the Nausea Relief (Model 3)." | 9.27 | AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial. ( Buse, DC; Lipton, RB; McGinley, JS; Shulman, KJ; Silberstein, SD; Wirth, RJ, 2018) |
| "Cilostazol induced a mild to moderate headache in all but 3 participants (Range 0-7 on Numerical Rating Scale)." | 9.27 | Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers. ( Falkenberg, K; Olesen, J, 2018) |
| "To test the hypothesis that sumatriptan iontophoretic transdermal system (TDS) is associated with lower rates of treatment-emergent nausea (TEN) relative to placebo, as well as to compare the efficacy of sumatriptan TDS in migraineurs with or without nausea at baseline." | 9.20 | Sumatriptan Iontophoretic Transdermal System Reduces Treatment-Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline - Results From a Randomized Controlled Trial. ( Bigal, ME; Lipton, RB; Newman, LC; Pierce, MW; Silberstein, SD, 2015) |
| "Successfully screened adult migraineurs who returned baseline diaries showing 2 to 7 migraine attacks monthly and < 15 headache and/or neck pain days/month received blister packs containing 3 sumatriptan/naproxen/1 placebo for treatment of 4 migraines." | 9.19 | Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it? ( Calhoun, AH; Ford, S, 2014) |
| "To evaluate the efficacy and safety of transdermal sumatriptan in migraine patients who have baseline nausea." | 9.16 | Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea. ( Schulman, EA, 2012) |
| "To evaluate the impact of a sumatriptan/naproxen sodium combination tablet on patient satisfaction, productivity, and functional disability in menstrual migraine treated during the mild pain phase of a single menstrual migraine attack associated with dysmenorrhea." | 9.15 | Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. ( Ballard, JE; Cady, RK; Derosier, FJ; Diamond, ML; Diamond, MP; Dorner, DP; Lener, ME; McDonald, SA; Runken, MC; White, J, 2011) |
| "To evaluate the efficacy and tolerability of sumatriptan-naproxen during the mild pain phase of a single menstrual migraine attack associated with dysmenorrhea." | 9.14 | Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. ( Cady, RK; Derosier, FJ; Diamond, ML; Lener, SE; Mannix, LK; Martin, VT; McDonald, SA; White, JD, 2009) |
| " We randomized patients to either naproxen 500 mg or sumatriptan 100 mg for headache recurrence after ED discharge." | 9.14 | Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan. ( Bijur, PE; Dua, N; Esses, D; Friedman, BW; Gallagher, EJ; Heins, A; Hochberg, M; Lipton, RB; Sasso, P; Solorzano, C; Xia, S, 2010) |
| "In the intention to treat group, two hour pain free rates were 16%, 40%, and 50% in the placebo group, sumatriptan 50 mg group, and the sumatriptan 100 mg group respectively (p < 0." | 9.12 | Pain free efficacy of sumatriptan in the early treatment of migraine. ( Ahmad, FE; Becker, WJ; Christie, SN; Jelinski, SE; Pryse-Phillips, W; Simpson, SD, 2006) |
| "To investigate the hypothesis that early treatment of a migraine attack with sumatriptan, while pain is still mild, results in higher pain free rates in comparison to delayed treatment, when pain is at least moderate, we performed a prospective, controlled and open label study." | 9.11 | Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan. ( Banik, N; Moeckesch, B; Schellenberg, R; Scholpp, J, 2004) |
| "Two studies were conducted comparing the time to onset of relief from moderate or severe migraine pain with the fast-disintegrating/rapid-release formulation of sumatriptan tablets 50 and 100 mg and placebo." | 9.11 | Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. ( Agosti, R; Barrett, PS; Brandes, JL; Dahlöf, CG; Jones, MW; Sheftell, FD, 2005) |
| "To evaluate the efficacy and tolerability of sumatriptan, 50-mg and 100-mg tablets, compared with placebo for treatment of migraine at the first sign of pain." | 9.10 | Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. ( Kwong, J; Mannix, LK; McNeal, S; O'Quinn, S; Putnam, DG; Richardson, MS; Winner, P, 2003) |
| " Nitroglycerin (NTG) administration commonly causes a headache with some features similar to those of a migraine." | 9.09 | The pharmacodynamics of sumatriptan in nitroglycerin-induced headache. ( Forrest, A; Fullerton, T; Gengo, FM; Komorowski-Swiatek, D, 1999) |
| "In a pilot study (5 patients) we investigated the effects of subcutaneous sumatriptan, a 5-HT1-like receptor agonist, on headache experienced during the withdrawal period of drug-induced headache." | 9.07 | Subcutaneous sumatriptan in the treatment of headache during withdrawal from drug-induced headache. ( Dichgans, J; Diener, HC; Haab, J; Peters, C; Pilgrim, A; Ried, S, 1991) |
| "For more than a century, aspirin has been used for the acute treatment of primary headaches." | 8.90 | Pharmacokinetics and safety of a new aspirin formulation for the acute treatment of primary headaches. ( D'Alonzo, L; Lecchi, M; Martelletti, P; Negro, A, 2014) |
| "The aim of this review is to describe: the mechanisms of action of triptans; the case-reports of acute myocardial infarction (AMI) associated with sumatriptan use; and the results of studies evaluating its tolerability and safety." | 8.86 | Sumatriptan therapy for headache and acute myocardial infarction. ( Ames, PR; Barra, S; Gaeta, G; Lanero, S; Madrid, A; Materazzi, C; Vitagliano, G, 2010) |
| " A systematic review of the medical literature was conducted to identify information regarding the safety of sumatriptan during pregnancy." | 8.82 | Safety of sumatriptan in pregnancy: a review of the data so far. ( Loder, E, 2003) |
| "To review the literature for treatment of migraine headaches with sumatriptan during pregnancy." | 8.82 | Treatment of migraine headaches with sumatriptan in pregnancy. ( Cross, LB; Eichner, SF; Hilaire, ML, 2004) |
| "In this study, we determine the effectiveness and adverse effects of sumatriptan when used in the emergency department (ED) as a first-line treatment for benign undifferentiated headaches, and determine if the International Headache Society (IHS) classification of migraine, probable migraine, or tension-type headache has any effect on the effectiveness of the treatment." | 7.74 | Sumatriptan for the treatment of undifferentiated primary headaches in the ED. ( Biros, M; Miner, JR; Moore, J; Smith, SW, 2007) |
| " In the present studies, therefore, we used Suncus murinus, a species of insectivore capable of emesis, to investigate if the vanilloid receptor agonist resiniferatoxin is capable of modeling the emesis associated with migraine." | 7.73 | Evaluation of the anti-emetic potential of anti-migraine drugs to prevent resiniferatoxin-induced emesis in Suncus murinus (house musk shrew). ( Andrews, PL; Cheng, FH; Moreaux, B; Ngan, MP; Rudd, JA; Sam, TS; Wai, MK; Wan, C, 2005) |
| "To study the efficacy and practicality of treating headache in professional footballers with intranasal sumatriptan." | 7.73 | Open label study of intranasal sumatriptan (Imigran) for footballer's headache. ( Heywood, J; McCrory, P; Ugoni, A, 2005) |
| "To investigate further the pharmacological mechanism of an anti-migraine drug, sumatriptan, a 5-HT1B/1D receptor agonist, we studied its effect on the cerebral circulation in seven anaesthetized rats, particularly during hypercapnia." | 7.71 | Effects of sumatriptan on cerebral blood flow under normo- and hypercapnia in rats. ( Dobashi, K; Fukuda, M; Kitamura, A; Maruyama, S; Sakai, F; Suzuki, N, 2002) |
| "To evaluate delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan." | 7.71 | Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. ( Källén, B; Lygner, PE, 2001) |
| "To compare the effects of oral rizatriptan, sumatriptan, naratriptan, and zolmitriptan on the relief and emergence of nausea during a migraine attack." | 7.71 | Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. ( Goadsby, PJ; Jiang, K; Lines, CR; Lipton, RB; Massiou, H; McCarroll, KA; Pascual, J; Vandormael, K, 2001) |
| "We report a case of ischemia limited to the upper limb caused by chronic use of ergotamine." | 7.71 | Successful treatment of threatening limb loss ischemia of the upper limb caused by ergotamine. A case report and review of the literature. ( Alanezi, KH; Cinà, CS; Safar, HA, 2002) |
| " Thus, the cost of chest pain-related care was estimated in migraineurs receiving almotriptan 12." | 7.71 | Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan. ( Barr, CE; Goldfarb, SD; Wang, JT, 2002) |
| "Perinatal and pregnancy outcome did not differ between patients who had and had not used sumatriptan after conception, at the resolution of these sample sizes." | 7.70 | Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study. ( Davis, RL; Ephross, SA; Fox, AW; Gutterman, DL; O'Quinn, S; Williams, V, 1999) |
| "5% of fertile Danish women use sumatriptan, and the drug is also taken during pregnancy." | 7.70 | Pregnancy outcome following prescription for sumatriptan. ( Nielsen, GL; Olesen, C; Olsen, J; Sorensen, HT; Steffensen, FH, 2000) |
| "A recent report has questioned the safety of sumatriptan in asthmatic migraineurs." | 7.68 | The safety of sumatriptan in asthmatic migraineurs. ( Lloyd, DK; Pilgrim, AJ, 1993) |
| "Headache is a common presenting condition for patients seen in the pediatric emergency department (ED)." | 7.01 | Sumatriptan as a First-Line Treatment for Headache in the Pediatric Emergency Department. ( Barry, D; Blume, H; Hartford, EA; Hauser Chatterjee, J; Law, E, 2023) |
| "Cranial allodynia associated with spontaneous migraine is reported as either responsive to triptan treatment or to be predictive of lack of triptan efficacy." | 6.90 | Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity. ( Akerman, S; Bose, P; Goadsby, PJ; Hoffmann, JR; Holland, PR; Karsan, N; Romero-Reyes, M, 2019) |
| "The patients were diagnosed with migraine based on IHS criteria but individual migraine attacks treated in the study were physician diagnosed; not necessarily required to meet IHS criteria." | 6.68 | Responsiveness of non-IHS migraine and tension-type headache to sumatriptan. ( Beach, ME; Cady, RK; Gutterman, D; Saiers, JA, 1997) |
| "Menstrual migraine (MM) is a form of headache that tends to occur with prolonged, intense and extremely disabling attacks in a short period around the menstrual cycle (usually 2 days before to 3 days after the onset of the menstrual flow)." | 6.47 | Evaluation of the use of sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea. ( Allais, G; Benedetto, C; Castagnoli Gabellari, I; Rolando, S, 2011) |
| "Results from The Spectrum Study suggested that early treatment of migraine attacks with sumatriptan 50-mg tablets while the pain is mild might enhance pain-free response and reduce headache recurrence." | 6.19 | Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. ( Cady, RK; Crisp, A; Jones, M; Lipton, RB; McNeal, S; Metz, A; O'Quinn, S; Putnam, DG; Sheftell, F, 2000) |
| "Our data suggest that sumatriptan reduces central sensitization (secondary hyperalgesia) without modulating peripheral sensitization (primary hyperalgesia) in a human pain model of capsaicin-induced sensitization." | 5.51 | Sumatriptan prevents central sensitization specifically in the trigeminal dermatome in humans. ( Basedau, H; Jürgens, T; May, A; Ortlieb, L; Peng, KP, 2022) |
| "Sumatriptan has been used for the acute treatment of migraine attacks." | 5.46 | Sumatriptan, an Antimigraine Drug, Inhibits Pentylenetetrazol-induced Seizures in NMRI Mice. ( Jand, A; Palizvan, MR, 2017) |
| " Compared to other active drugs, it only showed a lower significant effect compared with granisetron regarding headache change while it showed significantly higher effects only with placebo in both rescue medication needs and headache-free symptoms and valproate in only rescue medication need." | 5.41 | The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials. ( Abd-ElGawad, M; Abdelhay, HM; Abdelmonem, H; Abdelwadoud, GT; Ahmed, AE; Al-Dardery, NM; Alhosini, ANM; Kamel, MA; Mohamed, SW, 2023) |
| "Sumatriptan has a weak coronary constrictor effect." | 5.29 | [The migraine remedy sumatriptan (Imigran) and coronary heart disease]. ( Landmark, K; Nguyen, KN, 1995) |
| "Longitudinal nausea trajectories differed for AVP-825 and oral sumatriptan in the Overall Nausea model (Model 1) and TEN model (Model 2), but were more comparable across treatments for the Nausea Relief (Model 3)." | 5.27 | AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial. ( Buse, DC; Lipton, RB; McGinley, JS; Shulman, KJ; Silberstein, SD; Wirth, RJ, 2018) |
| "Cilostazol induced a mild to moderate headache in all but 3 participants (Range 0-7 on Numerical Rating Scale)." | 5.27 | Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers. ( Falkenberg, K; Olesen, J, 2018) |
| "This review was designated to evaluate the efficacy of parenteral ketorolac in treating acute migraine headache." | 5.22 | Efficacy of ketorolac in the treatment of acute migraine attack: A systematic review and meta-analysis. ( Abu Bakar, MA; Baharuddin, KA; Norhayati, MN; Nurathirah, MN; Yazid, MB, 2022) |
| "To test the hypothesis that sumatriptan iontophoretic transdermal system (TDS) is associated with lower rates of treatment-emergent nausea (TEN) relative to placebo, as well as to compare the efficacy of sumatriptan TDS in migraineurs with or without nausea at baseline." | 5.20 | Sumatriptan Iontophoretic Transdermal System Reduces Treatment-Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline - Results From a Randomized Controlled Trial. ( Bigal, ME; Lipton, RB; Newman, LC; Pierce, MW; Silberstein, SD, 2015) |
| "Successfully screened adult migraineurs who returned baseline diaries showing 2 to 7 migraine attacks monthly and < 15 headache and/or neck pain days/month received blister packs containing 3 sumatriptan/naproxen/1 placebo for treatment of 4 migraines." | 5.19 | Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it? ( Calhoun, AH; Ford, S, 2014) |
| "This study evaluated the effectiveness of a single fixed-dose tablet of sumatriptan 85 mg/naproxen sodium 500 mg (sumatriptan-naproxen) using a very early treatment paradigm in migraine patients whose attacks were historically accompanied by cutaneous allodynia." | 5.16 | Sumatriptan-naproxen migraine efficacy in allodynic patients: early intervention. ( Hoagland, NA; Hoagland, R; Landy, S, 2012) |
| "To evaluate the efficacy and safety of transdermal sumatriptan in migraine patients who have baseline nausea." | 5.16 | Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea. ( Schulman, EA, 2012) |
| " At the time of discharge, for patients randomized to comprehensive care, the research team reinforced their diagnosis, shared a migraine education presentation from the National Library of Medicine, provided them with six tablets of sumatriptan 100 mg and 14 tablets of naproxen 500 mg, and if they wished, provided them with an expedited free appointment to the institution's headache clinic." | 5.16 | A randomized controlled trial of a comprehensive migraine intervention prior to discharge from an emergency department. ( Adewumni, V; Bijur, PE; Campbell, CM; Esses, D; Friedman, BW; John Gallagher, E; Lipton, RB; Norton, J; Solomon, S; Solorzano, C, 2012) |
| "To evaluate the impact of a sumatriptan/naproxen sodium combination tablet on patient satisfaction, productivity, and functional disability in menstrual migraine treated during the mild pain phase of a single menstrual migraine attack associated with dysmenorrhea." | 5.15 | Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. ( Ballard, JE; Cady, RK; Derosier, FJ; Diamond, ML; Diamond, MP; Dorner, DP; Lener, ME; McDonald, SA; Runken, MC; White, J, 2011) |
| "To evaluate the efficacy and tolerability of sumatriptan-naproxen during the mild pain phase of a single menstrual migraine attack associated with dysmenorrhea." | 5.14 | Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. ( Cady, RK; Derosier, FJ; Diamond, ML; Lener, SE; Mannix, LK; Martin, VT; McDonald, SA; White, JD, 2009) |
| "To describe the pharmacokinetic and safety profiles of sumatriptan 85 mg formulated with RT Technology (RT) and naproxen sodium 500 mg in a fixed-dose combination tablet (sumatriptan/naproxen sodium) that targets both serotonergic dysmodulation and inflammation in migraine." | 5.14 | Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. ( Haberer, LJ; Lener, SE; McDonald, SA; Taylor, DR; Walls, CM, 2010) |
| " We randomized patients to either naproxen 500 mg or sumatriptan 100 mg for headache recurrence after ED discharge." | 5.14 | Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan. ( Bijur, PE; Dua, N; Esses, D; Friedman, BW; Gallagher, EJ; Heins, A; Hochberg, M; Lipton, RB; Sasso, P; Solorzano, C; Xia, S, 2010) |
| "To measure prostaglandin levels in the saliva of individuals during menstrual migraine associated with dysmenorrhea (MMaD) and in response to treatment with a single tablet combination of sumatriptan succinate and naproxen sodium." | 5.14 | Changes in salivary prostaglandin levels during menstrual migraine with associated dysmenorrhea. ( Cady, R; Derosier, F; Durham, PL; Martin, V; McDonald, S; Vause, CV, 2010) |
| "In order to investigate the plausible association of migraine recurrence with anxiety and depressive symptoms, a multicentre, randomized, double-blind, placebo-controlled, crossover clinical trial was conducted using sumatriptan as a vehicle drug." | 5.14 | Migraine recurrence is not associated with depressive or anxiety symptoms. Results of a randomized controlled trial. ( Charmoussi, S; Doitsini, S; Georgiadis, G; Kodounis, A; Mitsikostas, DD; Thomas, A; Vikelis, M; Xifaras, M; Zaglis, D, 2010) |
| "In the intention to treat group, two hour pain free rates were 16%, 40%, and 50% in the placebo group, sumatriptan 50 mg group, and the sumatriptan 100 mg group respectively (p < 0." | 5.12 | Pain free efficacy of sumatriptan in the early treatment of migraine. ( Ahmad, FE; Becker, WJ; Christie, SN; Jelinski, SE; Pryse-Phillips, W; Simpson, SD, 2006) |
| "The aim of this study was to determine whether clinical indicators of cutaneous allodynia predict the success of migraine therapy with sumatriptan using a brief questionnaire." | 5.12 | Clarification of developing and established clinical allodynia and pain-free outcomes. ( Landy, SH; McDonald, SA; McGinnis, JE, 2007) |
| "To investigate the hypothesis that early treatment of a migraine attack with sumatriptan, while pain is still mild, results in higher pain free rates in comparison to delayed treatment, when pain is at least moderate, we performed a prospective, controlled and open label study." | 5.11 | Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan. ( Banik, N; Moeckesch, B; Schellenberg, R; Scholpp, J, 2004) |
| "Two studies were conducted comparing the time to onset of relief from moderate or severe migraine pain with the fast-disintegrating/rapid-release formulation of sumatriptan tablets 50 and 100 mg and placebo." | 5.11 | Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. ( Agosti, R; Barrett, PS; Brandes, JL; Dahlöf, CG; Jones, MW; Sheftell, FD, 2005) |
| "To evaluate the efficacy and tolerability of sumatriptan, 50-mg and 100-mg tablets, compared with placebo for treatment of migraine at the first sign of pain." | 5.10 | Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. ( Kwong, J; Mannix, LK; McNeal, S; O'Quinn, S; Putnam, DG; Richardson, MS; Winner, P, 2003) |
| " Nitroglycerin (NTG) administration commonly causes a headache with some features similar to those of a migraine." | 5.09 | The pharmacodynamics of sumatriptan in nitroglycerin-induced headache. ( Forrest, A; Fullerton, T; Gengo, FM; Komorowski-Swiatek, D, 1999) |
| "In a pilot study (5 patients) we investigated the effects of subcutaneous sumatriptan, a 5-HT1-like receptor agonist, on headache experienced during the withdrawal period of drug-induced headache." | 5.07 | Subcutaneous sumatriptan in the treatment of headache during withdrawal from drug-induced headache. ( Dichgans, J; Diener, HC; Haab, J; Peters, C; Pilgrim, A; Ried, S, 1991) |
| " There is high confidence that adolescents receiving oral sumatriptan/naproxen and zolmitriptan nasal spray are more likely to be headache-free at 2 hours than those receiving placebo." | 5.01 | Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. ( Billinghurst, L; Gersz, EM; Gloss, D; Hershey, AD; Holler-Managan, Y; Leininger, E; Licking, N; Mack, K; Oskoui, M; Potrebic, S; Pringsheim, T; Sowell, M; Victorio, MC; Yonker, M; Zanitsch, H, 2019) |
| "For more than a century, aspirin has been used for the acute treatment of primary headaches." | 4.90 | Pharmacokinetics and safety of a new aspirin formulation for the acute treatment of primary headaches. ( D'Alonzo, L; Lecchi, M; Martelletti, P; Negro, A, 2014) |
| " Addition of metoclopramide 10 mg improves relief of nausea and vomiting." | 4.89 | Aspirin with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; Kirthi, V; Moore, RA, 2013) |
| " Addition of metoclopramide 10 mg improves relief of nausea and vomiting." | 4.86 | Aspirin with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; Kirthi, V; McQuay, HJ; Moore, RA, 2010) |
| "The aim of this review is to describe: the mechanisms of action of triptans; the case-reports of acute myocardial infarction (AMI) associated with sumatriptan use; and the results of studies evaluating its tolerability and safety." | 4.86 | Sumatriptan therapy for headache and acute myocardial infarction. ( Ames, PR; Barra, S; Gaeta, G; Lanero, S; Madrid, A; Materazzi, C; Vitagliano, G, 2010) |
| " A systematic review of the medical literature was conducted to identify information regarding the safety of sumatriptan during pregnancy." | 4.82 | Safety of sumatriptan in pregnancy: a review of the data so far. ( Loder, E, 2003) |
| "To review the literature for treatment of migraine headaches with sumatriptan during pregnancy." | 4.82 | Treatment of migraine headaches with sumatriptan in pregnancy. ( Cross, LB; Eichner, SF; Hilaire, ML, 2004) |
| " In placebo-controlled clinical trials, sumatriptan, administered subcutaneously, orally, intranasally or rectally was significantly more effective than placebo in relieving migraine headache and in producing relief or resolution of other symptoms associated with migraine, including nausea, photophobia and phonophobia." | 4.81 | Sumatriptan: pharmacological basis and clinical results. ( Dahlöf, CG, 2001) |
| " For the acute treatment of migraine attacks or tension-type headache, ibuprofen (10 mg per kg body weight) or acetaminophen (15 mg per kg body weight) are recommended with highest evidence, intranasal sumatriptan (10 to 20 mg) can be given as second choice." | 4.81 | [Treatment of idiopathic headache in childhood - recommendations of the German Migraine and Headache Society (DMKG)]. ( Evers, S; Gerber, WD; Naumann, E; Pothmann, R; Uberall, M, 2002) |
| "This pooled analysis (N=1773) used data from three randomized, placebo-controlled, phase III trials (studies A, B, and C) to determine the incidence of migraine-associated symptoms (defined as nausea, vomiting, photophobia, and phonophobia) 2 hours after a single oral dose of study medication (almotriptan, sumatriptan, or placebo)." | 4.81 | Almotriptan reduces the incidence of migraine-associated symptoms: a pooled analysis. ( Cady, R, 2002) |
| "In recent years several new treatments have been introduced in neurology, sumatriptan in migraine, riluzole in amyotrophic lateral sclerosis, interferon-beta in multiple sclerosis and rivastigmine in Alzheimer's disease." | 4.80 | [New therapies in neurology, but who benefits?]. ( de Haan, RJ; Vermeulen, M, 1999) |
| " Both neurogenic inflammation and c-fos expression are blocked by sumatriptan and ergot alkaloids via prejunctional mechanisms involving putative 5-HT receptors closely related to the 5-HT1D subtype on trigeminovascular fibers." | 4.78 | Neurogenic inflammation in the pathophysiology and treatment of migraine. ( Moskowitz, MA, 1993) |
| "Sumatriptan and the ergot alkaloids are useful tools for deciphering drug mechanisms in migraine and related headaches." | 4.78 | Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. ( Moskowitz, MA, 1992) |
| "Sumatriptan succinate and prochlorperazine maleate are a clinically proven combination for treating migraine and associated nausea and vomiting." | 4.12 | Development of Optimized Sumatriptan-Prochlorperazine Combined Orodispersible Films Without Disintegrant: in vitro, ex vivo and in vivo Characterization. ( Anwer, UU; Bukhari, NI; Hafiz, MA; Hussain, A; Javed, S; Rasool, F; Raza, SA; Shah, PA; Shamim, R, 2022) |
| " Sumatriptan, a medication usually prescribed for acute migraine and cluster headaches has been documented as potentially causing coronary vasospasm, thereby leading to MI." | 3.96 | Vasospasm induced myocardial ischaemia secondary to sumatriptan use. ( Ojha, U; Okonkwo, K, 2020) |
| " Methods We assessed in rats the roles of dose and repeat administration of systemic isosorbide dinitrate (ISDN), a nitric oxide donor, on the occurrence and development of cephalic/face and extracephalic/hindpaw mechanical allodynia as a surrogate of migraine pain, and the effect of acute systemic sumatriptan and olcegepant and chronic systemic propranolol on these behavioral changes." | 3.88 | Recurrent administration of the nitric oxide donor, isosorbide dinitrate, induces a persistent cephalic cutaneous hypersensitivity: A model for migraine progression. ( Dallel, R; Descheemaeker, A; Luccarini, P, 2018) |
| " Results VL-102-evoked acute and chronic mechanical cephalic and hind-paw allodynia in a dose-dependent manner, which was blocked by the migraine medications sumatriptan, propranolol, and topiramate." | 3.88 | Soluble guanylyl cyclase is a critical regulator of migraine-associated pain. ( Ben Aissa, M; Bennett, BM; Bertels, Z; Gaisina, IN; Gandhi, R; Lee, SH; Litosh, V; Moye, LS; Novack, M; Pradhan, AA; Thatcher, GR; Tipton, AF; Wang, Y, 2018) |
| " This project investigates the safety and effectiveness of pulsed focused ultrasound (FUS) in a validated rodent headache model of cutaneous allodynia associated with chronic migraine (CM) as compared to sumatriptan and ablative lesioning." | 3.88 | The use of focused ultrasound for the treatment of cutaneous allodynia associated with chronic migraine. ( Burdette, C; Frith, L; Gannon, S; Gee, L; Ghoshal, G; Hellman, A; Kaszuba, B; Kumar, V; Maietta, T; Neubauer, P; Panse, D; Pilitsis, JG; Qian, J; Shin, DS; Walling, I; Williams, E, 2018) |
| "Using the Marketscan database, the risk of major birth defects was ascertained in live-born infants whose birth mothers were exposed to sumatriptan, naratriptan, or sumatriptan/naproxen during pregnancy." | 3.88 | Use of existing electronic health care databases to evaluate medication safety in pregnancy: Triptan exposure in pregnancy as a case study. ( Bollinger, L; Cangialose, C; Chia, V; Mikol, DD; Xue, F; Yusuf, A, 2018) |
| "The present study showed that repeated IS stimulations induced long-lasting allodynia, increased BBB permeability, and upregulated VEGF expression, all of which could be attenuated by early sumatriptan treatment." | 3.88 | Recurrent Headache Increases Blood-Brain Barrier Permeability and VEGF Expression in Rats. ( Chen, L; Mi, X; Qin, G; Ran, L, 2018) |
| "Data were pooled from two replicate randomized controlled trials of 621 adult menstrual migraineurs with dysmenorrhea who treated migraine with sumatriptan-naproxen or placebo." | 3.80 | Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. ( Ballard, J; Derosier, FJ; Diamond, MP; Krishen, A; Lener, SE; Mannix, LK; Martin, VT; McDonald, SA, 2014) |
| "Accumulated data suggest that exposure to sumatriptan during pregnancy does not increase the risk of birth defects above the baseline rate." | 3.76 | Safety of triptans for migraine headaches during pregnancy and breastfeeding. ( Bozzo, P; Duong, S; Einarson, A; Nordeng, H, 2010) |
| "The triptans, serotonin 5-HT(1B/1D) receptor agonists exemplified by sumatriptan, are a mainstay migraine therapy but have class labeling contraindicating their use in patients with coronary artery disease." | 3.75 | Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs. ( Anderson, KD; Gould, RJ; Kane, SA; Koblan, KS; Lynch, JJ; Pittman, TJ; Regan, CP; Shen, YT, 2009) |
| "In this study, we determine the effectiveness and adverse effects of sumatriptan when used in the emergency department (ED) as a first-line treatment for benign undifferentiated headaches, and determine if the International Headache Society (IHS) classification of migraine, probable migraine, or tension-type headache has any effect on the effectiveness of the treatment." | 3.74 | Sumatriptan for the treatment of undifferentiated primary headaches in the ED. ( Biros, M; Miner, JR; Moore, J; Smith, SW, 2007) |
| " In the present studies, therefore, we used Suncus murinus, a species of insectivore capable of emesis, to investigate if the vanilloid receptor agonist resiniferatoxin is capable of modeling the emesis associated with migraine." | 3.73 | Evaluation of the anti-emetic potential of anti-migraine drugs to prevent resiniferatoxin-induced emesis in Suncus murinus (house musk shrew). ( Andrews, PL; Cheng, FH; Moreaux, B; Ngan, MP; Rudd, JA; Sam, TS; Wai, MK; Wan, C, 2005) |
| "To study the efficacy and practicality of treating headache in professional footballers with intranasal sumatriptan." | 3.73 | Open label study of intranasal sumatriptan (Imigran) for footballer's headache. ( Heywood, J; McCrory, P; Ugoni, A, 2005) |
| " This analysis examined productivity loss as a result of migraine after treatment with sumatriptan tablets and patients' usual non-triptan therapy when pain was mild (early intervention) versus when pain was moderate/severe." | 3.73 | The effect of early intervention with sumatriptan tablets on migraine-associated productivity loss. ( Adelman, JU; Kwong, WJ; Taylor, FR, 2005) |
| "Secretion of calcitonin gene-related peptide (CGRP) from trigeminal nerves and vasoactive intestinal peptide (VIP) from parasympathetic nerves is involved in the pathophysiology of migraine and rhinosinusitis." | 3.73 | Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. ( Bellamy, JL; Cady, RK; Durham, PL, 2006) |
| " The objective of this investigation was to develop a disease model to predict measures of headache in randomized placebo-controlled clinical trials investigating oral sumatriptan as a paradigm compound." | 3.73 | Prediction of headache response in migraine treatment. ( Danhof, M; Della Pasqua, OE; Maas, HJ, 2006) |
| "To investigate further the pharmacological mechanism of an anti-migraine drug, sumatriptan, a 5-HT1B/1D receptor agonist, we studied its effect on the cerebral circulation in seven anaesthetized rats, particularly during hypercapnia." | 3.71 | Effects of sumatriptan on cerebral blood flow under normo- and hypercapnia in rats. ( Dobashi, K; Fukuda, M; Kitamura, A; Maruyama, S; Sakai, F; Suzuki, N, 2002) |
| "Early treatment of migraine with sumatriptan 50 mg and 100 mg, while pain is mild, has been reported to enhance pain-free response 2 hours and 4 hours postdose and sustained pain-free response 2 to 24 hours postdose compared with treatment when pain has become moderate to severe." | 3.71 | Economic implications of early treatment of migraine with sumatriptan tablets. ( Cady, RK; Kwong, WJ; Lipton, RB; O'Quinn, S; Sheftell, F, 2001) |
| "To evaluate delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan." | 3.71 | Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. ( Källén, B; Lygner, PE, 2001) |
| "To compare the effects of oral rizatriptan, sumatriptan, naratriptan, and zolmitriptan on the relief and emergence of nausea during a migraine attack." | 3.71 | Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. ( Goadsby, PJ; Jiang, K; Lines, CR; Lipton, RB; Massiou, H; McCarroll, KA; Pascual, J; Vandormael, K, 2001) |
| " An economic model was constructed to estimate annual cost savings per 1,000 patients receiving almotriptan instead of sumatriptan as a function of differing rates of chest pain." | 3.71 | Cost savings in migraine associated with less chest pain on new triptan therapy. ( Barr, CE; Goldfarb, SD; Rowland, CR; Torigoe, Y; Wang, E; Wang, JT, 2002) |
| "We report a case of ischemia limited to the upper limb caused by chronic use of ergotamine." | 3.71 | Successful treatment of threatening limb loss ischemia of the upper limb caused by ergotamine. A case report and review of the literature. ( Alanezi, KH; Cinà, CS; Safar, HA, 2002) |
| " Thus, the cost of chest pain-related care was estimated in migraineurs receiving almotriptan 12." | 3.71 | Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan. ( Barr, CE; Goldfarb, SD; Wang, JT, 2002) |
| "Perinatal and pregnancy outcome did not differ between patients who had and had not used sumatriptan after conception, at the resolution of these sample sizes." | 3.70 | Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study. ( Davis, RL; Ephross, SA; Fox, AW; Gutterman, DL; O'Quinn, S; Williams, V, 1999) |
| "5% of fertile Danish women use sumatriptan, and the drug is also taken during pregnancy." | 3.70 | Pregnancy outcome following prescription for sumatriptan. ( Nielsen, GL; Olesen, C; Olsen, J; Sorensen, HT; Steffensen, FH, 2000) |
| "1997, sumatriptan-treated migraineurs had significantly higher depression PCRs (22." | 3.70 | Are triptans with enhanced lipophilicity used for the acute treatment of migraine associated with an increased consulting rate for depressive illness? ( Croft, P; Frischer, M; Goadsby, PJ; Millson, D, 2000) |
| " The purpose of our study was to evaluate the impact of sumatriptan on the quality of life of patients with migraine headaches." | 3.69 | Quality of life assessment among migraine patients treated with sumatriptan. ( Genzen, JR; Skobieranda, FG; Solomon, GD, 1995) |
| "A recent report has questioned the safety of sumatriptan in asthmatic migraineurs." | 3.68 | The safety of sumatriptan in asthmatic migraineurs. ( Lloyd, DK; Pilgrim, AJ, 1993) |
| "2hPF rates were higher for attacks treated when pain was mild vs moderate or severe: ubrogepant 50 mg (47." | 3.11 | Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain. ( Adams, AM; Burstein, R; Dodick, DW; Finnegan, M; Goadsby, PJ; Kuang, AW; Lai, J; Lipton, RB; Trugman, JM; Yu, SY, 2022) |
| "Headache is a common presenting condition for patients seen in the pediatric emergency department (ED)." | 3.01 | Sumatriptan as a First-Line Treatment for Headache in the Pediatric Emergency Department. ( Barry, D; Blume, H; Hartford, EA; Hauser Chatterjee, J; Law, E, 2023) |
| "Menstrual migraine is a subtype of migraine disease that is typically more disabling, longer-lasting, and more challenging to treat." | 3.01 | Comparative efficacy of different treatments for menstrual migraine: a systematic review and network meta-analysis. ( Qi, JZ; Zhang, H; Zhang, ZH, 2023) |
| "A total of 37 patients with migraine without aura were enrolled between July 2018 to December 2019." | 3.01 | Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial. ( Al-Karagholi, MA; Ashina, M; Christensen, CE; Coskun, H; Egeberg, A; Ghanizada, H; Hannibal, J; Thyssen, JP; Wienholtz, NKF; Zhang, DG, 2021) |
| "Thirty patients with migraine without aura received 200 mg cilostazol on two different study days." | 2.94 | Subcutaneous sumatriptan reduces cilostazol induced headache in migraine patients. ( Bjerg, HR; Falkenberg, K; Olesen, J, 2020) |
| "Sumatriptan is a serotonin receptor agonist and the most commonly used triptan for the acute treatment of migraine." | 2.94 | Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. ( Boinpally, R; Butler, M; Jakate, A; Lu, K; McGeeney, D; Periclou, A, 2020) |
| "Sixty patients with episodic migraine with and without aura, aged between 18 and 65 years, were included in the randomized prospective, open, comparative study." | 2.90 | [The efficacy of the second generation triptan migrepam in the treatment of migraine attacks: results of the comparative study]. ( Evdokimova, EM; Shagbazyan, AE; Tabeeva, GR, 2019) |
| "The origin of migraine pain is unknown but possibly implicates the dura mater, which is pain sensitive in proximity to the meningeal arteries." | 2.90 | Meningeal contribution to migraine pain: a magnetic resonance angiography study. ( Amin, FM; Ashina, M; Christensen, CE; de Koning, PJH; Ghanizada, H; Khan, S; Larsson, HBW; Olinger, ACR; Younis, S, 2019) |
| "Cranial allodynia associated with spontaneous migraine is reported as either responsive to triptan treatment or to be predictive of lack of triptan efficacy." | 2.90 | Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity. ( Akerman, S; Bose, P; Goadsby, PJ; Hoffmann, JR; Holland, PR; Karsan, N; Romero-Reyes, M, 2019) |
| "Using the Patient Perception of Migraine Questionnaire-Revised at 24 h postdose, DFN-02 mean scores were significantly superior to placebo for the subscales of efficacy (65." | 2.90 | DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment. ( Brand-Schieber, E; Lipton, RB; Munjal, S; Rapoport, AM, 2019) |
| "Initiating mechanisms of migraine headache remain poorly understood and a biomarker of migraine does not exist." | 2.90 | Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging. ( Amin, FM; Ashina, M; Birgens, H; Christensen, CE; Daldrup-Link, H; Fliedner, FP; Khan, S; Kjær, A; Larsson, HBW; Lindberg, U; Olinger, ACR; Tolnai, D; Younis, S, 2019) |
| "Cilostazol is an inhibitor of phosphodiesterase 3 and thus causes accumulation of cAMP." | 2.87 | Cilostazol induced migraine does not respond to sumatriptan in a double blind trial. ( Ashina, M; Dunga, BÓÁ; Falkenberg, K; Guo, S; Olesen, J, 2018) |
| "4% (16/119) who received placebo experienced at least 1 treatment-emergent adverse event (TEAE), the most common of which were injection site swelling (7." | 2.87 | Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study. ( Brand-Schieber, E; Landy, S; Munjal, S; Rapoport, AM, 2018) |
| "6% (89/219) of subjects reported treatment-emergent adverse events (TEAE), the most common of which were associated with the injection site: swelling (12." | 2.87 | Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study. ( Brand-Schieber, E; Landy, S; Munjal, S; Rapoport, AM, 2018) |
| " Results from the primary endpoint (SPID-30, defined as the sum of pain intensity differences from dosing to 30 minutes), key secondary efficacy endpoints and safety assessments have been reported in the primary publication (Tepper et al." | 2.84 | Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered ( Halker, R; Mahmoud, RA; McAllister, PJ; Siffert, J; Silberstein, S; Tepper, SJ; Winner, PK, 2017) |
| " Patients recorded ordinal migraine pain intensity and migraine-related disability before dosing (predose), and at 10, 15, 30, 45, 60, 90 and 120 minutes." | 2.84 | Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the CO ( Buse, DC; Lipton, RB; McGinley, JS; Shulman, KJ; Wirth, RJ, 2017) |
| "The headache had several migraine-like features in all participants and 20 individuals developed a migraine-like attack." | 2.84 | Towards a pragmatic human migraine model for drug testing: 2. Isosorbide-5-mononitrate in healthy individuals. ( Hansen, EK; Olesen, J, 2017) |
| "Current antimigraine drugs are believed, besides their direct vasoconstrictive effect, to inhibit calcitonin gene-related peptide (CGRP) release from trigeminal nerve endings during migraine." | 2.84 | A human trigeminovascular biomarker for antimigraine drugs: A randomised, double-blind, placebo-controlled, crossover trial with sumatriptan. ( Danser, A; Ibrahimi, K; MaassenVanDenBrink, A; Terwindt, GM; van den Meiracker, AH, 2017) |
| " Initially dosing with MSM while pain was mild was associated with the lowest daily disability [medication × pain at dosing F (4, 6336." | 2.84 | Acute migraine medication adherence, migraine disability and patient satisfaction: A naturalistic daily diary study. ( Nicholson, RA; Robbins, MS; Seng, EK, 2017) |
| " The objective of this study was to evaluate the safety and tolerability of DFN-02 (10 mg) in the acute treatment of episodic migraine with and without aura over a 6-month period based on the incidence of treatment-emergent adverse events and the evaluation of results of clinical laboratory tests, vital signs, physical examination, and electrocardiograms." | 2.84 | A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine. ( Allenby, K; Brand-Schieber, E; Cady, RK; Munjal, S; Rapoport, AM; Spierings, ELH, 2017) |
| "In the treatment of migraine attacks with 6 mg subcutaneous sumatriptan the number needed to treat (NNT) is 2." | 2.82 | [Sumatriptan 3 mg subcutaneous : Clinical relevance of acute treatment of migraine despite dose reduction]. ( Förderreuther, S; Gaul, C, 2022) |
| "Sumatriptan (ST) is a commonly prescribed drug for treating migraine." | 2.82 | Harnessing Intranasal Delivery Systems of Sumatriptan for the Treatment of Migraine. ( Akhtari, J; Asadi, P; Assadpour, S; Sahebkar, A; Shiran, MR, 2022) |
| "Headache is one of the most common symptoms of COVID." | 2.82 | Post-COVID Headache: A Literature Review. ( Chhabra, N; Grill, MF; Singh, RBH, 2022) |
| "A model for the testing of novel antimigraine drugs should ideally use healthy volunteers for ease of recruiting." | 2.82 | Toward a pragmatic migraine model for drug testing: I. Cilostazol in healthy volunteers. ( Ashina, M; Guo, S; Hansen, EK; Olesen, J, 2016) |
| "Only ketorolac NS was superior to placebo for 24-hour (ketorolac: 35." | 2.82 | A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine. ( Dash, PD; Gelaye, B; Kurth, T; Nitchie, H; Peterlin, BL; Rao, AS, 2016) |
| " Safety was evaluated by monitoring of adverse events in addition to laboratory and clinical assessments." | 2.82 | A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients. ( Aycardi, E; Bigal, ME; Chitra, R; Gutman, D; Hellriegel, E; Kansagra, S; Kidron, OS; Knebel, H; Kunta, J; Linder, S; Ma, Y; Pierce, M; Spiegelstein, O; Winner, PK, 2016) |
| "Ninety cases of acute migraine attack admitted to the emergency department were randomly allocated into two treatment groups: (1) 6 mg of sumatriptan subcutaneously or (2) propofol injected intravenously in 30 to 40 mg boluses, followed by 10 to 20 mg intermittent bolus doses to sedate the patients to Ramsey score of 3 to 4." | 2.80 | The Efficacy of Propofol vs. Subcutaneous Sumatriptan for Treatment of Acute Migraine Headaches in the Emergency Department: A Double-Blinded Clinical Trial. ( Esmaeili, A; Hashemian, H; Heiranizadeh, N; Hekmatimoghaddam, S; Moshtaghion, H; Rahimdel, A, 2015) |
| "Early treatment of migraine headaches is associated with improved outcome, but medication absorption after oral delivery may be delayed in migraineurs because of reduced gastric motility." | 2.80 | A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study). ( Cady, RK; Carothers, J; Djupesland, PG; Mahmoud, RA; McAllister, PJ; Messina, J; Spierings, EL, 2015) |
| "Both pretreatment migraine pain severity and treatment response are associated with changes in adipokine levels." | 2.80 | Ictal adipokines are associated with pain severity and treatment response in episodic migraine. ( Chai, NC; Dash, PD; Gelaye, B; Gower, BA; Peterlin, BL; Scher, AI; Tietjen, GE; Ward, TN; White, LW, 2015) |
| "Subjects experiencing 2-8 migraines/month in the past year were randomized 1:1 using computer-generated sequences to AVP-825 plus oral placebo tablet or an identical placebo delivery system plus 100 mg oral sumatriptan tablet for the first period; patients switched treatment for the second period in this controlled comparative design." | 2.80 | AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks. ( Cady, RK; Djupesland, PG; Mahmoud, RA; Messina, J; Shin, P; Siffert, J; Silberstein, S; Tepper, SJ, 2015) |
| "Migraine is a common and incapacitating neurologic disorder manifesting with episodic moderate to a severe headache and other symptoms such as photophobia, phonophobia, nausea, and vomiting." | 2.80 | Intravenous Valproate versus Subcutaneous Sumatriptan in Acute Migraine Attack. ( Ghaderibarmi, F; Tavakkoli, N; Togha, M, 2015) |
| " Adverse events were reported by 80%, 56%, and 60% of BGG492, sumatriptan, and placebo subjects, respectively." | 2.79 | Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. ( Brand, R; Campos, V; Diener, HC; Evers, S; Göbel, H; Gomez-Mancilla, B; Hariry, S; Johns, D; Jürgens, TP; Kalkman, HO; Pezous, N; Sommer, C; Sommer, M; Straube, A, 2014) |
| "Patients were treated for a single migraine attack." | 2.79 | BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. ( Dodick, D; Fischer, TZ; Goadsby, PJ; Manos, G; Marcus, R; Stock, D, 2014) |
| " Frequent dosing of SumaRT/Nap or naproxen sodium was well tolerated in this study." | 2.79 | Treatment of chronic migraine: a 3-month comparator study of naproxen sodium vs SumaRT/Nap. ( Beach, ME; Cady, R; Dexter, K; Freitag, F; Manley, HR; Nett, R, 2014) |
| "Naproxen sodium was associated with a statistically significant reduction in migraine headache days at month 3 compared to baseline (P = ." | 2.79 | SumaRT/Nap vs naproxen sodium in treatment and disease modification of migraine: a pilot study. ( Cady, R; Dexter, K; Freitag, F; O'Carroll, P; Shade, CL, 2014) |
| "Sumatriptan/naproxen treatment resulted in significantly higher medication satisfaction scores on the efficacy, functionality, and total efficacy subscales compared with placebo in all attacks in both studies." | 2.79 | Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. ( Cady, RK; Landy, SH; Nelsen, A; Runken, MC; White, J, 2014) |
| "Oral sumatriptan was well tolerated." | 2.79 | Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study. ( Fujita, M; Nishioka, H; Sakai, F; Sato, K, 2014) |
| " Patients recorded details of the treated migraine on a diary card and rated pain severity immediately before dosing and 30 minutes, 1 hour, 2 hours, and 4 hours after dosing using a 4-point scale (0 = none to 3 = severe)." | 2.79 | Promethazine plus sumatriptan in the treatment of migraine: a randomized clinical trial. ( Amini, A; Asadollahi, S; Forouzanfar, MM; Heidari, K; Shahrami, A; Vafaee, R, 2014) |
| "The loss of cognitive efficiency in migraine may be disabling and is often under recognized." | 2.78 | Evaluation of sumatriptan-naproxen in the treatment of acute migraine: a placebo-controlled, double-blind, cross-over study assessing cognitive function. ( Browning, R; Cady, RK; Edwards, KR; Farmer, KU; Rosenthal, BL, 2013) |
| "In this pilot study of women episodic migraineurs, the HMW : LMW ADP ratio level was associated with migraine severity and predictive of acute treatment response." | 2.78 | Ictal adiponectin levels in episodic migraineurs: a randomized pilot trial. ( Dash, PD; Gower, BA; Hammond, ER; Haythornthwaite, JA; Peterlin, BL; Tepper, SJ; Tietjen, GE; Ward, TN; White, LW, 2013) |
| "Headache response or headache relief (i." | 2.78 | Efficacy endpoints in migraine clinical trials: the importance of assessing freedom from pain. ( Farr, SJ; Marmura, MJ; Nahas, SJ; Newman, LC; Silberstein, SD, 2013) |
| "This sumatriptan auto-injector is a single-use system for the rapid subcutaneous delivery of 6 mg of sumatriptan succinate in the acute management of migraine pain." | 2.78 | An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan. ( Landy, SH; Ramos, E; Schweizer, E; Tepper, SJ; Wein, T, 2013) |
| " Migraine-associated gastroparesis can impair absorption and reduce bioavailability of oral migraine medications and thereby reduce and delay therapeutic efficacy." | 2.77 | Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. ( Goldstein, J; Pierce, MW; Pugach, N; Silberstein, S; Singer, R; Smith, TR, 2012) |
| " Subjects reporting headache pain 2 hours after dosing were randomly assigned into a 12-week double-blind phase, treating 1 moderate-to-severe migraine (attack 2) with placebo (n = 145), suma/nap 10/60 mg (n = 96), 30/180 mg (n = 97), or 85/500 mg (n = 152)." | 2.77 | Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. ( Derosier, FJ; Goodman, DK; Granberry, WK; Hershey, AD; Jimenez, TB; Lewis, D; Linder, SL; Pearlman, E; Rothner, AD; Runken, MC; Winner, PK, 2012) |
| "One third of patients who experience migraine-related nausea report that this symptom interferes with their ability to take oral medications." | 2.77 | A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. ( Goldstein, J; Griesser, J; Pierce, M; Pugach, N; Sebree, T; Smith, TR, 2012) |
| "Migraine is a widespread, relapsing, remittent syndrome." | 2.77 | Efficacy, end points and eventualities: sumatriptan/naproxen versus butalbital/paracetamol/caffeine in the treatment of migraine. ( Fox, AW, 2012) |
| "Rizatriptan 10-mg ODT was superior to placebo at providing two-hour pain relief and two-hour pain freedom in the treatment of acute migraine in those who do not respond to sumatriptan 100 mg." | 2.76 | Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. ( Connor, KM; Fan, X; Friedman, D; Ge, Y; Hewitt, D; Ho, T; Hustad, CM; Lasorda, J; Newman, L; Seeburger, JL; Taylor, FR; Zhang, Y, 2011) |
| "Sumatriptan was beneficial for 13 out of 14 newly diagnosed CFS migraine subjects." | 2.76 | Migraine headaches in chronic fatigue syndrome (CFS): comparison of two prospective cross-sectional studies. ( Baraniuk, JN; Merck, SJ; Ravindran, MK; Timbol, C; Zheng, Y, 2011) |
| "Subjects were instructed to treat migraines as early as possible and were allowed to rescue 2 hours post dose with a single dose of a naproxen-containing product, over-the-counter pain reliever, or anti-emetics." | 2.76 | Long-term evaluation of sumatriptan and naproxen sodium for the acute treatment of migraine in adolescents. ( Derosier, FJ; Hershey, AD; Lewis, D; Linder, SL; McDonald, SA; Pearlman, E; Richard, NE; Rothner, D; Runken, MC; Winner, PK, 2011) |
| "In the 90 patients with baseline Migraine-ACT scores ≤2 (indicating the need for a change in therapy), efficacy data were collected from patient diaries, and satisfaction was measured with the revised Patient Perception of Migraine Questionnaire (PPMQ-R)." | 2.76 | Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidence. ( Aurora, SK; Brandes, JL; Cady, RK; Farr, SJ; Fox, AW; Myers, JA; Rothrock, JF, 2011) |
| " sumatriptan on pharmacokinetic grounds." | 2.75 | Subcutaneous sumatriptan pharmacokinetics: delimiting the monoamine oxidase inhibitor effect. ( Fox, AW, 2010) |
| "Adult subjects (n = 117) with migraine were enrolled in a multicentre, randomised, double-blind, parallel group, placebo-controlled study." | 2.75 | Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study. ( Djupesland, PG; Docekal, P, 2010) |
| "Migraine is an episodic headache disorder characterized by a combination of neurological, gastrointestinal, and autonomic symptoms." | 2.74 | Zelrix: a novel transdermal formulation of sumatriptan. ( Du, W; Marbury, T; O'Neill, C; Pierce, M; Sebree, T; Siegel, S, 2009) |
| "Sumatriptan treatment during the aura preempted the development of headache in 34/38 (89%) attacks." | 2.74 | Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine. ( Aurora, SK; Barrodale, PM; Burstein, R; Jakubowski, M; McDonald, SA, 2009) |
| "Sumatriptan was rapidly absorbed after intranasal administration using the new device." | 2.74 | Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. ( Boeijinga, P; Danjou, P; Demazières, A; Djupesland, PG; Flint, A; Hewson, G; Luthringer, R; Sheldrake, CD, 2009) |
| "Dynamics of migraine pain intensity measured with the VAS 30 min, 1, 2, 6 and 24 h after the first dose of drug was a primary index of efficacy." | 2.74 | [Trimigren in stopping migraine attacks: an open prospective multicenter comparative study of rectal suppository and tablet forms of sumatriptan]. ( Azimova, IuE; Tabeeva, GR, 2009) |
| "Research suggests treating a migraine at the first sign of pain increases the likelihood of the best clinical outcome." | 2.73 | Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. ( Ames, MH; Byrd, SC; Couch, JR; Goldstein, J; Lener, SE; Mannix, LK; McDonald, SA; Silberstein, SD; Toso, C, 2008) |
| " Safety evaluations included adverse events and laboratory tests." | 2.73 | Twelve-month tolerability and safety of sumatriptan-naproxen sodium for the treatment of acute migraine. ( Alexander, WJ; Cady, RK; Frishberg, BM; Kori, SH; Lener, SE; Ruoff, GE; Winner, P; Zhang, Y, 2007) |
| "Triptan's efficacy in the treatment of migraine has never been reported in Taiwanese." | 2.73 | Intranasal sumatriptan study with high placebo response in Taiwanese patients with migraine. ( Fuh, JL; Wang, SJ; Wu, ZA, 2007) |
| "Sumatriptan-naproxen sodium was more effective than placebo for headache relief at 2 hours after dosing (study 1, 65% vs 28%; P<." | 2.73 | Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. ( Adelman, JU; Alexander, WJ; Barrett, PS; Brandes, JL; Kudrow, D; Lener, SE; O'Carroll, CP; O'Donnell, FJ; Spruill, SE; Stark, SR, 2007) |
| "Mean Migraine-Specific Quality of Life Questionnaire (MSQ) domain scores also increased by 13-15 points from baseline during this time and remained high." | 2.73 | Sumatriptan/Naproxen sodium for migraine: efficacy, health related quality of life, and satisfaction outcomes. ( Ames, M; Blumenthal, H; Burch, S; Diamond, M; Lener, S; Mauskop, A; McDonald, S; Smith, T, 2007) |
| "Migraines affect approximately 10% of the adult population worldwide." | 2.73 | A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. ( Dubé, LM; Jackson, D; Kaldeway, P; Morris, R; O'Neill, C; Sebree, T; Siegel, SJ, 2007) |
| "In this double-blind, double-dummy, randomised, parallel group, multicentre study, the efficacy of dosing and re-dosing of a fixed combination of indomethacin, prochlorperazine and caffeine (Indoprocaf) was compared with encapsulated sumatriptan in the acute treatment of two migraine attacks." | 2.73 | Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, mu ( Cerbo, R; Del Bene, E; Ferrari, A; Genco, S; Grazioli, I; Martelletti, P; Nappi, G; Pinessi, L; Sandrini, G; Sarchielli, P; Tamburro, P; Uslenghi, C; Zanchin, G, 2007) |
| "Treatment with sumatriptan/naproxen sodium allowed significantly more subjects to return to normal or mildly impaired functioning more quickly, and sumatriptan/naproxen sodium patients were significantly more satisfied with their treatment compared with other treatment groups." | 2.73 | Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomes. ( Ames, MH; Burch, SP; DeRossett, SE; Landy, S; McDonald, SA; Rapoport, A; Rothrock, J, 2007) |
| "To test this hypothesis in migraine patients in vivo using PET and alpha-[(11)C]methyl-l-tryptophan as a surrogate marker of brain 5-HT synthetic rate during different phases of their migraine attack and after acute antimigraine therapy with sumatriptan, and to compare them with normal controls." | 2.73 | Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis. ( Aubé, M; Diksic, M; Dobson, C; Hamel, E; Sakai, Y, 2008) |
| "Naratriptan was marketed for the treatment of migraine attacks as the "gentle triptan" in a low oral dose of 2." | 2.72 | Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review. ( Tfelt-Hansen, P, 2021) |
| "Probable migraine attacks are also prevalent and frequently underdiagnosed." | 2.72 | Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study. ( Cady, R; Dodick, D; Freitag, FG; Hutchinson, SL; Kuhn, TA; Tepper, SJ; Twomey, C, 2006) |
| "In conclusion, it is reassuring for migraineurs that it is worthwhile taking their medication in an appropriate formulation even if they have not been able to do so early in the course of the attack." | 2.72 | Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. ( Dahlöf, C; Linde, M; Mellberg, A, 2006) |
| "Data from migraineurs enrolled in the active arms of a randomized, double-blind, parallel group, placebo-controlled, clinical trial were analysed." | 2.72 | Does earlier headache response equate to earlier return to functioning in patients suffering from migraine? ( Mullins, CD; Pradel, FG; Subedi, P; Varghese, AA; Weis, KA, 2006) |
| "In some cases photo- and/or phonophobia (hyperexcitability) were not experienced at all, despite severe pain and nausea." | 2.72 | The natural course of migraine attacks. A prospective analysis of untreated attacks compared with attacks treated with a triptan. ( Dahlöf, C; Linde, M; Mellberg, A, 2006) |
| "Sumatriptan 4 mg SC was effective for the acute treatment of migraine attacks and was generally well tolerated in these patients." | 2.72 | A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. ( Byrd, S; Cady, R; Kori, S; Peters, K; Singer, R; Webster, C; Wendt, J, 2006) |
| "Patients reporting tension/stress headache were evaluated and diagnosed as having migraine with or without aura, probable migraine, tension-type headache, or another headache type." | 2.72 | Prevalence of migraine and response to sumatriptan in patients self-reporting tension/stress headache. ( Ames, MH; Barrett, PS; Byrd, S; Kaniecki, R; Kori, S; Ruoff, G; Smith, T, 2006) |
| "In 20 healthy subjects without migraine and in 20 healthy subjects with migraine without aura, platelet and erythrocyte aggregation were measured before and after intake of placebo, acetylsalicylic acid, ergotamine tartrate, zolmitriptan and sumatriptan." | 2.72 | The impact of different antimigraine compounds on platelet and erythrocyte aggregation. ( Akova-Oztürk, E; Evers, S; Frese, A; Heuel, T; Husstedt, IW, 2006) |
| "Most migraine patients with infrequent attacks are currently not treated with migrainespecific medication such as triptans." | 2.72 | Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study. ( Bach, FW; Daugaard, D; Riddersholm, B; Tfelt-Hansen, P; Tsiropoulos, I, 2006) |
| "A total of 179 migraineurs experiencing the first symptoms of a developing migraine attack." | 2.71 | Acupuncture versus placebo versus sumatriptan for early treatment of migraine attacks: a randomized controlled trial. ( Hager, S; Liao, J; Linde, K; Melchart, D; Thormaehlen, J; Weidenhammer, W, 2003) |
| "Seventy-two consecutive migraineurs with unilateral cranial autonomic symptoms were given sumatriptan 50-mg tablets to treat 1 migraine attack and were asked to record their clinical response to the drug at different time points." | 2.71 | Sumatriptan in migraine with unilateral cranial autonomic symptoms: an open study. ( Barbanti, P; Buzzi, MG; Fabbrini, G; Pesare, M; Vanacore, N, 2003) |
| "Eletriptan is a potent, selective 5-HT1B/1D receptor agonist with beneficial pharmacokinetic properties compared with sumatriptan." | 2.71 | Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. ( Dahlöf, C; Färkkilä, M; Muirhead, N; Olesen, J; Rasmussen, S; Sikes, C; Stovner, LJ; ter Bruggen, JP, 2003) |
| "Sumatriptan is a potent and selective vascular 5-HT1 receptor agonist effective for the treatment of migraine." | 2.71 | Pharmacokinetics of sumatriptan nasal spray in adolescents. ( Christensen, ML; Fuseau, E; Jabbour, JT; Mottern, RK, 2003) |
| "One hundred twelve patients with migraine with or without aura according to the diagnostic criteria of the International Headache Society were randomized to treat 2 migraine attacks with a fixed combination of indomethacin, prochlorperazine, and caffeine and 2 migraine attacks with sumatriptan." | 2.71 | Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial. ( Aloisio, A; Del Bianco, P; Di Monda, V; Fonzari, M; Grazioli, I; Nicolodi, M; Sicuteri, F; Uslenghi, C; Vecchiet, L, 2003) |
| "Zolmitriptan ODT is a convenient and beneficial alternative to conventional tablets and is preferred to sumatriptan conventional tablets by migraineurs." | 2.71 | Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet. ( Charlesworth, BR; Dowson, AJ, 2003) |
| "Menstrually associated migraine was defined as any migraine beginning on or between day -2 and day 4, with day 1 = first day of flow." | 2.71 | Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. ( Ames, M; Landy, S; Lener, M; Nett, R; Richardson, MS; Shackelford, S, 2003) |
| "Onset of effect is related to rate of absorption of sumatriptan." | 2.71 | Onset of effect of 5-HT1B/1D agonists: a model with pharmacokinetic validation. ( Fox, AW, 2004) |
| "The sumatriptan dose was 10 mg for a body weight of 20 to 39 kg and 20 mg for those with a body weight of >/==" BORDER="0">40 kg." | 2.71 | Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial. ( Ahonen, K; Hämäläinen, ML; Hoppu, K; Rantala, H, 2004) |
| "Sumatriptan tablets were generally well tolerated." | 2.71 | Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. ( Ahmad, F; Boswell, D; Carpay, J; Kinrade, F; Schoenen, J, 2004) |
| " Pharmacokinetic analysis included both noncompartmental and population modeling methods." | 2.71 | Pharmacokinetics of sumatriptan nasal spray in children. ( Christensen, ML; Fuseau, E; Jabbour, JT; Mottern, RK, 2004) |
| "Only almotriptan was significantly higher than placebo on the sustained pain-free rate-34." | 2.71 | Almotriptan improves response rates when treatment is within 1 hour of migraine onset. ( Cabarrocas, X; Dowson, AJ; Lainez, JM; Massiou, H, 2004) |
| "Patients assessed pain severity, migraine-associated symptoms, and functional disability at 0." | 2.71 | Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets. ( Battisti, WP; Johnson-Pratt, L; Kolodny, A; Polis, A; Skobieranda, F, 2004) |
| "Zolmitriptan nasal spray was also significantly superior to placebo for headache response at 4 hours, sustained headache response at 24 hours and sustained pain-free rate at 24 hours." | 2.71 | Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. ( Brandes, J; Dodick, D; Elkind, A; Mathew, N; Rodichok, L, 2005) |
| "When compared at 2 and 24 hours, aggressive (20 mg dosed up to four times) IV metoclopramide and 6 mg of subcutaneous sumatriptan relieved migraine headache pain comparably." | 2.71 | A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. ( Bijur, PE; Corbo, J; Esses, D; Friedman, BW; Gallagher, EJ; Lipton, RB; Solorzano, C, 2005) |
| "Almotriptan 12." | 2.71 | Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. ( Beneke, M; Diener, HC; Gebert, I; Gendolla, A, 2005) |
| "Most people who experience migraine use OTC medications to treat their symptoms, but no head-to-head clinical trials comparing these agents with prescription migraine therapies have been published." | 2.71 | Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. ( Baggish, J; Battikha, JP; Elkind, AH; Gallagher, RM; Goldstein, J; Hoffman, H; Saper, JR; Silberstein, SD; Smith, TR, 2005) |
| "The pathogenesis of migraine involves multiple peripheral and central neural mechanisms that individually have been successful targets for acute (abortive) and preventive treatment." | 2.71 | Sumatriptan and naproxen sodium for the acute treatment of migraine. ( Alexander, WJ; Littlefield, DE; Smith, TR; Spruill, SE; Stark, SR; Sunshine, A, 2005) |
| "Triptans are not identical and migraine sufferers respond differently to different triptans." | 2.71 | Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg. ( Diener, HC, 2005) |
| "Oral sumatriptan (100 mg) is an effective and well tolerated acute treatment for patients who report menstrually related migraine." | 2.71 | Managing migraine headaches experienced by patients who self-report with menstrually related migraine: a prospective, placebo-controlled study with oral sumatriptan. ( Aurora, SK; Dowson, AJ; Massiou, H, 2005) |
| "Sumatriptan is a selective agonist of 5HT1 (1B/1D) receptors, which has proved to be effective and safe for the acute treatment of migraine attacks." | 2.71 | Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients. ( Bertolini, A; Coccia, CP; Ferrari, A; Leone, S; Pinetti, D; Sternieri, E, 2005) |
| "Almotriptan is a novel and specific serotonin 5-HT1B/1D agonist for the acute treatment of migraine." | 2.70 | Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. ( Cabarrocas, X; Dowson, AJ; Laínez, JM; Massiou, H, 2002) |
| "Eletriptan 40 mg was superior to both sumatriptan doses in functional improvement (p < 0." | 2.70 | Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. ( Burgess, G; Färkkilä, M; Forster, E; Haughie, S; Sandrini, G, 2002) |
| "Almotriptan is a new selective serotonin 1B/1D agonist triptan migraine treatment." | 2.70 | Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. ( Brod, MI; Colman, SS; Gomez-Mancilla, B; Jirgens, KJ; Krishnamurthy, A; Rowland, CR, 2001) |
| "Sumatriptan absorption was delayed with the encapsulated tablet compared with the conventional tablet 0 to 2 hours after dosing, particularly during a migraine." | 2.70 | Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine. ( Coates, P; Fuseau, E; Leibowitz, M; McNeal, S; Metz, A; O'Quinn, S; Pereira, A; Petricoul, O; Purdon, H; Sabin, A; Salonen, R; Thein, S, 2001) |
| "Changes in migraine pain severity, clinical disability, and percent effectiveness following treatment with sumatriptan nasal spray, 20 mg, were significantly correlated with cognitive function measures across all subtests (P<." | 2.70 | Sumatriptan nasal spray and cognitive function during migraine: results of an open-label study. ( Batenhorst, A; Bleiberg, J; Cady, R; Farmer, K; O'Quinn, S; Putnam, G; Reeves, D, 2001) |
| "As part of the stratified treatment of migraine, those patients whose headaches are mild or moderate may benefit from nontriptan medications." | 2.70 | Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. ( Cady, R; DiSerio, F; Elkind, A; Freitag, FG; Gallagher, RM; Goldstein, J; Klapper, JA; Rapoport, AM; Sadowsky, C; Saper, JR; Smith, TR, 2001) |
| "Rizatriptan was also superior to sumatriptan in terms of the proportions of patients with no nausea, phonophobia or photophobia, and patients with normal function 2 h after treatment intake (p < 0." | 2.70 | Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine. ( Allen, C; Bussone, G; Hernandez, JF; Pascual, J; Patel, K; Vrijens, F, 2001) |
| "Sumatriptan was significantly better than alniditan 1." | 2.70 | The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. ( Dahlöf, C; de Beukelaar, F; Diener, HC; Ferrari, MD; Mathew, N; Olesen, J; Tfelt-Hansen, P, 2001) |
| "Rizatriptan ODT is an orally disintegrating formulation of rizatriptan, a selective 5-HT1B/1D receptor agonist." | 2.70 | Preference comparison of rizatriptan ODT 10-mg and sumatriptan 50-mg tablet in migraine. ( Bohidar, N; Boyle, D; Brandes, JL; Guerra, F; Johnson-Pratt, L; Kolodny, A; Loder, E; Santanello, N; Silberstein, S; Skobieranda, F; Wang, L, 2001) |
| "Sumatriptan was compared to placebo across 2 groups (non-Caucasian and Caucasian) and individual ethnic subgroups (black, Hispanic, and others)." | 2.70 | Efficacy and tolerability of subcutaneous sumatriptan for acute migraine: a comparison between ethnic groups. ( Asgharnejad, M; Burke-Ramirez, P; Davis, R; Laurenza, A; Webster, C, 2001) |
| "We studied nine bipolar patients with migraine, nine bipolar patients without it, seven migraine patients, and nine matched normal controls." | 2.70 | Sumatriptan challenge in bipolar patients with and without migraine: a neuroendocrine study of 5-HT1D receptor function. ( Connor, R; Herbison, P; Mahmood, T; Silverstone, T, 2002) |
| "A total of 1791 adult migraine sufferers were studied." | 2.70 | Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials. ( Dodick, DW, 2002) |
| "Frovatriptan treatment produced an adverse events profile similar to that of placebo, and in a direct comparison study was better tolerated than sumatriptan 100 mg." | 2.70 | Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. ( Géraud, G; Keywood, C; Spierings, EL, 2002) |
| " For 6 hours after treatment, a continuous electrocardiogram (ECG) was performed, and headache severity, adverse events, and vital signs were recorded." | 2.69 | Monitoring of acute migraine attacks: placebo response and safety data. ( Cutler, NR; Ford, NF; Fulmor, IE; Jhee, SS; Salazar, DE; Sramek, JJ, 1998) |
| "Sumatriptan (all doses) was similarly effective at relieving nausea and photophobia or phonophobia or both and at reducing clinical disability." | 2.69 | Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. ( Cunin, G; Pfaffenrath, V; Prendergast, S; Sjonell, G, 1998) |
| "Mean productivity loss 2 hours after dosing and across the work shift; percentages of patients returning to normal work performance within 2 hours after dosing and across the work shift; percentages of patients experiencing headache relief (reduction of moderate or severe predose pain to mild or no pain) 1 and 2 hours after dosing." | 2.69 | Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. ( Cady, RC; Jhingran, P; O'Quinn, S; Pait, DG; Ryan, R, 1998) |
| "The sumatriptan 50 mg was well tolerated; only 10% of patients reported adverse events, which were minor and transient." | 2.69 | [Evaluation of efficacy and tolerance sumatriptan at a dose of 50 mg in treatment of migraine attack]. ( Król, F; Prusiński, A, 1998) |
| "In the first migraine attack treated, headache improvement was experienced by 77." | 2.69 | Effect of operationalized computer diagnosis on the therapeutic results of sumatriptan in general practice. ( Göbel, H; Heinze, A; Heuss, D; Kuhn, K; Lindner, V, 1998) |
| "Forty-one migraine subjects (26 males, 15 females), mean age 36 +/- 2 years (range 36-39 years), and 20 healthy control subjects (14 males, six females), mean age 36 +/- 2 years (range 36-39 years) were randomized (double-blind) to receiving sumatriptan (group A) or placebo (group B)." | 2.69 | Succinate sumatriptan evaluation by Doppler echocardiography in patients with migraine. ( Amato, P; Arrostuto, A; Bologna, P; Bova, A; Bucca, V; Cardinale, A; Cecala, M; Di Pasquale, P; Follone, G; Licata, G; Maniscalchi, T; Parrinello, G; Paterna, S; Piovana, G; Tuttolomondo, A, 1998) |
| " Forty-five patients (88%) reported at least one adverse event and 23 (45%) experienced pressure, tightness, and/or pain in the chest, neck, and/or throat after administration of avitriptan." | 2.69 | Safety trial with the 5HT1B/1D agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/or pain in the chest, neck, and/or throat following sumatriptan. ( Dahlöf, CG; Falk, L; Lewis, CP; Risenfors, M, 1998) |
| "Migraine was alleviated earlier in the STG than in the CTG (median 3." | 2.69 | Subcutaneous sumatriptan compared with usual acute treatments for migraine: clinical and pharmacoeconomic evaluation. ( Bourgeois, P; Jacquy, J; Laloux, P; Monseu, G; Vakaet, A; van der Linden, C, 1998) |
| "Sumatriptan nasal spray was well tolerated, the incidence of adverse events with each dose of sumatriptan being similar to the placebo (20-27 and 23%, respectively)." | 2.69 | Sumatriptan nasal spray: a dose-ranging study in the acute treatment of migraine. ( Ashford, EA; Becker, WJ; Dahlof, C; Hassani, H; Peikert, A; Salonen, RJ, 1999) |
| "Sumatriptan is a highly effective treatment for migraine in adults but its efficacy in children has not been determined." | 2.69 | Intranasal sumatriptan for the acute treatment of migraine in children. ( Ueberall, MA; Wenzel, D, 1999) |
| "Diclofenac-potassium is a potent NSAID available as a fast-acting oral tablet, which has been shown to be safe and effective in several other acute pain indications." | 2.69 | Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. ( , 1999) |
| " Sumatriptan is more effective, but resulted in more adverse events." | 2.69 | Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG St ( Diener, HC, 1999) |
| "Sumatriptan is a novel drug for the treatment of acute migraine attacks." | 2.69 | [The efficacy of subcutaneous sumatriptan for the treatment of migraine attack]. ( Stepień, A, 1999) |
| "Sumatriptan was administered to 215 healthy subjects (i." | 2.69 | Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients. ( Cosson, VF; Fuseau, E, 1999) |
| "Eletriptan is a potent and selective agonist at human recombinant 5HT1B/1D receptors, with efficacy in animal models that predict antimigraine activity." | 2.69 | Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. ( Ferrari, MD; Goadsby, PJ; Jackson, NC; Olesen, J; Poole, PH; Senard, JM; Stovner, LJ, 2000) |
| "We evaluated the acute antimigraine efficacy of intravenous and oral CP-122,288 in two double-blind studies." | 2.69 | No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials. ( Christianssen, I; Diener, HC; Ellis, P; Ferrari, MD; Hettiarachchi, J; Kleinermans, D; Kok, JG; Olesen, J; Poole, PH; Roon, KI, 2000) |
| "Three-hundred-and-twenty-eight migraine sufferers treated a first migraine attack with a nontriptan standard care medication: a mixture containing phenazone, butalbital and caffeine (optalidon) or indomethacin plus prochlorperazine plus caffeine (difmetre) or paracetamol 100 mg (tachipirine), depending on their habits." | 2.69 | Efficacy and safety of sumatriptan 50 mg in patients not responding to standard care, in the treatment of mild to moderate migraine. The Sumatriptan 50 mg Italian Study Group. ( Cavazzuti, L; Fabbri, L; Pini, LA, 1999) |
| "Oral sumatriptan 50 mg has been found to have good efficacy and tolerability in the acute treatment of migraine but has been less well studied than the 100 mg dose." | 2.69 | A double-blind placebo-controlled study assessing the efficacy and tolerability of 50 mg sumatriptan tablets in the acute treatment of migraine. Sumatriptan Tablets S2CM07 Study Group. ( Ashford, EA; Brautaset, NJ; Hassani, H; Reunanen, M; Saiers, J; Savani, N; Szirmai, I, 1999) |
| " Compared with the 25 mg dose, the 100 mg and 50 mg doses were significantly more likely to provide headache relief at 2, 3, and 4 h after dosing and complete headache resolution at 3 and 4 h after dosing (P < 0." | 2.69 | Patient preference for oral sumatriptan 25 mg, 50 mg, or 100 mg in the acute treatment of migraine: a double-blind, randomized, crossover study. Sumatriptan Tablets S2CM11 Study Group. ( Ashford, EA; Gibbs, M; Hassani, H; Salonen, R, 1999) |
| " Fewer patients required rescue medication in the active groups (1% 100 mg to 13% 6 mg) compared with placebo (17%), and more patients were able to work and function normally two hours after dosing (41%, 100 mg; 20%, placebo)." | 2.69 | A dose-defining study of sumatriptan suppositories in the acute treatment of migraine. ( Bertin, L; Brion, N; Färkkilä, M; Göbel, H; Wessely, P, 1999) |
| "Zolmitriptan, 2." | 2.69 | A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. ( Chitra, R; Dennish, G; Gallagher, RM; Spierings, EL, 2000) |
| "Sumatriptan treatment tended to reduce median productivity loss 2 hours after injection compared with placebo (25." | 2.69 | Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. ( Batenhorst, AS; Cady, RK; Henry, D; O'Quinn, SO; Putnam, DG; Schulman, EA; Watson, CB, 2000) |
| ") In a subset of patients experiencing headache relief after 2 attacks, headache recurrence 4 to 24 hours after initial dosing was reported by 55 naratriptan- and 77 sumatriptan-treated patients (41% and 57%, respectively; P = 0." | 2.69 | Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group. ( Becker, W; Boswell, D; Crisp, A; Göbel, H; Hauge, T; Mihout, B; Niewold, J; Tørring, J; Winter, P, 2000) |
| "Zolmitriptan was the only triptan that decreased temporal artery diameter significantly (by 12% +/- 3%, P < ." | 2.69 | Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches. ( de Hoon, JN; Struijker-Boudier, HA; Troost, J; Van Bortel, LM; Willigers, JM, 2000) |
| "The sumatriptan 20-mg dose was superior to placebo with respect to the cumulative percentages of patients first reporting complete relief within 2 hours of dosing (Kaplan-Meier)." | 2.69 | A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. ( Asgharnejad, M; Austin, R; Laurenza, A; Nett, R; Peykamian, M; Rothner, AD; Saper, J; Winner, P, 2000) |
| " Headache response 2 hours after dosing was reported by 76% of patients taking the 10-mg dose and 72% of those taking the 20-mg dose." | 2.69 | One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study. ( Asgharnejad, M; Austin, R; Laurenza, A; Nett, R; Peykamian, M; Rothner, AD; Winner, P, 2000) |
| "Oral sumatriptan was similarly effective at relieving the associated symptoms and at reducing clinical disability in most attacks." | 2.69 | Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks. ( Benassuti, C; Bussone, G; Cortelli, P; Fabbri, L; Manzoni, GC; Roncolato, M, 2000) |
| " The incidence and nature of adverse events in this study were similar to that seen in previous studies." | 2.68 | The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group. ( Bonellie, G; Facchinetti, F; Kangasniemi, P; Pascual, J; Shuaib, A, 1995) |
| "Aspirin is commonly used to treat migraine attacks, although sumatriptan, a much more expensive treatment, is also effective." | 2.68 | The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. ( Chazot, G; Henry, P; Mulder, LJ; Scheldewaert, RG; Schoenen, J; Tfelt-Hansen, P, 1995) |
| "Sumatriptan was found to be effective in 22 (92%) out of 24 patients." | 2.68 | Efficacy and tolerability of oral sumatriptan in the treatment of acute migraine. ( Amayo, EO; Jowi, JO; Kwasa, TO, 1995) |
| "Patients (n = 667) treated up to three migraine attacks in a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial." | 2.68 | Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. ( Alderton, CJ; Cutler, NR; Davis, RL; Ferrari, MD; Paulsgrove, LA; Rapoport, AM; Visser, WH, 1995) |
| "Oral sumatriptan 100 mg was well tolerated, and repeated administration did not alter the pattern or severity of adverse events." | 2.68 | Oral sumatriptan for the long-term treatment of migraine: clinical findings. ( Cutler, N; Hazelrigg, R; Jamerson, B; Rapoport, A; Rederich, G, 1995) |
| "Oral sumatriptan was similarly effective at relieving nausea and photophobia and at reducing clinical disability." | 2.68 | Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. ( Clements, B; Cutler, N; Davis, R; Mushet, GR; Whitcher, L, 1995) |
| "When sumatriptan was compared to placebo, significantly more of the 209 evaluable patients reported headache relief at one hour (56% v 8%, p < 0." | 2.68 | [Sumatriptan treatment of migraine in general practice. A randomized, double-blind, placebo-controlled cross-over study]. ( Cleal, A; Holm-Thomsen, OE; Nielsen, MR; Olesen, J; Pilgrim, AJ; Russell, MB, 1995) |
| "We studied 20 patients with migraine without aura, 15 of whom were evaluated under all three conditions and five of whom were evaluated under only two conditions." | 2.68 | Cerebral blood flow during migraine attacks without aura and effect of sumatriptan. ( Arndt, JW; Blokland, JA; Ferrari, MD; Haan, J; Minnee, P; Pauwels, EK; Saxena, PR; Zwinderman, AH, 1995) |
| "The impact of short-term treatment for migraine attacks on these variables was evaluated in an open prospective 6-month study at the Gothenburg Migraine Clinic." | 2.68 | Health-related quality of life under six months' treatment of migraine--an open clinic-based longitudinal study. ( Dahlöf, CG, 1995) |
| "Sumatriptan 6 mg s." | 2.68 | Introduction of a novel self-injector for sumatriptan. A controlled clinical trial in general practice. ( Hansen, EW; Jensen, K; Krøis, EH; Pedersen, OS; Tfelt-Hansen, P, 1995) |
| "Sumatriptan-treated patients used rescue medication for 19% of their attacks, compared to 59% for comparator drugs (p = 0." | 2.68 | Comparison of subcutaneous sumatriptan with usual acute treatments for migraine. French Sumatriptan Study Group. ( Bertin, L; Boureau, F; Chazot, G; d'Allens, H; Emile, J, 1995) |
| "Patients of either sex, with migraine with or without aura, between the ages of 18 and 65 years." | 2.68 | A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. ( Le Force, B; Margul, B; Ricalde, O; Saper, J; Winner, P, 1996) |
| "Pain ratings from 268 migraine patients have been used to compare the visual analogue scale (VAS) and a four-point verbal rating scale." | 2.68 | Response measures in the acute treatment of migraine. ( Flaten, O; Skovlund, E, 1995) |
| "More sumatriptan-treated patients than placebo-treated patients reported adverse events (29% versus 16%) but the difference was not statistically significant." | 2.68 | [Evaluation of the efficacy of oral sumatriptan in the management of migraine attacks. Clinical results]. ( Albano, O; Bassi, A; Cassiano, MA; Centonze, V; Di Bari, M; Fabbri, L; Polito, MB, 1995) |
| "Two hundred sixty-six adult migraineurs (International Headache Society criteria) completed a multicenter, double-blind, double-dummy, cross-over study." | 2.68 | A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. ( Ashford, E; Bertin, L; Bès, A; Pilgrim, AJ; Touchon, J, 1996) |
| "Whether the primary mechanisms of migraine are vascular or neurogenic is, as yet, unresolved." | 2.68 | Changes in cerebral blood flow velocity after treatment with sumatriptan or placebo and implications for the pathophysiology of migraine. ( Auerbach, P; Diener, HC; Eppe, T; Limmroth, V; May, A; Wosnitza, G, 1996) |
| " We studied whether pharmacokinetic or pharmacodynamic differences may explain these different clinical effects." | 2.68 | Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. ( Burggraaf, J; Cohen, AF; Ferrari, MD; Fowler, PA; Muller, LM; Schoemaker, RC; Visser, WH, 1996) |
| "Sumatriptan was also associated with significant reductions in the average number of migraine-related general outpatient and urgent care services (P < ." | 2.68 | Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic, and clinical consequences. ( Beall, DG; Beck, A; Clements, BD; Cohen, JA; Miller, DW; Pait, G, 1996) |
| "Rizatriptan (MK-462) is a new 5-hydroxytryptamine1D (serotonin1D; 5-HT1D) receptor agonist for the acute treatment of migraine that has improved pharmacokinetic properties compared with sumatriptan succinate." | 2.68 | Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group. ( Ferrari, MD; Jiang, K; Lines, CR; Reines, SA; Terwindt, GM; Visser, WH, 1996) |
| "Patients treated migraines with their usual therapy for 12 to 18 weeks followed by subcutaneous sumatriptan for 6 months." | 2.68 | Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine. ( Clements, B; Gutterman, DL; Miller, D; Mushet, GR; Pait, G, 1996) |
| "Oral sumatriptan is an effective acute treatment for migraine in adults, but its efficacy in children is still undetermined." | 2.68 | Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults? ( Hämäläinen, ML; Hoppu, K; Santavuori, P, 1997) |
| "Sumatriptan was generally well tolerated." | 2.68 | The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache. ( Cull, RE; Dunbar, A; Price, WH, 1997) |
| "Nineteen volunteer female migraineurs, age range 33 to 62 years, at low risk for ischemic heart disease were included." | 2.68 | A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using 13NH3 positron emission tomography. ( Barrington, SF; Lewis, LD; Lewis, PJ; Maisey, MN; Marsden, PK, 1997) |
| " Adverse events were mild and consisted mainly of bitter taste at the back of the throat and events typical of sumatriptan administered by other routes (headache, lightheadedness and tingling)." | 2.68 | Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. ( Duquesnoy, C; Fuseau, E; Hussey, EK; Moore, KH; Pakes, GE; Shaw, S, 1997) |
| "Median time to recurrence was shorter after subcutaneous (12." | 2.68 | Oral and subcutaneous sumatriptan in the acute treatment of migraine: an open randomized cross-over study. ( Carpay, HA; Matthijsse, P; Mulder, PG; Steinbuch, M, 1997) |
| "The patients were diagnosed with migraine based on IHS criteria but individual migraine attacks treated in the study were physician diagnosed; not necessarily required to meet IHS criteria." | 2.68 | Responsiveness of non-IHS migraine and tension-type headache to sumatriptan. ( Beach, ME; Cady, RK; Gutterman, D; Saiers, JA, 1997) |
| "5 mg dose was on the shoulder of the dose-response curve (2-h headache response rate 64%), showing similar efficacy to the 5 mg dose (67%)." | 2.68 | Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy. ( Sawyer, J; Schoenen, J, 1997) |
| "The annual cost of managing migraine totals billions of US dollars." | 2.68 | Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine. A retrospective cost-efficacy analysis. ( Kozma, CM; Lawrence, BJ; Payne, K, 1996) |
| "Adult patients with moderate to severe migraine initially received customary therapy for migraine episodes for 12 weeks, followed by 24 weeks' treatment with self-administered subcutaneous sumatriptan 6 mg." | 2.68 | A multinational investigation of the impact of subcutaneous sumatriptan. I: Design, methods and clinical findings. ( Adams, J; Berto, P; Bouchard, J; Brueggenjuergen, B; Cortelli, P; Dahlöf, C; Edwards, CE; Heywood, J; Hirsch, J; Jansen, JP; Lindsay, P; Nyth, AL; Pham, S; Price, KL, 1997) |
| "The Short Form-36 Health Survey and the Migraine-Specific Quality of Life Questionnaire were completed at a screening visit (base-line), at the end of the 12-week customary therapy phase, and at 12 and 24 weeks of the sumatriptan phase." | 2.68 | A multinational investigation of the impact of subcutaneous sumatriptan. II: Health-related quality of life. ( Adams, J; Bouchard, J; Cortelli, P; Dahlöf, C; Heywood, J; Hirsch, J; Jansen, JP; Miller, DW; Pham, S, 1997) |
| "Patients diagnosed with migraine treated their symptoms for 24 weeks with subcutaneous sumatriptan after a 12-week period of treating symptoms with their customary (non-sumatriptan) therapy." | 2.68 | A multinational investigation of the impact of subcutaneous sumatriptan. III: Workplace productivity and non-workplace activity. ( Adams, J; Bouchard, J; Cortelli, P; Dahlöf, C; Heywood, J; Hirsch, J; Jansen, JP; Miller, DW; Pham, S, 1997) |
| "Sumatriptan was considered by most patients (67 to 85%) to be dependable and fast-acting, and to have a long duration of effect, allowing a quick return to normal activities." | 2.68 | A multinational investigation of the impact of subcutaneous sumatriptan. IV: Patient satisfaction. ( Babiak, L; Bouchard, J; Cortelli, P; Dahlöf, C; Heywood, J; Jansen, JP; Joseph, A; Pham, S; Price, KL, 1997) |
| "Sumatriptan was superior to placebo in treating headache recurrence: 74 vs 49% (p = 0." | 2.67 | Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. ( Anderson, BA; Ashford, E; Bates, D; Ferrari, MD; James, MH; Nappi, G; Pilgrim, A, 1994) |
| "When sumatriptan was compared to placebo, significantly more of the 209 evaluable patients reported headache relief at 1 h (56% vs 8%, p < 0." | 2.67 | A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice. ( Cleal, A; Holm-Thomsen, OE; Olesen, J; Pilgrim, AJ; Rishøj Nielsen, M; Russell, MB, 1994) |
| "Sumatriptan was generally well tolerated, the most frequently reported event being taste disturbance." | 2.67 | Intranasal sumatriptan for the acute treatment of migraine. International Intranasal Sumatriptan Study Group. ( Ashford, E; Dahlöf, C; Dawson, R; Gilhus, NE; Lüben, V; Noronha, D; Salonen, R; Warter, JM, 1994) |
| "Oral sumatriptan was consistently effective in the treatment of headache recurrence." | 2.67 | Oral sumatriptan in the treatment of recurrent headache. ( Cady, RK; Crummett, D; Littlejohn, TW; Rubino, J, 1994) |
| "Sumatriptan is a new anti-migraine drug which has been shown in clinical studies to be efficacious in up to 80% of attacks treated." | 2.67 | [Sumatriptan in the treatment of migraine in general practice]. ( Midelfart, E; Winnem, M, 1994) |
| "Treatment with sumatriptan during the migraine attack was accompanied by a significant increase in the duration of ES2 (p < or = 0." | 2.67 | Exteroceptive suppression of temporalis muscle activity during migraine attack and migraine interval before and after treatment with sumatriptan. ( Dworschak, M; Ensink, FB; Göbel, H; Heuss, D; Krapat, S; Soyka, D, 1994) |
| "More sumatriptan-treated patients were completely pain free compared with placebo-treated patients at both 2 h (24% versus 12%) and 4 h (48% versus 18)." | 2.67 | Oral sumatriptan compared with placebo in the acute treatment of migraine. ( Byrne, M; Nappi, G; Roncolato, M; Sicuteri, F; Zerbini, O, 1994) |
| "Other migraine symptoms (nausea, vomiting, photo- and phonophobia) were effectively treated with sumatriptan." | 2.67 | Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study. ( Bulcke, J; Caekebeke, J; De Keyser, J; Dehaene, I; Hildebrand, G; Joffroy, A; Laloux, P; Louis, P; Monseu, G; Schoenen, J, 1994) |
| "Sumatriptan was significantly more effective than placebo in relieving or reducing headache severity after 30 minutes." | 2.67 | Subcutaneous sumatriptan in acute treatment of migraine: a multicentre New Zealand trial. ( Arthur, GP; Bergin, PS; Flanagan, M; Parkin, PJ; Pollock, M; Samson, SA; Thomson, AN, 1993) |
| "Sumatriptan was well tolerated, and the frequency and severity of adverse events did not change with repeated administration." | 2.67 | Efficacy of subcutaneous sumatriptan in repeated episodes of migraine. ( Cady, RK; Dexter, J; Markley, H; Osterhaus, JT; Sargent, JD; Webster, CJ, 1993) |
| "Sumatriptan was superior to placebo for headache relief (32 [78%] vs." | 2.67 | Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. Early-Morning Migraine Sumatriptan Study Group. ( Bousser, MG; D'Allens, H; Richard, A, 1993) |
| "Sumatriptan was well tolerated." | 2.67 | Long-term experience with sumatriptan in the treatment of migraine. ( Martin, PM; Pilgrim, AJ; Tansey, MJ, 1993) |
| "Sumatriptan also treated nausea and photophobia more effectively in menstrual-migraine patients than did placebo." | 2.67 | Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. ( Solbach, MP; Waymer, RS, 1993) |
| "Sumatriptan was well tolerated and the majority of adverse events were mild and transient." | 2.67 | Sumatriptan injection is superior to placebo in the acute treatment of migraine--with regard to both efficacy and general well-being. ( Dahlöf, C; Edwards, C; Toth, A, 1992) |
| "The results of the very first large-scale placebo-controlled dose-response trial with the novel selective 5-hydroxytryptamine1-like (5HT1-like) receptor agonist sumatriptan are presented." | 2.67 | Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group. ( Bayliss, EM; Ferrari, MD; Ludlow, S; Pilgrim, AJ; Visser, WH, 1992) |
| " Adverse events were dose related; the most common types were injection site reactions and tingling." | 2.67 | Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. ( Couch, J; Dexter, J; Flamenbaum, W; Goldstein, J; Mathew, NT; Rapoport, A; Saper, J; Sheftell, F; Silberstein, S; Solomon, S, 1992) |
| "Sumatriptan was well tolerated and the majority of adverse events were mild and transient." | 2.67 | Subcutaneous sumatriptan in the acute treatment of migraine. Sumatriptan International Study Group. ( Ensink, FB, 1991) |
| "The headache in migraine attacks may be caused by dilatation of certain cranial arteries or arteriovenous anastomoses, by neurogenic dural plasma extravasation, or by both of these mechanisms." | 2.67 | Treatment of migraine attacks with sumatriptan. ( , 1991) |
| "Patients treated up to three migraine attacks at home over a 3-month period and recorded the results on a diary card." | 2.67 | Sumatriptan--an oral dose-defining study. The Oral Sumatriptan Dose-Defining Study Group. ( , 1991) |
| "Sumatriptan was significantly more effective than placebo in relieving headache (moderate/severe reduced to mild/none) at 2 h (50 vs." | 2.67 | Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. The Oral Sumatriptan International Multiple-Dose Study Group. ( , 1991) |
| "Sumatriptan was significantly more effective than Cafergot at reducing the intensity of headache from severe or moderate to mild or none; 66% (145/220) of those treated with sumatriptan improved in this way by 2 h, compared with 48% (118/246) of those treated with Cafergot (p less than 0." | 2.67 | A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. ( , 1991) |
| "If the migraine had not improved at 1 h, patients had the option of taking a second identical injection." | 2.67 | Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. The Sumatriptan Auto-Injector Study Group. ( , 1991) |
| "A similar number of patients reported migraine recurrence, within 24 h in both treatment groups." | 2.67 | A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group. ( , 1991) |
| " Safety monitoring involved collection of all adverse events, regardless of their relationship to treatment, and included routine laboratory screening tests and some special investigations." | 2.67 | The safety and tolerability of sumatriptan: an overview. ( Brown, EG; Endersby, CA; Smith, RN; Talbot, JC, 1991) |
| "The efficacy in acute migraine of oral sumatriptan was assessed in a double-blind, randomised, placebo-controlled, crossover study of 61 patients (mean age 39 [SD 10] years)." | 2.67 | Oral sumatriptan in acute migraine. ( Anthony, M; Bladin, PF; Donnan, GA; Goadsby, PJ; Lance, JW; Symington, G; Zagami, AS, 1991) |
| "Patients with residual migraines received another injection; those who had originally received sumatriptan received either a second active injection (n = 187) or placebo (n = 178), while those who had received placebo received a second placebo injection (n = 335)." | 2.67 | Treatment of acute migraine with subcutaneous sumatriptan. ( Cady, RK; Kirchner, JR; Rothrock, JF; Sargent, JD; Skaggs, H; Wendt, JK, 1991) |
| " AVP-825 was well tolerated in controlled trials, with the most common adverse events localized at the administration-site (abnormal taste, nasal discomfort); these were mostly mild, leading to only one discontinuation." | 2.58 | A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine. ( Silberstein, SD, 2018) |
| "In more than 50% of women migraineurs the occurrence of migraine attacks correlates strongly with the perimenstrual period." | 2.58 | Menstrual migraine: a review of current and developing pharmacotherapies for women. ( Allais, G; Benedetto, C; Chiarle, G; Sinigaglia, S, 2018) |
| "Migraine is a common, disabling disorder, and many patients remain dissatisfied with existing treatments." | 2.55 | AVP-825: a novel intranasal delivery system for low-dose sumatriptan powder in the treatment of acute migraine. ( Silberstein, S, 2017) |
| "Introduction Migraine headache is a neurological disorder whose attacks are associated with nausea, vomiting, photophobia and phonophobia." | 2.55 | Comparative tolerability of treatments for acute migraine: A network meta-analysis. ( Bhambri, R; Chan, K; Donnet, A; Druyts, E; Goadsby, PJ; Ramos, E; Stark, R; Thorlund, K; Toor, K; Wu, P, 2017) |
| "Migraine headache is a common disorder; patients attending Emergency Departments (ED) for migraine symptoms internationally account for 1-3% of total ED annual attendances." | 2.53 | Systematic review: Is Metoclopramide more effective than Sumatriptan in relieving pain from migraine in adults in the Emergency Department (ED) setting? ( Barleycorn, D, 2016) |
| " Expert commentary: A new formulation of a low-dose sumatriptan intranasal powder administered via a novel breath-powered delivery device appears to be a safe and efficacious option for the acute management of a migraine ideally suited for this situation." | 2.53 | The efficacy and safety of sumatriptan intranasal powder in adults with acute migraine. ( Freitag, FG; Shumate, DA, 2016) |
| "Migraine is a neurological disorder resulting in large socioeconomic burden." | 2.53 | Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. ( Han, W; Li, M; Wang, J; Xu, H, 2016) |
| "AVP-825 has the potential to provide migraine patients with improved intranasal administration of sumatriptan that may enhance efficacy and tolerability." | 2.52 | A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine. ( Cady, R, 2015) |
| "Mild migraine attack can be treated with acetaminophen or NSAIDs either alone or combined with metoclopramide." | 2.52 | [Update on Current Care Guideline: Migraine]. ( , 2015) |
| "Chronic migraine is a frequent, severely disabling headache that often evolves from EM." | 2.50 | Chronic migraine in women. ( Cady, RK, 2014) |
| "Although the pathogenesis of migraine is very complex and has not been thoughtfully elucidated, general consensus exists to date that this condition should be considered a primary neurovascular disorder with an important inflammatory component." | 2.50 | Adiponectin and migraine: systematic review of clinical evidence. ( Borghi, L; Lippi, G; Mattiuzzi, C; Meschi, T; Targher, G, 2014) |
| "Sumatriptan is an abortive medication for migraine attacks, belonging to the triptan family." | 2.50 | Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. ( Derry, CJ; Derry, S; Moore, RA, 2014) |
| "Migraine is a common, disabling condition and a burden for the individual, health services and society." | 2.49 | Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; Moore, RA, 2013) |
| "Diclofenac is an established analgesic, and new formulations using the potassium or epolamine salts, which can be dissolved in water, have been developed for rapid absorption, which may be beneficial in acute migraine." | 2.49 | Diclofenac with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; Moore, RA; Rabbie, R, 2013) |
| "Studies on the acute treatment of migraine in children and adolescents are rare and difficult to design." | 2.49 | The efficacy of triptans in childhood and adolescence migraine. ( Evers, S, 2013) |
| "The fastest and most complete migraine relief occurs with SQ dosing; a needle-free option is available for patients fearful of injections." | 2.49 | Sumatriptan : treatment across the full spectrum of migraine. ( Marcus, DA; Silberstein, SD, 2013) |
| "The acute treatment of migraine requires matching patient need to drug and formulation." | 2.49 | Clinical implications for breath-powered powder sumatriptan intranasal treatment. ( Tepper, SJ, 2013) |
| "The TACs include cluster headache, paroxysmal hemicrania, and short-lasting neuralgiform headache attacks with conjunctival injection and tearing; hemicrania continua, although classified separately by the International Headache Society, shares many features of both migraine and the TACs." | 2.49 | Primary headache disorders. ( Benoliel, R; Eliav, E, 2013) |
| "Sumatriptan TDS is a useful addition to the treatment options available to migraine patients." | 2.49 | Sumatriptan iontophoretic transdermal system: a review of its use in patients with acute migraine. ( Garnock-Jones, KP, 2013) |
| "SC sumatriptan has high efficacy and a rapid onset of action compared with other available triptans and formulations presumably because of its short Tmax, high Cmax, and avoidance of enteral absorption." | 2.49 | A review of needle-free sumatriptan injection for rapid control of migraine. ( Farr, SJ; Freitag, FG; Rothrock, JF; Smith, EF, 2013) |
| "Nausea is a common symptom of migraine, and current treatment guidelines recommend non-oral formulations for nauseated or vomiting patients." | 2.49 | Sumatriptan iontophoretic transdermal system: history, study results, and use in clinical practice. ( Felker, E; O'Neill, C; Pierce, M; Sebree, T, 2013) |
| "Naproxen is a non-steroidal anti-inflammatory drug (NSAID); its efficacy in acute migraine has not been established by systematic reviews." | 2.49 | Naproxen with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; Law, S; Moore, RA, 2013) |
| "Migraine is a common disabling condition and a burden for the individual, health services, and society." | 2.49 | Sumatriptan plus naproxen for acute migraine attacks in adults. ( Derry, S; Law, S; Moore, RA, 2013) |
| "Migraine is number seven in WHO's list of all diseases causing disability and the third most costly neurological disorder in Europe." | 2.49 | Animal migraine models for drug development: status and future perspectives. ( Jansen-Olesen, I; Olesen, J; Tfelt-Hansen, P, 2013) |
| "Part 1 discusses the risks for Torsade de Pointes, vasospasm, and ischemia, with a review and discussion of case reports of triptan-associated cardiovascular events in migraineurs with and without CAD risk factors or documented CAD; of the epidemiology and studies of triptans, vasospasm, and cardiovascular morbidity; and of the relationship of variant angina, migraine, and vasospastic disease." | 2.49 | QT prolongation, Torsade de Pointes, myocardial ischemia from coronary vasospasm, and headache medications. Part 1: review of serotonergic cardiac adverse events with a triptan case. ( Cho, L; Stillman, MJ; Tepper, DE; Tepper, S, 2013) |
| "Sumatriptan was developed more than 20 years ago as a 5-HT1B/1D receptor agonist, the first drug in a new class of specific anti-migraine drugs, the triptans." | 2.49 | Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine. ( Hougaard, A; Tfelt-Hansen, P, 2013) |
| "Sumatriptan is a 5-HT-1B/D receptor agonist considered to activate receptors involved in the pathophysiology specific to migraine." | 2.48 | Pharmacological synergy: the next frontier on therapeutic advancement for migraine. ( Blumenfeld, A; Cady, R; Gennings, C, 2012) |
| "Oral sumatriptan has been shown to be an effective drug for the treatment of a single acute attack of migraine." | 2.48 | WITHDRAWN: Oral sumatriptan for acute migraine. ( Gray, RN; McCrory, DC, 2012) |
| "Sumatriptan is an abortive medication for migraine attacks, belonging to the triptan family." | 2.48 | Sumatriptan (oral route of administration) for acute migraine attacks in adults. ( Derry, CJ; Derry, S; Moore, RA, 2012) |
| "Diclofenac is an established analgesic, and new formulations using the potassium or epolamine salts, which can be dissolved in water, have been developed for rapid absorption, which may be beneficial in acute migraine." | 2.48 | Diclofenac with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; Moore, RA; Rabbie, R, 2012) |
| "Sumatriptan is an abortive medication for migraine attacks, belonging to the triptan family." | 2.48 | Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. ( Derry, CJ; Derry, S; Moore, RA, 2012) |
| "Sumatriptan is an abortive medication for migraine attacks, belonging to the triptan family." | 2.48 | Sumatriptan (rectal route of administration) for acute migraine attacks in adults. ( Derry, CJ; Derry, S; Moore, RA, 2012) |
| "Sumatriptan is an abortive medication for migraine attacks, belonging to the triptan family." | 2.48 | Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. ( Derry, CJ; Derry, S; Moore, RA, 2012) |
| "The features of migraine attacks and the contexts in which migraine attacks occur vary from attack to attack and from patient to patient." | 2.48 | Therapeutic applications for subcutaneous triptans in the acute treatment of migraine. ( Erlichson, K; Waight, J, 2012) |
| "The acute antimigraine efficacy of these remedies is very much dependent on the formulation used where, in general, parenteral formulations are more effective in reliving the symptoms of a migraine attack." | 2.48 | Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment. ( Dahlöf, C; Maassen Van Den Brink, A, 2012) |
| "Pure menstrual migraine (PMM) and menstrually related migraine (MRM) are difficult challenges in migraine management." | 2.48 | Treatment of perimenstrual migraine with triptans: an update. ( Candela, S; Casolla, B; D'Alonzo, L; Lionetto, L; Martelletti, P; Negro, A; Simmaco, M, 2012) |
| " Pharmacologically, pharmacokinetic parameters, in particular bioavailability, T(max) and C(max) are responsible for the wide efficacy of the compound and the limited adverse effect (AE) profile." | 2.48 | Sumatriptan succinate : pharmacokinetics of different formulations in clinical practice. ( Casolla, B; Lionetto, L; Martelletti, P; Negro, A; Simmaco, M, 2012) |
| "Sumatriptan 100 mg was the treatment with lowest estimated costs (€20." | 2.48 | Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison. ( Asseburg, C; Martikainen, J; Oksanen, T; Peura, P; Purmonen, T; Turunen, J, 2012) |
| "Migraine has a 1-year prevalence of 10% and high socioeconomic costs." | 2.47 | Emerging migraine treatments and drug targets. ( Ashina, M; Olesen, J, 2011) |
| "In patients whose migraine attacks have historically failed to respond to oral triptans, this route of administration has also proven to be more consistent and effective." | 2.47 | Sumatriptan needle-free subcutaneous (Sumavel(®) DosePro™) approved for the acute treatment of migraine, with or without aura, and cluster headaches. ( Freitag, FG, 2011) |
| "Menstrual migraine (MM) is a form of headache that tends to occur with prolonged, intense and extremely disabling attacks in a short period around the menstrual cycle (usually 2 days before to 3 days after the onset of the menstrual flow)." | 2.47 | Evaluation of the use of sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea. ( Allais, G; Benedetto, C; Castagnoli Gabellari, I; Rolando, S, 2011) |
| "Rizatriptan 10 mg has demonstrated, in a head-to-head study, higher response rates and a more rapid onset of action than sumatriptan 100 mg, together with a favorable tolerability profile." | 2.46 | Efficacy and tolerability of rizatriptan 10 mg compared with sumatriptan 100 mg: an evidence-based analysis. ( Göbel, H, 2010) |
| "Migraineurs often do not use acute migraine-specific medications." | 2.46 | Meeting acute migraine treatment needs through novel treatment formulations. ( Silberstein, SD, 2010) |
| " For oral formulations, these limitations include difficulty in taking an oral medication due to the nausea and vomiting that often accompany migraine, and inconsistent absorption, whereas nasal and subcutaneous formulations may be associated with low bioavailability and an undesirable rate of adverse events, respectively." | 2.46 | Transdermal delivery of sumatriptan for the treatment of acute migraine. ( Pierce, MW, 2010) |
| " In AT1, which was previously published in part, group differences in adverse events (AEs) were analyzed using the Fisher exact test, and response rates were compared using logistic regression." | 2.46 | Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: Results of a new analysis of data from five previously published studies. ( Campbell, JC; Hu, X; MacGregor, EA; Pawsey, SP, 2010) |
| "Many migraineurs awake early in the morning with their attack progressing and already associated with nausea and vomiting." | 2.46 | Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine. ( Freitag, F; Pearlman, SH; Rapoport, AM, 2010) |
| "Migraine is a common, disabling condition and a burden for the individual, health services and society." | 2.46 | Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; McQuay, HJ; Moore, RA, 2010) |
| "The history of recurrence in early sumatriptan randomised clinical trials is described." | 2.45 | What can be learned from the history of recurrence in migraine? A comment. ( Tfelt-Hansen, P, 2009) |
| " Safety was evaluated based on the frequency of reported adverse events, and treatment with eASA was associated with lower incidence of adverse events than was with sumatriptan." | 2.44 | Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. ( Diener, HC; Lampl, C; Voelker, M, 2007) |
| "Only sumatriptan nasal spray has been approved for the treatment of acute migraine with or without aura in adolescents aged 12-17 years in Europe." | 2.44 | Sumatriptan nasal spray in the acute treatment of migraine in adolescents and children. ( Brouwer, OF; Callenbach, PM; Gooskens, RH; Linssen, WH; Mulder, PG; Pels, LP; van der Zwan, JL, 2007) |
| " In an oral formulation, which is the patients' preferred dosing route, sumatriptan FDT/RRT may therefore constitute an advance in the management of acute migraine attacks." | 2.44 | Sumatriptan fast-disintegrating/rapid-release tablets in the acute treatment of migraine. ( Barbanti, P; Cruccu, G; Le Pera, D, 2007) |
| "The annual cost of migraine is euro27 billion in Europe, $US1." | 2.44 | Over-the-counter triptans for migraine : what are the implications? ( Steiner, TJ; Tfelt-Hansen, P, 2007) |
| "The clinical efficacy in migraine was compared for oral and subcutaneous sumatriptan and naratriptan." | 2.44 | Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment. ( Tfelt-Hansen, P, 2007) |
| "The prevalence of migraine is 8% in men and 12-15% in women." | 2.44 | [Current diagnosis and treatment of migraine]. ( Diener, HC; Katsarava, Z; Limmroth, V, 2008) |
| "Menstrually related migraine (MRM) headache is common in women and associated with substantial disability." | 2.44 | Acute treatment and prevention of menstrually related migraine headache: evidence-based review. ( Davenport, WJ; Dodick, D; Pringsheim, T, 2008) |
| "The paradigm of early treatment of the migraine attack at mild pain intensity has become one alternative to circumventing the problem of compromised oral absorption of symptomatic drugs due to migraine-induced gastrointestinal dysmotility." | 2.43 | Cutaneous allodynia and migraine: another view. ( Dahlöf, C, 2006) |
| "In the acute migraine attack, a single dose of either ibuprofen 10 mg/kg or paracetamol 15 mg/kg has been shown to be effective, with only a few adverse effects." | 2.43 | [Pharmacologic treatment of acute migraine attack in children]. ( Auvin, S; Cuvellier, JC; Joriot, S; Vallée, L, 2005) |
| "The direct and indirect costs of migraine headache have a tremendous economic impact in the US." | 2.43 | Oral serotonin receptor agonists: a review of their cost effectiveness in migraine. ( Lofland, JH; Nash, DB, 2005) |
| "The debilitating effect of migraine has fueled the search for more specific agents to treat its characteristic and associated symptoms." | 2.43 | Evaluating the triptans. ( Loder, EW; Mathew, NT, 2005) |
| "Rizatriptan was somewhat less costly and more effective than sumatriptan." | 2.43 | Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine. ( Hay, JW; Zhang, L, 2005) |
| "We found nine clinical guidelines on migraine; one guideline, not supported by references, was excluded." | 2.43 | Pharmacologic treatment of migraine. Comparison of guidelines. ( Schuurmans, A; van Weel, C, 2005) |
| "The management of pediatric migraine requires a balance of biobehavioral measures coupled with agents for acute treatment and, if needed, daily preventive medicines." | 2.43 | The treatment of pediatric migraine. ( Lewis, DW; Sowell, M; Winner, P; Yonker, M, 2005) |
| "Treatment of pediatric migraine includes an individually tailored regimen of both nonpharmacologic and pharmacologic measures." | 2.43 | Symptomatic treatment of migraine in children: a systematic review of medication trials. ( Berger, MY; Bruijn, JK; Damen, L; Koes, BW; Passchier, J; Verhagen, AP, 2005) |
| "Eletriptan 20 mg was superior to sumatriptan 50 mg and similar to sumatriptan 100 mg for pain relief while it was similar to sumatriptan 50 mg for pain free." | 2.43 | Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain--results of a model-based meta-analysis that accounts for encapsulation. ( Alderman, J; Cox, E; Mandema, JW, 2005) |
| "These structures could play the role of migraine attack generators, modulating intrinsic vascular tone and central pain transmission." | 2.43 | [Positron emission tomographic studies of migraine]. ( Chollet, F; Denuelle, M; Fabre, N; Géraud, G; Payoux, P, 2005) |
| "A patient with migraine needs acute treatment as early as possible when the attack occurs." | 2.43 | The treatment of acute migraine. ( Olesen, J, 2005) |
| "A similar pattern was observed for migraine-free results 2 hours postdose (50 mg, 42%; 100 mg, 47%; placebo, 20%; P < 0." | 2.43 | Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. ( Ames, M; Landy, S; Richardson, M; Winner, P, 2005) |
| "It can be concluded that migraine patients who respond infrequently to sumatriptan should be switched to a different triptan, as lack of response to one triptan does not predict likelihood of responsiveness to another." | 2.43 | Infrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials. ( Dahlöf, CG, 2006) |
| "The pathophysiology of migraine is complex and involves multiple neurophysiological pathways." | 2.43 | Polytherapy in the preventive and acute treatment of migraine: fundamentals for changing the approach. ( Bigal, ME; Krymchantowski, AV, 2006) |
| "Until recently, primary headache disorders, such as migraine and cluster headache were considered to be vascular in origin." | 2.43 | Functional neuroimaging of primary headache disorders. ( Cohen, AS; Goadsby, PJ, 2006) |
| "Headache associated with the chronic use of medications has become a significant problem in the management of headache." | 2.43 | [Medication-overuse headache]. ( Katsarava, Z; Rabe, K, 2006) |
| "The selection of an acute antimigraine drug also depends upon the stratification of the patient's migraine attack by peak intensity, time to peak intensity, level of associated symptoms such as nausea and vomiting, time to associated symptoms, comorbid diseases and concomitant treatments that might cause drug-drug interactions." | 2.42 | The triptan formulations : how to match patients and products. ( Bigal, ME; Rapoport, AM; Sheftell, FD; Tepper, SJ, 2003) |
| "Oral sumatriptan has been shown to be an effective drug for the treatment of a single acute attack of migraine." | 2.42 | Oral sumatriptan for acute migraine. ( Gray, RN; McCrory, DC, 2003) |
| "Sumatriptan was then launched as an oral tablet, shortly followed by the development of second-generation triptans that are now available in several formulations." | 2.42 | Clinical applications of new therapeutic deliveries in migraine. ( Dahlöf, C, 2003) |
| "Naratriptan is an effective and well-tolerated treatment for acute attacks of migraine." | 2.42 | Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials. ( Ashcroft, DM; Millson, D, 2004) |
| "Although the migraine clinical trials literature is enormous, we identified only nine published double-blind studies which compare an oral triptan with a non-triptan acute treatment." | 2.42 | Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a review. ( Bigal, ME; Goadsby, PJ; Lipton, RB, 2004) |
| "Here we discuss the management of migraine in childhood." | 2.42 | Managing migraine in children. ( , 2004) |
| "Migraine is a very common disorder." | 2.42 | [Pitfall in migraine treatment]. ( Araki, N, 2003) |
| " Potential explanations for differences among triptans in the incidence of CNS side-effects may relate to pharmacological and pharmacokinetic differences, including receptor binding, lipophilicity, and the presence of active metabolites." | 2.42 | Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. ( Dodick, DW; Martin, V, 2004) |
| " Also, some nasal preparations have significant adverse effects or are not well absorbed and therefore do not work consistently; others are more challenging to administer as a result of their delivery apparatus." | 2.42 | Intranasal medications for the treatment of migraine and cluster headache. ( Bigal, ME; Rapoport, AM; Sheftell, FD; Tepper, SJ, 2004) |
| "Frovatriptan has no clinically significant pharmacokinetic interactions with drugs used for migraine prophylaxis or with commonly prescribed medications." | 2.42 | Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine. ( Balbisi, EA, 2004) |
| " Compared to sumatriptan, the second-generation triptans have a higher oral bioavailability and longer plasma half-life." | 2.42 | Migraine: pathophysiology, pharmacology, treatment and future trends. ( Centurión, D; de Vries, P; Saxena, PR; Valdivia, LF; Villalón, CM, 2003) |
| "The treatment of migraine takes into consideration the intensity of the headache and the accompanying symptoms." | 2.42 | [Treatment and prophylaxis of an acute migraine attack]. ( Diener, HC; Gendolla, A, 2004) |
| "Symptomatic therapy of migraine now includes three main classes of drugs: ergot alkaloids, nonsteroidal antiinflammatory drugs (NSAIDs) and triptans." | 2.42 | Acute drug treatment of migraine attack. ( Abbate, M; Gangemi, S; Narbone, MC, 2004) |
| "The so-called menstrual migraine, which occurs immediately before, during or at the end of the menstrual flow, has been a largely undefined condition, including some clinical subtypes which are not well defined." | 2.42 | Update on menstrual migraine: from clinical aspects to therapeutical strategies. ( Allais, G; Benedetto, C, 2004) |
| "Dissatisfaction with migraine therapy on the basis of these factors is common." | 2.42 | Diagnosis and management of migraine headaches. ( Lawrence, EC, 2004) |
| "For many of the patients with migraine, triptan provides complete pain relief in some attacks but not in others." | 2.42 | [Mechanism based prevention and treatment of migraine]. ( Sakai, F, 2004) |
| "Sumatriptan (Imitrex) has been available for the longest time within the class, is most flexible in form and has been given successfully to the most number of patients." | 2.42 | Sumatriptan: a decade of use and experience in the treatment of migraine. ( Bigal, ME; Rapoport, AM; Sheftell, FD; Tepper, SJ, 2004) |
| "Migraine is a common disorder with a prevalence of 9-10% in Hungary." | 2.41 | [Treatment of migraine in patients with hypertension and ischemic heart disease]. ( Csiba, L; Ficzere, A, 2002) |
| "Sumatriptan is a potent serotonin 5HT(1B/1D) agonist widely used in the treatment of migraine; the effectiveness of the intranasal formulation (20mg) has been well established in several clinical studies." | 2.41 | Clinical pharmacokinetics of intranasal sumatriptan. ( Barrow, A; Fuseau, E; Ibbotson, T; Moore, KH; Petricoul, O, 2002) |
| " Compared to sumatriptan, the second-generation triptans have a higher oral bioavailability and longer plasma half-life." | 2.41 | An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. ( Centurión, D; De Vries, P; Saxena, PR; Valdivia, LF; Villalón, CM, 2002) |
| "Zolmitriptan is a potent 5-HT(1B/1D) agonist whose targets include the peripheral and central components of the trigeminovascular system." | 2.41 | Zolmitriptan: differences from sumatriptan. ( Boes, CJ; Goadsby, PJ, 2001) |
| "Rizatriptan 10 mg was generally superior to sumatriptan on a measure of time-to-pain-relief within 2 h, where pain relief was defined as a reduction of pain to mild or none (odds ratio for rizatriptan versus sumatriptan 100 mg = 1." | 2.41 | Rizatriptan: pharmacological differences from sumatriptan and clinical results. ( Lines, CR; McCarroll, KA; Visser, WH, 2001) |
| "The potential advantages of eletriptan lie firstly in its lipophilicity reflected as an increased rate of absorption and Tmax compared to sumatriptan." | 2.41 | Eletriptan: pharmacological differences and clinical results. ( Giffin, N, 2001) |
| "With sumatriptan, this finding has proven to be a consequence of the form in which the drug was administered rather than the inherent properties of the drug." | 2.41 | Sumatriptan nasal spray for migraine: a review of studies in patients aged 17 years and younger. ( Hämäläinen, M; Jones, M; Loftus, J; Saiers, J, 2002) |
| "The acute treatment and prophylaxis of migraine headache are discussed in this article." | 2.41 | [The problems of migraine headache treatment]. ( Vaitkus, A; Vilionskis, A, 2002) |
| "Two new intranasal migraine medications, sumatriptan and dihydroergotamine mesylate, may offer specific advantages for patients who are seeking alternatives to various oral or parenteral migraine abortive therapies." | 2.41 | Newer intranasal migraine medications. ( Logemann, CD; Rankin, LM, 2000) |
| "Triptans, 5-HT1B/1D agonists used in migraine treatment, are rarely involved in serious coronary events due to vasospasm." | 2.41 | [Cardiovascular side-effects of triptanes in migraine exist but are rare. 5-HT receptor mediated extracranial vasoconstriction is the most common cause]. ( Hedenmalm, K, 2000) |
| " As additional triptans and new dosage formulations are developed and approved, it is anticipated that the treatment of migraine headaches in children may change significantly in the next several years." | 2.41 | Childhood migraine. ( Turk, WR, 2000) |
| "Migraine headaches are a common medical problem that physicians frequently encounter in their practice." | 2.41 | Treatment of acute migraine attacks. ( Weintraub, JR, 2000) |
| "In the past ten years, migraine has really entered the field of science, with a number of major advances Despite theses advances, a lot has still to be done to understand what migraine really is and to improve the management of migraine sufferers." | 2.41 | [Migraine, ten years of progress]. ( Bousser, MG, 2000) |
| "Sumatriptan has a low oral bioavailability (14%) and all the newer triptans have an improved oral bioavailability and for one, risatriptan, the rate of absorption is faster." | 2.41 | Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. ( De Vries, P; Saxena, PR; Tfelt-Hansen, P, 2000) |
| "The work on migraine can also have implications for the increasing number of additional neurological episodic disorders having the common denominator of channelopathy." | 2.41 | The impact of pharmacogenetics for migraine. ( Ferrari, MD; Frants, RR; Ophoff, RA; Roon, KI; van den Maagdenberg, AM, 2001) |
| "All papers on cluster headaches were reviewed according to preset criteria under the following headings: classification, epidemiology, aetiology, pathophysiology, and clinical features." | 2.41 | Cluster headache: review of the literature. ( Zakrzewska, JM, 2001) |
| "Effective antimigraine agents such as ergots, triptans, opioids, and valproate inhibit preclinical neurogenic dural extravasation, suggesting that this activity may be a predictor of potential clinical efficacy of novel agents." | 2.41 | Neurogenic inflammation in the context of migraine. ( Hargreaves, RJ; Williamson, DJ, 2001) |
| "Complicated migraine and migraine variants are relatively uncommon forms of migraine." | 2.41 | Complicated migraine and migraine variants. ( Rothner, AD, 2001) |
| "The firsttopic, "Overview of Migraine: Compelling Effects on Patients and Society," was presented for Dedie Downey Russell, CNP, ANP/GNP, MS." | 2.41 | Managing migraine: strategies for successful patient outcomes. ( Jamieson, DG; Moriarty-Sheehan, M; Russell, DD, 2001) |
| "Its clinical efficacy on migraine and cluster headache had been already confirmed in about 100 western countries." | 2.41 | [Anti-migraine drug sumatriptan succinate, a 5-HT1B/1D-receptor agonist]. ( Danjo, T; Iwasawa, Y, 2001) |
| "Sumatriptan has been used effectively to treat adult patients with migraine headaches, but its efficacy in children has not been established." | 2.41 | Efficacy of sumatriptan in the treatment of migraine: a review of the literature. ( McAlhany, A, 2001) |
| "Oral rizatriptan 10 mg was more effective than oral sumatriptan, naratriptan, and zolmitriptan on stringent outcome measures of pain-free response at 2 hours, symptom-free response at 2 hours, and 24-hour sustained pain-free response." | 2.41 | Comparison of rizatriptan and other triptans on stringent measures of efficacy. ( Adelman, JU; Diener, HC; Ferrari, MD; Lines, CR; Lipton, RB; McCarroll, KA; Vandormael, K, 2001) |
| "Rizatriptan is a potent, selective 5-HT1B/1D receptor agonist shown to be fast, effective and well tolerated in the acute treatment of migraine." | 2.41 | Patient satisfaction with rizatriptan versus other triptans: direct head-to-head comparisons. ( Gerth, WC; Mannix, LK; McCarroll, KA; Santanello, NC; Vandormael, K; Zhang, Q, 2001) |
| "There exist increasing options for migraine treatment that may further improve the clinical effects of the older and newer triptans through early treatment of migraine at the stages of mild migraine pain, or even during the prodromal phase of the attack." | 2.41 | Acute treatment of migraine and the role of triptans. ( Freitag, FG, 2001) |
| "Migraine is a recurrent clinical syndrome characterised by combinations of neurological, gastrointestinal and autonomic manifestations." | 2.41 | Practical approaches to migraine management. ( Diamond, S; Wenzel, R, 2002) |
| "Most patients with migraine consider drugs that can be administered orally to be the most user-friendly." | 2.41 | Integrating the triptans into clinical practice. ( Dahlöf, C, 2002) |
| "Recurrence of migraine, long-term usage, and side effects of serotonin1D agonists are included in the review." | 2.40 | Serotonin 1D (5-HT1D) agonists and other agents in acute migraine. ( Mathew, NT, 1997) |
| "Although headache is among the most common pain complaints seen by physicians, the measurement of health-related quality of life (HRQoL) in headache patients is in its earliest stages." | 2.40 | Evolution of the measurement of quality of life in migraine. ( Solomon, GD, 1997) |
| " A higher lipophilicity explains (except for alniditan) their greater oral bioavailability and better central nervous system penetration." | 2.40 | Acute migraine therapy: the newer drugs. ( Schoenen, J, 1997) |
| "Headaches are a common entity in the ambulatory population." | 2.40 | Diagnosis, prophylaxis, and treatment of headaches in the athlete. ( Kaplan, B; Swain, RA, 1997) |
| "Several generic and migraine-specific questionnaires have been evaluated for reliability and validity in migraine." | 2.40 | Quality of life in migraine. ( Mannix, LK; Solomon, GD, 1998) |
| "Sumatriptan is a selective agonist at serotonin 5-HT1-like receptors, including 5-HT1B/1D subtypes." | 2.40 | Sumatriptan. An updated review of its use in migraine. ( Markham, A; Perry, CM, 1998) |
| "With an onset of headache relief as early as 15 min postdose compared with placebo, sumatriptan nasal spray is an important treatment option for patients who seek rapid headache relief and/or a convenient dosing form, whose migraine-associated nausea and vomiting render the use of an oral medication impractical, and those who prefer not to use an injectable form of migraine medication." | 2.40 | Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types. ( Ashford, E; Saiers, J; Salonen, R; Woessner, M, 1998) |
| "To evaluate the efficacy, speed of onset, and adverse events of 6 mg subcutaneous, 100 mg oral, and 20 mg intranasal sumatriptan in the treatment of migraine attacks." | 2.40 | Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. ( Tfelt-Hansen, P, 1998) |
| "About a third of migraine patients in Sweden seem to be particularly sorely afflicted having 1-6 severe attacks a month and accounting for more than 80 per cent of the annual total of about 14 million attacks in the country as a whole." | 2.40 | [New triptan preparations can help the migraine patient. Pharmacodynamic and pharmacokinetic progresses]. ( Dahlöf, CG, 1998) |
| "Zolmitriptan (previously known as 311C90) is a serotoninergic 5-HT1B/D agonist with high oral bioavailability with a double, central and peripheral, action mechanism." | 2.40 | [Clinical efficacy of zolmitriptan in migraine]. ( Leira, R; Noya, M, 1998) |
| "Menstrual migraine may be debilitating, long-lasting, and refractory to treatment." | 2.40 | Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses. ( Saiers, J; Salonen, R, 1999) |
| "Sumatriptan is an effective and well tolerated agent in the treatment of migraine." | 2.40 | Sumatriptan. A pharmacoeconomic review of its use in migraine. ( Coukell, AJ; Lamb, HM, 1997) |
| "We believe that the use of these migraine models will provide even better treatment for migraine patients in the next millennium." | 2.40 | Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. ( De Vries, P; Saxena, PR; Villalón, CM, 1999) |
| "Sumatriptan was the first specific serotonin-1B/D agonist for the treatment of acute migraine attacks." | 2.40 | Acute management of migraine: triptans and beyond. ( Diener, HC; Limmroth, V, 1999) |
| "Rizatriptan is an orally active serotonin 5-HT1 receptor agonist selective for the 5-HT(1B/1D) subtypes." | 2.40 | Rizatriptan: a review of its efficacy in the management of migraine. ( Dooley, M; Faulds, D, 1999) |
| "At this stage in the migraine process, activation of specific subtypes of 5-HT1 receptors has proven clinically effective in relieving migraine pain." | 2.40 | The biology of serotonin receptors: focus on migraine pathophysiology and treatment. ( Hamel, E, 1999) |
| "Thus sumatriptan has become the de facto gold standard and will be thus employed here." | 2.40 | The scientific basis of medication choice in symptomatic migraine treatment. ( Goadsby, PJ, 1999) |
| "Sumatriptan nasal spray is a single-dose device that delivers 5 mg, 10 mg, or 20 mg of sumatriptan (dosage availability dependent upon country) in a 0." | 2.40 | Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies. ( Dahlöf, C, 1999) |
| "Oral sumatriptan, which is a well tolerated, effective acute treatment for migraine, and is selectively available in different countries in 100 mg, 50 mg, and 25 mg tablets." | 2.40 | Defining optimal dosing for sumatriptan tablets in the acute treatment of migraine. ( Mathew, NT; Salonen, R, 1999) |
| "We recently discovered the anti-migraine prophylactic action of centrally acting anti-cholinesterase agents, that seems a further support to the central theory of migraine." | 2.40 | Triptans. A support to the central link between serotonin and acetylcholine in migraine. ( Nicolodi, M; Sicuteri, F, 1999) |
| " Zolmitriptan introduced in 1994 is an agonists of 5-HT 1B/1D receptor, is active both peripherally and centrally, is well absorbed from the digestive tract and has a good bioavailability index /40%/." | 2.40 | [Emergency treatment of migraine attacks with particular reference to agonists of 5-HT1B/1D receptor]. ( Prusiński, A, 1999) |
| "Sumatriptan is a potent and selective agonist at a vascular serotonin1 (5-hydroxytryptamine1; 5-HT1) receptor subtype (similar to 5-HT1D) and is used in acute treatment of migraine and cluster headache." | 2.39 | Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. ( McTavish, D; Plosker, GL, 1994) |
| "Sumatriptan is a potent and selective serotonin1D receptor agonist, which can be administered orally and via the subcutaneous or intranasal route." | 2.39 | Acute treatment of migraine attacks. ( Ferrari, MD; Haan, J, 1995) |
| "Sumatriptan is a potent vasoconstrictor of intracranial arteries." | 2.39 | The mode of action of sumatriptan is vascular? A debate. ( Goadsby, PJ; Humphrey, PP, 1994) |
| "Sumatriptan was an effective treatment for migraine with and without aura and when used at any time during the attack." | 2.39 | The clinical profile of sumatriptan: efficacy in migraine. ( Pilgrim, AJ, 1994) |
| " The majority of adverse events (defined as any medical event irrespective of possible causal relationship to treatment) were mild to moderate in intensity, transient and resolved spontaneously." | 2.39 | The clinical profile of sumatriptan: safety and tolerability. ( Lloyd, K, 1994) |
| "Sumatriptan is a novel serotonin 1 (5-hydroxytryptamine 1; 5-HT1)-like agonist which has been shown to be effective in the treatment of acute migraine." | 2.39 | Sumatriptan clinical pharmacokinetics. ( Scott, AK, 1994) |
| "The medical treatment of migraine has two objective points: therapy for treating symptoms of an acute attack and prophylactic therapy for reducing frequency and severity of migraine attacks." | 2.39 | [Drug therapy of migraine--a review of the literature]. ( Marterer, A; Wessely, P, 1995) |
| "Sumatriptan is a very effective agent that has joined the ranks of other effective abortive migraine treatments, such as ergotamine, dihydroergotamine, and nonsteroidal anti-inflammatory agents, as well as narcotic analgesics." | 2.39 | Migraine: a pharmacologic review with newer options and delivery modalities. ( Baumel, B, 1994) |
| "In treating migraine the first and most important thing is to get the correct diagnosis which depends on the history and the absence of abnormal physical signs." | 2.39 | Migraine treatment: the British perspective. ( Wilkinson, M, 1994) |
| "Optimal migraine therapy begins with an accurate diagnosis and knowledge of the symptoms that the patient finds most disturbing." | 2.39 | Overview of diagnosis and treatment of migraine. ( Lipton, RB; Silberstein, SD, 1994) |
| "The original migraine therapy, ergotamine, is highly effective in its rectal suppository formulation, when used at a subnauseating dosage." | 2.39 | Headache. ( Raskin, NH, 1994) |
| "About every second (53%) migraineur using subcutaneous sumatriptan reports headache recurrence." | 2.39 | Clinical experiences from Sweden on the use of subcutaneously administered sumatriptan in migraine and cluster headache. ( Dahlöf, C; Ekbom, K; Persson, L, 1994) |
| "The prevalence of migraine (12% in the western industrial countries) and its genetic causes are now undoubted." | 2.39 | [Migraine--summary of diagnostic and therapeutic strategies]. ( Bauchinger, B; Klingler, D, 1994) |
| "Sumatriptan is a potent and selective agonist at the vascular 5HT1 receptor which mediates constriction of certain large cranial blood vessels and/or inhibits the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater following activation of the trigeminovascular system." | 2.39 | Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience. ( Diener, HC; Pfaffenrath, V; Schoenen, J; Steiner, TJ; Wilkinson, M, 1995) |
| "Women with migraine often experience a worsening of symptoms at menopause." | 2.39 | Approach to the patient with migraine. ( Baringer, JR; Raskin, NH, 1996) |
| "Sumatriptan has both vascular and neurogenic effects, both of which may be necessary for a good clinical outcome." | 2.39 | [Drug treatment of migraine attacks. Pharmacological considerations]. ( Salvesen, R, 1996) |
| "When attacks are a frequent occurrence, migraine prophylaxis should first be initiated." | 2.38 | [Treatment of migraine attacks with sumatriptan]. ( Pfaffenrath, V, 1993) |
| "Successful treatment of migraine requires that the physician understand the pathophysiology underlying migraine and educate the migraineur in the management of this chronic pain syndrome." | 2.38 | Recent advances in migraine management. ( Cady, RK; Shealy, CN, 1993) |
| "Sumatriptan is a selective 5-HT1-like agonist, which is effective in the treatment of migraine and cluster headache." | 2.38 | Sumatriptan in the acute treatment of migraine. ( Lloyd, K; Pilgrim, AJ; Tansey, MJ, 1993) |
| "Sumatriptan is a new serotonin receptor agonist that is useful in the treatment of migraine headache." | 2.38 | Sumatriptan: a new serotonin agonist for the treatment of migraine headache. ( Susman, JL, 1993) |
| " New medications, such as sumatriptan, and new dosage forms of older medications, including dihydroergotamine, NSAIDs, and phenothiazines are available to treat acute attacks." | 2.38 | Therapeutic advances in migraine. ( Solomon, GD, 1993) |
| "This paper reviews the therapeutics of migraine in the context of the clinical problem and its prevalence." | 2.38 | The therapeutics of migraine. ( Welch, KM, 1993) |
| "The antimigraine efficacy of many drugs may be mediated less through their primary modes of action than through the common pathway of serotonergic transmission stabilization." | 2.38 | Acute and prophylactic treatment of migraine: practical approaches and pharmacologic rationale. ( Raskin, NH, 1993) |
| "Treatment with sumatriptan has been well tolerated with only minor, transient, acute side effects reported." | 2.38 | Sumatriptan in the treatment of migraine. ( Ferrari, MD, 1993) |
| "Oral sumatriptan was superior to Cafergot (2 mg ergotamine plus 200 mg caffeine) and somewhat better than aspirin (900 mg) plus metoclopramide (10 mg)." | 2.38 | Sumatriptan for the treatment of migraine attacks--a review of controlled clinical trials. ( Tfelt-Hansen, P, 1993) |
| "Sumatriptan is a serotonin agonist that has been studied for the acute treatment of migraine and cluster headache." | 2.38 | Sumatriptan: a selective 5-hydroxytryptamine receptor agonist for the acute treatment of migraine. ( Fullerton, T; Gengo, FM, 1992) |
| "That the 'primary' phenomenon in migraine with aura is neuronal ('spreading depression') seems increasingly probable, but the relationship of migraine with and without aura and of both to tension headache remains uncertain." | 2.38 | Headache and migraine. ( Ziegler, DK, 1992) |
| "Sumatriptan is a novel, highly effective drug against migraine and cluster headache attacks." | 2.38 | Clinical effects and mechanism of action of sumatriptan in migraine. ( Ferrari, MD; Saxena, PR, 1992) |
| "When considering treatment for migraine patient, the physician should bear in mind how little is known about this remarkably complex and diverse condition with no miracle cure or single uniform method of treatment." | 2.38 | [Management of migraine]. ( Bousser, MG; Massiou, H, 1992) |
| "Sumatriptan has a rapid onset of action and a large volume of distribution." | 2.38 | Sumatriptan: a new drug for vascular headache. ( Hsu, VD, 1992) |
| "Sumatriptan is an agonist of 5-HT1 -like receptors and exerts a selective vasoconstricting effect on the arteries of the head, particularly in the rami of the carotid artery." | 2.38 | [Sumatriptan and its use in treatment of migraine and cluster headaches]. ( Prusiński, A, 1992) |
| "Sumatriptan is a highly selective 5 HT1 receptor subtype agonist." | 2.38 | [Sumatriptan--future development, alternative features and potential new indications]. ( Arnold, WS, 1992) |
| "Sumatriptan is a serotonin1 (5-HT1) receptor agonist, which is effective in the acute treatment of migraine headache." | 2.38 | Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. ( Clissold, SP; Dechant, KL, 1992) |
| "The antimigraine drugs sumatriptan and dihydroergotamine block the development of plasma extravasation and ultrastructural changes, as well as plasma calcitonin gene-related peptide (CGRP) increase in the superior sagittal sinus following electrical trigeminal ganglion stimulation." | 2.38 | The trigemino-vascular system and migraine. ( Buzzi, MG; Moskowitz, MA, 1992) |
| "It is proposed that the migraine attack is explicable by an interaction between the brain and the cranial circulation in subjects with unstable vascular and pain-control mechanisms." | 2.38 | The pathophysiology of migraine: a tentative synthesis. ( Lance, JW, 1992) |
| "Sumatriptan is a highly selective 5-HT1-like receptor agonist which selectively constricts cranial blood vessels (including those in the dura mater)." | 2.38 | Rationale for the use of 5-HT1-like agonists in the treatment of migraine. ( Connor, HE; Feniuk, W; Humphrey, PP; Perren, MJ; Whalley, ET, 1991) |
| "The drugs used in migraine therapy can be divided into two groups: agents that abort an established migraine attack and agents used prophylactically to reduce the number of migraine attacks." | 2.38 | Pharmacology of antimigraine drugs. ( Den Boer, MO; Saxena, PR, 1991) |
| " No findings of toxicological significance were observed in rats and dogs after chronic dosing for 1 year or more." | 2.38 | Preclinical studies on the anti-migraine drug, sumatriptan. ( Feniuk, W; Humphrey, PP; Jackson, MR; Marriott, AS; Tanner, RJ; Tucker, ML, 1991) |
| "Although migraine is one of the most common chronic diseases and is the subject of numerous studies, there is still a considerable proportion of patients who are not satisfied with their acute treatment." | 1.91 | [Integrating new migraine treatments into clinical practice (part 1) : management of acute migraine attack]. ( Fumal, A; Timmermans, G, 2023) |
| "Sumatriptan acts as a synergist of the NTG vasodilating action." | 1.91 | Duality in response of intracranial vessels to nitroglycerin revealed in rats by imaging photoplethysmography. ( Iurkova, PM; Kamshilin, AA; Nippolainen, E; Potapenko, AV; Sokolov, AY; Volynsky, MA; Zaytsev, VV, 2023) |
| "Migraine is a common, polygenic disorder that is characterized by moderate to severe headache attacks." | 1.91 | Multi-omic analyses of triptan-treated migraine attacks gives insight into molecular mechanisms. ( Cohen, AS; Demharter, S; Ernst, M; Falkenberg, K; Hansen, TF; Kogelman, LJA; Olesen, J; Ottosson, F; Russo, F; Stentoft-Hansen, V; Tfelt-Hansen, P, 2023) |
| " In vivo pharmacokinetic study demonstrated improved brain bioavailability of SUT-NEsG as compared to orally administered sumatriptan solution (SUT-SL)." | 1.91 | Quality by design for sumatriptan loaded nano-ethosomal mucoadhesive gel for the therapeutic management of nitroglycerin induced migraine. ( Alharbi, HM; Almari, AH; Batool, S; Din, FU; Fatease, AA; Lahiq, AA; Shafique, U; Sohail, S, 2023) |
| "Medication overuse headache was modeled by repeated sumatriptan administration in male and female mice." | 1.72 | A prolactin-dependent sexually dimorphic mechanism of migraine chronification. ( Dodick, DW; Ikegami, D; Khanna, R; Kopruszinski, CM; Moutal, A; Navratilova, E; Patwardhan, A; Porreca, F; Yue, X, 2022) |
| "Sumatriptan was the most prescribed triptan (261,736/1,038,472, 25." | 1.72 | Triptan medication use among patients with migraine with contraindications in the US. ( Dhamoon, MS; Pace, A; Pero, A, 2022) |
| "Current migraine therapy was triptans, however, riptans can cause contraction of blood vessels." | 1.62 | Design, synthesis and biological evaluation of pyridinylmethylenepiperidine derivatives as potent 5-HT ( Chen, K; Deng, K; Jin, C; Wang, T; Wang, Z; Xue, Y; Yi, C; Zhong, W, 2021) |
| "Pretreatment with propranolol or nor-BNI prior to restraint stress prevented both transient cutaneous allodynia and priming, demonstrated by a lack of umbellulone-induced cutaneous allodynia." | 1.62 | A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain. ( Chessell, IP; Dodick, DW; Kopruszinski, CM; Navratilova, E; Porreca, F; Swiokla, J, 2021) |
| "Existent animal models of migraine are not without drawbacks and limitations." | 1.62 | Advantages of imaging photoplethysmography for migraine modeling: new optical markers of trigemino-vascular activation in rats. ( Kamshilin, AA; Osipchuk, AV; Sokolov, AY; Volynsky, MA; Zaytsev, VV, 2021) |
| "Twenty-seven migraine patients were assessed during a spontaneous migraine attack, including headache characteristics and treatment effect." | 1.62 | Changes in the gene expression profile during spontaneous migraine attacks. ( Buil, A; Courraud, J; Erola, P; Falkenberg, K; Hansen, TF; Kogelman, LJA; Laursen, SS; Michoel, T; Olesen, J, 2021) |
| "Headache disorders are highly prevalent and debilitating, with limited treatment options." | 1.56 | Low-dose interleukin-2 reverses behavioral sensitization in multiple mouse models of headache disorders. ( Cao, YQ; Cloud, ME; Czerpaniak, K; Hotchkiss, RS; Huang, L; Li, D; Liu, X; Unsinger, J; Zhang, J, 2020) |
| "This suggests the presence of a migraine-like state, because nitric oxide donors are reliable triggers of attacks in migraine patients but not controls." | 1.56 | Repetitive stress in mice causes migraine-like behaviors and calcitonin gene-related peptide-dependent hyperalgesic priming to a migraine trigger. ( Akopian, AN; Avona, A; Burgos-Vega, C; Dussor, G; Garcia-Martinez, LF; Lackovic, J; Mason, BN; Moldovan Loomis, C; Motina, M; Price, TJ; Quigley, L; Wajahat, N, 2020) |
| "All patients were diagnosed as migraine by headache specialists and were treated with triptans, which resulted in satisfactory pain relief." | 1.51 | Orofacial Pain and Menstrually Related Migraine. ( Hatori, K; Hsu, YC; Imamura, Y; Nishihara, C; Noma, N; Ozasa, K; Young, A, 2019) |
| "Morphine was more detrimental than sumatriptan, consistent with clinical observations of higher medication overuse headache risk with opioids." | 1.51 | Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache. ( Dodick, DW; Nation, KM; Navratilova, E; Porreca, F, 2019) |
| "Health outcomes included migraine frequency and duration as well as adverse events (AEs) discussed by the TGA committee." | 1.51 | Cost-Effectiveness of Reclassifying Triptans in Australia: Application of an Economic Evaluation Approach to Regulatory Decisions. ( Cutler, H; Gauld, N; Gumbie, M; Haywood, P; Mumford, V; Parkinson, B, 2019) |
| "Migraine is a debilitating condition; however, the pharmacological effects on central nervous system networks after successful therapy are poorly understood." | 1.51 | Modulation of brain networks by sumatriptan-naproxen in the inflammatory soup migraine model. ( Barmettler, G; Becerra, L; Bishop, J; Borsook, D; Burstein, R; Chang, PC; Kainz, V, 2019) |
| "Sumatriptan, an acute migraine treatment blocked acute blood flow changes in response to TRPA1 or transient receptor potential vanilloid receptor-1 agonists." | 1.48 | Induction of chronic migraine phenotypes in a rat model after environmental irritant exposure. ( Hurley, JH; Johnson, PL; Kunkler, PE; Oxford, GS; Zhang, L, 2018) |
| "10, p < 0." | 1.48 | Use and overuse of triptans in Austria - a survey based on nationwide healthcare claims data. ( Gall, W; Wöber, C; Zebenholzer, K, 2018) |
| "Eligible respondents had ICHD-3-beta migraine, reported ≥3 monthly headache days (MHDs) in the past 3 months, ≥1 MHD in the past 30 days, and currently took acute headache medication." | 1.48 | Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. ( Alam, A; Buse, DC; Dodick, DW; Fanning, KM; Lipton, RB; Munjal, S; Reed, ML; Schwedt, TJ, 2018) |
| "Curcumin has antioxidative properties that could be useful in various diseases due to its ability to act on multiple targets of various cellular pathways." | 1.48 | The effect of intravenous administration of liposomal curcumin in addition to sumatriptan treatment in an experimental migraine model in rats. ( Bolboacă, SD; Bulboacă, AC; Bulboacă, AE; Porfire, A; Sfrângeu, CA; Stănescu, IC; Tefas, L, 2018) |
| "Numerous publications have reported on migraines misdiagnosed as endodontic pathologies." | 1.48 | Midface migraine with concomitant dental disease: A report of two cases. ( Hayashi, M; Imamura, Y; Noma, N; Watanabe, K; Yan, Z; Young, A, 2018) |
| " As of 2018, the FDA Adverse Event Reporting System public dashboard lists a total of 2889 reports of safety problems with the patch, 904 of which were classified as serious." | 1.48 | Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process. ( Burch, RC; Loder, EW; Rayhill, M, 2018) |
| "41." | 1.46 | Clinical characteristics and overuse patterns of medication overuse headache: Retrospective case-series study. ( Kluonaitis, K; Petrauskiene, E; Ryliskiene, K, 2017) |
| "The complex pathophysiology of migraine is not yet clearly understood; therefore, experimental models are essential for the investigation of the processes related to migraine headache, which include cortical spreading depression (CSD) and NO donor-induced neurovascular changes." | 1.46 | Nitroglycerin enhances the propagation of cortical spreading depression: comparative studies with sumatriptan and novel kynurenic acid analogues. ( Knapp, L; Kocsis, K; Szita, B; Toldi, J; Vécsei, L, 2017) |
| "Sumatriptan has been used for the acute treatment of migraine attacks." | 1.46 | Sumatriptan, an Antimigraine Drug, Inhibits Pentylenetetrazol-induced Seizures in NMRI Mice. ( Jand, A; Palizvan, MR, 2017) |
| "The development of new anti-migraine treatments is limited by the difficulty inassessing migraine pain in laboratory animals." | 1.46 | Depression of home cage wheel running: a reliable and clinically relevant method to assess migraine pain in rats. ( Kandasamy, R; Lee, AT; Morgan, MM, 2017) |
| "Sumatriptan uptake was not affected by the Met420del polymorphism, but was strongly reduced by Arg61Cys and Gly401Ser, and completely abolished by Gly465Arg and Cys88Arg." | 1.43 | OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. ( Abu Abed, M; Brockmöller, J; Dos Santos Pereira, JN; Faltraco, F; Knoch, T; Kuron, D; Matthaei, J; Prukop, T; Tzvetkov, MV, 2016) |
| "Background The development of novel migraine therapies has been slow, in part because of the small number of clinically relevant animal models." | 1.43 | The effects of acute and preventive migraine therapies in a mouse model of chronic migraine. ( Charles, A; McGuire, B; Pradhan, AA; Tarash, I; Tipton, AF, 2016) |
| "However, patients who experience migraine-associated nausea and/or vomiting can have difficulty swallowing tablets and may delay taking anti-migraine medication." | 1.43 | Sumatriptan iontophoretic transdermal system for acute treatment of episodic migraine. ( Chaudhry, H; Cohen, SP, 2016) |
| "A 17-year old male migraineur developed a sudden episode of unconsciousness after receiving a single dose of intranasal sumatriptan for the treatment of prolonged migraine-associated symptoms." | 1.43 | Critical neural targets for (the level of) human consciousness: Arousal arrest and unconsciousness after sumatriptan administration. ( Brander, A; Heikkilä, HT; Herrala, L; Långsjö, JW; Lehtimäki, K; Ruohonen, J; Saarinen, K; Sajanti, A; Sandell, S, 2016) |
| "Many migraineurs also display alterations in blink reflexes, known to involve brainstem circuits." | 1.43 | Pharmacology of reflex blinks in the rat: a novel model for headache research. ( Andreou, AP; Jones, MG; McMahon, SB; Spanswick, D, 2016) |
| "To assess migraine-related healthcare resource use and associated costs for subjects prescribed S/NS vs." | 1.42 | Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA. ( Bell, CF; Bowers, B; D'Souza, A; Eaddy, M; Goodwin, B; Runken, MC; Shah, M, 2015) |
| "Most pharmacological trials deal with migraine as if it were a clinically homogeneous disease, and when detailing its characteristics, they usually report only the presence, or absence, of aura and attack frequency but provide no information on pain location, a non-trivial clinical detail." | 1.42 | Pharmacological trials in migraine: it's time to reappraise where the headache is and what the pain is like. ( Barbanti, P; Egeo, G, 2015) |
| " Absorption of SS delivered by MNs was similar to that observed after subcutaneous injection and was associated with high bioavailability (ca." | 1.42 | Improvement of transdermal delivery of sumatriptan succinate using a novel self-dissolving microneedle array fabricated from sodium hyaluronate in rats. ( Kamiyama, F; Katsumi, H; Kusamori, K; Quan, YS; Sakane, T; Wu, D; Yamamoto, A, 2015) |
| "Clonidine was the most frequently prescribed (49." | 1.42 | Prescribing patterns of anti-migraine medicines in South Africa using a claims database. ( Truter, I, 2015) |
| "Acute migraine headache among children and adolescents is common and treatment is challenging." | 1.42 | Intranasal sumatriptan for migraine in children. ( Goldman, RD; Meckler, GD, 2015) |
| "This chronic basal hyperalgesia occurred in a dose-dependent fashion and persisted for days after cessation of NTG administration." | 1.40 | Characterization of a novel model of chronic migraine. ( Charles, A; Evans, CJ; McGuire, B; Pradhan, AA; Smith, ML; Tarash, I, 2014) |
| "Sumatriptan was the first medication of this group." | 1.40 | Sumatriptan in clinical practice: effectiveness in migraine and the problem of psychiatric comorbidity. ( Lionetto, L; Martelletti, P; Napoletano, F, 2014) |
| "Because migraine attacks can be disabling, with many patients unable to perform their usual activities, it is important for prescribers and their patients to be confident that they will be able to assemble and apply sumatriptan TDS in the middle of an attack." | 1.40 | Sumatriptan transdermal system can be correctly assembled and applied during migraine attacks. ( Foster, S; Jennings, C; Meadows, KP; O'Neill, C; Pierce, M, 2014) |
| "Sumatriptan succinate is a drug of choice for migraine." | 1.40 | Application of design of experiment for polyox and xanthan gum coated floating pulsatile delivery of sumatriptan succinate in migraine treatment. ( Jagdale, SC; Pawar, CR, 2014) |
| " BMS-742413 has good intranasal bioavailability in the rabbit and shows a robust, dose-dependent inhibition of CGRP-induced increases in marmoset facial blood flow." | 1.39 | Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migr ( Cantor, GH; Chaturvedula, PV; Conway, CM; Davis, C; Denton, R; Dubowchik, GM; Keavy, D; Macci, R; Macor, JE; Mathias, N; Mercer, SE; Moench, P; Pin, SS; Schartman, R; Signor, L; Thalody, G; Whiterock, V; Xu, C, 2013) |
| "Simultaneous development of migraine-like headache and stroke in the same patient makes it difficult to differentiate between migraine-induced stroke and migraine-like headache attributed to ischemic stroke." | 1.38 | Basilar artery occlusion in migraine-like headache: a possible triggering effect of sumatriptan. ( Boz, C; Gazioglu, S; Ozmenoglu, M, 2012) |
| "The acute antimigraine efficacy of these remedies is very much dependent on the formulation used where, in general, parenteral formulations are more effective in relieving the symptoms of a migraine attack." | 1.38 | Headache currents commentary. ( Peatfield, R, 2012) |
| "The third woman had migraine but the attacks were not associated with HS." | 1.38 | Headache in three new cases of Harlequin syndrome with accompanying pharmacological comparison with migraine. ( Goadsby, PJ; Mathias, CJ; Viana, M, 2012) |
| "Triptans were used as a model, because migraine is common in children, and is the only indication for triptans." | 1.37 | Evolution of paediatric off-label use after new significant medicines become available for adults: a study on triptans in Finnish children 1994-2007. ( Airaksinen, M; Hoppu, K; Kaukonen, AM; Klaukka, T; Lindkvist, J, 2011) |
| "The diagnosis of menstrual-associated migraine was made in accordance with a supplement to the International Classification of Headache Disorders." | 1.37 | [A comparative analysis on the efficacy of sumamigren in treatment menstrual and non-menstrual migraine attacks]. ( Gromova, SA; Tabeeva, GR, 2011) |
| "Although many high-quality migraine clinical trials have been performed in the emergency department (ED) setting, almost as many different primary outcome measures have been used, making data aggregation and meta-analysis difficult." | 1.36 | Standardizing emergency department-based migraine research: an analysis of commonly used clinical trial outcome measures. ( Bijur, PE; Friedman, BW; Lipton, RB, 2010) |
| "Her abdominal pain was relieved with sumatriptan, a migraine-specific serotonin(1B/1D) agonist." | 1.36 | Abdominal migraine associated with ecchymosis of the legs and buttocks: does the symptom imply an unknown mechanism of migraine? ( Haginoya, K; Kakisaka, Y; Tsuchiya, S; Uematsu, M; Wakusawa, K, 2010) |
| " Hence, this method demonstrated to be adequate for in vitro studies of NAP and SUMA in the combinational dosage form, since there is no official monograph, collaborating to the official codes." | 1.36 | In vitro dissolution profile comparison of an anti-migraine combinational drug in dosage form. ( Bhojraj, S; Hiremath, VB; Kaliaperumal, K; Nanjan, MJ, 2010) |
| "Migraine is a common neurological disorder often treated with triptans." | 1.36 | Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. ( Andrews, JS; Chichorro, J; De Felice, M; Dodick, D; Dussor, G; Lai, J; Maddaford, S; Meng, ID; Ossipov, MH; Porreca, F; Rakhit, S; Wang, R, 2010) |
| "Therefore, goshuyuto may ameliorate migraine by preventing the hyper-aggregation of platelets in migraine with aura." | 1.35 | Goshuyuto, a traditional Japanese medicine for migraine, inhibits platelet aggregation in guinea-pig whole blood. ( Hibino, T; Kanno, H; Kase, Y; Takeda, A; Terawaki, K; Yuzurihara, M, 2008) |
| "Experienced migraineurs who reported a mild migraine pain phase, dissatisfaction with the previous sumatriptan treatment and some dissatisfaction with their current treatment regimen had no experience with sumatriptan at the 100 mg dose were enrolled in an open-label, single group study." | 1.35 | Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan. ( Burch, SP; Cady, RK; Kwong, WJ; Landy, S; McDonald, SA; Nelsen, AC; Newman, LC; O'Carroll, P, 2008) |
| "Prospective studies of antimigraine drugs should take this relationship into account when extrapolating efficacy data from adults to adolescents." | 1.35 | Analysis of the relationship between age and treatment response in migraine. ( Danhof, M; Della Pasqua, OE; Maas, HJ, 2009) |
| "The complete RCT model involved three submodels: i) the input-output submodel for the prediction of events (using the sigmoid dose-response relationship as the basic model), ii) the execution submodel for deviations from a randomized, controlled two-arm parallel trial related to either patient-specific or investigator-specific elements or both: placebo or nocebo effect, errors of measurement, effect of concomitant therapy, regression to the mean phenomenon, blinding process, loss to follow-up and randomization process, iii) the covariate distribution submodel." | 1.35 | Revisiting the level of evidence in randomized controlled clinical trials: A simulation approach. ( Bajard, A; Boissel, JP; Chabaud, S; Nony, P; Pérol, D, 2009) |
| "For the treatment of migraine, hydroxypropyl methylcellulose (HPMC) K4M and K15M based microspheres containing sumatriptan succinate (SS) were prepared by spray-drying technique." | 1.35 | Formulation and evaluation of nasal mucoadhesive microspheres of sumatriptan succinate. ( Chauk, DS; Gattani, SG; Jain, SA; Mahajan, HS; Tekade, AR, 2009) |
| "Migraine is like any other chronic illness." | 1.35 | Pharmacological management for the adult migraine sufferer. ( Meyer, H, 2009) |
| " Based on a population pharmacokinetic model, mean concentration-time profiles were generated by varying the absorption rate constant and lag time." | 1.35 | Relevance of absorption rate and lag time to the onset of action in migraine. ( Danhof, M; Della Pasqua, OE; Maas, HJ; Spruit, MA, 2008) |
| "Three migraine attacks have been studied in 30 patients aged 39." | 1.34 | [Efficacy of sumamigren at early and late stages of migraine attack]. ( Azimova, IuE; Tabeeva, GR, 2007) |
| "The relationship between migraine and cardiopathy has not been sufficiently established and controversy exists concerning its favouring role in coronary artery disease." | 1.33 | Acute migraine attack, angina-like chest pain with documented ST-segment elevation and slow coronary flow. ( Cam, N; Erden, I; Uyarel, H, 2005) |
| "The acute migraine trial based on this design was successful in both proof of concept and dose range selection." | 1.33 | A group sequential adaptive treatment assignment design for proof of concept and dose selection in headache trials. ( Diener, HC; Hall, DB; Meier, U, 2005) |
| "For SHI compared with PHI migraine patients, there was a hurdle to receiving sumatriptan at all (2." | 1.33 | Accessing a new medication in Germany: a novel approach to assess a health insurance-related barrier. ( Christensen, DB; Ibrahim, MA; Kaufman, JS; Krobot, KJ; Miller, WC; Preisser, JS, 2005) |
| "Severe migraine attacks are treated with triptans." | 1.33 | [Therapy of severe migraine attacks: practical tips]. ( Göbel, H, 2005) |
| " The analysis was based on phase I pharmacokinetic naratriptan data, sumatriptan pharmacodynamic data, and naratriptan preclinical (animal) potency information, together with general knowledge as to how migraine affects oral absorption." | 1.33 | Uncertainty analysis in pharmacokinetics and pharmacodynamics: application to naratriptan. ( Aarons, L; Gueorguieva, I; Nestorov, IA; Rowland, M, 2005) |
| "This may lead to misdiagnosis as migraine and delayed appropriate diagnosis and treatment." | 1.33 | The risks of sumatriptan administration in patients with unrecognized subarachnoid haemorrhage (SAH). ( Keller, H; Pfadenhauer, K; Schönsteiner, T, 2006) |
| "Rizatriptan ODT was preferred by 68." | 1.33 | Assessment of clinical, service, and cost outcomes of a conversion program of sumatriptan to rizatriptan ODT in primary care patients with migraine headaches. ( Billups, SJ; Carroll, N; Delate, T; Gershovich, OE; Hoffman, CK, 2006) |
| "Sumatriptan is a serotonin 5-HT(1B/1D) receptor agonist that is used for the acute treatment of migraine attacks." | 1.33 | Sumatriptan fast-disintegrating/rapid-release tablets. ( Keating, GM; Moen, MD, 2006) |
| " Disease dynamics must be considered to evaluate treatment response adequately and optimise the dosing regimen in migraine." | 1.33 | A model-based approach to treatment comparison in acute migraine. ( Danhof, M; Della Pasqua, O; Maas, HJ, 2006) |
| "Treatment with sumatriptan repressed NGF- and MAPK-stimulated CGRP promoter activity." | 1.32 | Stimulation of the calcitonin gene-related peptide enhancer by mitogen-activated protein kinases and repression by an antimigraine drug in trigeminal ganglia neurons. ( Durham, PL; Russo, AF, 2003) |
| "Adding a preventive medication to migraine management reduced the use of other migraine medications, as well as visits to physician offices and emergency departments." | 1.32 | Migraine preventive medication reduces resource utilization. ( Chmiel, JJ; Silberstein, SD; Winner, PK, 2003) |
| "To determine the level of concern among migraineurs about migraine prescription medication tolerability and adverse effects and the impact of these concerns on their self-management of migraine." | 1.32 | Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. ( Gallagher, RM; Kunkel, R, 2003) |
| "A total of 300 migraine patients (11." | 1.32 | Incidence and determinants of antidepressant drug use in migraine patients. ( Buurma, H; Egberts, AC; Leufkens, HG; Rahimtoola, H; Tijssen, CC, 2003) |
| "Migraine headaches are a frequently encountered neurologic problem in children." | 1.32 | Parental satisfaction with sumatriptan nasal spray in childhood migraine. ( Kring, D; Pakalnis, A; Paolicchi, J, 2003) |
| "For many migraine patients, triptan therapy provides complete pain relief in some attacks but not in others." | 1.32 | Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. ( Burstein, R; Collins, B; Jakubowski, M, 2004) |
| "Triptans are widely used to treat migraine but have been associated with stroke, myocardial infarction (MI), and ischemic heart disease (IHD) in case reports." | 1.32 | Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. ( Brown, MM; Hall, GC; MacRae, KD; Mo, J, 2004) |
| "Among migraineurs, triptan consumers reported more frequent and severe headaches than non-consumers, and reported a higher incidence of nausea and vomiting." | 1.32 | Use and misuse of triptans in France: data from the GRIM2000 population survey. ( Auray, JP; Chazot, G; Dartigues, JF; Duru, G; El Hasnaoui, A; Gaudin, AF; Henry, P; Lantéri-Minet, M; Lucas, C; Pradalier, A, 2004) |
| "Migraine is the headache most commonly encountered in primary care practice." | 1.32 | Effective treatment of migraine. Terminating acute attacks, reducing their frequency. ( Edmeads, J; Pringsheim, T, 2004) |
| "We identified individuals with migraines, age 18 to 65 years, in 371 primary care practices in Germany in 1994 (MediPlus, IMS Health database)." | 1.32 | Quantifying delay in access to new medical treatment: an application of risk advancement period methodology. ( Christensen, DB; Ibrahim, MA; Kaufman, JS; Krobot, KJ; Miller, WC; Preisser, JS, 2004) |
| "The anti-migraine agent sumatriptan constricts cerebral blood vessels, and also blocks neuropeptide release from meningeal sensory neurons." | 1.32 | The anti-migraine agent sumatriptan induces a calcium-dependent discharge in meningeal sensory neurons. ( Levy, D; Strassman, AM, 2004) |
| "Productivity and satisfaction with migraine therapy also were assessed." | 1.32 | Triptan therapy impacts health and productivity. ( Mackowiak, JI; Solari, PG; Weaver, MB, 2004) |
| "It is suggested that during a migraine attack capsaicin-sensitive trigeminal sensory nerves release calcitonin gene related peptide (CGRP), resulting in cranial vasodilatation and central nociception." | 1.32 | Effects of sumatriptan on capsaicin-induced carotid haemodynamic changes and CGRP release in anaesthetized pigs. ( Arulmani, U; Garrelds, IM; Heiligers, JP; Sánchez-López, A; Saxena, PR; Villalón, CM; Willems, EW, 2004) |
| "Treatment of migraine with triptans is highly effective, although cost considerations may prompt a change in therapy." | 1.32 | Switching patients with migraine from sumatriptan to other triptans increases primary care costs. ( Browning, D; Martin, A; Savani, N, 2004) |
| "Sumatriptan was not able to reverse either the kainic acid-induced or the NMDA-induced hyperalgesia." | 1.32 | Indomethacin, alone and combined with prochlorperazine and caffeine, but not sumatriptan, abolishes peripheral and central sensitization in in vivo models of migraine. ( Galeotti, N; Ghelardini, C; Grazioli, I; Uslenghi, C, 2004) |
| " A qualitative model for pharmacokinetic properties was then used to guide the synthesis toward molecules likely to have oral bioavailability in humans." | 1.31 | Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation. ( Barrett, V; Brockwell, M; Cambridge, D; Farrant, DR; Foster, C; Giles, H; Glen, RC; Hill, AP; Hobbs, H; Honey, A; Jandu, KS; Martin, GR; Salmon, J; Selwood, DL; Smith, D; Woollard, P, 2001) |
| "Data from most clinical trials of migraine drugs use standard endpoints of level of pain relief at 2 hours and percentage of patients who are pain free at 2 hours." | 1.31 | Evaluating the efficacy of migraine therapy. ( Chawluk, JB, 2000) |
| "Their clinical diagnoses were migraine with aura, migraine without aura, cluster headache, and others." | 1.31 | Evidence against strong correlation between chest symptoms and ischemic coronary changes after subcutaneous sumatriptan injection. ( Endo, M; Igarashi, H; Sakai, F; Suzuki, N; Tomita, M, 2002) |
| "In direct head-to-head comparative clinical trials, oral rizatriptan 10 mg enabled more migraine sufferers to function normally at 2 h after dosing than oral sumatriptan, naratriptan, and zolmitriptan." | 1.31 | Restoring migraine sufferers' ability to function normally: a comparison of rizatriptan and other triptans in randomized trials. ( Bussone, G; D'Amico, D; Gerth, W; Lines, CR; McCarroll, KA, 2002) |
| "Sumatriptan has direct scavenging activity on free radicals and NO." | 1.31 | Sumatriptan scavenges superoxide, hydroxyl, and nitric oxide radicals: in vitro electron spin resonance study. ( Ikeda, Y; Jimbo, H; Satoh, K; Shimazu, M, 2002) |
| "Then, if the patient decides it is a migraine, he or she weighs various factors to decide whether to take sumatriptan." | 1.31 | Decision making in migraine patients taking sumatriptan: an exploratory study. ( Campbell, MA; Hennigar, AW; Ivers, H; McGrath, PJ; Purdy, RA, 2000) |
| "Stuttering is an abnormality in the fluency of speech, which is characterized by interruption of the normal rhythm due to involuntary repetition and prolongation, or arrest, of uttered letters or syllables." | 1.31 | Acquired transient stuttering during a migraine attack. ( Famularo, G; Perino, M; Tarroni, P, 2000) |
| "In the migraine attack an increased area of the R3 component on the pain side was observed; it was suppressed by zolmitriptan, which confirmed its action on the central trigeminal circuits, though the clinical relevance of this effect could be questioned." | 1.31 | Zolmitriptan reverses blink reflex changes induced during the migraine attack in humans. ( de Tommaso, M; Guido, M; Libro, G; Puca, F; Sciruicchio, V, 2000) |
| "In an experimental migraine model, it has been shown that electrical stimulation of the rat trigeminal ganglion induced an increase in the lengths of CGRP-immunoreactive axons, increased size and number of pleomorphic axonal varicosities in the dura mater, and an increased number of c-jun and c-fos protein-expressing nerve cells in the trigeminal complex." | 1.31 | Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model. ( Chadaide, Z; Csillik, AE; Knyihár-Csillik, E; Mihály, A; Tajti, J; Vécsei, L, 2000) |
| " In early clinical trials, rizatriptan was shown to have good bioavailability and favorable effects on quality of life." | 1.31 | Rizatriptan versus usual care in long-term treatment of migraine. ( Silberstein, SD, 2000) |
| " Therefore, it is quite possible that both drugs produce adverse immunological effects in vivo in cases of high dosage or obstruction of elimination." | 1.31 | [Effect of migraine medications on monocyte chemotaxis] . ( Krumholz, W; Menges, T; Ogal, H; Szalay, G, 2000) |
| "Almotriptan is a new 5-HT(1B/1D) receptor agonist whose clinical efficacy for the treatment of migraine attacks has been demonstrated in Phase III clinical trials." | 1.31 | Functional profile of almotriptan in animal models predictive of antimigraine activity. ( Bou, J; Fernández, AG; Gras, J; Llenas, J; Palacios, JM, 2000) |
| "Almotriptan is a new 5-HT(1B/1D) receptor agonist effective for treating acute migraine attacks with or without aura." | 1.31 | Cardiovascular safety profile of almotriptan, a new indolic derivative for the treatment of migraine. ( Cardelús, I; Gras, J; Llenas, J; Palacios, JM, 2000) |
| "Migraine headache is proposed to be mediated by nitric oxide (NO)." | 1.31 | Cortical spreading depression produces increased cGMP levels in cortex and brain stem that is inhibited by tonabersat (SB-220453) but not sumatriptan. ( Hirst, WD; Parsons, AA; Read, SJ; Upton, N, 2001) |
| "Eletriptan is a new 5-HT 1B/1D agonist with high potency and selectivity at 5-HT 1B/1D receptors." | 1.31 | Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. ( Diener, HC; McHarg, A, 2000) |
| "Since triptans exert their anti-migraine effect by virtue of agonist action on 5-HT(1D/B) receptors, we suggest that these drugs prevent the release of CGRP from perivascular nerve terminals in the dura mater by an action at 5-HT(1D/B) receptors." | 1.31 | Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model. ( Chadaide, Z; Csillik, B; Knyihár-Csillik, E; Tajti, J; Vécsei, L, 2001) |
| "The effects of classical and new anti-migraine drugs such as acetylsalicylic acid (ASA), sumatriptan and the new high efficacy 5-HT1B/1D agonist donitriptan (4-[4-[2-(2-aminoethyl)-1H-indol-5-yloxyl]acetyl]piperazinyl-1-yl]benzonitrile) were evaluated in comparison with the established model of neurogenic inflammation in the meninges." | 1.31 | An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system. ( Diener, HC; Guehring, H; Katsarava, Z; Liedert, B; Limmroth, V; Michel, MC; Schmitz, K, 2001) |
| "Data concerning status migrainosus in children and adolescents is sparse." | 1.31 | Status migrainosus in children and adolescents. ( Akhtar, ND; Murray, MA; Rothner, AD, 2001) |
| "The overall prevalence of migraine was 8." | 1.31 | [Diagnosis and recent treatment of migraine]. ( Sakai, F, 2000) |
| "The common strategy to treat a migraine attack as soon as it begins, made for classical acute antimigraine treatments such as ergotamine and analgesics, has not been transposed to the triptans." | 1.31 | When should triptans be taken during a migraine attack? ( Schoenen, J, 2001) |
| "One hundred consecutive migraine patients attending our clinics were asked to treat three attacks with each medication and then fill out a preference questionnaire." | 1.31 | An open preference study with sumatriptan 50 mg and zolmitriptan 2.5 mg in 100 migraine patients. ( Leira, R; Muñoz, R; Pascual, J, 2001) |
| "In the present study, 23 patients with migraine without aura were monitored during a migraine attack." | 1.31 | Immunological aspects in migraine: increase of IL-10 plasma levels during attack. ( Bassi, A; Cassiano, MA; Causarano, V; Centonze, V; Marinaro, M; Munno, I, 2001) |
| "All patients using an abortive migraine drug (ergotamine or sumatriptan) and subsequently treated with either coumarin (index group) or low-dose acetylsalicylic acid (control group) were analyzed." | 1.31 | Reduction in the intensity of abortive migraine drug use during coumarin therapy. ( Buurma, H; Egberts, AC; Leufkens, HG; Rahimtoola, H; Tijssen, CC, 2001) |
| "Sumatriptan treatment had beneficial effects on aspects of health state and mood during the postictal period." | 1.31 | Effects of medication use on health state in postictal migraineurs. ( de Geus, EJ; Linssen, WH; Mulder, EJ; Passchier, J, 2001) |
| " Nonsteroidal anti-inflammatory drugs (NSAID) such as tolfenamic acid and naproxen sodium combined with sumatriptan have demonstrated efficacy in reducing recurrence observed with the single use of this drug." | 1.31 | Dexamethasone decreases migraine recurrence observed after treatment with a triptan combined with a nonsteroidal anti-inflammatory drug. ( Barbosa, JS; Krymchantowski, AV, 2001) |
| "Patients with migraine using sumatriptan therapy." | 1.31 | Different approaches to valuing the lost productivity of patients with migraine. ( Frick, KD; Locklear, JC; Lofland, JH, 2001) |
| "The lifetime prevalence of several psychiatric disorders was determined by the National Institute of Mental Health diagnostic interview schedule and personality factors were measured by the 16 Personality Factors (16PF) Questionnaire." | 1.31 | Sumatriptan responsiveness and clinical, psychiatric and psychologic features in migraine patients. ( Becker, WJ; Dalby, JT; Meckling, SK; Rose, MS, 2001) |
| "Here we establish a link between migraine aura and headache by demonstrating that cortical spreading depression, implicated in migraine visual aura, activates trigeminovascular afferents and evokes a series of cortical meningeal and brainstem events consistent with the development of headache." | 1.31 | Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. ( Boas, DA; Bolay, H; Dunn, AK; Huang, Z; Moskowitz, MA; Reuter, U, 2002) |
| "Rizatriptan was associated with significantly lower triptan tablet use and additional medication use per attack than the other triptans." | 1.31 | Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain. ( Fité, B; López-Gil, A; Pascual, J, 2002) |
| "Clinically effective antimigraine drugs such as Sumatriptan show little selectivity between h5-HT1D and h5-HT1B receptors." | 1.30 | Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor. ( Beer, MS; Guiblin, AR; Heald, A; Hunt, PA; Jelley, RA; Matassa, VG; Reeve, AJ; Sohal, B; Stanton, JA; Sternfeld, F; Street, LJ; Watt, AP, 1999) |
| " The optimum compound was 1-(3-[5-(1,2, 4-triazol-4-yl)-1H-indol-3-yl]propyl)-4-(2-(3-fluorophenyl)ethyl)p ipe razine (7f) which has excellent selectivity for h5-HT1D receptors over other 5-HT receptor subtypes and good oral bioavailability in three species." | 1.30 | 3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents. ( Beer, MS; Chambers, MS; Goodacre, S; Hobbs, SC; Hunt, P; Jelley, RA; MacLeod, AM; Matassa, VG; Rathbone, D; Reeve, AJ; Stanton, JA; Sternfeld, F; Street, LJ; Watt, AP, 1999) |
| "The pathophysiologies of migraine and cluster headache have a specific modifying property on cognitive processing reflected by a loss of cognitive habituation or an increased cognitive processing time." | 1.30 | Cognitive processing in primary headache: a study on event-related potentials. ( Bauer, B; Evers, S; Grotemeyer, KH; Husstedt, IW; Suhr, B, 1997) |
| "Several acutely acting antimigraine drugs, including ergotamine and sumatriptan, have the ability to constrict porcine arteriovenous anastomoses as well as the human isolated coronary artery." | 1.30 | Effects of avitriptan, a new 5-HT 1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential. ( Bax, WA; De Vries, P; Heiligers, JP; Maassen vandenBrink, A; Saxena, PR; Wang, W; Yocca, FD, 1997) |
| "Sumatriptan has been shown to be most effective in migraine attacks, but with transient, slight side effects and high rebound attack rates." | 1.30 | Sumatriptan treatment of acute migraine attacks in a Saudi population. ( al Deeb, S; al Kawi, Z; Bohlega, S; Cheung, P; Yaqub, B, 1997) |
| "The neurogenic inflammation theory of migraine pain proposes that substance P, acting through NK-1 receptors, causes dural inflammation which enhances migraine pain." | 1.30 | The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs. ( Hipskind, PA; Johnson, KW; Lobb, KL; Nixon, JA; Phebus, LA; Stengel, PW, 1997) |
| "Cluster headache is a rare but very typical disease." | 1.30 | [Cluster headache: misjudged because unknown]. ( Koudstaal, PJ; Ridderikhoff, J, 1997) |
| "The prevalence of migraine is 12 to 20% in women and 8 to 12% in man." | 1.30 | [Migraine--diagnosis, differential diagnosis and therapy]. ( Diener, HC, 1997) |
| "Since sumatriptan exerts its anti-migraine effect by virtue of its agonist action on 5-HT1D receptors, we suggest that sumatriptan prevents the release of CGRP from dural perivascular terminals by an action at 5-HT1D receptors." | 1.30 | Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model. ( Knyihár-Csillik, E; Samsam, M; Sáry, G; Slezák, S; Tajti, J; Vécsei, L, 1997) |
| " They are almost always benign, but can be mistaken for a serious adverse event by the patient." | 1.30 | The site of common side effects of sumatriptan. ( Lipton, RB; Newman, LC; Solomon, S, 1997) |
| "Of the prophylactic antimigraine drugs tested, methysergide and lisuride behaved as efficacious agonists (Emax > or = 90% relative to 5-HT) whereas pitozifen and (-)propranolol acted as a partial agonist (60%) and an antagonist, respectively." | 1.30 | Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy. ( Audinot-Bouchez, V; Chaput, C; Conte, C; Lavielle, G; Lochon, S; Millan, MJ; Newman-Tancredi, A; Verrièle, L, 1997) |
| "The other two had migraine without aura." | 1.30 | Recurrent neck pain as a variant of migraine: description of four cases. ( Accornero, N; De Marinis, M, 1997) |
| "Major depression and migraine are commonly comorbid." | 1.30 | Co-administration of fluoxetine and sumatriptan: the Canadian experience. ( Joffe, RT; Sokolov, ST, 1997) |
| "Sumatriptan blunted the increase in blood flow following stimulation of the trigeminal ganglion." | 1.30 | Trigeminal ganglion elicited increases in nucleus trigeminal caudalis blood flow: a novel migraine model. ( McCall, RB, 1997) |
| "Zolmitriptan is a newly developed 5HT1B/1D receptor agonist with both peripheral and central sites of action in the trigeminovascular system due to greater lipophilicity relative to the more hydrophilic antimigraine compound sumatriptan." | 1.30 | Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat. ( Goadsby, PJ; Hoskin, KL, 1998) |
| "To cater to the special situation of much reduced oral bioavailability which occurs in severe migraine attacks with pronounced nausea and vomiting, sumatriptan can also be used in a subcutaneous form that can be self-administered." | 1.30 | Practicability and acceptance of subcutaneous self-administration of the selective serotonin agonist sumatriptan. ( Baar, H; Beckmann-Reinhold, A; Beiküfner, HD; Böhme, K; Göbel, H, 1998) |
| "Oral sumatriptan was effective in clinical practice at doses of 25 and 50 mg." | 1.30 | Dosing of oral sumatriptan: a review of our first 104 patients. ( Becker, J; Frizelis, K; Kunkel, RS; Solomon, GD, 1998) |
| "No drug abuse was recorded, but bleeding occurred after the use of several antimigrainous drugs." | 1.30 | Multiple intracerebral hemorrhages and vasospasm following antimigrainous drug abuse. ( Derex, L; Nighoghossian, N; Trouillas, P, 1998) |
| "The antimigraine drugs ergotamine and sumatriptan may cause angina-like symptoms, possibly resulting from coronary artery constriction." | 1.30 | Coronary side-effect potential of current and prospective antimigraine drugs. ( Bax, WA; Ferrari, MD; MaassenVanDenBrink, A; Reekers, M; Saxena, PR, 1998) |
| "Pretreatment with sumatriptan (n = 9) produced a highly significant reduction in the ratio of extravasation within the dura to 1." | 1.30 | Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine. ( Diener, HC; Effert, R; Goadsby, PJ; Hargreaves, RJ; Knorr, M; May, A; Shepheard, SL; Wessing, A, 1998) |
| "Neurogenic dural inflammation has been proposed as a source of pain during migraine." | 1.30 | A fluorescence-based method for assessing dural protein extravasation induced by trigeminal ganglion stimulation. ( Johnson, KW; Phebus, LA, 1998) |
| "Many acutely acting antimigraine drugs have the ability to constrict porcine arteriovenous anastomoses as well as the human isolated coronary artery." | 1.30 | BMS-181885, a 5-HT1B/1D receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential. ( Bax, WA; De Vries, P; Heiligers, JP; Maassen VanDenBrink, A; Saxena, PR; Yocca, FD, 1998) |
| "The cGMP was measured during a migraine attack and 60 min following the administration of sumatriptan 6 mg subcutaneously." | 1.30 | Level of nitric oxide-dependent cGMP in patients with migraine. ( Chalimoniuk, M; Stepien, A, 1998) |
| "Sumatriptan was associated with significant reductions in migraine-related use of general outpatient services, telephone calls, urgent care services, and emergency department visits (P < 0." | 1.30 | Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes. ( Batenhorst, A; Beall, D; Beck, A; Clements, B; Cohen, JA; Miller, DW; Pait, DG; Rawlings, J, 1999) |
| "The number of monthly migraine disability days decreased from 6." | 1.30 | Cost-effectiveness of sumatriptan in a managed care population. ( Legg, RF; Mackowiak, JI; Nemec, NL; Sclar, DA; Tarnai, J, 1997) |
| "We studied the recurrence rate of migraine attacks with the use of sumatriptan plus tolfenamic acid among patients who presented frequent recurrence with sumatriptan." | 1.30 | Tolfenamic acid decreases migraine recurrence when used with sumatriptan. ( Adriano, M; Fernandes, D; Krymchantowski, AV, 1999) |
| "*Zolmitriptan (Zomig) is an antimigraine drug similar to sumatriptan." | 1.30 | Zolmitriptan. ( , 1999) |
| "The question whether symptom-free migraine patients show cognitive impairments compared to matched control subjects is addressed, and also whether migraine patients show transient cognitive impairments induced by an attack." | 1.30 | Interictal and postictal cognitive changes in migraine. ( de Geus, EJ; Linssen, WH; Mulder, EJ; Orlebeke, JF; Passchier, J, 1999) |
| "At 5 years, 11% of migraineurs reported use of sumatriptan in the prior month." | 1.30 | Headache medication-use among primary care headache patients in a health maintenance organization. ( Black, LK; Galer, BS; Saunders, K; Von Korff, M, 1999) |
| "9% of the patients withdrew from the study because of insufficient efficacy or adverse events." | 1.30 | Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment. ( Göbel, H; Heinze, A; Heinze-Kuhn, K; Lindner, V; Stolze, H, 1999) |
| "Physician office visits related to migraine increased by 7." | 1.30 | HMO direct costs and health care resources use after implementation of a monthly limit on sumatriptan. ( Dans, PE; Duncan, BS; Goldfarb, SD; Sloan, AS, 1999) |
| " However, knowledge of the long-term use of sumatriptan in unselected patients was lacking." | 1.30 | Use and overuse of sumatriptan. Pharmacoepidemiological studies based on prescription register and interview data. ( Gaist, D, 1999) |
| "CGRP may have a role in migraine through its potent cranial vasodilator effects or by an action on trigeminal nerve activity, both of which are targeted by 5HT(1B/1D)agonist drugs but does not itself produce PPE." | 1.30 | Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288. ( Edvinsson, L; Goadsby, PJ; Knight, YE, 1999) |
| " Overall, the mean percentages of attacks per patient in which headache relief had been obtained 4 h after dosing were 71%, 71%, and 80% for the 25 mg, 50 mg, and 100 mg doses, respectively." | 1.30 | Patient-selected dosing in a six-month open-label study evaluating oral sumatriptan in the acute treatment of migraine. Sumatriptan Tablets S2CM10 Study Group. ( Ashford, EA; Dowson, AJ; Flöter, T; Hassani, H; Prendergast, S; Roberts, GW; Szczudlik, A, 1999) |
| "(1) Zolmitriptan is an antimigraine drug similar to sumatriptan." | 1.30 | Zolmitriptan: new product. Similar to sumatriptan. ( , 1999) |
| "Alniditan is a new migraine-abortive agent." | 1.29 | Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamin ( Gommeren, W; Haegeman, G; Heylen, L; Lesage, AS; Leysen, JE; Luyten, WH; Schotte, A; Van de Weyer, I; Van Gompel, P; Vanhoenacker, P; Wouters, R, 1996) |
| "Identification of migraine triggers is an extremely important part of migraine therapy." | 1.29 | [Stabilization treatments of migraine]. ( Dworak, N; Nater, B; Regli, F, 1995) |
| "To investigate human migraine, we used positron emission tomography to examine the changes in regional cerebral blood flow as an index of neuronal activity in the human brain during spontaneous migraine attacks." | 1.29 | Brain stem activation in spontaneous human migraine attacks. ( Coenen, HH; Diener, HC; Jüptner, M; Kaube, H; Limmroth, V; May, A; Schayck, RV; Weiller, C, 1995) |
| "Although migraine is inextricably bound up with 5-hydroxytryptamine and its many receptors, its precise mechanisms continue to elude us and there is still no clear evidence supporting either a vascular or neurogenic hypothesis unequivocally." | 1.29 | Migraine to the year 2000. ( Sandler, M, 1995) |
| "We have investigated the novel antimigraine drug sumatriptan, a selective agonist for 5HT1 receptors." | 1.29 | Assessment of peripheral vascular effects of antimigraine drugs in humans. ( Blauw, GJ; Bruning, TA; Camps, J; Chang, PC; Ferrari, MD; Saxena, PR; van Es, NM; van Zwieten, PA, 1995) |
| "Patients with a history of migraine occasionally have similar headaches precipitated by ECT." | 1.29 | Sumatriptan prophylaxis for postelectroconvulsive therapy headaches. ( DeBattista, C; Mueller, K, 1995) |
| "The increase obtained in migraine after ergotamine is more evident than that obtained in cases of cluster headache." | 1.29 | Upregulated expression of peripheral serotonergic receptors in migraine and cluster headache by sumatriptan. ( Giacovazzo, M; Martelletti, P; Rinaldi, C; Stirparo, G, 1994) |
| "Sumatriptan has a weak coronary constrictor effect." | 1.29 | [The migraine remedy sumatriptan (Imigran) and coronary heart disease]. ( Landmark, K; Nguyen, KN, 1995) |
| " Because sumatriptan does not appear to cross the blood-brain barrier and has a short half-life, it was deemed relatively safe to prescribe sumatriptan with antidepressant treatments." | 1.29 | The safety of concomitant use of sumatriptan and antidepressant treatments. ( Bergeron, R; Blier, P, 1995) |
| "Nine percent failed to respond at all." | 1.29 | Subcutaneous sumatriptan in a clinical setting: the first 100 consecutive patients with acute migraine in a tertiary care center. ( Arrowsmith, F; Baskin, S; Rapoport, AM; Sheftell, FD; Siegel, S; Weeks, RE, 1994) |
| "Sumatriptan appears to cause peripheral venoconstriction only at high doses locally applied (in the hand vein), by acting on 5HT2 receptors." | 1.29 | Amplifying effect of sumatriptan on noradrenaline venoconstriction in migraine patients. ( Anselmi, B; Curradi, C; Franchi, G; Panconesi, A; Tarquini, B, 1993) |
| "Sumatriptan was found to suppress the CPH attacks as well as indomethacin." | 1.29 | Intracranial hypertension and sumatriptan efficacy in a case of chronic paroxysmal hemicrania which became bilateral. (The mechanism of indomethacin in CPH). ( Hannerz, J; Jogestrand, T, 1993) |
| "Treatment with sumatriptan was associated with significant (P < ." | 1.29 | Improvements in health-related quality of life with sumatriptan treatment for migraine. ( Cady, RK; Grice, RB; Gutterman, DL; Jhingran, P; Miller, D; Rubino, J, 1996) |
| "Sumatriptan has shown to be effective in the treatment of an acute migraine- and cluster-headache." | 1.29 | [Sumatriptan--side effects and problems in routine clinical practice]. ( Aull, S; Marterer, A; Schnider, P; Wessely, P; Wöber, C, 1995) |
| " We measured long-term use of sumatriptan and within-patient consistency and change over time of headache relief, headache recurrence, and chest symptoms after sumatriptan." | 1.29 | Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. ( de Vriend, RH; Ferrari, MD; Jaspers, MW; Visser, WH, 1996) |
| "Although in migraineurs a number of studies have been done after nitroglycerin-induced attacks, there is no reported EEG study before and after nitroglycerin-induced sumatriptan-treated attacks." | 1.29 | EEG and topographic frequency analysis in migraine attack before and after sumatriptan infusion. ( Karageorgiou, C; Tagaris, G; Thomaides, T, 1996) |
| "The average number of migraine attacks per month was 3." | 1.29 | How does sumatriptan perform in clinical practice? ( Dahlöf, CG, 1995) |
| "Treatment with sumatriptan was efficient in 89." | 1.29 | [18 months long-term analysis of effectiveness, safety and tolerance of sumatriptan s.c. in acute therapy of migraine attacks]. ( Christiani, K; Dworschak, M; Göbel, H; Heinze, A; Heuss, D; Lindner, V; Stolze, H, 1996) |
| "Sumatriptan was more effective than previously used agents in three fourths." | 1.29 | Sumatriptan use in a large group-model health maintenance organization. ( Addy, SN; Greiner, DL, 1996) |
| " If oral bioavailability in the infant is similar to that in adults (14%), the weight-adjusted infant dose is reduced to 0." | 1.29 | Distribution and excretion of sumatriptan in human milk. ( Dusci, LJ; Hackett, LP; Ilett, KF; Paech, M; Wojnar-Horton, RE; Yapp, P, 1996) |
| "Serotonin syndrome has been reported exclusively in patients on medications for psychiatric illness and Parkinsonism, despite the fact that the putative action of many antimigraine agents also involves the serotonin system." | 1.29 | Serotonin syndrome complicating migraine pharmacotherapy. ( Lucker, C; Mathew, NT; Tietjen, GE, 1996) |
| "Several acutely acting antimigraine drugs, including sumatriptan and other second generation 5-HT1D receptor agonists, have the ability to constrict porcine carotid arteriovenous anastomoses as well as the human isolated coronary artery." | 1.29 | Investigations with GMC2021 in experimental models predictive of antimigraine activity and coronary side-effect potential. ( Barf, T; Bax, WA; De Vries, P; Heiligers, JP; Maassen VanDenBrink, A; Saxena, PR; Wikström, H, 1996) |
| "The effects of 2 antimigraine drugs sumatriptan and dihydroergotamine on dilatation of the middle meningeal artery elicited by stimulation of the trigeminal ganglion at the entry point of the first and second divisions was investigated in cats." | 1.29 | Effect of antimigraine drugs on dural blood flows and resistances and the responses to trigeminal stimulation. ( Lambert, G; Michalicek, J, 1996) |
| "Several acutely acting antimigraine drugs, including sumatriptan and other second generation 5-HT1D receptor agonists, have the ability to constrict porcine arteriovenous anastomoses." | 1.29 | Effects of S20749, a close analogue of sumatriptan, on porcine carotid haemodynamics and human isolated coronary artery. ( Heiligers, JP; Lemaitre, BG; Maassen vandenBrink, A; Saxena, PR; Scalbert, E, 1996) |
| "The median number of visits made by study subjects to the headache clinic fell significantly following sumatriptan test dosing (P < 0." | 1.29 | Impact of sumatriptan on clinic utilization and costs of care in migraineurs. ( Genzen, JR; Litaker, DG; Solomon, GD, 1996) |
| "The antinociceptive effect of the antimigraine drug sumatriptan was assessed in mice and rats (hot-plate, abdominal constriction and paw-pressure tests) and in guinea pigs (paw-pressure test)." | 1.29 | The central cholinergic system has a role in the antinociception induced in rodents and guinea pigs by the antimigraine drug sumatriptan. ( Bartolini, A; Figini, M; Galeotti, N; Gessa, GL; Ghelardini, C; Imperato, A; Nicolodi, M; Sicuteri, F, 1996) |
| "Treatment with sumatriptan reduced the numbers of Fos-positive cells found in laminae I and IIo of the TNC and C2 (6, 13 cells and 9 cells, respectively) after mechanical stimulation." | 1.29 | Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. ( Goadsby, PJ; Hoskin, KL; Kaube, H, 1996) |
| "Sumatriptan was used by 453 patients, during 25 months (median), for 28000 attacks (median: 33 attacks/patient)." | 1.29 | Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. ( de Vriend, RH; Ferrari, MD; Jaspers, NM; Visser, WH, 1996) |
| "1." | 1.28 | Lack of effect of the antimigraine drugs, sumatriptan, ergotamine and dihydroergotamine on arteriovenous anastomotic shunting in the dura mater of the pig. ( den Boer, MO; Saxena, PR; Somers, JA, 1992) |
| "The interactions of four abortive anti-migraine agents and four prophylactic anti-migraine agents with 5-HT1D receptors in bovine brain were analyzed using radioligand binding techniques and adenylate cyclase assays." | 1.28 | 5-Hydroxtryptamine1D receptor agonism predicts antimigraine efficacy. ( Deliganis, AV; Peroutka, SJ, 1991) |
| " Pharmacokinetic and pharmacodynamic variables were similar in all groups studied and were not altered by the presence of food, alcohol, dihydroergotamine or prophylactic migraine treatments." | 1.28 | The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. ( Baber, NS; Fowler, PA; Keene, ON; Lacey, LF; Tanner, RJ; Thomas, M, 1991) |
| "All major controlled trials in migraine employed a parallel group design to avoid carryover effects and to ensure blinding was not compromised; however, because of the rarity of cluster headache, a crossover trial was performed in this indication." | 1.28 | Methodology of clinical trials of sumatriptan in migraine and cluster headache. ( Pilgrim, AJ, 1991) |
| "Pre-treatment with dihydroergotamine and, to a lesser extent, sumatriptan, attenuated this increase." | 1.28 | Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. ( Buzzi, MG; Moskowitz, MA, 1991) |
| "Sumatriptan was not used in patients with chronic daily headaches; in the 8 cases of acute migraine or status migrainosus in which it was used, improvement was rapid and complete in seven." | 1.28 | The hospital management of severe migrainous headache. ( Goadsby, PJ; Jauslin, P; Lance, JW, 1991) |
| "Since several antimigraine agents reduce cranial arteriovenous anastomotic blood flow in the anaesthetized pig, we have investigated the carotid haemodynamic effects of sumatriptan." | 1.28 | Role of 5-HT1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. ( den Boer, MO; Heiligers, JP; Humphrey, PP; Saxena, PR; Villalón, CM, 1991) |
| "In the treatment of migraine demonstrated to date, the impressive effectiveness of GR43175 must reinforce the evidence in favour of an important vascular component being involved in the aetiology of the disease." | 1.28 | The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. ( Connor, HE; Feniuk, W; Humphrey, PP; Oxford, AW; Perren, MJ, 1989) |
| "Patients with severe attacks of migraine have attended special pain or headache clinics for treatment and assessment." | 1.28 | Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine. ( Brand, J; Doenicke, A; Färkkilä, M; Goasguen, J; Perrin, VL; Tfelt-Hansen, P, 1989) |
| "In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT 1-like receptor agonist." | 1.28 | Early clinical experience with subcutaneous GR43175 in acute migraine: an overview. ( Brand, J; Dano, P; Doenicke, A; Findley, LJ; Iversen, HK; Melchart, D; Sahlender, HM; Tfelt-Hansen, P, 1989) |
| "Ten patients with acute, non-medicated, migraine (15 attacks) were assessed for severity of headache and associated symptoms (nausea, vomiting and photophobia)." | 1.28 | Initial clinical experience with the use of subcutaneous GR43175 in treating acute migraine. ( Advenier, C; Bayliss, EM; Bons, J; Brion, N; Plas, J, 1989) |
| "Sumatriptan succinate is a novel compound currently in development for the acute treatment of migraine." | 1.28 | Development and validation of a liquid chromatographic-mass spectrometric assay for the determination of sumatriptan in plasma. ( Lant, MS; Oxford, J, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (0.74) | 18.7374 |
| 1990's | 471 (38.83) | 18.2507 |
| 2000's | 463 (38.17) | 29.6817 |
| 2010's | 228 (18.80) | 24.3611 |
| 2020's | 42 (3.46) | 2.80 |
| Authors | Studies |
|---|---|
| Glen, RC | 2 |
| Martin, GR | 3 |
| Hill, AP | 2 |
| Hyde, RM | 1 |
| Woollard, PM | 1 |
| Salmon, JA | 1 |
| Buckingham, J | 1 |
| Robertson, AD | 1 |
| Leysen, JE | 1 |
| Gommeren, W | 1 |
| Heylen, L | 1 |
| Luyten, WH | 1 |
| Van de Weyer, I | 1 |
| Vanhoenacker, P | 1 |
| Haegeman, G | 1 |
| Schotte, A | 1 |
| Van Gompel, P | 1 |
| Wouters, R | 1 |
| Lesage, AS | 1 |
| MacLeod, AM | 2 |
| Street, LJ | 3 |
| Reeve, AJ | 3 |
| Jelley, RA | 3 |
| Sternfeld, F | 3 |
| Beer, MS | 3 |
| Stanton, JA | 3 |
| Watt, AP | 3 |
| Rathbone, D | 2 |
| Matassa, VG | 3 |
| Ennis, MD | 2 |
| Ghazal, NB | 2 |
| Hoffman, RL | 2 |
| Smith, MW | 1 |
| Schlachter, SK | 1 |
| Lawson, CF | 1 |
| Im, WB | 1 |
| Pregenzer, JF | 1 |
| Svensson, KA | 1 |
| Lewis, RA | 1 |
| Hall, ED | 1 |
| Sutter, DM | 1 |
| Harris, LT | 1 |
| McCall, RB | 3 |
| Guiblin, AR | 1 |
| Hunt, PA | 1 |
| Heald, A | 1 |
| Sohal, B | 1 |
| Chambers, MS | 1 |
| Goodacre, S | 1 |
| Hobbs, SC | 1 |
| Hunt, P | 1 |
| Meng, CQ | 1 |
| Rakhit, S | 2 |
| Lee, DK | 1 |
| Kamboj, R | 1 |
| McCallum, KL | 1 |
| Mazzocco, L | 1 |
| Dyne, K | 1 |
| Slassi, A | 1 |
| Jandu, KS | 1 |
| Barrett, V | 1 |
| Brockwell, M | 1 |
| Cambridge, D | 1 |
| Farrant, DR | 1 |
| Foster, C | 1 |
| Giles, H | 1 |
| Hobbs, H | 1 |
| Honey, A | 1 |
| Salmon, J | 1 |
| Smith, D | 1 |
| Woollard, P | 1 |
| Selwood, DL | 1 |
| Xu, YC | 1 |
| Johnson, KW | 4 |
| Phebus, LA | 3 |
| Cohen, M | 1 |
| Nelson, DL | 1 |
| Schenck, K | 1 |
| Walker, CD | 1 |
| Fritz, JE | 1 |
| Kaldor, SW | 1 |
| LeTourneau, ME | 1 |
| Murff, RE | 1 |
| Zgombick, JM | 1 |
| Calligaro, DO | 1 |
| Audia, JE | 1 |
| Schaus, JM | 1 |
| Chaturvedula, PV | 1 |
| Mercer, SE | 1 |
| Pin, SS | 1 |
| Thalody, G | 1 |
| Xu, C | 1 |
| Conway, CM | 1 |
| Keavy, D | 1 |
| Signor, L | 1 |
| Cantor, GH | 1 |
| Mathias, N | 1 |
| Moench, P | 1 |
| Denton, R | 1 |
| Macci, R | 1 |
| Schartman, R | 1 |
| Whiterock, V | 1 |
| Davis, C | 1 |
| Macor, JE | 1 |
| Dubowchik, GM | 1 |
| Bell, IM | 1 |
| Blanco, MJ | 1 |
| Benesh, DR | 1 |
| Knobelsdorf, JA | 1 |
| Khilevich, A | 1 |
| Cortez, GS | 1 |
| Mokube, F | 1 |
| Aicher, TD | 1 |
| Groendyke, TM | 1 |
| Marmsater, FP | 1 |
| Tang, TP | 1 |
| Clemens-Smith, A | 1 |
| Muhlhauser, MA | 1 |
| Swanson, S | 1 |
| Catlow, J | 1 |
| Emkey, R | 1 |
| Johnson, MP | 2 |
| Schkeryantz, JM | 1 |
| Jin, C | 1 |
| Yi, C | 1 |
| Zhong, W | 1 |
| Xue, Y | 1 |
| Chen, K | 1 |
| Deng, K | 1 |
| Wang, Z | 1 |
| Wang, T | 1 |
| Ikegami, D | 1 |
| Navratilova, E | 3 |
| Yue, X | 1 |
| Moutal, A | 1 |
| Kopruszinski, CM | 2 |
| Khanna, R | 1 |
| Patwardhan, A | 1 |
| Dodick, DW | 12 |
| Porreca, F | 4 |
| Gaul, C | 1 |
| Förderreuther, S | 1 |
| Ohk, B | 1 |
| Seong, S | 1 |
| Lee, J | 1 |
| Gwon, M | 1 |
| Kang, W | 1 |
| Lee, H | 1 |
| Yoon, Y | 1 |
| Yoo, H | 1 |
| Assadpour, S | 1 |
| Shiran, MR | 1 |
| Asadi, P | 1 |
| Akhtari, J | 1 |
| Sahebkar, A | 1 |
| Nurathirah, MN | 1 |
| Yazid, MB | 1 |
| Norhayati, MN | 1 |
| Baharuddin, KA | 1 |
| Abu Bakar, MA | 1 |
| Zormpas, S | 2 |
| Matsou, A | 2 |
| Antunes, DM | 2 |
| Panos, C | 2 |
| Dolgorukova, A | 1 |
| Potapenko, AV | 2 |
| Murzina, AA | 1 |
| Lyubashina, OA | 1 |
| Y Sokolov, A | 1 |
| Javed, S | 1 |
| Hussain, A | 1 |
| Shah, PA | 1 |
| Raza, SA | 1 |
| Anwer, UU | 1 |
| Shamim, R | 1 |
| Rasool, F | 1 |
| Hafiz, MA | 1 |
| Bukhari, NI | 1 |
| Pero, A | 1 |
| Pace, A | 1 |
| Dhamoon, MS | 1 |
| Lipton, RB | 26 |
| Goadsby, PJ | 29 |
| Burstein, R | 7 |
| Adams, AM | 1 |
| Lai, J | 2 |
| Yu, SY | 1 |
| Finnegan, M | 1 |
| Kuang, AW | 1 |
| Trugman, JM | 1 |
| Peng, KP | 1 |
| Jürgens, T | 1 |
| Basedau, H | 1 |
| Ortlieb, L | 1 |
| May, A | 8 |
| Chhabra, N | 1 |
| Grill, MF | 1 |
| Singh, RBH | 1 |
| Guo, S | 4 |
| Ernstsen, C | 2 |
| Hay-Schmidt, A | 2 |
| Kristensen, DM | 2 |
| Ashina, M | 8 |
| Olesen, J | 29 |
| Christensen, SL | 2 |
| Fumal, A | 1 |
| Timmermans, G | 1 |
| Hauser Chatterjee, J | 1 |
| Hartford, EA | 1 |
| Law, E | 1 |
| Barry, D | 1 |
| Blume, H | 1 |
| Chanchlani, R | 1 |
| Agrawal, A | 1 |
| Janjua, D | 1 |
| Hafsa, SN | 1 |
| Abdelmonem, H | 1 |
| Abdelhay, HM | 1 |
| Abdelwadoud, GT | 1 |
| Alhosini, ANM | 1 |
| Ahmed, AE | 1 |
| Mohamed, SW | 1 |
| Al-Dardery, NM | 1 |
| Abd-ElGawad, M | 1 |
| Kamel, MA | 1 |
| Zhang, H | 1 |
| Qi, JZ | 1 |
| Zhang, ZH | 1 |
| Sokolov, AY | 2 |
| Volynsky, MA | 2 |
| Iurkova, PM | 1 |
| Zaytsev, VV | 2 |
| Nippolainen, E | 1 |
| Kamshilin, AA | 2 |
| Kogelman, LJA | 2 |
| Falkenberg, K | 6 |
| Ottosson, F | 1 |
| Ernst, M | 1 |
| Russo, F | 1 |
| Stentoft-Hansen, V | 1 |
| Demharter, S | 1 |
| Tfelt-Hansen, P | 35 |
| Cohen, AS | 2 |
| Hansen, TF | 3 |
| Tajti, J | 4 |
| Csáti, A | 1 |
| Szok, D | 1 |
| Shafique, U | 1 |
| Din, FU | 1 |
| Sohail, S | 1 |
| Batool, S | 1 |
| Almari, AH | 1 |
| Lahiq, AA | 1 |
| Fatease, AA | 1 |
| Alharbi, HM | 1 |
| Oskoui, M | 1 |
| Pringsheim, T | 3 |
| Holler-Managan, Y | 1 |
| Potrebic, S | 2 |
| Billinghurst, L | 1 |
| Gloss, D | 1 |
| Hershey, AD | 4 |
| Licking, N | 1 |
| Sowell, M | 2 |
| Victorio, MC | 1 |
| Gersz, EM | 1 |
| Leininger, E | 1 |
| Zanitsch, H | 1 |
| Yonker, M | 2 |
| Mack, K | 1 |
| Araya, EI | 1 |
| Turnes, JM | 1 |
| Barroso, AR | 1 |
| Chichorro, JG | 1 |
| Rønde Bjerg, H | 1 |
| Yamani, N | 1 |
| Tabeeva, GR | 5 |
| Evdokimova, EM | 1 |
| Shagbazyan, AE | 1 |
| Nishihara, C | 1 |
| Hatori, K | 1 |
| Hsu, YC | 1 |
| Ozasa, K | 1 |
| Young, A | 2 |
| Imamura, Y | 2 |
| Noma, N | 2 |
| Zhang, J | 1 |
| Czerpaniak, K | 1 |
| Huang, L | 1 |
| Liu, X | 1 |
| Cloud, ME | 1 |
| Unsinger, J | 1 |
| Hotchkiss, RS | 1 |
| Li, D | 1 |
| Cao, YQ | 1 |
| Bjerg, HR | 1 |
| Alsayed, AH | 1 |
| Avona, A | 1 |
| Mason, BN | 2 |
| Lackovic, J | 1 |
| Wajahat, N | 1 |
| Motina, M | 1 |
| Quigley, L | 1 |
| Burgos-Vega, C | 1 |
| Moldovan Loomis, C | 1 |
| Garcia-Martinez, LF | 2 |
| Akopian, AN | 1 |
| Price, TJ | 1 |
| Dussor, G | 2 |
| Jakate, A | 1 |
| Boinpally, R | 1 |
| Butler, M | 1 |
| Lu, K | 1 |
| McGeeney, D | 1 |
| Periclou, A | 1 |
| Okonkwo, K | 1 |
| Ojha, U | 1 |
| Diener, HC | 34 |
| Swiokla, J | 1 |
| Chessell, IP | 1 |
| Lim, C | 1 |
| Singh, M | 1 |
| Wienholtz, NKF | 1 |
| Christensen, CE | 3 |
| Zhang, DG | 1 |
| Coskun, H | 1 |
| Ghanizada, H | 2 |
| Al-Karagholi, MA | 1 |
| Hannibal, J | 1 |
| Egeberg, A | 1 |
| Thyssen, JP | 1 |
| Davidsson, OB | 1 |
| Olofsson, IA | 1 |
| Kogelman, LJ | 1 |
| Andersen, MA | 1 |
| Rostgaard, K | 1 |
| Hjalgrim, H | 1 |
| Ala, M | 1 |
| Ghasemi, M | 1 |
| Mohammad Jafari, R | 1 |
| Dehpour, AR | 1 |
| Osipchuk, AV | 1 |
| Tanaka, M | 1 |
| Török, N | 1 |
| Vécsei, L | 5 |
| Buil, A | 1 |
| Erola, P | 1 |
| Courraud, J | 1 |
| Laursen, SS | 1 |
| Michoel, T | 1 |
| Silberstein, S | 8 |
| Winner, PK | 5 |
| McAllister, PJ | 2 |
| Tepper, SJ | 12 |
| Halker, R | 1 |
| Mahmoud, RA | 3 |
| Siffert, J | 2 |
| Hsu, CR | 1 |
| Chen, YH | 1 |
| Tai, MC | 1 |
| Lu, DW | 1 |
| Dallel, R | 1 |
| Descheemaeker, A | 1 |
| Luccarini, P | 1 |
| McGinley, JS | 3 |
| Shulman, KJ | 3 |
| Wirth, RJ | 3 |
| Buse, DC | 4 |
| Menshawy, A | 1 |
| Ahmed, H | 1 |
| Ismail, A | 1 |
| Abushouk, AI | 1 |
| Ghanem, E | 1 |
| Pallanti, R | 1 |
| Negida, A | 1 |
| Silberstein, SD | 12 |
| Ben Aissa, M | 1 |
| Tipton, AF | 2 |
| Bertels, Z | 1 |
| Gandhi, R | 1 |
| Moye, LS | 1 |
| Novack, M | 1 |
| Bennett, BM | 1 |
| Wang, Y | 1 |
| Litosh, V | 1 |
| Lee, SH | 1 |
| Gaisina, IN | 1 |
| Thatcher, GR | 1 |
| Pradhan, AA | 3 |
| Kluonaitis, K | 1 |
| Petrauskiene, E | 1 |
| Ryliskiene, K | 1 |
| Kunkler, PE | 1 |
| Zhang, L | 2 |
| Johnson, PL | 1 |
| Oxford, GS | 1 |
| Hurley, JH | 1 |
| Allais, G | 3 |
| Chiarle, G | 1 |
| Sinigaglia, S | 1 |
| Benedetto, C | 3 |
| Dunga, BÓÁ | 1 |
| Zebenholzer, K | 1 |
| Gall, W | 1 |
| Wöber, C | 4 |
| de Hoon, J | 2 |
| Van Hecken, A | 1 |
| Vandermeulen, C | 1 |
| Herbots, M | 1 |
| Kubo, Y | 1 |
| Lee, E | 1 |
| Eisele, O | 1 |
| Vargas, G | 1 |
| Gabriel, K | 1 |
| Schwedt, TJ | 1 |
| Alam, A | 1 |
| Reed, ML | 1 |
| Fanning, KM | 1 |
| Munjal, S | 7 |
| Bulboacă, AE | 1 |
| Bolboacă, SD | 1 |
| Stănescu, IC | 1 |
| Sfrângeu, CA | 1 |
| Porfire, A | 1 |
| Tefas, L | 1 |
| Bulboacă, AC | 1 |
| Brand-Schieber, E | 6 |
| Rapoport, AM | 14 |
| Nakamura, M | 1 |
| Jang, IS | 1 |
| Borchard-Tuch, C | 1 |
| Walling, I | 1 |
| Panse, D | 1 |
| Gee, L | 1 |
| Maietta, T | 1 |
| Kaszuba, B | 1 |
| Kumar, V | 1 |
| Gannon, S | 1 |
| Hellman, A | 1 |
| Neubauer, P | 1 |
| Frith, L | 1 |
| Williams, E | 1 |
| Ghoshal, G | 1 |
| Shin, DS | 1 |
| Burdette, C | 1 |
| Qian, J | 1 |
| Pilitsis, JG | 1 |
| Landy, S | 11 |
| Yusuf, A | 1 |
| Chia, V | 1 |
| Xue, F | 1 |
| Mikol, DD | 1 |
| Bollinger, L | 1 |
| Cangialose, C | 1 |
| Watanabe, K | 1 |
| Hayashi, M | 1 |
| Yan, Z | 1 |
| Nation, KM | 1 |
| Loder, EW | 2 |
| Rayhill, M | 1 |
| Burch, RC | 1 |
| Mi, X | 1 |
| Ran, L | 1 |
| Chen, L | 1 |
| Qin, G | 1 |
| Khan, S | 2 |
| Amin, FM | 2 |
| Younis, S | 2 |
| Olinger, ACR | 2 |
| de Koning, PJH | 1 |
| Larsson, HBW | 2 |
| Akerman, S | 2 |
| Karsan, N | 1 |
| Bose, P | 1 |
| Hoffmann, JR | 1 |
| Holland, PR | 1 |
| Romero-Reyes, M | 1 |
| Parkinson, B | 1 |
| Gumbie, M | 1 |
| Cutler, H | 1 |
| Gauld, N | 1 |
| Mumford, V | 1 |
| Haywood, P | 1 |
| Bishop, J | 1 |
| Becerra, L | 1 |
| Barmettler, G | 1 |
| Chang, PC | 2 |
| Kainz, V | 1 |
| Borsook, D | 1 |
| Hugentobler, E | 1 |
| Fliedner, FP | 1 |
| Tolnai, D | 1 |
| Birgens, H | 1 |
| Daldrup-Link, H | 1 |
| Kjær, A | 1 |
| Lindberg, U | 1 |
| Edwards, KR | 1 |
| Rosenthal, BL | 1 |
| Farmer, KU | 1 |
| Cady, RK | 27 |
| Browning, R | 1 |
| Jones, S | 1 |
| Lang, E | 1 |
| Peterlin, BL | 3 |
| Tietjen, GE | 4 |
| Gower, BA | 2 |
| Ward, TN | 2 |
| White, LW | 2 |
| Dash, PD | 3 |
| Hammond, ER | 1 |
| Haythornthwaite, JA | 1 |
| Newman, LC | 6 |
| Marmura, MJ | 1 |
| Nahas, SJ | 2 |
| Farr, SJ | 4 |
| Lanteri-Minet, M | 2 |
| Tfelt-Hansen, PC | 3 |
| Derry, S | 15 |
| Moore, RA | 15 |
| Kirthi, V | 3 |
| Rabbie, R | 2 |
| Evers, S | 6 |
| Marcus, DA | 2 |
| Depré, M | 1 |
| Macleod, C | 1 |
| Palcza, J | 1 |
| Behm, M | 1 |
| de Lepeleire, I | 1 |
| Han, T | 1 |
| Panebianco, D | 1 |
| Smith, W | 1 |
| Blanchard, R | 1 |
| Chodakewitz, J | 1 |
| Murphy, M | 1 |
| Benoliel, R | 1 |
| Eliav, E | 1 |
| Garnock-Jones, KP | 1 |
| Yang, LP | 1 |
| Gomez-Mancilla, B | 2 |
| Brand, R | 1 |
| Jürgens, TP | 2 |
| Göbel, H | 14 |
| Sommer, C | 1 |
| Straube, A | 1 |
| Sommer, M | 1 |
| Campos, V | 1 |
| Kalkman, HO | 1 |
| Hariry, S | 1 |
| Pezous, N | 1 |
| Johns, D | 1 |
| Marcus, R | 1 |
| Dodick, D | 5 |
| Stock, D | 1 |
| Manos, G | 1 |
| Fischer, TZ | 1 |
| Cady, R | 17 |
| Nett, R | 4 |
| Dexter, K | 2 |
| Freitag, F | 3 |
| Beach, ME | 2 |
| Manley, HR | 2 |
| O'Carroll, P | 2 |
| Shade, CL | 1 |
| Rothrock, JF | 9 |
| Freitag, FG | 7 |
| Smith, EF | 1 |
| Pierce, M | 6 |
| O'Neill, C | 4 |
| Felker, E | 1 |
| Sebree, T | 5 |
| Landy, SH | 4 |
| Nelsen, A | 1 |
| White, J | 3 |
| Runken, MC | 5 |
| Smith, ML | 1 |
| McGuire, B | 2 |
| Tarash, I | 2 |
| Evans, CJ | 1 |
| Charles, A | 2 |
| Law, S | 3 |
| Hämäläinen, M | 2 |
| Fujita, M | 1 |
| Sato, K | 1 |
| Nishioka, H | 1 |
| Sakai, F | 6 |
| Asadollahi, S | 1 |
| Heidari, K | 1 |
| Vafaee, R | 1 |
| Forouzanfar, MM | 1 |
| Amini, A | 1 |
| Shahrami, A | 1 |
| Napoletano, F | 1 |
| Lionetto, L | 3 |
| Martelletti, P | 7 |
| Jansen-Olesen, I | 2 |
| Spierings, EL | 7 |
| Evans, RW | 4 |
| Goldstein, J | 7 |
| Smith, T | 3 |
| Pugach, N | 3 |
| Griesser, J | 2 |
| Chessman, AW | 1 |
| Martin, VT | 2 |
| Ballard, J | 1 |
| Diamond, MP | 2 |
| Mannix, LK | 7 |
| Derosier, FJ | 7 |
| Lener, SE | 8 |
| Krishen, A | 2 |
| McDonald, SA | 11 |
| Wang, X | 1 |
| Fang, Y | 1 |
| Liang, J | 1 |
| Yan, M | 1 |
| Hu, R | 1 |
| Pan, X | 1 |
| Vikelis, M | 2 |
| Mitsikostas, DD | 2 |
| Lippi, G | 1 |
| Meschi, T | 1 |
| Mattiuzzi, C | 1 |
| Borghi, L | 1 |
| Targher, G | 1 |
| Calhoun, AH | 1 |
| Ford, S | 1 |
| Meadows, KP | 1 |
| Foster, S | 1 |
| Jennings, C | 1 |
| Grände, G | 1 |
| Labruijere, S | 1 |
| Haanes, KA | 1 |
| MaassenVanDenBrink, A | 5 |
| Edvinsson, L | 7 |
| Derry, CJ | 5 |
| Moshtaghion, H | 1 |
| Heiranizadeh, N | 1 |
| Rahimdel, A | 1 |
| Esmaeili, A | 1 |
| Hashemian, H | 1 |
| Hekmatimoghaddam, S | 1 |
| Chen, TB | 1 |
| Chen, YT | 1 |
| Fuh, JL | 2 |
| Tang, CH | 1 |
| Wang, SJ | 2 |
| Lecchi, M | 1 |
| D'Alonzo, L | 2 |
| Negro, A | 3 |
| Schytz, HW | 1 |
| Bendtsen, L | 1 |
| Goodwin, B | 1 |
| Shah, M | 1 |
| Eaddy, M | 1 |
| D'Souza, A | 1 |
| Bowers, B | 1 |
| Bell, CF | 1 |
| Tepper, DE | 2 |
| Messina, J | 2 |
| Carothers, J | 1 |
| Djupesland, PG | 4 |
| Tokuoka, K | 1 |
| Takayanagi, R | 1 |
| Suzuki, Y | 1 |
| Watanabe, M | 1 |
| Kitagawa, Y | 1 |
| Yamada, Y | 1 |
| Barbanti, P | 4 |
| Egeo, G | 1 |
| Jagdale, SC | 1 |
| Pawar, CR | 1 |
| Chai, NC | 1 |
| Gelaye, B | 2 |
| Scher, AI | 1 |
| Wu, D | 1 |
| Quan, YS | 1 |
| Kamiyama, F | 1 |
| Kusamori, K | 1 |
| Katsumi, H | 1 |
| Sakane, T | 1 |
| Yamamoto, A | 1 |
| Truter, I | 1 |
| Winner, P | 10 |
| Linder, S | 2 |
| Hansen, EK | 2 |
| Shin, P | 1 |
| Goldman, RD | 1 |
| Meckler, GD | 1 |
| Bigal, ME | 8 |
| Pierce, MW | 3 |
| Bajard, A | 2 |
| Chabaud, S | 2 |
| Cornu, C | 1 |
| Castellan, AC | 1 |
| Malik, S | 1 |
| Kurbatova, P | 1 |
| Volpert, V | 1 |
| Eymard, N | 1 |
| Kassai, B | 1 |
| Nony, P | 2 |
| Hansraj, GP | 1 |
| Singh, SK | 2 |
| Kumar, P | 1 |
| Farkas, B | 1 |
| Kardos, P | 1 |
| Orosz, S | 1 |
| Tarnawa, I | 1 |
| Csekő, C | 1 |
| Lévay, G | 1 |
| Farkas, S | 1 |
| Lendvai, B | 1 |
| Kovács, P | 1 |
| Jensen, C | 1 |
| Riddle, M | 1 |
| Ghaderibarmi, F | 1 |
| Tavakkoli, N | 1 |
| Togha, M | 1 |
| Syed, YY | 1 |
| Matthaei, J | 1 |
| Kuron, D | 1 |
| Faltraco, F | 1 |
| Knoch, T | 1 |
| Dos Santos Pereira, JN | 1 |
| Abu Abed, M | 1 |
| Prukop, T | 1 |
| Brockmöller, J | 1 |
| Tzvetkov, MV | 1 |
| Rao, AS | 1 |
| Kurth, T | 1 |
| Nitchie, H | 1 |
| Ibrahimi, K | 1 |
| Danser, A | 1 |
| Terwindt, GM | 2 |
| van den Meiracker, AH | 1 |
| Barleycorn, D | 1 |
| Girotra, P | 1 |
| Cohen, SP | 1 |
| Chaudhry, H | 1 |
| Tepper, D | 1 |
| Sufka, KJ | 1 |
| Staszko, SM | 1 |
| Johnson, AP | 1 |
| Davis, ME | 1 |
| Davis, RE | 1 |
| Smitherman, TA | 1 |
| Hunter, P | 1 |
| Shumate, DA | 1 |
| Gutman, D | 1 |
| Hellriegel, E | 1 |
| Aycardi, E | 1 |
| Kunta, J | 1 |
| Chitra, R | 2 |
| Kansagra, S | 1 |
| Kidron, OS | 1 |
| Knebel, H | 1 |
| Ma, Y | 1 |
| Spiegelstein, O | 1 |
| Seng, EK | 1 |
| Robbins, MS | 1 |
| Nicholson, RA | 1 |
| Thorlund, K | 1 |
| Toor, K | 1 |
| Wu, P | 1 |
| Chan, K | 1 |
| Druyts, E | 1 |
| Ramos, E | 2 |
| Bhambri, R | 1 |
| Donnet, A | 1 |
| Stark, R | 1 |
| Aschenbrenner, DS | 1 |
| Långsjö, JW | 1 |
| Lehtimäki, K | 1 |
| Ruohonen, J | 1 |
| Sajanti, A | 1 |
| Sandell, S | 1 |
| Heikkilä, HT | 1 |
| Brander, A | 1 |
| Saarinen, K | 1 |
| Herrala, L | 2 |
| Al-Salama, ZT | 1 |
| Scott, LJ | 1 |
| Jones, MG | 1 |
| Andreou, AP | 1 |
| McMahon, SB | 1 |
| Spanswick, D | 1 |
| Novitskaya, ES | 1 |
| Cates, CA | 1 |
| Bowes, OM | 1 |
| Vivian, AJ | 1 |
| Xu, H | 1 |
| Han, W | 1 |
| Wang, J | 1 |
| Li, M | 1 |
| Kaiser, EA | 1 |
| Kuburas, A | 1 |
| Loomis, MM | 1 |
| Latham, JA | 1 |
| Russo, AF | 2 |
| Knapp, L | 1 |
| Szita, B | 1 |
| Kocsis, K | 1 |
| Toldi, J | 1 |
| Jand, A | 1 |
| Palizvan, MR | 1 |
| Kandasamy, R | 1 |
| Lee, AT | 1 |
| Morgan, MM | 1 |
| Cady, RJ | 1 |
| Allenby, K | 1 |
| Spierings, ELH | 1 |
| O'Quinn, S | 11 |
| Mansbach, H | 3 |
| Salonen, R | 11 |
| Couch, JR | 2 |
| Byrd, SC | 1 |
| Ames, MH | 3 |
| Toso, C | 1 |
| Kurul, SH | 1 |
| Demirpence, S | 1 |
| Kiray, M | 1 |
| Tugyan, K | 1 |
| Yilmaz, O | 1 |
| Kose, G | 1 |
| Cleves, C | 1 |
| Hibino, T | 1 |
| Yuzurihara, M | 1 |
| Terawaki, K | 1 |
| Kanno, H | 1 |
| Kase, Y | 1 |
| Takeda, A | 1 |
| Dahlöf, C | 25 |
| Kwong, WJ | 5 |
| Burch, SP | 2 |
| Nelsen, AC | 2 |
| Adelman, JU | 6 |
| Kaniecki, RG | 3 |
| White, JD | 2 |
| Maas, HJ | 5 |
| Danhof, M | 5 |
| Della Pasqua, OE | 3 |
| Lockwood, AH | 1 |
| Marbury, T | 1 |
| Siegel, S | 2 |
| Du, W | 1 |
| Aurora, SK | 4 |
| Barrodale, PM | 1 |
| Jakubowski, M | 5 |
| Oh, SY | 1 |
| Seo, MW | 1 |
| Kim, YH | 1 |
| Choi, KD | 1 |
| Kim, DS | 1 |
| Shin, BS | 1 |
| Mathew, NT | 10 |
| Stark, S | 1 |
| Bukenya, D | 1 |
| Diamond, ML | 4 |
| Pérol, D | 1 |
| Boissel, JP | 1 |
| Chawluk, JB | 1 |
| Luthringer, R | 1 |
| Sheldrake, CD | 1 |
| Flint, A | 1 |
| Boeijinga, P | 1 |
| Danjou, P | 1 |
| Demazières, A | 1 |
| Hewson, G | 1 |
| Dahlöf, CG | 12 |
| Hauge, AW | 1 |
| Ghelardini, C | 3 |
| Galeotti, N | 3 |
| Vivoli, E | 1 |
| Grazioli, I | 4 |
| Uslenghi, C | 4 |
| Lynch, JJ | 1 |
| Shen, YT | 1 |
| Pittman, TJ | 1 |
| Anderson, KD | 1 |
| Koblan, KS | 1 |
| Gould, RJ | 1 |
| Regan, CP | 1 |
| Kane, SA | 1 |
| Jain, SA | 1 |
| Chauk, DS | 1 |
| Mahajan, HS | 1 |
| Tekade, AR | 1 |
| Gattani, SG | 1 |
| Fox, AW | 12 |
| Meyer, H | 1 |
| Beau-Salinas, F | 1 |
| Jonville-Béra, AP | 1 |
| Cissoko, H | 1 |
| Bensouda-Grimaldi, L | 1 |
| Autret-Leca, E | 1 |
| Azimova, IuE | 2 |
| Kostic, MA | 1 |
| Gutierrez, FJ | 1 |
| Rieg, TS | 1 |
| Moore, TS | 1 |
| Gendron, RT | 1 |
| Balaguer-Fernández, C | 2 |
| Padula, C | 1 |
| Femenía-Font, A | 2 |
| Merino, V | 2 |
| Santi, P | 1 |
| López-Castellano, A | 2 |
| Friedman, BW | 5 |
| Bijur, PE | 5 |
| Haberer, LJ | 1 |
| Walls, CM | 1 |
| Taylor, DR | 1 |
| DeLeon, D | 1 |
| Douglas, C | 1 |
| Schwiebert, P | 1 |
| Solorzano, C | 4 |
| Esses, D | 4 |
| Xia, S | 1 |
| Hochberg, M | 2 |
| Dua, N | 1 |
| Heins, A | 1 |
| Sasso, P | 1 |
| Gallagher, EJ | 3 |
| Durham, PL | 3 |
| Vause, CV | 1 |
| Derosier, F | 2 |
| McDonald, S | 2 |
| Martin, V | 2 |
| Khoury, CK | 1 |
| McQuay, HJ | 2 |
| MacGregor, EA | 1 |
| Pawsey, SP | 1 |
| Campbell, JC | 1 |
| Hu, X | 1 |
| Kakisaka, Y | 1 |
| Wakusawa, K | 1 |
| Haginoya, K | 1 |
| Uematsu, M | 1 |
| Tsuchiya, S | 1 |
| Hiremath, VB | 1 |
| Kaliaperumal, K | 1 |
| Bhojraj, S | 1 |
| Nanjan, MJ | 1 |
| Kodounis, A | 1 |
| Zaglis, D | 1 |
| Xifaras, M | 1 |
| Doitsini, S | 1 |
| Georgiadis, G | 1 |
| Thomas, A | 1 |
| Charmoussi, S | 1 |
| Duong, S | 1 |
| Bozzo, P | 1 |
| Nordeng, H | 1 |
| Einarson, A | 1 |
| Loder, E | 3 |
| De Felice, M | 1 |
| Ossipov, MH | 1 |
| Wang, R | 1 |
| Meng, ID | 1 |
| Chichorro, J | 1 |
| Andrews, JS | 1 |
| Maddaford, S | 1 |
| Docekal, P | 1 |
| Stone, K | 1 |
| Torgovnick, J | 1 |
| Sethi, NK | 1 |
| Arsura, E | 1 |
| Keller, DL | 1 |
| Shaffer, CR | 1 |
| Pearlman, SH | 1 |
| Barra, S | 1 |
| Lanero, S | 1 |
| Madrid, A | 1 |
| Materazzi, C | 1 |
| Vitagliano, G | 1 |
| Ames, PR | 1 |
| Gaeta, G | 1 |
| Seeburger, JL | 1 |
| Taylor, FR | 2 |
| Friedman, D | 1 |
| Newman, L | 1 |
| Ge, Y | 1 |
| Zhang, Y | 2 |
| Hustad, CM | 1 |
| Lasorda, J | 1 |
| Fan, X | 1 |
| Hewitt, D | 1 |
| Ho, T | 1 |
| Connor, KM | 1 |
| Ravindran, MK | 1 |
| Zheng, Y | 1 |
| Timbol, C | 1 |
| Merck, SJ | 1 |
| Baraniuk, JN | 1 |
| Ballard, JE | 1 |
| Lener, ME | 1 |
| Dorner, DP | 1 |
| Lindkvist, J | 1 |
| Airaksinen, M | 1 |
| Kaukonen, AM | 1 |
| Klaukka, T | 1 |
| Hoppu, K | 3 |
| Gazioglu, S | 1 |
| Boz, C | 1 |
| Ozmenoglu, M | 1 |
| Pearlman, E | 2 |
| Lewis, D | 2 |
| Rothner, D | 1 |
| Linder, SL | 2 |
| Richard, NE | 1 |
| Sheshala, R | 1 |
| Khan, N | 1 |
| Darwis, Y | 1 |
| Brandes, JL | 5 |
| Myers, JA | 2 |
| Hoagland, R | 1 |
| Hoagland, NA | 1 |
| Gromova, SA | 1 |
| Castagnoli Gabellari, I | 1 |
| Rolando, S | 1 |
| Frampton, JE | 1 |
| Sheftell, F | 5 |
| Ruoff, G | 2 |
| Peykamian, M | 3 |
| White, WB | 1 |
| Thompson, AH | 1 |
| Adams, BE | 1 |
| Goodman, DK | 2 |
| Blumenfeld, A | 1 |
| Gennings, C | 1 |
| Schulman, EA | 2 |
| McCrory, DC | 2 |
| Gray, RN | 2 |
| Smith, TR | 5 |
| Singer, R | 2 |
| Rizzoli, PB | 1 |
| Erlichson, K | 1 |
| Waight, J | 1 |
| Peatfield, R | 1 |
| Oberhardt, F | 1 |
| Maassen Van Den Brink, A | 1 |
| Viana, M | 1 |
| Mathias, CJ | 1 |
| Williams, SH | 1 |
| Kehr, HA | 1 |
| Rothner, AD | 6 |
| Jimenez, TB | 1 |
| Granberry, WK | 1 |
| Casolla, B | 2 |
| Candela, S | 1 |
| Simmaco, M | 2 |
| McQuay, H | 1 |
| Norton, J | 1 |
| Adewumni, V | 1 |
| Campbell, CM | 1 |
| Solomon, S | 8 |
| John Gallagher, E | 1 |
| Asseburg, C | 1 |
| Peura, P | 1 |
| Oksanen, T | 1 |
| Turunen, J | 1 |
| Purmonen, T | 1 |
| Martikainen, J | 1 |
| Pini, LA | 2 |
| Guerzoni, S | 1 |
| Cainazzo, M | 1 |
| Ciccarese, M | 1 |
| Prudenzano, MP | 1 |
| Livrea, P | 1 |
| Wein, T | 1 |
| Schweizer, E | 1 |
| Stillman, MJ | 1 |
| Tepper, S | 4 |
| Cho, L | 1 |
| Hougaard, A | 1 |
| Yong, JW | 1 |
| Anand, G | 1 |
| Sheftell, FD | 6 |
| Ficzere, A | 1 |
| Csiba, L | 1 |
| Dowson, AJ | 7 |
| Massiou, H | 7 |
| Laínez, JM | 3 |
| Cabarrocas, X | 2 |
| Fukuda, M | 1 |
| Suzuki, N | 3 |
| Maruyama, S | 1 |
| Dobashi, K | 1 |
| Kitamura, A | 1 |
| Fuseau, E | 6 |
| Petricoul, O | 2 |
| Moore, KH | 2 |
| Barrow, A | 1 |
| Ibbotson, T | 1 |
| Hirata, K | 1 |
| Tomita, M | 2 |
| Igarashi, H | 2 |
| Endo, M | 1 |
| Richardson, MS | 3 |
| Bowers, BW | 1 |
| Petrie, JL | 1 |
| Wyderski, RJ | 1 |
| Naik, M | 1 |
| Potluri, R | 1 |
| Almasri, E | 1 |
| Arnold, GL | 1 |
| Limmroth, V | 6 |
| Bussone, G | 4 |
| D'Amico, D | 1 |
| McCarroll, KA | 5 |
| Gerth, W | 1 |
| Lines, CR | 6 |
| Ferrari, MD | 36 |
| Roon, KI | 3 |
| Ikeda, Y | 2 |
| Jimbo, H | 1 |
| Shimazu, M | 1 |
| Satoh, K | 1 |
| Robbins, L | 1 |
| Sandrini, G | 3 |
| Färkkilä, M | 5 |
| Burgess, G | 1 |
| Forster, E | 1 |
| Haughie, S | 1 |
| Villalón, CM | 6 |
| Centurión, D | 2 |
| Valdivia, LF | 2 |
| De Vries, P | 8 |
| Saxena, PR | 27 |
| Katsarava, Z | 4 |
| Boes, CJ | 1 |
| Visser, WH | 10 |
| Giffin, N | 1 |
| Pascual, J | 13 |
| Kayser, V | 1 |
| Aubel, B | 1 |
| Hamon, M | 2 |
| Bourgoin, S | 2 |
| Jones, M | 4 |
| Loftus, J | 2 |
| Saiers, J | 5 |
| Vilionskis, A | 1 |
| Vaitkus, A | 1 |
| Huff, R | 1 |
| Chio, CL | 1 |
| TenBrink, R | 1 |
| Bergh, CL | 1 |
| Meisheri, K | 1 |
| Higdon, NR | 1 |
| Hall, E | 1 |
| Nappi, G | 6 |
| Sances, G | 1 |
| Melchart, D | 4 |
| Thormaehlen, J | 1 |
| Hager, S | 1 |
| Liao, J | 1 |
| Linde, K | 1 |
| Weidenhammer, W | 1 |
| Rahimtoola, H | 4 |
| Buurma, H | 4 |
| Tijssen, CC | 4 |
| Leufkens, HG | 4 |
| Egberts, AC | 4 |
| Cockey, CD | 1 |
| Chmiel, JJ | 1 |
| Schoenen, J | 15 |
| Muirhead, N | 2 |
| Sikes, CR | 1 |
| Zsombok, T | 1 |
| Juhasz, G | 1 |
| Budavari, A | 1 |
| Vitrai, J | 1 |
| Bagdy, G | 1 |
| Carpay, JA | 2 |
| Linssen, WH | 4 |
| Koehler, PJ | 2 |
| Arends, LR | 1 |
| Tiedink, HG | 1 |
| Fabbrini, G | 1 |
| Vanacore, N | 1 |
| Pesare, M | 1 |
| Buzzi, MG | 4 |
| Deleu, D | 2 |
| Hanssens, Y | 2 |
| Lewit, EJ | 1 |
| Steiner, T | 1 |
| Stovner, LJ | 4 |
| ter Bruggen, JP | 1 |
| Rasmussen, S | 2 |
| Sikes, C | 2 |
| Meredith, JT | 1 |
| Wait, S | 1 |
| Brewer, KL | 1 |
| Christensen, ML | 2 |
| Mottern, RK | 2 |
| Jabbour, JT | 2 |
| Ramadan, NM | 1 |
| Gallagher, RM | 5 |
| Kunkel, R | 1 |
| Goldman, MD | 1 |
| Login, IS | 1 |
| Di Monda, V | 1 |
| Nicolodi, M | 4 |
| Aloisio, A | 1 |
| Del Bianco, P | 1 |
| Fonzari, M | 1 |
| Vecchiet, L | 1 |
| Sicuteri, F | 5 |
| Loftus, BD | 1 |
| Létienne, R | 2 |
| Verscheure, Y | 1 |
| John, GW | 2 |
| Charlesworth, BR | 1 |
| Putnam, DG | 3 |
| McNeal, S | 3 |
| Kwong, J | 1 |
| Shackelford, S | 2 |
| Ames, M | 4 |
| Lener, M | 1 |
| Schuh-Hofer, S | 1 |
| Boehnke, C | 1 |
| Reuter, U | 2 |
| Siekmann, W | 1 |
| Lindauer, U | 1 |
| Arnold, G | 1 |
| Dirnagl, U | 1 |
| Lisotto, C | 1 |
| Mainardi, F | 1 |
| Maggioni, F | 1 |
| Zanchin, G | 2 |
| Kosinski, M | 1 |
| Bjorner, JB | 1 |
| Ware, JE | 1 |
| Batenhorst, A | 3 |
| Major, PW | 1 |
| Grubisa, HS | 1 |
| Thie, NM | 1 |
| Dobson, CF | 1 |
| Tohyama, Y | 1 |
| Diksic, M | 2 |
| Hamel, E | 5 |
| Pakalnis, A | 1 |
| Kring, D | 1 |
| Paolicchi, J | 1 |
| Collins, B | 1 |
| Ryan, R | 3 |
| Sun, W | 2 |
| Hettiarachchi, J | 3 |
| Hall, GC | 1 |
| Brown, MM | 1 |
| Mo, J | 1 |
| MacRae, KD | 1 |
| Finfgeld, DL | 1 |
| Ashcroft, DM | 1 |
| Millson, D | 3 |
| Iizuka, T | 1 |
| Lucas, C | 1 |
| Auray, JP | 1 |
| Gaudin, AF | 1 |
| Dartigues, JF | 1 |
| Duru, G | 1 |
| Henry, P | 3 |
| Pradalier, A | 3 |
| Chazot, G | 3 |
| El Hasnaoui, A | 1 |
| Levy, D | 3 |
| Ahonen, K | 1 |
| Hämäläinen, ML | 2 |
| Rantala, H | 1 |
| Carpay, J | 1 |
| Ahmad, F | 2 |
| Kinrade, F | 1 |
| Boswell, D | 4 |
| Krobot, KJ | 3 |
| Miller, WC | 3 |
| Kaufman, JS | 3 |
| Christensen, DB | 3 |
| Preisser, JS | 3 |
| Ibrahim, MA | 3 |
| Edmeads, J | 2 |
| Lines, C | 3 |
| Araki, N | 1 |
| Bassi, S | 1 |
| Amersey, R | 1 |
| Henderson, R | 1 |
| Morris, GK | 1 |
| Strassman, AM | 1 |
| Kolodny, A | 2 |
| Polis, A | 1 |
| Battisti, WP | 1 |
| Johnson-Pratt, L | 2 |
| Skobieranda, F | 2 |
| Barrows, C | 1 |
| Saunders, W | 1 |
| Austin, R | 3 |
| Putnam, G | 2 |
| Eikermann, A | 2 |
| Gessner, U | 1 |
| Haag, G | 2 |
| Lange, R | 2 |
| Müller-Schwefe, G | 1 |
| Voelker, M | 3 |
| Weaver, MB | 1 |
| Mackowiak, JI | 3 |
| Solari, PG | 1 |
| Christoph-Diener, H | 1 |
| Ferrari, M | 2 |
| Balbisi, EA | 1 |
| Arulmani, U | 1 |
| Heiligers, JP | 7 |
| Garrelds, IM | 1 |
| Sánchez-López, A | 1 |
| Willems, EW | 2 |
| Hilaire, ML | 1 |
| Cross, LB | 1 |
| Eichner, SF | 1 |
| Mellick, LB | 1 |
| Mellick, GA | 1 |
| Savani, N | 4 |
| Martin, A | 1 |
| Browning, D | 1 |
| Scholpp, J | 1 |
| Schellenberg, R | 1 |
| Moeckesch, B | 1 |
| Banik, N | 1 |
| de Liano, H | 1 |
| Englert, R | 1 |
| Floeter, T | 1 |
| Gallai, V | 1 |
| Hartung, E | 1 |
| Jimenez, MD | 1 |
| Manzoni, GC | 3 |
| Mueller-Schwefe, G | 1 |
| Pinessi, L | 4 |
| Prat, J | 1 |
| Puca, FM | 1 |
| Titus, F | 3 |
| Gendolla, A | 2 |
| Narbone, MC | 1 |
| Abbate, M | 1 |
| Gangemi, S | 1 |
| Kato, K | 1 |
| Manaka, S | 1 |
| Nakashima, K | 1 |
| Takeshima, T | 1 |
| Kowa, H | 1 |
| Morillo, LE | 2 |
| Linde, M | 3 |
| Elam, M | 1 |
| Lundblad, L | 1 |
| Olausson, H | 1 |
| Lawrence, EC | 1 |
| Dash, S | 1 |
| Bogdanova, O | 1 |
| Xavier, A | 1 |
| Farkas, J | 1 |
| Pullicino, P | 1 |
| Drucker, P | 1 |
| Géraud, G | 5 |
| Muñoz, P | 1 |
| Cheng, FH | 1 |
| Andrews, PL | 1 |
| Moreaux, B | 1 |
| Ngan, MP | 1 |
| Rudd, JA | 1 |
| Sam, TS | 1 |
| Wai, MK | 1 |
| Wan, C | 1 |
| Brandes, J | 1 |
| Elkind, A | 3 |
| Mathew, N | 2 |
| Rodichok, L | 1 |
| Corbo, J | 2 |
| Cuvellier, JC | 2 |
| Joriot, S | 2 |
| Auvin, S | 2 |
| Vallée, L | 2 |
| Annequin, D | 1 |
| Tourniaire, B | 1 |
| Thibault, P | 1 |
| Curran, MP | 1 |
| Evans, HC | 1 |
| Wagstaff, AJ | 1 |
| Lofland, JH | 4 |
| Nash, DB | 3 |
| McGinnis, JE | 2 |
| Ahn, AH | 1 |
| Basbaum, AI | 1 |
| Uyarel, H | 1 |
| Erden, I | 1 |
| Cam, N | 1 |
| Hall, DB | 1 |
| Meier, U | 1 |
| Kori, SH | 2 |
| Gebert, I | 1 |
| Beneke, M | 1 |
| Agosti, R | 1 |
| Jones, MW | 1 |
| Barrett, PS | 3 |
| Vollono, C | 1 |
| Capuano, A | 1 |
| Mei, D | 1 |
| Ferraro, D | 1 |
| Pierguidi, L | 1 |
| Evangelista, M | 1 |
| Di Trapani, G | 1 |
| Hay, JW | 1 |
| Schuurmans, A | 1 |
| van Weel, C | 1 |
| Clayton, AH | 1 |
| West, SG | 1 |
| McGarvey, E | 1 |
| Leslie, C | 1 |
| Keller, A | 1 |
| Lewis, DW | 1 |
| Blanchet, JC | 1 |
| Sole, E | 1 |
| Le Grand, B | 1 |
| McCrory, P | 1 |
| Heywood, J | 6 |
| Ugoni, A | 1 |
| Damen, L | 1 |
| Bruijn, JK | 1 |
| Verhagen, AP | 1 |
| Berger, MY | 1 |
| Passchier, J | 3 |
| Koes, BW | 1 |
| Mandema, JW | 1 |
| Cox, E | 1 |
| Alderman, J | 1 |
| Saper, JR | 3 |
| Elkind, AH | 1 |
| Battikha, JP | 1 |
| Hoffman, H | 1 |
| Baggish, J | 1 |
| Sunshine, A | 1 |
| Stark, SR | 2 |
| Littlefield, DE | 1 |
| Spruill, SE | 2 |
| Alexander, WJ | 3 |
| Denuelle, M | 1 |
| Fabre, N | 1 |
| Payoux, P | 1 |
| Chollet, F | 1 |
| Gueorguieva, I | 1 |
| Nestorov, IA | 1 |
| Aarons, L | 1 |
| Rowland, M | 1 |
| Brenner, SR | 1 |
| Allena, M | 1 |
| Magis, D | 1 |
| Sternieri, E | 1 |
| Pinetti, D | 1 |
| Coccia, CP | 1 |
| Leone, S | 1 |
| Bertolini, A | 1 |
| Ferrari, A | 2 |
| Richardson, M | 2 |
| Zinck, T | 1 |
| Illum, R | 1 |
| Bellamy, JL | 1 |
| Hutchinson, SL | 1 |
| Twomey, C | 1 |
| Kuhn, TA | 1 |
| Mellberg, A | 2 |
| Søndergaard, J | 1 |
| Foged, A | 1 |
| Kragstrup, J | 1 |
| Gaist, D | 4 |
| Gram, LF | 3 |
| Sindrup, SH | 2 |
| Muckadell, HU | 1 |
| Larsen, BO | 1 |
| Herborg, H | 1 |
| Andersen, M | 2 |
| Pfadenhauer, K | 1 |
| Schönsteiner, T | 1 |
| Keller, H | 1 |
| Wooten, JD | 1 |
| Webster, C | 3 |
| Blumenthal, HJ | 3 |
| Wenzel, RG | 1 |
| Krymchantowski, AV | 4 |
| Pradel, FG | 1 |
| Subedi, P | 1 |
| Varghese, AA | 1 |
| Mullins, CD | 1 |
| Weis, KA | 1 |
| Repaka, A | 1 |
| Wenger, J | 1 |
| Sitaraman, SV | 1 |
| Jelinski, SE | 1 |
| Becker, WJ | 5 |
| Christie, SN | 1 |
| Ahmad, FE | 1 |
| Pryse-Phillips, W | 2 |
| Simpson, SD | 1 |
| Gershovich, OE | 1 |
| Billups, SJ | 1 |
| Delate, T | 1 |
| Hoffman, CK | 1 |
| Carroll, N | 1 |
| Dalla Volta, G | 2 |
| Griffini, S | 1 |
| Pezzini, A | 1 |
| Moen, MD | 1 |
| Keating, GM | 1 |
| Carpay, HA | 2 |
| Paternoster, J | 1 |
| Toosi, B | 1 |
| Wendt, J | 1 |
| Peters, K | 1 |
| Kori, S | 2 |
| Byrd, S | 2 |
| Iversen, HK | 4 |
| Arora, A | 1 |
| Arora, S | 1 |
| Kaniecki, R | 2 |
| Heuel, T | 1 |
| Frese, A | 1 |
| Akova-Oztürk, E | 1 |
| Husstedt, IW | 3 |
| Barnes, N | 1 |
| Millman, G | 1 |
| James, E | 1 |
| Rabe, K | 1 |
| Gupta, S | 1 |
| van den Maagdenberg, AM | 3 |
| van den Brink, AM | 1 |
| Della Pasqua, O | 2 |
| Unger, J | 1 |
| Miner, JR | 1 |
| Smith, SW | 1 |
| Moore, J | 1 |
| Biros, M | 1 |
| Bach, FW | 1 |
| Daugaard, D | 1 |
| Tsiropoulos, I | 1 |
| Riddersholm, B | 1 |
| Diamond, S | 4 |
| Feoktistov, A | 1 |
| Nissan, G | 1 |
| Busch, V | 2 |
| Kaube, S | 1 |
| Schulte-Mattler, W | 1 |
| Kaube, H | 4 |
| Ruoff, GE | 1 |
| Frishberg, BM | 1 |
| Wu, ZA | 1 |
| Davenport, RJ | 1 |
| Anisimov, VV | 1 |
| Kudrow, D | 1 |
| O'Carroll, CP | 1 |
| O'Donnell, FJ | 1 |
| Lampl, C | 2 |
| Ducros, A | 1 |
| Callenbach, PM | 1 |
| Pels, LP | 1 |
| Mulder, PG | 2 |
| Gooskens, RH | 1 |
| van der Zwan, JL | 1 |
| Brouwer, OF | 1 |
| Bigal, M | 1 |
| Rapoport, A | 5 |
| Aurora, S | 1 |
| Blumenthal, H | 1 |
| Diamond, M | 1 |
| Mauskop, A | 1 |
| Lener, S | 1 |
| Burch, S | 1 |
| Mehrotra, S | 1 |
| Vanmolkot, KR | 1 |
| Frants, RR | 4 |
| Flexman, AM | 1 |
| Del Vicario, G | 1 |
| Schwarz, SK | 1 |
| Siegel, SJ | 1 |
| Dubé, LM | 1 |
| Kaldeway, P | 1 |
| Morris, R | 1 |
| Jackson, D | 1 |
| Cerbo, R | 2 |
| Del Bene, E | 1 |
| Genco, S | 1 |
| Sarchielli, P | 1 |
| Tamburro, P | 1 |
| Le Pera, D | 1 |
| Cruccu, G | 1 |
| Del Rio-Sancho, S | 1 |
| Silver, S | 1 |
| Gano, D | 1 |
| Gerretsen, P | 1 |
| Hill, KP | 1 |
| Hope, O | 1 |
| Kreutzkamp, B | 1 |
| Steiner, TJ | 3 |
| DeRossett, SE | 1 |
| Rothrock, J | 1 |
| Schreiber, CP | 1 |
| Spruit, MA | 1 |
| Schmidt-Wilcke, T | 1 |
| Schuierer, G | 1 |
| Leinisch, E | 1 |
| Almas, M | 1 |
| Albert, KS | 1 |
| Parsons, B | 1 |
| Sakai, Y | 1 |
| Dobson, C | 1 |
| Aubé, M | 1 |
| Davenport, WJ | 1 |
| Nakazato, Y | 1 |
| Tamura, N | 1 |
| Shimazu, K | 1 |
| Humphrey, PP | 9 |
| Regli, F | 1 |
| Nater, B | 1 |
| Dworak, N | 1 |
| Monzón, MJ | 1 |
| Noya, M | 2 |
| Alberca, R | 1 |
| Casado, JL | 1 |
| Arenas, C | 1 |
| Moreno, A | 1 |
| Serrano, V | 1 |
| Targa, C | 1 |
| Massons, J | 1 |
| Facchinetti, F | 1 |
| Bonellie, G | 1 |
| Kangasniemi, P | 2 |
| Shuaib, A | 2 |
| Scholz, MJ | 3 |
| Dachs, R | 1 |
| Vitillo, J | 1 |
| Stirparo, G | 2 |
| Rinaldi, C | 2 |
| Fusco, BM | 1 |
| Plosker, GL | 1 |
| McTavish, D | 1 |
| Sjaastad, O | 3 |
| Haan, J | 5 |
| Jayamaha, JE | 1 |
| Street, MK | 1 |
| Mulder, LJ | 4 |
| Scheldewaert, RG | 1 |
| Weiller, C | 1 |
| Jüptner, M | 1 |
| Schayck, RV | 1 |
| Coenen, HH | 1 |
| Sandler, M | 1 |
| van Es, NM | 1 |
| Bruning, TA | 1 |
| Camps, J | 1 |
| Blauw, GJ | 1 |
| van Zwieten, PA | 1 |
| Kwasa, TO | 1 |
| Jowi, JO | 1 |
| Amayo, EO | 1 |
| Solomon, GD | 6 |
| Skobieranda, FG | 1 |
| Genzen, JR | 2 |
| Leung, M | 1 |
| Ong, M | 1 |
| DeBattista, C | 1 |
| Mueller, K | 1 |
| Luciani, RJ | 1 |
| Osterhaus, JT | 2 |
| Gutterman, DL | 6 |
| Cutler, NR | 2 |
| Alderton, CJ | 1 |
| Paulsgrove, LA | 1 |
| Davis, RL | 5 |
| Sargent, J | 1 |
| Kirchner, JR | 2 |
| Davis, R | 3 |
| Kirkhart, B | 1 |
| Rederich, G | 1 |
| Cutler, N | 2 |
| Hazelrigg, R | 1 |
| Jamerson, B | 1 |
| Mushet, GR | 2 |
| Clements, B | 3 |
| Whitcher, L | 1 |
| Bousser, MG | 5 |
| Russell, MB | 3 |
| Holm-Thomsen, OE | 2 |
| Nielsen, MR | 1 |
| Cleal, A | 2 |
| Pilgrim, AJ | 13 |
| Giacovazzo, M | 1 |
| Akpunonu, BE | 2 |
| Mutgi, AB | 2 |
| Federman, DJ | 1 |
| Volinsky, FG | 1 |
| Brickman, K | 1 |
| Gilbert, C | 1 |
| Asgharnejad, M | 5 |
| Stratton, SJ | 1 |
| LaPorta, LD | 1 |
| Gerson, C | 1 |
| Nguyen, KN | 1 |
| Landmark, K | 1 |
| Blier, P | 1 |
| Bergeron, R | 1 |
| Kelly, KM | 1 |
| Walton-Shirley, M | 1 |
| Flowers, K | 1 |
| Whiteside, JH | 1 |
| Enbergs, A | 1 |
| James, MH | 1 |
| Bates, D | 2 |
| Pilgrim, A | 2 |
| Ashford, E | 6 |
| Anderson, BA | 1 |
| Lloyd, K | 2 |
| Szabo, CP | 1 |
| Garcia, G | 1 |
| Kaufman, MB | 1 |
| Colucci, RD | 1 |
| Blokland, JA | 1 |
| Arndt, JW | 1 |
| Minnee, P | 1 |
| Zwinderman, AH | 1 |
| Pauwels, EK | 1 |
| Scott, AK | 2 |
| Cowan, S | 1 |
| Marterer, A | 3 |
| Wessely, P | 4 |
| Kolosova, OA | 1 |
| Osipova, VV | 1 |
| Khomak, EB | 1 |
| Bobeĭko, LA | 1 |
| Anzola, GP | 1 |
| Magoni, M | 1 |
| Cavazos, JE | 1 |
| Caress, JB | 1 |
| Chilukuri, VR | 1 |
| Devlin, T | 1 |
| Gray, L | 1 |
| Hurwitz, BJ | 1 |
| Sykes, RS | 1 |
| Castle, W | 1 |
| Palmer, J | 1 |
| Baumel, B | 1 |
| Prusiński, A | 5 |
| Peters, RH | 1 |
| Meyburg, HW | 1 |
| Westendorp, PH | 1 |
| Westerhof, PW | 1 |
| Dawson, R | 2 |
| Ensink, FB | 3 |
| Gilhus, NE | 2 |
| Shevlin, P | 1 |
| Rishøj Nielsen, M | 1 |
| Delrée, P | 1 |
| Moonen, G | 1 |
| Wilkinson, M | 3 |
| Lüben, V | 2 |
| Noronha, D | 1 |
| Warter, JM | 1 |
| Bärtsch, P | 1 |
| Maggi, S | 1 |
| Kleger, GR | 1 |
| Ballmer, PE | 1 |
| Baumgartner, RW | 1 |
| Raskin, NH | 5 |
| Blau, JN | 2 |
| Ekbom, K | 2 |
| Persson, L | 2 |
| Rubino, J | 2 |
| Crummett, D | 1 |
| Littlejohn, TW | 1 |
| Grotemeyer, KH | 2 |
| Midelfart, E | 1 |
| Winnem, M | 1 |
| Anaya Ordóñez, S | 1 |
| Matas Hoces, A | 1 |
| Panconesi, A | 2 |
| Anselmi, B | 2 |
| Curradi, C | 2 |
| Perfetto, F | 1 |
| Piluso, A | 1 |
| Franchi, G | 2 |
| Chiari, M | 1 |
| Van de Geijn, EJ | 1 |
| Pfaffenrath, V | 7 |
| Baumhackl, U | 1 |
| Klingler, D | 2 |
| Bauchinger, B | 1 |
| Krapat, S | 2 |
| Dworschak, M | 2 |
| Heuss, D | 3 |
| Soyka, D | 1 |
| Kumar, KL | 1 |
| Bateman, DN | 2 |
| Luman, W | 1 |
| Gray, RS | 1 |
| Welch, KM | 5 |
| Bax, W | 1 |
| van Coevorden, RS | 2 |
| van Huijgevoort, JA | 1 |
| Timmerman, H | 2 |
| Meyler, WJ | 1 |
| Lloyd, DK | 4 |
| Arnold, WS | 2 |
| Weeks, RE | 1 |
| Baskin, S | 1 |
| Arrowsmith, F | 1 |
| Byrne, M | 1 |
| Roncolato, M | 2 |
| Zerbini, O | 1 |
| Osborne, MJ | 1 |
| Austin, RC | 1 |
| Dawson, KJ | 1 |
| Lange, L | 1 |
| Lobo, BL | 1 |
| Hay, E | 1 |
| Grundemar, L | 1 |
| Charles, PD | 1 |
| Davis, TL | 1 |
| Bulcke, J | 1 |
| Caekebeke, J | 1 |
| Dehaene, I | 1 |
| De Keyser, J | 1 |
| Hildebrand, G | 1 |
| Joffroy, A | 1 |
| Laloux, P | 2 |
| Louis, P | 1 |
| Monseu, G | 3 |
| Meyer, C | 1 |
| d'Allens, H | 3 |
| van Luijn, JC | 1 |
| Neighbor, ML | 1 |
| Nançoz, R | 1 |
| Black, P | 1 |
| Caldwell, J | 1 |
| Siderov, J | 1 |
| Zalcberg, J | 1 |
| Chambers, B | 1 |
| Fabinyi, G | 1 |
| Kobari, M | 1 |
| Fukuuchi, Y | 1 |
| Tanahashi, N | 1 |
| Konno, S | 1 |
| Takeda, H | 1 |
| Tarquini, B | 1 |
| Klepser, M | 1 |
| Shealy, CN | 1 |
| Olsen, TS | 2 |
| Tansey, MJ | 2 |
| Susman, JL | 1 |
| Nightingale, SL | 1 |
| Hannington-Kiff, JG | 1 |
| Moskowitz, MA | 7 |
| Cutrer, FM | 1 |
| Bax, WA | 6 |
| Meijler, WJ | 1 |
| Peroutka, SJ | 5 |
| Thomson, AN | 1 |
| Arthur, GP | 1 |
| Bergin, PS | 1 |
| Pollock, M | 1 |
| Parkin, PJ | 1 |
| Flanagan, M | 1 |
| Samson, SA | 1 |
| Marani, E | 1 |
| Van Mil, JW | 1 |
| Dexter, J | 2 |
| Sargent, JD | 2 |
| Markley, H | 1 |
| Webster, CJ | 1 |
| Hilden, J | 1 |
| Sørensen, SA | 1 |
| Richard, A | 1 |
| Martin, PM | 1 |
| Hannerz, J | 1 |
| Jogestrand, T | 1 |
| Holdcroft, C | 1 |
| Fan, E | 1 |
| Linville, D | 1 |
| Ting, V | 1 |
| Villemure, JG | 1 |
| Chia, LS | 1 |
| Piper, RD | 1 |
| Ekman, R | 1 |
| Lambert, GA | 1 |
| Long, K | 1 |
| Long, R | 1 |
| Solbach, MP | 1 |
| Waymer, RS | 1 |
| Vijayan, N | 1 |
| Jensen, K | 1 |
| Hansen, EW | 1 |
| Krøis, EH | 1 |
| Pedersen, OS | 1 |
| Jhingran, P | 2 |
| Miller, D | 2 |
| Grice, RB | 1 |
| Boureau, F | 2 |
| Emile, J | 1 |
| Bertin, L | 3 |
| Graf, WD | 1 |
| Riback, PS | 1 |
| Schnider, P | 1 |
| Aull, S | 1 |
| Baringer, JR | 1 |
| Fuller, RW | 1 |
| Ravishankar, K | 1 |
| Sanin, LC | 1 |
| Ricalde, O | 1 |
| Le Force, B | 1 |
| Saper, J | 3 |
| Margul, B | 1 |
| Mueller, L | 1 |
| Ciervo, CA | 1 |
| Skovlund, E | 1 |
| Flaten, O | 1 |
| de Vriend, RH | 3 |
| Jaspers, MW | 1 |
| Martínez Lage, JM | 1 |
| Rodríguez y, MC | 1 |
| Vázquez, C | 1 |
| Centonze, V | 2 |
| Polito, MB | 1 |
| Di Bari, M | 1 |
| Fabbri, L | 3 |
| Cassiano, MA | 2 |
| Bassi, A | 2 |
| Albano, O | 1 |
| Long, LL | 1 |
| Weisz, MA | 1 |
| Burk, S | 1 |
| Hallas, J | 2 |
| Wiedemann, M | 1 |
| de Lima, VM | 1 |
| Hanke, W | 1 |
| Thomaides, T | 1 |
| Tagaris, G | 1 |
| Karageorgiou, C | 1 |
| Touchon, J | 1 |
| Bès, A | 1 |
| Stolze, H | 2 |
| Heinze, A | 3 |
| Christiani, K | 1 |
| Lindner, V | 3 |
| Auerbach, P | 1 |
| Wosnitza, G | 1 |
| Eppe, T | 1 |
| Katchourine, I | 1 |
| Vincent, D | 2 |
| Greiner, DL | 1 |
| Addy, SN | 1 |
| Salvesen, R | 2 |
| Jaspers, NH | 1 |
| Ottervanger, JP | 1 |
| Valkenburg, HA | 1 |
| Grobbee, DE | 1 |
| Stricker, BH | 1 |
| Jacob, J | 1 |
| Duncan, JS | 1 |
| Wojnar-Horton, RE | 1 |
| Hackett, LP | 1 |
| Yapp, P | 1 |
| Dusci, LJ | 1 |
| Paech, M | 1 |
| Ilett, KF | 1 |
| Connor, HE | 4 |
| Lucker, C | 1 |
| del Arco, C | 1 |
| Romón, T | 1 |
| del Olmo, E | 1 |
| Castro, E | 1 |
| Pazos, A | 1 |
| Burggraaf, J | 1 |
| Muller, LM | 1 |
| Schoemaker, RC | 1 |
| Fowler, PA | 2 |
| Cohen, AF | 1 |
| Loi, V | 1 |
| Lai, M | 1 |
| Pisano, MR | 1 |
| Del Zompo, M | 1 |
| Maassen VanDenBrink, A | 5 |
| Barf, T | 1 |
| Wikström, H | 1 |
| Lambert, G | 1 |
| Michalicek, J | 1 |
| Roberts-Thomson, I | 1 |
| Argyrides, J | 1 |
| Pannall, P | 1 |
| Frewin, D | 1 |
| Scalbert, E | 1 |
| Lemaitre, BG | 1 |
| Cohen, JA | 2 |
| Beall, DG | 1 |
| Miller, DW | 4 |
| Beck, A | 2 |
| Pait, G | 2 |
| Clements, BD | 1 |
| Van Gelderen, EM | 1 |
| Reines, SA | 1 |
| Jiang, K | 2 |
| Furlong, S | 1 |
| Crowley, M | 1 |
| Turner, CJ | 1 |
| Litaker, DG | 1 |
| Barliński, J | 1 |
| Figini, M | 1 |
| Imperato, A | 1 |
| Gessa, GL | 1 |
| Bartolini, A | 1 |
| Hoskin, KL | 2 |
| Scott, RJ | 1 |
| Aitchison, WR | 1 |
| Barker, PR | 1 |
| McLaren, GI | 1 |
| Catarci, T | 1 |
| Jaspers, NM | 1 |
| Bauer, B | 1 |
| Suhr, B | 1 |
| Wang, W | 1 |
| Yocca, FD | 2 |
| Gruffydd-Jones, K | 1 |
| Hood, CA | 1 |
| Price, DB | 1 |
| Sciberras, DG | 1 |
| Polvino, WJ | 1 |
| Gertz, BJ | 1 |
| Cheng, H | 1 |
| Stepanavage, M | 1 |
| Wittreich, J | 1 |
| Olah, T | 1 |
| Edwards, M | 1 |
| Mant, T | 1 |
| Gilbert, GJ | 2 |
| Lilley, LL | 2 |
| Guanci, R | 2 |
| Abbrescia, VD | 1 |
| Pearlstein, L | 1 |
| Kotler, M | 1 |
| al Deeb, S | 1 |
| al Kawi, Z | 1 |
| Yaqub, B | 1 |
| Bohlega, S | 1 |
| Cheung, P | 1 |
| Santavuori, P | 1 |
| Stengel, PW | 1 |
| Lobb, KL | 1 |
| Nixon, JA | 1 |
| Hipskind, PA | 1 |
| Ridderikhoff, J | 1 |
| Koudstaal, PJ | 1 |
| Aarup, AL | 1 |
| Bikhazi, P | 1 |
| Jackson, C | 1 |
| Ruckenstein, MJ | 1 |
| Cull, RE | 1 |
| Price, WH | 1 |
| Dunbar, A | 1 |
| Knyihár-Csillik, E | 3 |
| Samsam, M | 1 |
| Sáry, G | 1 |
| Slezák, S | 1 |
| Lewis, PJ | 1 |
| Barrington, SF | 1 |
| Marsden, PK | 1 |
| Maisey, MN | 1 |
| Lewis, LD | 1 |
| Newman-Tancredi, A | 1 |
| Conte, C | 1 |
| Chaput, C | 1 |
| Verrièle, L | 1 |
| Audinot-Bouchez, V | 1 |
| Lochon, S | 1 |
| Lavielle, G | 1 |
| Millan, MJ | 1 |
| Hussey, EK | 1 |
| Shaw, S | 1 |
| Duquesnoy, C | 1 |
| Pakes, GE | 1 |
| De Marinis, M | 1 |
| Accornero, N | 1 |
| Mazer, C | 1 |
| Joffe, RT | 1 |
| Sokolov, ST | 1 |
| Fish, DN | 1 |
| Beall, HD | 1 |
| Goodwin, SD | 1 |
| Fox, JL | 1 |
| Kelly, AM | 1 |
| Ardagh, M | 1 |
| Curry, C | 1 |
| D'Antonio, J | 1 |
| Zebic, S | 1 |
| Matthijsse, P | 1 |
| Steinbuch, M | 1 |
| Gutterman, D | 2 |
| Saiers, JA | 1 |
| Cleland, PG | 1 |
| Barnes, D | 1 |
| Elrington, GM | 1 |
| Loizou, LA | 1 |
| Rawes, GD | 1 |
| Legg, RF | 2 |
| Sclar, DA | 2 |
| Nemec, NL | 2 |
| Tarnai, J | 2 |
| Swain, RA | 1 |
| Kaplan, B | 1 |
| Fisher, H | 1 |
| Baker, CC | 1 |
| Mullican, W | 1 |
| DeBussey, S | 1 |
| Petty, MA | 1 |
| Elands, J | 1 |
| Linnik, MD | 1 |
| Lee, WS | 1 |
| McCarty, DR | 1 |
| Hibert, M | 1 |
| Baron, BM | 1 |
| Sawyer, J | 1 |
| Del Bianco, PL | 1 |
| Zurlinden, J | 2 |
| Scheen, AJ | 1 |
| González-Espinosa, LE | 1 |
| Gómez-Viera, N | 1 |
| Olivera-Leal, I | 1 |
| Reyes-Lorente, R | 1 |
| Jhee, SS | 1 |
| Salazar, DE | 1 |
| Ford, NF | 1 |
| Fulmor, IE | 1 |
| Sramek, JJ | 1 |
| Castro, ME | 1 |
| Brune, K | 1 |
| Gerber, WD | 2 |
| Steurer, J | 1 |
| Daley, J | 1 |
| Delbanco, TL | 1 |
| Hartman, EE | 1 |
| Cunin, G | 1 |
| Sjonell, G | 1 |
| Prendergast, S | 2 |
| Myllylä, VV | 1 |
| Havanka, H | 1 |
| Rautakorpi, I | 1 |
| Turkka, J | 1 |
| Vapaatalo, H | 1 |
| Eskerod, O | 1 |
| Cady, RC | 2 |
| Pait, DG | 2 |
| Baar, H | 1 |
| Beiküfner, HD | 1 |
| Böhme, K | 1 |
| Beckmann-Reinhold, A | 1 |
| Vergouwe, MN | 2 |
| Ophoff, RA | 3 |
| Ogunyemi, A | 1 |
| Adams, D | 1 |
| Perry, CM | 1 |
| Markham, A | 1 |
| Frey, B | 1 |
| Zeiler, K | 1 |
| Frizelis, K | 1 |
| Becker, J | 1 |
| Kunkel, RS | 1 |
| Naylor, SL | 1 |
| Dauwerse, HG | 1 |
| Król, F | 1 |
| Nighoghossian, N | 1 |
| Derex, L | 1 |
| Trouillas, P | 1 |
| Reekers, M | 1 |
| Takagi, H | 1 |
| Takashima, M | 1 |
| Liou, SY | 1 |
| Woessner, M | 1 |
| Boes-Hansen, S | 1 |
| Cederberg, CG | 1 |
| Hardebo, JE | 1 |
| Henriksson, A | 1 |
| Lay, CL | 1 |
| Shepheard, SL | 1 |
| Knorr, M | 1 |
| Effert, R | 1 |
| Wessing, A | 1 |
| Hargreaves, RJ | 2 |
| Quijano, J | 1 |
| Knudsen, JF | 1 |
| Friedman, B | 1 |
| Chen, M | 1 |
| Goldwasser, JE | 1 |
| Kuhn, K | 1 |
| Porter, LM | 1 |
| Paterna, S | 2 |
| Di Pasquale, P | 2 |
| Parrinello, G | 2 |
| Amato, P | 1 |
| Bucca, V | 1 |
| Cecala, M | 1 |
| Cardinale, A | 2 |
| Maniscalchi, T | 2 |
| Tuttolomondo, A | 2 |
| Bova, A | 2 |
| Arrostuto, A | 1 |
| Follone, G | 2 |
| Bologna, P | 2 |
| Piovana, G | 2 |
| Licata, G | 2 |
| Falk, L | 1 |
| Risenfors, M | 1 |
| Lewis, CP | 1 |
| Stewart, S | 1 |
| Gorman, DG | 1 |
| Leira, R | 2 |
| Stepien, A | 3 |
| Chalimoniuk, M | 1 |
| Sternon, J | 1 |
| Vakaet, A | 1 |
| Jacquy, J | 1 |
| Bourgeois, P | 1 |
| van der Linden, C | 1 |
| Fullerton, T | 2 |
| Komorowski-Swiatek, D | 1 |
| Forrest, A | 1 |
| Gengo, FM | 2 |
| Chan, WN | 1 |
| Evans, JM | 1 |
| Hadley, MS | 1 |
| Herdon, HJ | 1 |
| Jerman, JC | 1 |
| Parsons, AA | 4 |
| Read, SJ | 4 |
| Stean, TO | 1 |
| Thompson, M | 1 |
| Upton, N | 2 |
| Pinto, A | 1 |
| Cottone, C | 1 |
| Colomba, D | 1 |
| D'Angelo, A | 1 |
| Ortoleva, A | 1 |
| Garofalo, L | 1 |
| Capodieci, E | 1 |
| Giubilato, A | 1 |
| Moran, JA | 1 |
| Beall, D | 1 |
| Rawlings, J | 1 |
| Farkas, V | 1 |
| Shane, R | 1 |
| Payne, K | 1 |
| Kozma, CM | 2 |
| Lawrence, BJ | 1 |
| Coukell, AJ | 1 |
| Lamb, HM | 1 |
| Bouchard, J | 4 |
| Cortelli, P | 5 |
| Jansen, JP | 4 |
| Pham, S | 4 |
| Hirsch, J | 3 |
| Edwards, CE | 1 |
| Adams, J | 3 |
| Berto, P | 1 |
| Brueggenjuergen, B | 1 |
| Nyth, AL | 1 |
| Lindsay, P | 1 |
| Price, KL | 2 |
| Joseph, A | 1 |
| Babiak, L | 1 |
| Evans, KW | 1 |
| Boan, JA | 1 |
| Evans, JL | 1 |
| Rhodes, KF | 1 |
| Buckingham, JC | 1 |
| Kennard, C | 1 |
| Peikert, A | 1 |
| Ashford, EA | 4 |
| Hassani, H | 4 |
| Salonen, RJ | 1 |
| Johnson, NE | 2 |
| Batenhorst, AS | 3 |
| Ueberall, MA | 1 |
| Wenzel, D | 1 |
| Adriano, M | 1 |
| Fernandes, D | 1 |
| White, LR | 1 |
| Pait, GD | 1 |
| Kowacs, PA | 1 |
| Piovesan, EJ | 1 |
| Tatsui, CE | 1 |
| Lange, MC | 1 |
| Ribas, LC | 1 |
| Werneck, LC | 1 |
| Foster, JM | 1 |
| Houghton, LA | 2 |
| Whorwell, PJ | 1 |
| Morris, J | 1 |
| Peatfield, RC | 1 |
| Goldstein, D | 1 |
| Mulder, EJ | 2 |
| Orlebeke, JF | 1 |
| de Geus, EJ | 2 |
| Von Korff, M | 1 |
| Black, LK | 1 |
| Saunders, K | 1 |
| Galer, BS | 1 |
| Trion, M | 1 |
| Vermeulen, M | 1 |
| de Haan, RJ | 1 |
| Putnam, GP | 1 |
| Bolden-Watson, CP | 1 |
| Heinze-Kuhn, K | 1 |
| Dooley, M | 1 |
| Faulds, D | 1 |
| Manning, P | 1 |
| McNeil, CJ | 1 |
| Hunter, AJ | 1 |
| Hasegawa, E | 1 |
| Goldfarb, SD | 4 |
| Duncan, BS | 1 |
| Dans, PE | 1 |
| Sloan, AS | 1 |
| Cosson, VF | 1 |
| DeRaps, PK | 1 |
| Senard, JM | 2 |
| Jackson, NC | 1 |
| Poole, PH | 2 |
| Vishwanathan, K | 1 |
| Bartlett, MG | 1 |
| Stewart, JT | 1 |
| Logemann, CD | 1 |
| Rankin, LM | 1 |
| Knight, YE | 1 |
| Ellis, P | 1 |
| Christianssen, I | 1 |
| Kleinermans, D | 1 |
| Kok, JG | 1 |
| Shepheard, S | 1 |
| Cumberbatch, M | 1 |
| Williamson, D | 1 |
| Mason, G | 1 |
| Webb, J | 1 |
| Boyce, S | 1 |
| Hill, R | 1 |
| Hargreaves, R | 1 |
| Cavazzuti, L | 1 |
| Brautaset, NJ | 1 |
| Reunanen, M | 1 |
| Szirmai, I | 1 |
| Gibbs, M | 1 |
| Roberts, GW | 1 |
| Flöter, T | 1 |
| Szczudlik, A | 2 |
| Brion, N | 2 |
| Wöber-Bingöl, C | 1 |
| Ephross, SA | 1 |
| Williams, V | 1 |
| Olesen, C | 2 |
| Steffensen, FH | 1 |
| Sorensen, HT | 1 |
| Nielsen, GL | 1 |
| Olsen, J | 2 |
| Dennish, G | 1 |
| Ivers, H | 1 |
| McGrath, PJ | 1 |
| Purdy, RA | 1 |
| Hennigar, AW | 1 |
| Campbell, MA | 1 |
| Perino, M | 1 |
| Famularo, G | 1 |
| Tarroni, P | 1 |
| Lutz, G | 1 |
| Zupping, R | 1 |
| Sweet, R | 1 |
| Boska, MD | 1 |
| Schultz, L | 1 |
| Nelson, J | 1 |
| Kailasam, J | 1 |
| Gentry, P | 1 |
| Chernyshev, O | 1 |
| Palmer, JB | 2 |
| Valette, C | 1 |
| de Tommaso, M | 1 |
| Guido, M | 1 |
| Libro, G | 1 |
| Sciruicchio, V | 1 |
| Puca, F | 1 |
| Hedenmalm, K | 1 |
| Bartleson, JD | 1 |
| Henry, D | 1 |
| Watson, CB | 1 |
| O'Quinn, SO | 1 |
| Kappos, L | 1 |
| Esperanca, P | 1 |
| Turk, WR | 1 |
| Farmer, K | 2 |
| Bleiberg, J | 2 |
| Reeves, D | 2 |
| Winter, P | 1 |
| Crisp, A | 2 |
| Becker, W | 1 |
| Hauge, T | 1 |
| Mihout, B | 1 |
| Niewold, J | 1 |
| Tørring, J | 1 |
| Rainero, I | 2 |
| Savi, L | 2 |
| Valfrè, W | 2 |
| Limone, P | 2 |
| Calvelli, P | 2 |
| Del Rizzo, P | 2 |
| Gianotti, L | 2 |
| Taliano, M | 1 |
| Ghigo, E | 2 |
| Arvat, E | 2 |
| Al-Shekhlee, A | 1 |
| Reed, R | 1 |
| Metz, A | 2 |
| de Hoon, JN | 1 |
| Willigers, JM | 1 |
| Troost, J | 1 |
| Struijker-Boudier, HA | 1 |
| Van Bortel, LM | 1 |
| Laurenza, A | 3 |
| Scholz, M | 1 |
| Csillik, AE | 1 |
| Chadaide, Z | 2 |
| Mihály, A | 1 |
| Weintraub, JR | 1 |
| Biddle, AK | 1 |
| Shih, YC | 1 |
| Ryan, RE | 1 |
| Krumholz, W | 1 |
| Szalay, G | 1 |
| Ogal, H | 1 |
| Menges, T | 1 |
| Bou, J | 3 |
| Domènech, T | 1 |
| Puig, J | 1 |
| Heredia, A | 1 |
| Gras, J | 5 |
| Fernández-Forner, D | 1 |
| Beleta, J | 1 |
| Palacios, JM | 5 |
| Llenas, J | 4 |
| Fernández, AG | 1 |
| Cardelús, I | 1 |
| Hirst, WD | 1 |
| Stone, P | 1 |
| Rosamond, W | 1 |
| Frischer, M | 1 |
| Croft, P | 1 |
| Yazdi, K | 1 |
| Buzath, A | 1 |
| Millson, DS | 2 |
| Gawel, M | 1 |
| Wiebe, S | 1 |
| Joish, VN | 1 |
| Cady, PS | 1 |
| Colman, SS | 1 |
| Brod, MI | 1 |
| Krishnamurthy, A | 1 |
| Rowland, CR | 2 |
| Jirgens, KJ | 1 |
| McHarg, A | 1 |
| Gawel, MJ | 1 |
| Worthington, I | 1 |
| Maggisano, A | 1 |
| Benassuti, C | 1 |
| Zakrzewska, JM | 1 |
| Sabin, A | 1 |
| Pereira, A | 1 |
| Thein, S | 1 |
| Leibowitz, M | 1 |
| Purdon, H | 1 |
| Coates, P | 1 |
| Rice, L | 1 |
| Black, L | 2 |
| Caro, G | 1 |
| Getsios, D | 2 |
| Caro, JJ | 2 |
| Raggio, G | 1 |
| Burrows, M | 1 |
| Williamson, DJ | 1 |
| Csillik, B | 1 |
| Källén, B | 1 |
| Lygner, PE | 1 |
| DiSerio, F | 1 |
| Klapper, JA | 1 |
| Sadowsky, C | 1 |
| Liedert, B | 1 |
| Guehring, H | 1 |
| Schmitz, K | 1 |
| Michel, MC | 1 |
| Gruffyd-Jones, K | 1 |
| Kies, B | 1 |
| Middleton, A | 1 |
| Røsjø , Ø | 1 |
| Akhtar, ND | 1 |
| Murray, MA | 1 |
| Moriarty-Sheehan, M | 1 |
| Jamieson, DG | 1 |
| Russell, DD | 1 |
| Combremont, PC | 1 |
| Marcus, EM | 1 |
| Wiedemann, B | 1 |
| Hernandez, JF | 1 |
| Allen, C | 4 |
| Vrijens, F | 1 |
| Patel, K | 1 |
| Yamane, K | 1 |
| Yamada, K | 1 |
| Naritomi, H | 1 |
| Hashimoto, S | 1 |
| Iwata, M | 1 |
| Gentile, S | 1 |
| Vandormael, K | 4 |
| Malbecq, W | 1 |
| Iwasawa, Y | 1 |
| Danjo, T | 1 |
| McCarroll, K | 2 |
| Einecke, D | 1 |
| Pham, B | 1 |
| Ueda, T | 1 |
| Torihara, Y | 1 |
| Tsuneyoshi, N | 1 |
| de Beukelaar, F | 1 |
| Muñoz, R | 1 |
| Zagami, AS | 2 |
| Lance, JW | 4 |
| Fenster, DL | 1 |
| Bohidar, N | 1 |
| Wang, L | 1 |
| Boyle, D | 1 |
| Guerra, F | 1 |
| Santanello, N | 1 |
| Munno, I | 1 |
| Marinaro, M | 1 |
| Causarano, V | 1 |
| Barbosa, JS | 1 |
| Llupià, J | 1 |
| McAlhany, A | 1 |
| Ueberall, M | 1 |
| Dowson, A | 1 |
| Gerth, WC | 1 |
| Santanello, NC | 1 |
| Zhang, Q | 1 |
| Locklear, JC | 1 |
| Frick, KD | 1 |
| Kim, SS | 1 |
| Chatterton, ML | 1 |
| Burke-Ramirez, P | 1 |
| Wilkinson, F | 1 |
| Shankland, WE | 1 |
| Cortijo, J | 1 |
| Morcillo, EJ | 1 |
| Dayno, J | 1 |
| Meckling, SK | 1 |
| Rose, MS | 1 |
| Dalby, JT | 1 |
| Mulder, JM | 1 |
| Autret, A | 1 |
| Mondon, K | 1 |
| Mahmood, T | 1 |
| Silverstone, T | 1 |
| Connor, R | 1 |
| Herbison, P | 1 |
| Bolay, H | 1 |
| Dunn, AK | 1 |
| Huang, Z | 1 |
| Boas, DA | 1 |
| Canario, JR | 1 |
| Shenenberger, DW | 1 |
| Pothmann, R | 1 |
| Uberall, M | 1 |
| Naumann, E | 1 |
| Wang, JT | 2 |
| Barr, CE | 2 |
| Torigoe, Y | 1 |
| Wang, E | 1 |
| Von, S | 1 |
| Safar, HA | 1 |
| Alanezi, KH | 1 |
| Cinà, CS | 1 |
| Cates, C | 1 |
| Fité, B | 1 |
| López-Gil, A | 1 |
| Wenzel, R | 1 |
| Keywood, C | 1 |
| Calero Muñoz, S | 1 |
| Fariñas Balaguer, O | 1 |
| Nieto Márquez, L | 1 |
| Cobo Guerrero, S | 1 |
| Mattsson, P | 1 |
| Banerjee, M | 1 |
| Findley, LJ | 2 |
| Callaghan, N | 1 |
| Grimes, S | 1 |
| Ng, K | 1 |
| Critchley, M | 1 |
| Breckenridge, AM | 1 |
| Thomson, C | 1 |
| Walters, DJ | 1 |
| Ziegler, DK | 1 |
| Caekebeke, JF | 1 |
| Zwetsloot, CP | 1 |
| Jansen, J | 1 |
| Liaño, H | 1 |
| Welch, K | 1 |
| Edwards, C | 1 |
| Toth, A | 1 |
| Rose, FC | 1 |
| Curtin, T | 1 |
| Brooks, AP | 1 |
| Roberts, JA | 1 |
| Inman, W | 1 |
| Kubota, K | 1 |
| Thomsen, LL | 1 |
| den Boer, MO | 3 |
| Somers, JA | 1 |
| Bayliss, EM | 3 |
| Ludlow, S | 1 |
| Couch, J | 1 |
| Flamenbaum, W | 1 |
| Hsu, VD | 1 |
| Pearce, JM | 2 |
| Fowler, P | 1 |
| Keene, ON | 2 |
| Read, NW | 1 |
| Turner, P | 1 |
| Feczko, JM | 1 |
| Ollat, H | 1 |
| Green, C | 1 |
| Dechant, KL | 1 |
| Clissold, SP | 1 |
| Feniuk, W | 5 |
| Perren, MJ | 3 |
| Whalley, ET | 1 |
| Deliganis, AV | 1 |
| Haab, J | 1 |
| Peters, C | 2 |
| Ried, S | 1 |
| Dichgans, J | 2 |
| Lacey, LF | 1 |
| Thomas, M | 1 |
| Tanner, RJ | 2 |
| Baber, NS | 1 |
| Marriott, AS | 1 |
| Jackson, MR | 1 |
| Tucker, ML | 1 |
| Brown, EG | 1 |
| Endersby, CA | 1 |
| Smith, RN | 1 |
| Talbot, JC | 1 |
| Rudzio, M | 1 |
| Noe, A | 1 |
| Haux, R | 1 |
| Ehrmann, R | 1 |
| Bastings, E | 1 |
| Jauslin, P | 1 |
| Friberg, L | 1 |
| Sperling, B | 1 |
| Donnan, GA | 1 |
| Symington, G | 1 |
| Anthony, M | 1 |
| Bladin, PF | 1 |
| Wendt, JK | 1 |
| Skaggs, H | 1 |
| Tehindrazanarivelo, A | 1 |
| Chaplin, S | 1 |
| Oxford, AW | 1 |
| Perrin, VL | 2 |
| Goasguen, J | 1 |
| Doenicke, A | 5 |
| Brand, J | 4 |
| Dano, P | 1 |
| Sahlender, HM | 2 |
| Bons, J | 1 |
| Plas, J | 1 |
| Advenier, C | 1 |
| Baar, HA | 1 |
| Tryba, M | 1 |
| Oxford, J | 1 |
| Lant, MS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura[NCT02873221] | Phase 3 | 1,254 participants (Actual) | Interventional | 2016-09-13 | Completed | ||
| The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache[NCT03422796] | 30 participants (Actual) | Interventional | 2017-11-01 | Completed | |||
| Investigation of PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine[NCT03881644] | 37 participants (Actual) | Interventional | 2018-07-17 | Completed | |||
| A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Cross-Over Study Evaluating the Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acut[NCT01667679] | Phase 3 | 275 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache. Development of a Pragmatic Migraine Model[NCT02486276] | 30 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| Phase 1, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Effect on Blood Pressure of AMG 334 Given Concomitantly With Subcutaneous Sumatriptan (Imitrex™) in Healthy Subjects[NCT02741310] | Phase 1 | 34 participants (Actual) | Interventional | 2016-02-22 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of DFN-02 in Episodic Migraine With or Without Aura[NCT02856802] | Phase 2 | 107 participants (Actual) | Interventional | 2016-07-11 | Completed | ||
| [NCT02569853] | Phase 3 | 268 participants (Actual) | Interventional | 2015-09-21 | Completed | ||
| Pretreatment With Sumatriptan on Cilostazol Induced Headache in Healthy Volunteers. Development of a Pragmatic Migraine Model[NCT03156920] | 30 participants (Actual) | Interventional | 2017-05-23 | Completed | |||
| Investigation of Vascular Inflammation in Migraine Without Aura Using Molecular Nano-imaging and Black Blood Imaging MRI[NCT02549898] | 34 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
| An Evaluation of Treximet in the Treatment of Acute Migraine Headache: A Placebo-Controlled, Double-Blind, Crossover Study, Assessing Cognitive Function.[NCT00837044] | 30 participants (Anticipated) | Interventional | 2009-02-28 | Recruiting | |||
| A Randomized Double-blind Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache[NCT03472872] | Phase 4 | 500 participants (Actual) | Interventional | 2017-09-05 | Terminated (stopped due to no longer recruiting or studying) | ||
| A Double-Blind, Randomized, Placebo-Controlled, 3-Period, Single Dose Crossover Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK0974 in Migraine Patients[NCT00701389] | Phase 1 | 24 participants (Actual) | Interventional | 2007-11-20 | Completed | ||
| A Multi-centre, Randomized, Double-blind, Parallel Group, Active and Placebo Controlled, Proof of Concept Study in Patients With Acute Migraine to Assess the Efficacy, Safety and Tolerability of Single Oral Doses of BGG492[NCT00892203] | Phase 2 | 75 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Phase IIb: Double-Blind, Randomized, Placebo Controlled, Dose-ranging Trial of BMS-927711 for the Acute Treatment of Migraine[NCT01430442] | Phase 2 | 1,026 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Treximet in the Treatment of Chronic Migraine[NCT01090050] | Phase 4 | 56 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| A Randomized, Double-blind, Single Migraine Attack, Placebo-controlled, Parallel-group Multicenter Study to Evaluate the Efficacy and Tolerability of Trexima (Sumatriptan Succinate.Naproxen Sodium) Tablets vs Placebo When Administered During the Mild Pain[NCT00329355] | Phase 3 | 351 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Randomized, Double-blind, Single Migraine Attack, Placebo -Controlled, Patallel-group Multicenter Study to Evaluate the Efficacy and Tolerability or Trexima (Sumatriptan Succinate/Naproxen Sodium) Tablets vs Placebo When Administered During the Mild Pai[NCT00329459] | Phase 3 | 320 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of a Single 20 mg Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine With or Without Aura[NCT01462812] | Phase 3 | 223 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine (The KSPN Migraine Study)[NCT01807234] | Phase 4 | 72 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Randomized, Double-Blind, Crossover, Comparator Pilot Study of DFN-11 Injection (Strength A vs. Strength B) for Rapidly Escalating Migraine[NCT02571049] | Phase 2 | 24 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| [NCT02279082] | Phase 3 | 167 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| A Single Center Randomized Open-Label Two Arm Crossover Study of Subject Productivity Improvement and Satisfaction With Migraine Treatment Using Treximet vs Usual Triptan[NCT01086358] | Phase 4 | 60 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)[NCT00382993] | Phase 3 | 169 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)[NCT00383162] | Phase 3 | 173 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Open-label, 6 Month Crossover Study Evaluating Migraine Patient Satisfaction Comparing Treximet to 2 Aleve and 100mg Imitrex Taken Concomitantly[NCT01450995] | Phase 4 | 50 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| The Check Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine. A Multi-Center, Randomized Double-Blind, Clinical Control Trial.[NCT02657031] | Phase 4 | 54 participants (Actual) | Interventional | 2016-03-17 | Completed | ||
| Intravenous Fluids in Benign Headaches Trail: A Randomized Single Blind Clinical Trial[NCT03185130] | Phase 4 | 58 participants (Actual) | Interventional | 2017-05-16 | Completed | ||
| Acute Mountain Sickness Treatment: A Double-blind Comparison of Metoclopramide vs. Ibuprofen[NCT01522326] | 300 participants (Anticipated) | Interventional | 2012-03-01 | Completed | |||
| A Prospective, Randomized, Single Blind, Parallel-group, Placebo Controlled Clinical Study to Evaluate the Short-term Effectiveness of Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation (OS-TNS) in Reducing Migraine Related Pain[NCT02438553] | 40 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| A Randomized, Double-blind, Multi-center, Placebo-controlled, Cross-over Study to Determine the Consistency of Response for Trexima (Sumatriptan 85mg/Naproxen Sodium 500mg) Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migrai[NCT00240630] | Phase 3 | 646 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| A Randomized, Double-blind, Multi-center, Placebo-controlled, Cross-over Study to Determine the Consistency of Response for Trexima* (Sumatriptan 85mg/Naproxen Sodium 500mg) Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migra[NCT00240617] | Phase 3 | 623 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg for the Treatment of Acute Migraine in Sumatriptan Non-Responders[NCT00894556] | Phase 3 | 109 participants (Actual) | Interventional | 2009-06-10 | Completed | ||
| Identify Unique Set of Proteins in Cerebrospinal Fluid, Which Are Believed to be Found in Chronic Fatigue Syndrome Participants, But Not in Healthy Controls.[NCT00810329] | 160 participants (Actual) | Observational | 2007-07-31 | Completed | |||
| Study TXA107977, a Long-Term Safety Study of a Combination Product Containing Sumatriptan Succinate and Naproxen Sodium for the Treatment of Migraine in Adolescents[NCT00488514] | Phase 3 | 656 participants (Actual) | Interventional | 2007-07-13 | Completed | ||
| A Multicenter, Open-label Evaluation of Treatment Satisfaction, Tolerability, Safety and Preference for Sumavel DosePro for Treatment of Migraine in Subjects Currently Treated With Triptans[NCT01016834] | Phase 4 | 246 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine When Administered Dur[NCT00573170] | Phase 3 | 375 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Assessment of the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet Treatment on Blood Pressure When Administered Intermittently for Six Months for the Acute Treatment of Migraine Attacks, With or[NCT00792636] | Phase 4 | 407 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months[NCT00792103] | Phase 3 | 198 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| TXA107979: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product Containing Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents[NCT00843024] | Phase 3 | 589 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| The Efficacy and Tolerability of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled Study[NCT00724815] | Phase 3 | 530 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Phase 3 Open-Label Study to Assess Subcutaneous Self-Injection With Sumatriptan Succinate Using an Auto-injector During a Single Migraine Attack[NCT00510419] | Phase 3 | 73 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Phase 2a Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura[NCT00877838] | Phase 2 | 40 participants (Anticipated) | Interventional | 2009-05-31 | Recruiting | ||
| Effects of Myofascial Trigger Points Therapy in Migraine.[NCT05646160] | 100 participants (Anticipated) | Interventional | 2018-01-15 | Recruiting | |||
| "An Open-label Study to Evaluate Completeness of Response Following Treatment With Treximet™ for Migraine"[NCT00893737] | Phase 4 | 147 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Evaluation of CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Saliva of Menstrual Migraine Patients Before and After Treatment With Treximet™[NCT01329562] | Phase 4 | 41 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Calcitonin Gene-related Peptide (CGRP) Levels in the Pathogenesis of Chronic Migraine[NCT01071096] | Phase 4 | 20 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy Opf Trexima in the Acute Treatment of Migraine Headaches[NCT00433732] | Phase 3 | 1,400 participants | Interventional | 2004-08-31 | Completed | ||
| A Double-Blind Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches[NCT00434083] | Phase 3 | 1,200 participants | Interventional | 2004-07-31 | Completed | ||
| a Randomized Pilot Study of Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients[NCT05632133] | Phase 3 | 200 participants (Anticipated) | Interventional | 2022-06-01 | Recruiting | ||
| Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging[NCT01741246] | 78 participants (Actual) | Observational | 2011-09-30 | Completed | |||
| Safety and Efficacy of Lacosamide Versus Propranolol in Migraine[NCT05851781] | Phase 3 | 600 participants (Actual) | Interventional | 2022-06-01 | Completed | ||
| TreximetTM in the Prevention and Modification of Disease Progression in Migraine[NCT01300546] | Phase 4 | 40 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Full-Factorial, Parallel-Group Study Evaluating Safety and Efficacy of Naltrexone-Acetaminophen Combination in Acute Migraine Treatment in Adults, With Exploratory Focus on Co-Occurring[NCT05685225] | Phase 2 | 300 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs are AEs with an onset that occurs after receiving study drug. (NCT02873221)
Timeframe: 56 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Usual Care | 65 |
| Ubrogepant 50 mg | 66.3 |
| Ubrogepant 100 mg | 72.6 |
"On the C-SSRS, the 5 types of suicidal ideation are:~Type 1: Wish to be dead Type 2: Non-specific active suicidal thoughts Type 3: Active suicidal ideation with any methods (not plan) without intent to act Type 4: Active suicidal ideation with some intent to act, without specific plan Type 5: Active suicidal ideation with specific plan and intent" (NCT02873221)
Timeframe: 56 Weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Suicidal Ideation | Suicidal Behavior | |
| Ubrogepant 100 mg | 2 | 0 |
| Ubrogepant 50 mg | 3 | 0 |
| Usual Care | 5 | 0 |
ECG findings considered potentially clinically significant (PCS) meeting either the lower-limit or higher-limit PCS criteria. (NCT02873221)
Timeframe: 56 Weeks
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| PR interval (msec) PR >= 250 | QRS interval (msec) QRS >= 150 | QTc Bazett (msec) QTcB > 500 | QTc Bazett (msec) Increase > 60 (msec) | QTc Fridericia (msec) QTcF > 500 | QTc Fridericia (msec) Increase > 60 (msec) | |
| Ubrogepant 100 mg | 0 | 0 | 0 | 5 | 0 | 0 |
| Ubrogepant 50 mg | 0 | 1 | 0 | 1 | 0 | 0 |
| Usual Care | 0 | 1 | 0 | 0 | 0 | 1 |
Hematology, Chemistry and Urinalysis results considered potentially clinically significant (PCS) meeting either the lower-limit or higher-limit PCS criteria. (NCT02873221)
Timeframe: 56 Weeks
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Basophils Absolute Cell Count (10**9/L) >2×ULN | Eosinophils Absolute Cell Count (10**9/L) >2×ULN | Hematocrit (RATIO) <0.9×LLN | Hematocrit (RATIO) >1.1×ULN | Hemoglobin (g/L) <0.9×LLN | Hemoglobin (g/L) >1.1×ULN | Lymphocytes Absolute Cell Count (10**9/L) <0.7×LLN | Lymphocytes Absolute Cell Count (10**9/L) >1.3×ULN | Monocytes Absolute Cell Count (10**9/L) <0.5×LLN | Monocytes Absolute Cell Count (10**9/L) >2×ULN | Neutrophils Absolute Cell Count (10**9/L) <0.7×LLN | Neutrophils Absolute Cell Count (10**9/L) >1.3×ULN | Platelet Count (Thrombocytes) (10**9/L) <0.5×LLN | Platelet Count (Thrombocytes) (10**9/L) >1.5×ULN | Red Blood Cell Count (10**12/L) <0.9×LLN | Red Blood Cell Count (10**12/L) >1.1×ULN | White Blood Cell Count (10**9/L) <0.9×LLN | White Blood Cell Count (10**9/L) >1.5×ULN | Alanine Aminotransferase (SGPT) (U/L) >3×ULN | Albumin (g/L) <0.8×LLN | Albumin (g/L) >1.2×ULN | Alkaline Phosphatase (U/L) >3×ULN | Aspartate Aminotransferase (SGOT) (U/L) >3×ULN | Bicarbonate (HCO3) (mmol/L) <0.9×LLN | Bicarbonate (HCO3) (mmol/L) >1.1×ULN | Bilirubin, Total (umol/L) >1.5×ULN | Blood Urea Nitrogen (mmol/L) >1.5×ULN | Calcium (mmol/L) <0.9×LLN | Calcium (mmol/L) >1.1×ULN | Chloride (mmol/L) <0.9×LLN | Chloride (mmol/L) >1.1×UL | Cholesterol, Total (mmol/L) >1.6×ULN | Creatine Kinase (U/L) >2×ULN | Creatinine (umol/L) >1.5×ULN | Glucose, Non-fasting (mmol/L) <0.8×LLN | Glucose, Non-fasting (mmol/L) >2×ULN | Lactate Dehydrogenase (U/L) >3×ULN | Phosphorus (mmol/L) <0.9×LLN | Phosphorus (mmol/L) >1.1×ULN | Potassium (mmol/L) <0.9×LLN | Potassium (mmol/L) >1.1×ULN | Protein, Total (g/L) <0.9×LLN | Protein, Total (g/L) >1.1×ULN | Sodium (mmol/L) <0.9×LLN | Sodium (mmol/L) >1.1×ULN | Triglycerides (mmol/L) >2×ULN | Uric Acid (Urate) (umol/L) >1.2×ULN | Glucose Positive | pH (pH) <0.9×LLN | pH (pH) >1.1×ULN | Protein (g/L) Positive | Specific Gravity >1.1×ULN | |
| Ubrogepant 100 mg | 0 | 1 | 6 | 1 | 6 | 1 | 5 | 8 | 0 | 0 | 6 | 17 | 0 | 1 | 3 | 2 | 17 | 4 | 8 | 0 | 0 | 0 | 9 | 37 | 0 | 2 | 1 | 3 | 0 | 1 | 0 | 2 | 57 | 1 | 0 | 1 | 0 | 42 | 21 | 3 | 33 | 4 | 0 | 0 | 2 | 17 | 22 | 23 | 0 | 0 | 0 | 0 |
| Ubrogepant 50 mg | 0 | 0 | 2 | 0 | 3 | 0 | 5 | 6 | 0 | 0 | 5 | 14 | 0 | 2 | 5 | 2 | 9 | 2 | 4 | 1 | 0 | 0 | 2 | 22 | 0 | 4 | 3 | 1 | 0 | 0 | 0 | 1 | 43 | 1 | 0 | 1 | 0 | 38 | 15 | 1 | 32 | 2 | 0 | 0 | 0 | 20 | 27 | 17 | 0 | 0 | 0 | 0 |
| Usual Care | 0 | 1 | 3 | 2 | 7 | 2 | 11 | 8 | 0 | 0 | 6 | 22 | 0 | 2 | 1 | 2 | 17 | 5 | 4 | 0 | 0 | 0 | 2 | 25 | 0 | 3 | 6 | 2 | 0 | 0 | 0 | 4 | 56 | 1 | 0 | 1 | 0 | 45 | 21 | 0 | 28 | 3 | 0 | 0 | 0 | 30 | 26 | 21 | 0 | 0 | 0 | 0 |
Vital sign measurements considered potentially clinically significant (PCS) meeting either the lower-limit or higher-limit PCS criteria. (NCT02873221)
Timeframe: 56 Weeks
| Intervention | Participants (Count of Participants) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBP (mmHg) (Sitting) <= 90 and Decrease of >= 20 | SBP (mmHg) (Sitting) >= 180 and Increase of >= 20 | SBP (mmHg) (Standing) <= 90 and Decrease of >= 20 | SBP (mmHg) (Standing) >= 180 and Increase of >= 20 | Standing - Sitting SBP (mmHg) <= -20 | DBP (mmHg) (Sitting) <= 50 and Decrease of >= 15 | DBP (mmHg) (Sitting) >= 105 and Increase of >= 15 | DBP (mmHg) (Standing) <= 50 and Decrease of >= 15 | DBP (mmHg) (Standing) >= 105 and Increase of >= 15 | Standing - Sitting DBP (mmHg) <= -15 | PR (beats/min) (Sitting) <= 50, Decrease of >= 15 | PR (beats/min) (Sitting) >= 120, Increase of >= 15 | PR (beats/min) (Standing) <= 50, Decrease of >= 15 | PR (beats/min)(Standing) >= 120, Increase of >= 15 | Standing - Sitting Pulse Rate (beats/min) >= 25 | Weight (kg) Decrease of >= 7% | Weight (kg) Increase of >= 7% | |
| Ubrogepant 100 mg | 12 | 1 | 11 | 1 | 49 | 4 | 6 | 4 | 11 | 36 | 7 | 1 | 3 | 13 | 35 | 53 | 61 |
| Ubrogepant 50 mg | 20 | 0 | 11 | 0 | 40 | 5 | 3 | 4 | 14 | 42 | 5 | 2 | 3 | 9 | 37 | 48 | 69 |
| Usual Care | 11 | 0 | 12 | 0 | 58 | 6 | 6 | 5 | 12 | 38 | 4 | 1 | 2 | 14 | 42 | 58 | 73 |
"SPID-30 is defined as the sum of the pain intensity differences (measured as area under the curve) from dosing (Baseline) through 30 minutes post-dose for headaches with a Baseline intensity of mild, moderate, or severe. The range of possible scores is -60 to +90. A higher number indicates a greater reduction in pain intensity. Negative values indicate worsening pain. A value of 0 indicates that there was no change in pain intensity from Baseline through 30 minutes. Results are from an analysis of covariance (ANCOVA) model with treatment, period, and treatment sequence as fixed effects and participant as a random effect. The Last Observation Carried Forward (LOCF) imputation method (missing values were replaced by carrying forward the preceding value) was used for this analysis." (NCT01667679)
Timeframe: Baseline and 30 minutes post-dose (up to 24 weeks)
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| 20 mg Sumatriptan Nasal Powder | 10.80 |
| 100 mg Sumatriptan Tablet | 7.41 |
Pain freedom is defined as a pain level reduced to none (Grade 0). (NCT01667679)
Timeframe: 120 minutes post-dose (up to 24 weeks)
| Intervention | minutes (Median) |
|---|---|
| 20 mg Sumatriptan Nasal Powder | 91 |
| 100 mg Sumatriptan Tablet | 121 |
Change from Baseline in albumin and total protein was assessed at Visit 3 (the start of Treatment Period 2) and Visit 4 (the end-of-study visit). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value is the last non-missing value prior to or on the start date of Treatment Period 1. (NCT01667679)
Timeframe: Baseline and Visits 3 (up to 12 weeks) and 4 (up to 24 weeks)
| Intervention | grams per Liter (grams/L) (Mean) | |||
|---|---|---|---|---|
| albumin, Visit 3, n=108, 94 | albumin, Visit 4, n=123, 110 | total protein, Visit 3, n=108, 94 | total protein, Visit 4, n=122, 110 | |
| 100 mg Sumatriptan+PBO (TP1)/20 mg Sumatriptan+PBO (TP2) | -0.9 | -0.5 | -1.2 | -1.0 |
| 20 mg Sumatriptan+PBO (TP1)/100 mg Sumatriptan+PBO (TP2) | -0.8 | -0.9 | -1.0 | -1.2 |
Change from Baseline in ALP and ALT was assessed at Visit 3 (the start of Treatment Period 2) and Visit 4 (the end-of-study visit). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value is the last non-missing value prior to or on the start date of Treatment Period 1. (NCT01667679)
Timeframe: Baseline and Visits 3 (up to 12 weeks) and 4 (up to 24 weeks)
| Intervention | International Units per Liter (IU/L) (Mean) | |||
|---|---|---|---|---|
| ALP, Visit 3, n=108, 94 | ALP, Visit 4, n=123, 110 | ALT, Visit 3, n=108, 94 | ALT, Visit 4, n=123, 110 | |
| 100 mg Sumatriptan+PBO (TP1)/20 mg Sumatriptan+PBO (TP2) | 0.0 | -1.0 | 0.0 | -0.9 |
| 20 mg Sumatriptan+PBO (TP1)/100 mg Sumatriptan+PBO (TP2) | -0.5 | -1.7 | 0.4 | 0.4 |
Change from Baseline in AST and GGT was assessed at Visit 3 (the start of Treatment Period 2) and Visit 4 (the end-of-study visit). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value is the last non-missing value prior to or on the start date of Treatment Period 1. (NCT01667679)
Timeframe: Baseline and Visits 3 (up to 12 weeks) and 4 (up to 24 weeks)
| Intervention | International Units per Liter (IU/L) (Mean) | |||
|---|---|---|---|---|
| AST, Visit 3, n=108, 92 | AST, Visit 4, n=123, 110 | GGT, Visit 3, n=108, 94 | GGT, Visit 4, n=123, 110 | |
| 100 mg Sumatriptan+PBO (TP1)/20 mg Sumatriptan+PBO (TP2) | 0.5 | -1.2 | 0.0 | -0.7 |
| 20 mg Sumatriptan+PBO (TP1)/100 mg Sumatriptan+PBO (TP2) | -0.2 | 0.6 | 0.8 | 0.4 |
Change from Baseline in creatinine was assessed at Visit 3 (the start of Treatment Period 2) and Visit 4 (the end-of-study visit). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value is the last non-missing value prior to or on the start date of Treatment Period 1. (NCT01667679)
Timeframe: Baseline and Visits 3 (up to 12 weeks) and 4 (up to 24 weeks)
| Intervention | micromoles per Liter (µmol/L) (Mean) | |
|---|---|---|
| Visit 3, n=108, 94 | Visit 4, n=123, 110 | |
| 100 mg Sumatriptan+PBO (TP1)/20 mg Sumatriptan+PBO (TP2) | -0.7 | -0.6 |
| 20 mg Sumatriptan+PBO (TP1)/100 mg Sumatriptan+PBO (TP2) | -1.9 | -1.3 |
Change from Baseline in hematocrit (proportion of total blood volume that is composed of red blood cells) was assessed at Visit 3 (the start of Treatment Period 2) and Visit 4 (the end-of-study visit). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.The Baseline value is the last non-missing value prior to or on the start date of Treatment Period 1. (NCT01667679)
Timeframe: Baseline and Visits 3 (up to 12 weeks) and 4 (up to 24 weeks)
| Intervention | proportion (Mean) | |
|---|---|---|
| Visit 3, n=108, 94 | Visit 4, n=124, 110 | |
| 100 mg Sumatriptan+PBO (TP1)/20 mg Sumatriptan+PBO (TP2) | -0.005 | -0.002 |
| 20 mg Sumatriptan+PBO (TP1)/100 mg Sumatriptan+PBO (TP2) | -0.002 | -0.005 |
Change from Baseline in hemoglobin was assessed at Visit 3 (the start of Treatment Period 2) and Visit 4 (the end-of-study visit). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value is the last non-missing value prior to or on the start date of Treatment Period 1. (NCT01667679)
Timeframe: Baseline and Visits 3 (up to 12 weeks) and 4 (up to 24 weeks)
| Intervention | grams per Liter (g/L) (Mean) | |
|---|---|---|
| Visit 3 | Visit 4 | |
| 100 mg Sumatriptan+PBO (TP1)/20 mg Sumatriptan+PBO (TP2) | -1.3 | -0.8 |
| 20 mg Sumatriptan+PBO (TP1)/100 mg Sumatriptan+PBO (TP2) | -1.3 | -2.7 |
Change from Baseline in pulse was assessed at Visit 3 (the start of Treatment Period 2) and Visit 4 (the end-of-study visit). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value is the last non-missing value prior to or on the start date of Treatment Period 1. (NCT01667679)
Timeframe: Baseline and Visits 3 (up to 12 weeks) and 4 (up to 24 weeks)
| Intervention | beats per minute (Mean) | |
|---|---|---|
| Visit 3, n=110, 95 | Visit 4, n=124, 111 | |
| 100 mg Sumatriptan+PBO (TP1)/20 mg Sumatriptan+PBO (TP2) | 0.1 | -0.2 |
| 20 mg Sumatriptan+PBO (TP1)/100 mg Sumatriptan+PBO (TP2) | 0.1 | -2.2 |
Change from Baseline in red blood cell count was assessed at Visit 3 (the start of Treatment Period 2) and Visit 4 (the end-of-study visit). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value is the last non-missing value prior to or on the start date of Treatment Period 1. (NCT01667679)
Timeframe: Baseline and Visits 3 (up to 12 weeks) and 4 (up to 24 weeks)
| Intervention | 10^12 cells per Liter (Mean) | |
|---|---|---|
| Visit 3, n=109, 95 | Visit 4, n=124, 110 | |
| 100 mg Sumatriptan+PBO (TP1)/20 mg Sumatriptan+PBO (TP2) | -0.04 | -0.02 |
| 20 mg Sumatriptan+PBO (TP1)/100 mg Sumatriptan+PBO (TP2) | -0.02 | -0.05 |
Change from Baseline in sodium, potassium, chloride, calcium, and glucose was assessed at Visit 3 (the start of Treatment Period 2) and Visit 4 (the end-of-study visit). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value is the last non-missing value prior to or on the start date of Treatment Period 1. (NCT01667679)
Timeframe: Baseline and Visits 3 (up to 12 weeks) and 4 (up to 24 weeks)
| Intervention | mmoles/L (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| sodium, Visit 3, n=108, 94 | sodium, Visit 4, n=122, 110 | potassium, Visit 3, n=108, 94 | potassium, Visit 4, n=122, 110 | chloride, Visit 3, n=108, 94 | chloride, Visit 4, n=122, 110 | calcium, Visit 3, n=108, 94 | calcium, Visit 4, n=123, 110 | glucose, Visit 3, n=108, 94 | glucose, Visit 4, n=123, 110 | |
| 100 mg Sumatriptan+PBO (TP1)/20 mg Sumatriptan+PBO (TP2) | -0.5 | -0.2 | -0.04 | -0.00 | 0.0 | 0.2 | -0.016 | -0.006 | 0.05 | 0.24 |
| 20 mg Sumatriptan+PBO (TP1)/100 mg Sumatriptan+PBO (TP2) | -0.3 | -0.3 | -0.08 | -0.10 | -0.1 | 0.2 | -0.019 | -0.011 | 0.34 | 0.20 |
Change from Baseline in SBP and DBP was assessed at Visit 3 (the start of Treatment Period 2) and Visit 4 (the end-of-study visit). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value is the last non-missing value prior to or on the start date of Treatment Period 1. (NCT01667679)
Timeframe: Baseline and Visits 3 (up to 12 weeks) and 4 (up to 24 weeks)
| Intervention | millimeters of mercury (mmHg) (Mean) | |||
|---|---|---|---|---|
| SBP, Visit 3, n=110, 95 | SBP, Visit 4, n=124, 111 | DBP, Visit 3, n=110, 95 | DBP, Visit 4, n=124, 111 | |
| 100 mg Sumatriptan+PBO (TP1)/20 mg Sumatriptan+PBO (TP2) | 1.5 | 2.0 | 1.0 | -0.2 |
| 20 mg Sumatriptan+PBO (TP1)/100 mg Sumatriptan+PBO (TP2) | 0.1 | 1.6 | -0.2 | 0.2 |
Change from Baseline in total bilirubin was assessed at Visit 3 (the start of Treatment Period 2) and Visit 4 (the end-of-study visit). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value is the last non-missing value prior to or on the start date of Treatment Period 1. (NCT01667679)
Timeframe: Baseline and Visits 3 (up to 12 weeks) and 4 (up to 24 weeks)
| Intervention | Units per Liter (U/L) (Mean) | |
|---|---|---|
| Visit 3, n=108, 94 | Visit 4, n=123, 110 | |
| 100 mg Sumatriptan+PBO (TP1)/20 mg Sumatriptan+PBO (TP2) | -0.2 | 0.2 |
| 20 mg Sumatriptan+PBO (TP1)/100 mg Sumatriptan+PBO (TP2) | 0.2 | -0.6 |
Change from Baseline in urea was assessed at Visit 3 (the start of Treatment Period 2) and Visit 4 (the end-of-study visit). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value is the last non-missing value prior to or on the start date of Treatment Period 1. (NCT01667679)
Timeframe: Baseline and Visits 3 (up to 12 weeks) and 4 (up to 24 weeks)
| Intervention | millimoles per Liter (mmol/L) (Mean) | |
|---|---|---|
| Visit 3, n=108, 94 | Visit 4, n=123, 110 | |
| 100 mg Sumatriptan+PBO (TP1)/20 mg Sumatriptan+PBO (TP2) | 0.079 | 0.308 |
| 20 mg Sumatriptan+PBO (TP1)/100 mg Sumatriptan+PBO (TP2) | 0.070 | 0.156 |
Change from Baseline in urinalysis values was assessed at Visit 3 (the start of Treatment Period 2) and Visit 4 (the end-of-study visit). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value is the last non-missing value prior to or on the start date of Treatment Period 1. (NCT01667679)
Timeframe: Baseline and Visits 3 (up to 12 weeks) and 4 (up to 24 weeks)
| Intervention | pH (Mean) | |
|---|---|---|
| Visit 3, n=108, 95 | Visit 4, n=124, 109 | |
| 100 mg Sumatriptan+PBO (TP1)/20 mg Sumatriptan+PBO (TP2) | -0.03 | -0.07 |
| 20 mg Sumatriptan+PBO (TP1)/100 mg Sumatriptan+PBO (TP2) | -0.04 | 0.01 |
Change from Baseline in white blood cell (WBC) count, basinophils, monocytes, neutrophils, lymphocytes, eosinophils, and platelets was assessed at Visit 3 (the start of Treatment Period 2) and Visit 4 (the end-of-study visit). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value is the last non-missing value prior to or on the start date of Treatment Period 1. (NCT01667679)
Timeframe: Baseline and Visits 3 (up to 12 weeks) and 4 (up to 24 weeks)
| Intervention | 10^9 cells per Liter (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WBC Count, Visit 3, n=109, 95 | WBC Count, Visit 4, n=124, 110 | Basophils, Visit 3, n=108, 95 | Basophils, Visit 4, n=124, 110 | Monocytes, Visit 3, n=108, 95 | Monocytes, Visit 4, n=124, 110 | Neutrophils, Visit 3, n=108, 95 | Neutrophils, Visit 4, n=124, 110 | Lymphocytes, Visit 3, n=108, 95 | Lymphocytes, Visit 4, n=124, 110 | Eosinophils, Visit 3, n=108, 95 | Eosinophils, Visit 4, n=124, 110 | Platelets, Visit 3, n=109, 93 | Platelets, Visit 4, n=123, 110 | |
| 100 mg Sumatriptan+PBO (TP1)/20 mg Sumatriptan+PBO (TP2) | -0.19 | -0.09 | 0.000 | -0.001 | -0.022 | -0.026 | -0.134 | -0.057 | -0.038 | -0.020 | 0.006 | 0.013 | -8.2 | -7.5 |
| 20 mg Sumatriptan+PBO (TP1)/100 mg Sumatriptan+PBO (TP2) | -0.10 | -0.05 | 0.000 | 0.000 | -0.030 | -0.014 | -0.052 | -0.059 | -0.049 | 0.012 | -0.001 | 0.012 | -1.9 | -4.0 |
Participants were required to record their clinical disability score in their e-diaries immediately before intake of study medication (Baseline) and at 10, 15, 30, 45, 60, 90, and 120 minutes post-dose. Participants graded their disability on the following scale: 0, no disability, able to function normally; 1, performance of daily activities mildly impaired, can still do everything but with difficulty; 2, performance of daily activities moderately impaired, unable to do some things; 3, performance of daily activities severely impaired, cannot do all or most things, bed rest may be necessary. Mean change from Baseline was calculated as the post-Baseline value minus the Baseline value. (NCT01667679)
Timeframe: Baseline and 10, 15, 30, 45, 60, 90, and 120 minutes post-dose (up to 24 weeks)
| Intervention | scores on a scale (Least Squares Mean) | ||||||
|---|---|---|---|---|---|---|---|
| 10 minutes post-dose | 15 minutes post-dose | 30 minutes post-dose | 45 minutes post-dose | 60 minutes post-dose | 90 minutes post-dose | 120 minutes post-dose | |
| 100 mg Sumatriptan Tablet | -0.03 | -0.09 | -0.26 | -0.43 | -0.56 | -0.72 | -0.85 |
| 20 mg Sumatriptan Nasal Powder | -0.08 | -0.18 | -0.42 | -0.60 | -0.73 | -0.83 | -0.92 |
Participants were required to record their headache severity score in their e-diaries immediately before intake of study medication (Baseline) and at 10, 15, 30, 45, 60, 90, and 120 minutes post-dose. Participants graded their headaches on the following severity scale: 0, none; 1, mild; 2, moderate; 3, severe. Mean change from Baseline was calculated as the post-Baseline value minus the Baseline value. (NCT01667679)
Timeframe: Baseline and 10, 15, 30, 45, 60, 90, and 120 minutes post-dose (up to 24 weeks)
| Intervention | scores on a scale (Least Squares Mean) | ||||||
|---|---|---|---|---|---|---|---|
| 10 minutes post-dose | 15 minutes post-dose | 30 minutes post-dose | 45 minutes post-dose | 60 minutes post-dose | 90 minutes post-dose | 120 minutes post-dose | |
| 100 mg Sumatriptan Tablet | -0.09 | -0.18 | -0.38 | -0.60 | -0.79 | -0.98 | -1.15 |
| 20 mg Sumatriptan Nasal Powder | -0.11 | -0.26 | -0.56 | -0.77 | -0.93 | -1.09 | -1.19 |
"SPID-30 is defined as the sum of the pain intensity differences (measured as area under the curve) from dosing (Baseline) through 30 minutes post-dose for headaches with a Baseline intensity of mild and moderate/severe (rated on a 4-point scale: 0=none, 1=mild, 2=moderate, and 3=severe). The range of possible scores for all participants is -60 to +90. For participants with a mild headache at Baseline, the SPID range is -60 to +30. For participants with a moderate/severe headache at Baseline, the SPID range is -30 to +90. A higher number indicates a greater reduction in pain intensity. Negative values indicate worsening pain. A value of 0 indicates that there was no change in pain intensity from Baseline through 30 minutes. Results are from an ANCOVA model with treatment, period, and treatment sequence as fixed effects and participant as a random effect. The LOCF imputation method (missing values were replaced by carrying forward the preceding value) was used for this analysis." (NCT01667679)
Timeframe: Baseline and 30 minutes post-dose (up to 24 weeks)
| Intervention | scores on a scale (Least Squares Mean) | |
|---|---|---|
| mild attacks, n=113, 109 | moderate/severe attacks, n=158, 168 | |
| 100 mg Sumatriptan Tablet | 0.24 | 10.07 |
| 20 mg Sumatriptan Nasal Powder | 3.90 | 13.83 |
An adverse event is defined as any untoward medical occurrence associated with the use of an investigational product in humans, whether or not it is considered related to the investigational product. This includes any occurrence that was new in onset or aggravated in severity or frequency from the Baseline condition. (NCT01667679)
Timeframe: Baseline compared to Vist 2, 3 and 4
| Intervention | participants (Number) | |
|---|---|---|
| Treatment-emergent Adverse Event | Treatment-emergent Serious Adverse Event | |
| 100 mg Sumatriptan Tablet | 73 | 0 |
| 20 mg Sumatriptan Nasal Powder | 118 | 0 |
"The Baseline value is the last non-missing value prior to or on the start date of Treatment Period 1. Clinical significance was determined by the Investigator (per clinical judgement). A categorization of normal or abnormal was made per the investigators' clinical judgment of the ECG, taking the participants' demographic characteristics and other medical conditions into account. CS = clinically significant. CNS = clinically not significant." (NCT01667679)
Timeframe: Baseline and Visits 3 (up to 12 weeks) and 4 (up to 24 weeks)
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline, normal; n=133, 129 | Baseline, abnormal, CS; n=133, 129 | Baseline, abnormal, CNS; n=133, 129 | Visit 3, normal; n=110, 95 | Visit 3, abnormal, CS; n=110, 95 | Visit 3, abnormal, CNS; n=110, 95 | Visit 4, normal; n=124, 111 | Visit 4, abnormal, CS; n=124, 111 | Visit 4, abnormal, CNS; n=123, 111 | |
| 100 mg Sumatriptan+PBO (TP1)/20 mg Sumatriptan+PBO (TP2) | 99 | 0 | 30 | 70 | 0 | 25 | 73 | 1 | 37 |
| 20 mg Sumatriptan+PBO (TP1)/100 mg Sumatriptan+PBO (TP2) | 96 | 1 | 36 | 79 | 0 | 31 | 90 | 0 | 34 |
"The Baseline value is the last non-missing value prior to or on the start date of Treatment Period 1. Data are based on standard reads, with 1+, 2+, and 3+ indicating increasing amounts of metabolites in urine." (NCT01667679)
Timeframe: Baseline and Visits 3 (up to 12 weeks) and 4 (up to 24 weeks)
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protein, Baseline, negative | Protein, Baseline, trace | Protein, Baseline, 1+ | Protein, Baseline, 2+ | Protein, Visit 3, negative | Protein, Visit 3, trace | Protein, Visit 3, 1+ | Protein, Visit 3, 2+ | Protein, Visit 4, negative | Protein, Visit 4, trace | Protein, Visit 4, 1+ | Protein, Visit 4, 2+ | Glucose, Baseline, negative | Glucose, Baseline, trace | Glucose, Baseline, 3+ | Glucose, Visit 3, negative | Glucose, Visit 3, trace | Glucose, Visit 3, 3+ | Glucose, Visit 4, negative | Glucose, Visit 4, trace | Glucose, Visit 4, 1+ | Glucose, Visit 4, 3+ | Ketones, Baseline, negative | Ketones, Baseline, trace | Ketones, Baseline, 1+ | Ketones, Baseline, 2+ | Ketones, Visit 3, negative | Ketones, Visit 3, trace | Ketones, Visit 3, 1+ | Ketones, Visit 3, 2+ | Ketones, Visit 4, negative | Ketones, Visit 4, trace | Ketones, Visit 4, 1+ | Blood, Baseline, negative | Blood, Baseline, trace | Blood, Baseline, 1+ | Blood, Baseline, 2+ | Blood, Baseline, 3+ | Blood, Visit 3, negative | Blood, Visit 3, trace | Blood, Visit 3, 1+ | Blood, Visit 3, 2+ | Blood, Visit 3, 3+ | Blood, Visit 4, negative | Blood, Visit 4, trace | Blood, Visit 4, 1+ | Blood, Visit 4, 2+ | Blood, Visit 4, 3+ | WBCs, Baseline, negative | WBCs, Baseline, trace | WBCs, Baseline, 1+ | WBCs, Baseline, 2+ | WBCs, Baseline, 3+ | WBCs, Visit 3, negative | WBCs, Visit 3, trace | WBCs, Visit 3, 1+ | WBCs, Visit 3, 2+ | WBCs, Visit 3, 3+ | WBCs, Visit 4, negative | WBCs, Visit 4, trace | WBCs, Visit 4, 1+ | WBCs, Visit 4, 2+ | WBCs, Visit 4, 3+ | |
| 100 mg Sumatriptan+PBO (TP1)/20 mg Sumatriptan+PBO (TP2) | 105 | 19 | 3 | 2 | 75 | 15 | 5 | 0 | 90 | 12 | 6 | 1 | 126 | 2 | 1 | 94 | 1 | 0 | 108 | 1 | 0 | 0 | 121 | 7 | 1 | 0 | 88 | 6 | 0 | 1 | 101 | 8 | 0 | 116 | 4 | 3 | 1 | 5 | 78 | 6 | 4 | 2 | 5 | 94 | 6 | 5 | 3 | 1 | 101 | 8 | 11 | 5 | 4 | 75 | 7 | 4 | 6 | 3 | 85 | 7 | 5 | 8 | 4 |
| 20 mg Sumatriptan+PBO (TP1)/100 mg Sumatriptan+PBO (TP2) | 112 | 16 | 5 | 0 | 92 | 11 | 4 | 1 | 104 | 17 | 3 | 0 | 132 | 1 | 0 | 107 | 0 | 1 | 122 | 0 | 1 | 1 | 124 | 7 | 0 | 2 | 102 | 5 | 1 | 0 | 119 | 3 | 2 | 116 | 7 | 2 | 5 | 3 | 94 | 4 | 5 | 2 | 3 | 111 | 3 | 1 | 4 | 5 | 99 | 12 | 12 | 7 | 3 | 90 | 8 | 4 | 5 | 1 | 105 | 5 | 4 | 8 | 2 |
Concomitant medications are defined as non-study medications with a start or stop date between the first dose of study medication and the end of safety follow-up, inclusive. Derm. = dermatologic; incl. - including. (NCT01667679)
Timeframe: up to 24 weeks
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any concomitant medication | Agents acting on the renin-angiotensin system | Other therapeutic products | Allergens | Anabolic agents for systemic use | Analgesics | Anesthetics | Anti-acne preparations | Anti-Parkinson drugs | Antianemic preparations | Antibacterials for systemic use | Antibiotics and chemotherapeutics for derm. use | Antidiarrrheals, intestinal antiinflammatories | Antiemetics and antinauseants | Antiepileptics | Antigout preparations | Antihistamines for systemic use | Antiinflammatory and antirheumatic products | Antimyotics for systemic use | Antiobesity preparations, exluding diet products | Antiprotozoals | Antiseptics and disinfectants | Antithrombotic agents | Antivirals for systemic use | Beta blocking agents | Calcium channel blockers | Cardiac therapy | Corticosteroids for systemic use | Corticosteroids, dermatologic preparations | Cough and cold preparations | Diuretics | Drugs for acid related disorders | Drugs for functional gastrointestinal disorders | Drugs for obstructive airways diseases | Drugs for treatment of bone diseases | Drugs used in diabetes | Ectoparasiticides, incl. scabacides, insecticides | Gynecological antiinfectives and antiseptics | Immune sera and immunoglobulins | Laxatives | Lipid modifying agents | Mineral supplements | Muscle relaxants | Nasal preparations | Opthalmologicals | Other alimentary tract and metabolism products | Other dermatological preparations | Other gynecologicals | Other nervous system drugs | Otologicals | Psychoanaleptics | Psycholeptics | Sex hormones and modulators of the genital system | Thyroid therapy | Unspecified herbal and traditional medicine | Urologicals | Vaccines | Vitamins | |
| 100 mg Sumatriptan+PBO (TP1)/20 mg Sumatriptan+PBO (TP2) | 226 | 14 | 2 | 4 | 1 | 148 | 6 | 2 | 3 | 20 | 17 | 2 | 6 | 12 | 4 | 1 | 39 | 143 | 3 | 3 | 1 | 0 | 8 | 3 | 15 | 8 | 1 | 8 | 1 | 9 | 7 | 23 | 3 | 26 | 1 | 9 | 0 | 2 | 1 | 3 | 20 | 22 | 16 | 27 | 6 | 5 | 1 | 21 | 3 | 0 | 60 | 31 | 59 | 16 | 12 | 4 | 2 | 56 |
| 20 mg Sumatriptan+PBO (TP1)/100 mg Sumatriptan+PBO (TP2) | 218 | 12 | 2 | 3 | 1 | 143 | 6 | 2 | 3 | 18 | 13 | 0 | 7 | 11 | 5 | 1 | 38 | 135 | 1 | 3 | 0 | 1 | 8 | 2 | 18 | 9 | 1 | 7 | 1 | 8 | 6 | 22 | 5 | 20 | 1 | 7 | 1 | 1 | 1 | 4 | 23 | 20 | 12 | 25 | 7 | 5 | 1 | 21 | 3 | 1 | 57 | 31 | 62 | 18 | 11 | 3 | 1 | 57 |
The Baseline value is the last non-missing value prior to or on the start date of Treatment Period 1. Clinical significance was determined by the Investigator (per clinical judgement). CS = clinically significant. CNS = clinically not significant. (NCT01667679)
Timeframe: Baseline and Visits 3 (up to 12 weeks) and 4 (up to 24 weeks)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Baseline, CS; n=133, 129 | Baseline, CNS; n=133, 129 | Visit 3, CS; n=110, 95 | Visit 3, CNS; n=110, 95 | Visit 4, CS; n=124, 111 | Visit 4, CNS; n=124, 111 | |
| 100 mg Sumatriptan+PBO (TP1)/20 mg Sumatriptan+PBO (TP2) | 0 | 129 | 2 | 93 | 0 | 111 |
| 20 mg Sumatriptan+PBO (TP1)/100 mg Sumatriptan+PBO (TP2) | 1 | 132 | 1 | 109 | 0 | 124 |
Percentage of attacks in which pain freedom (defined as pain level reduced to none [Grade 0]) was achieved at 10, 15, 30, 45, 60, 90, and 120 minutes after the initial dose for all attacks. (NCT01667679)
Timeframe: Baseline and 10, 15, 30, 45, 60, 90, and 120 minutes post-dose (up to 24 weeks)
| Intervention | percentage of attacks (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 10 minutes post-dose | 15 minutes post-dose | 30 minutes post-dose | 45 minutes post-dose | 60 minutes post-dose | 90 minutes post-dose | 120 minutes post-dose | |
| 100 mg Sumatriptan Tablet | 1.3 | 3.7 | 10.8 | 21.3 | 32.9 | 44.9 | 56.3 |
| 20 mg Sumatriptan Nasal Powder | 2.5 | 7.2 | 18.2 | 31.0 | 41.2 | 52.8 | 60.4 |
Percentage of attacks in which pain reduction (defined as a decrease in pain intensity of at least one point on the following scale: 0, none; 1, mild; 2, moderate; 3, severe) was achieved at 10, 15, 30, 45, 60, 90, and 120 minutes after the initial dose for all attacks. (NCT01667679)
Timeframe: 10, 15, 30, 45, 60, 90, and 120 minutes
| Intervention | percentage of attacks (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 10 minutes post-dose | 15 minutes post-dose | 30 minutes post-dose | 45 minutes post-dose | 60 minutes post-dose | 90 minutes post-dose | 120 minutes post-dose | |
| 100 mg Sumatriptan Tablet | 10.2 | 19.6 | 35.2 | 49.9 | 59.8 | 69.8 | 75.2 |
| 20 mg Sumatriptan Nasal Powder | 11.5 | 26.4 | 49.0 | 60.7 | 67.2 | 74.6 | 78.0 |
Percentage of attacks treated at a severity of moderate (Grade 2) or severe (Grade 3) in which pain relief (defined as pain level reduced to none [Grade 0] or mild [Grade 1]) was achieved at 10, 15, 30, 45, 60, 90, and 120 minutes after the initial dose for all attacks. (NCT01667679)
Timeframe: Baseline and 10, 15, 30, 45, 60, 90, and 120 minutes post-dose (up to 24 weeks)
| Intervention | percentage of attacks (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 10 minutes post-dose | 15 minutes post-dose | 30 minutes post-dose | 45 minutes post-dose | 60 minutes post-dose | 90 minutes post-dose | 120 minutes post-dose | |
| 100 mg Sumatriptan Tablet | 11.5 | 20.9 | 38.7 | 53.9 | 62.6 | 72.0 | 76.9 |
| 20 mg Sumatriptan Nasal Powder | 13.8 | 27.9 | 53.8 | 65.0 | 72.1 | 77.4 | 79.6 |
"Plasma concentrations of sumatriptan were quantified using a validated high performance liquid chromatographic method with tandem mass spectrometry detection.~Area under the plasma concentration-time curve from time 0 to 6 hours post dose (AUC6hr) after the 2nd 6 mg dose of sumatriptan was estimated using the linear trapezoidal method. Sumatriptan plasma concentrations below the lower limit of quantification (LLOQ; 0.100 ng/mL) were set to 0 before data analysis.~Log-transformed AUC6hr was analyzed using a linear mixed effects model with treatment as a fixed effect and subject as a random effect.~Sumatriptan Alone data include participants from both Groups A (Parts 1 and 2) and B (Part 1 only)." (NCT02741310)
Timeframe: Day 2 and day 5 at 1 hour (prior to 2nd sumatriptan injection), 1 hour 10 minutes, 1.25, 1.5, 2, 3, 4.5, and 7 hours relative to the first 6 mg dose of sumatriptan.
| Intervention | hr*ng/mL (Geometric Least Squares Mean) |
|---|---|
| Sumatriptan Alone | 133.33 |
| Erenumab + Sumatriptan | 130.59 |
"Plasma concentrations of sumatriptan were quantified using a validated high performance liquid chromatographic method with tandem mass spectrometry detection. The area under the plasma concentration-time curve from time 0 to infinity (AUCinf) after the 2nd 6 mg dose of sumatriptan was estimated as the sum of AUClast and Clast/λz where Clast is the last observed concentration and λz is the first-order terminal rate constant estimated via linear regression of the terminal log-linear decay phase. Sumatriptan plasma concentrations below the lower limit of quantification (LLOQ) (0.100 ng/mL) were set to 0 before data analysis.~Log-transformed AUCinf was analyzed using a linear mixed effects model with treatment as a fixed effect and subject as a random effect. Sumatriptan Alone data include participants from both Groups A (Parts 1 and 2) and B (Part 1 only)." (NCT02741310)
Timeframe: Day 2 and day 5 at 1 hour (prior to 2nd sumatriptan injection), 1 hour 10 minutes, 1.25, 1.5, 2, 3, 4.5, and 7 hours relative to the first 6 mg dose of sumatriptan.
| Intervention | hr*ng/mL (Geometric Least Squares Mean) |
|---|---|
| Sumatriptan Alone | 144.32 |
| Erenumab + Sumatriptan | 144.81 |
"Plasma concentrations of sumatriptan were quantified using a validated high performance liquid chromatographic method with tandem mass spectrometry detection. Sumatriptan plasma concentrations below the lower limit of quantification (LLOQ) (0.100 ng/mL) were set to 0 before data analysis.~Log-transformed maximum observed plasma concentration (Cmax) was analyzed using a linear mixed effects model with treatment as a fixed effect and subject as a random effect. Sumatriptan Alone data include participants from both Groups A (Parts 1 and 2) and B (Part 1 only)." (NCT02741310)
Timeframe: Day 2 and day 5 at predose, 1 hour (prior to 2nd sumatriptan injection), 1 hour 10 minutes, 1.25, 1.5, 2, 3, 4.5, and 7 hours relative to the first 6 mg dose of sumatriptan.
| Intervention | ng/mL (Geometric Least Squares Mean) |
|---|---|
| Sumatriptan Alone | 83.50 |
| Erenumab + Sumatriptan | 79.00 |
"Mean arterial pressure (MAP) is the average arterial pressure during a single cardiac cycle. MAP was calculated as diastolic blood pressure (DBP) + 0.33 * (systolic blood pressure [SBP]-DBP). Individual time-weighted average in MAP were calculated as area under the measurement-time curve from predose through 2.5 hours of MAP divided by the time period over which the measurements were made (ie, AUCmap0-2.5 hr /2.5 hours).~Data were analyzed using a linear mixed effects regression model with fixed effects for treatment and period and random effect for subject; Sumatriptan Alone data include participants from both Groups A (Parts 1 and 2) and B (Part 1 only)." (NCT02741310)
Timeframe: Days 2 and 5 from predose to 2.5 hours after sumatriptan dosing.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Sumatriptan Alone | 87.40 |
| Erenumab + Sumatriptan | 87.36 |
"Two validated assays were used to detect the presence of anti-erenumab antibodies. All samples were first tested in an electrochemiluminescence-based bridging assay to detect antibodies capable of binding to erenumab (Binding Antibody Assay). Samples confirmed to be positive for binding antibodies were subsequently tested in a cell-based assay to determine neutralizing activity against erenumab (Neutralizing Antibody Assay). If a post-dose sample was positive for binding antibodies and demonstrated neutralizing activity at the same time point, the sample was defined as positive for neutralizing antibodies.~Binding/neutralizing antibody positive is defined as participants with an antibody positive postbaseline results and with a negative or no result at baseline." (NCT02741310)
Timeframe: Baseline and day 89
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Binding antibody positive | Neutralizing antibody positive | |
| Group A: Placebo + Sumatriptan | 0 | 0 |
| Group B: Erenumab + Sumatriptan | 1 | 1 |
"Adverse events (AEs) were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 and according to the following:~Grade 1 = Mild AE, asymptomatic or mild symptoms; Grade 2 = Moderate, minimal, local or noninvasive intervention indicated; Grade 3 = Severe or medically significant but not immediately life-threatening; Grade 4 = Life-threatening consequences, urgent intervention indicated; Grade 5 = Death related to AE." (NCT02741310)
Timeframe: From the first dose of study drug (sumatriptan, placebo or erenumab) until 84 days after the last dose (89 days). Part 1 includes AEs from day 1 to predose on day 4 and Part 2 includes AEs from day 4 through day 89.
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Any adverse event | Adverse event ≥ grade 2 | Adverse event ≥ grade 3 | Adverse event ≥ grade 4 | Serious adverse events | AE leading to discontinuation of study drug | Fatal adverse events | |
| Part 1 Group A: Placebo + Sumatriptan | 11 | 1 | 0 | 0 | 0 | 2 | 0 |
| Part 1 Group B: Placebo + Sumatriptan | 19 | 0 | 0 | 0 | 0 | 2 | 0 |
| Part 2 Group A: Placebo + Sumatriptan | 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part 2 Group B: Erenumab + Sumatriptan | 17 | 3 | 0 | 0 | 0 | 0 | 0 |
Freedom from headache pain at 2 hours after the first dose of study medication taken within one hour after experiencing a migraine attack of moderate to severe headache pain during the DB1 treatment period, e.g., headache pain rating of moderate [Grade 2] or severe [Grade 3] predose and reduced to none [Grade 0] postdose). Mild headache pain was recorded as Grade 1. If the subject was not able to use study medication for the first migraine after randomization, they were instructed to use the study medication for the next attack. If the subject experienced insufficient relief from the first dose of study medication, they were permitted to take a second dose of study medication or rescue medication 2 or more hours after the first dose, and only after completing the 2 hours' postdose assessments. If no relief was experienced from the first dose of study medication after 2 hours only rescue medication could be administered. Maximum 2 doses of study medication per 24 hours. (NCT02856802)
Timeframe: 2 hours after study medication administration
| Intervention | Participants (Count of Participants) |
|---|---|
| DFN-02 (DB1) | 21 |
| Placebo (DB1) | 9 |
Number of participants with their MBS among nausea, photophobia and phonophobia absent at 10, 15, 20, 30, 60, 90, and 120 minutes after the first dose of study medication taken for a migraine attack during DB1 treatment period are summarized by treatment group and time point for the full analysis set (FAS1). The corresponding p-values from Fisher's exact test were computed for the comparison between treatment groups. Subjects who reported a MBS predose and reported the status of the MBS at the particular postdose time point were analyzed. (NCT02856802)
Timeframe: 2 hours after study medication administration
| Intervention | Participants (Count of Participants) |
|---|---|
| DFN-02 (DB1) | 29 |
| Placebo (DB1) | 15 |
In Double-blind Treatment Period 2 (DB2), freedom from headache pain 2 hours after the first dose of study medication taken within one hour of experiencing a migraine attack for any headache pain level, e.g., mild [Grade 1], moderate [Grade 2], or severe [Grade 3] and reduced to none [Grade 0] after study medication administration. If the subject was not able to use study medication for the first migraine after randomization, they were instructed to use the study medication for the next attack. (NCT02856802)
Timeframe: 2 hours after study medication administration
| Intervention | Participants (Count of Participants) |
|---|---|
| DFN-02 (DB2) | 19 |
| Placebo (DB2) | 17 |
(NCT02569853)
Timeframe: 1 hour
| Intervention | Percentage of responders (Number) |
|---|---|
| DFN-11 | 34.6 |
| Placebo | 19.8 |
(NCT02569853)
Timeframe: 2 hours
| Intervention | Percentage of responders (Number) |
|---|---|
| DFN-11 - Double-Blind | 51.0 |
| Placebo - Double-Blind | 30.8 |
Participants were assessed throughout the study for adverse events. An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an adverse event. (NCT00701389)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Participants (Number) |
|---|---|
| 100 mg Sumatriptan/600 mg Telcagepant | 9 |
| 100 mg Sumatriptan/Telcagepant Placebo | 12 |
| Sumatriptan Placebo/600 mg Telcagepant | 8 |
| Sumatriptan Placebo/Telcagepant Placebo | 10 |
Participants were assessed throughout the study for adverse events. An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an adverse event. The number of participants who were discontinued from the study due to adverse event was summarized. (NCT00701389)
Timeframe: up to 10 weeks
| Intervention | Participants (Number) |
|---|---|
| 100 mg Sumatriptan/600 mg Telcagepant | 0 |
| 100 mg Sumatriptan/Telcagepant Placebo | 0 |
| Sumatriptan Placebo/600 mg Telcagepant | 0 |
| Sumatriptan Placebo/Telcagepant Placebo | 0 |
In each treatment period (1 through 4), duplicate readings of semi-recumbent blood pressure (BP) were completed using an automated blood pressure machine at predose, 30, 60, 90, 120, 150, 180, and 360 minutes postdose. Mean arterial pressure (MAP) was calculated as follows: MAP = Diastolic Blood Pressure (DBP) + (0.33 * Pulse Pressure [PP]) where PP = Systolic Blood Pressure [SBP] minus DBP. Only mean arterial pressure measurements up to and including 150 minutes postdose (including the predose measurement) were used to calculate the time-weighted averages. Time-weighted averages for each participant were obtained by calculating the area under the measurement-time curve of mean arterial pressure divided by the time period over which measurements were made (i.e. 150 minutes). (NCT00701389)
Timeframe: Predose up to 150 minutes postdose of each treatment period (up to 10 weeks)
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| 100 mg Sumatriptan/600 mg Telcagepant | 89.0 |
| 100 mg Sumatriptan/Telcagepant Placebo | 87.5 |
In each treatment period (1 through 4), duplicate readings of semi-recumbent blood pressure (BP) were completed using an automated blood pressure machine at predose, 30, 60, 90, 120, 150, 180, and 360 minutes postdose. Mean arterial pressure (MAP) was calculated as follows: MAP = Diastolic Blood Pressure (DBP) + (0.33 * Pulse Pressure [PP]) where PP = Systolic Blood Pressure [SBP] minus DBP. Only mean arterial pressure measurements up to and including 150 minutes postdose (including the predose measurement) were used to calculate the time-weighted averages. Time-weighted averages for each participant were obtained by calculating the area under the measurement-time curve of mean arterial pressure divided by the time period over which measurements were made (i.e. 150 minutes). (NCT00701389)
Timeframe: Predose up to 150 minutes postdose of each treatment period (up to 10 weeks)
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Sumatriptan Placebo/600 mg Telcagepant | 84.7 |
| Sumatriptan Placebo/Telcagepant Placebo | 83.5 |
"Pain freedom was defined as participants reporting a value of none on the four-point numeric rating scale (none=0, mild =1, moderate =2, severe =3) from baseline. Participants with baseline moderate pain or severe pain were included in the analysis." (NCT01430442)
Timeframe: Baseline, 2 hours post-dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment A: Rimegepant, 10 mg | 14 |
| Treatment B: Rimegepant, 25 mg | 12 |
| Treatment C: Rimegepant, 75 mg | 27 |
| Treatment D: Rimegepant, 150 mg | 28 |
| Treatment E: Rimegepant, 300 mg | 33 |
| Treatment F: Rimegepant, 600 mg | 20 |
| Treatment P: Rimegepant Placebo-Matching Capsules | 31 |
| Treatment G: Sumatriptan 100 mg | 35 |
"Participants were considered to have sustained pain freedom if all of their reported pain readings in the interval are none on the four point numeric rating scale (no pain=0, mild pain=1, moderate pain=2, severe pain=3). The intervals are inclusive of the endpoints. Sustained pain freedom was analyzed with a Cochran Mantel Haenszel (CMH) test for general association that compares the ED90 to placebo, and controls for baseline pain severity." (NCT01430442)
Timeframe: 2 hours to 24 hours post dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment A: Rimegepant, 10 mg | 9 |
| Treatment B: Rimegepant, 25 mg | 10 |
| Treatment C: Rimegepant, 75 mg | 24 |
| Treatment D: Rimegepant, 150 mg | 24 |
| Treatment E: Rimegepant, 300 mg | 29 |
| Treatment F: Rimegepant, 600 mg | 17 |
| Treatment P: Rimegepant Placebo-Matching Capsules | 15 |
| Treatment G: Sumatriptan 100 mg | 26 |
"Participants were considered to have sustained pain freedom if all of their reported pain readings in the interval are none on the four point numeric rating scale (no pain=0, mild pain=1, moderate pain=2, severe pain=3). The intervals are inclusive of the endpoints. Sustained pain freedom was analyzed with a CMH test for general association that compares the ED90 to placebo, and controls for baseline pain severity." (NCT01430442)
Timeframe: 2 hours to 48 hours post dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment A: Rimegepant, 10 mg | 8 |
| Treatment B: Rimegepant, 25 mg | 9 |
| Treatment C: Rimegepant, 75 mg | 24 |
| Treatment D: Rimegepant, 150 mg | 24 |
| Treatment E: Rimegepant, 300 mg | 29 |
| Treatment F: Rimegepant, 600 mg | 17 |
| Treatment P: Rimegepant Placebo-Matching Capsules | 15 |
| Treatment G: Sumatriptan 100 mg | 26 |
"Total migraine freedom is defined as complete absence of migraine symptoms. A participant was positive for total migraine freedom at a particular time point if he/she reports the absence of: pain, nausea, photophobia, and phonophobia. This corresponds to reporting none on each of the four-point numeric rating scale (none =0, mild =1, moderate =2, severe =3) from baseline associated with these symptoms. Participants with baseline moderate pain or severe pain were included in the analysis." (NCT01430442)
Timeframe: Baseline, 2 hours post dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment A: Rimegepant, 10 mg | 13 |
| Treatment B: Rimegepant, 25 mg | 11 |
| Treatment C: Rimegepant, 75 mg | 24 |
| Treatment D: Rimegepant, 150 mg | 22 |
| Treatment E: Rimegepant, 300 mg | 26 |
| Treatment F: Rimegepant, 600 mg | 16 |
| Treatment P: Rimegepant Placebo-Matching Capsules | 24 |
| Treatment G: Sumatriptan 100 mg | 32 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition, unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or suspected transmission of an infectious agent, or encompassed any other clinically significant event that could jeopardize the subject or require medical or surgical intervention to prevent one of the aforementioned outcomes. (NCT01430442)
Timeframe: AEs: from first dose to end of treatment visit (up to 7 weeks); SAE: from signing of informed consent to 30 days after the last dose (up to 11 weeks).
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| AEs | SAEs | Participants discontinued due to AEs | |
| Treatment A: Rimegepant, 10 mg | 15 | 0 | 0 |
| Treatment B: Rimegepant, 25 mg | 10 | 0 | 0 |
| Treatment C: Rimegepant, 75 mg | 18 | 0 | 0 |
| Treatment D: Rimegepant, 150 mg | 12 | 3 | 0 |
| Treatment E: Rimegepant, 300 mg | 18 | 0 | 0 |
| Treatment F: Rimegepant, 600 mg | 14 | 0 | 0 |
| Treatment G: Sumatriptan 100 mg | 17 | 0 | 0 |
| Treatment P: Rimegepant Placebo-Matching Capsules | 29 | 0 | 0 |
Self-assessed grade of compliance with lifestyle modification changes (where A=1, B=2, C=3, D=4, and F=5) in the Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. Lower scores indicate a better outcome. Higher scores indicate a worse outcome. (NCT01090050)
Timeframe: Day 121
| Intervention | Units on a scale (Mean) |
|---|---|
| Sumatriptan/Naproxen Sodium | 2.00 |
| Naproxen Sodium | 2.40 |
Comparing the number of migraine headache days during Baseline Period days 1-30 to number of migraine headache days reported in Treatment Period days 91-120 in the Sumatriptan/Naproxen Sodium arm versus (vs.) Naproxen Sodium arm. Percent change=[(total headache days during Treatment Period Month 3(days 91-120)-total headache days during Baseline(days 1-30)/total headache days during Baseline(days 1-30)]*100%) (NCT01090050)
Timeframe: Day 121 (following 30 day Baseline Period and Treatment Period days 91-120.
| Intervention | percent migraine headache days per month (Mean) |
|---|---|
| Sumatriptan/Naproxen Sodium | -8.06 |
| Naproxen Sodium | -56.37 |
"Change in Migraine Disability Assessment (MIDAS) total score (effect migraine headaches have on subjects daily function) from Baseline (Day 31) to 3 months after Baseline to end of Treatment Period Month 3(Day 121) following final dose of study medication in the Sumatriptan/Naproxen Sodium arm vs. the Naproxen Sodium arm.~Total score of disability ranges:~0 to 5, MIDAS Grade I, Little or no disability~6 to 10, MIDAS Grade II, Mild disability~11 to 20, MIDAS Grade III, Moderate disability~21+, MIDAS Grade IV, Severe disability Score ranges from 0-450. No subscales are present." (NCT01090050)
Timeframe: Baseline MIDAS collected at Day 31, Post final dose study at Day 121.
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Day 31 | Day 121 | |
| Naproxen Sodium | 81.2 | 16.4 |
| Sumatriptan/Naproxen Sodium | 76.6 | 56.3 |
Number of subjects with at least 50% reduction in number of migraine headache days reported in Baseline vs. Treatment Period months 1(days 31-60), 2(days 61-90), and 3(days 91-120)in the Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. (NCT01090050)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 92, and 121 respectively.
| Intervention | participants (Number) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | 4 | 3 | 4 |
| Sumatriptan/Naproxen Sodium | 3 | 0 | 3 |
"Comparing mean migraine duration from onset to pain free from Baseline Period (Days 1-30), to each of the Treatment Period Months 1(days 31-60), 2(days 61-90), and 3(days 91-120) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. Percent change was calculated by determining percent change in each subject, from each Treatment Period month compared to Baseline. The following formula was used for each treatment period month calculation.~e.g. Percent change=[(mean migraine duration from onset to pain free during Treatment Period Month 3(days 91-120)-mean migraine duration from onset to pain free during Baseline(days 1-30)/mean duration from onset to pain free during Baseline(days 1-30)]*100%)" (NCT01090050)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121 respectively.
| Intervention | percent hours of migraine duration (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | 26.37 | 28.91 | 19.65 |
| Sumatriptan/Naproxen Sodium | 167.83 | 176.18 | 151.49 |
"Comparing mean migraine duration from time of treatment to pain free from Baseline Period (Days 1-30), to each of the Treatment Period Months 1(days 31-60), 2(days 61-90), and 3(days 91-120) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. Percent change was calculated by determining percent change in each subject, from each Treatment Period month compared to Baseline. The following formula was used for each treatment period month calculation.~e.g. Percent change=[(mean migraine duration from time of treatment to pain free during Treatment Period Month 3(days 91-120)-mean migraine duration from time of treatment to pain free during Baseline(days 1-30)/mean duration from time of treatment to pain free during Baseline(days 1-30)]*100%)" (NCT01090050)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121 respectively.
| Intervention | percent hours of migraine duration (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | 24.58 | 28.45 | 23.15 |
| Sumatriptan/Naproxen Sodium | 176.70 | 175.78 | 151.12 |
"Comparing the number of doses of study medication taken during Baseline Period(days 1-30) of triptans(Group A) and non-steroidal anti-inflammatory drugs(NSAIDS)(Group B)to the number of doses of study medication taken during Treatment Period Months 1(days 31-60), 2(days 61-90), and 3(days 91-120)in the Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm.~e.g.Percent change=[(number of doses of study medication during Treatment Period Month 3(days 91-120)-number of doses of study medication during Baseline(days 1-30)/number of doses of study medication during Baseline(days 1-30)]*100%)." (NCT01090050)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 92, and 121 respectively.
| Intervention | percent doses of study medication (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | 825.6 | 239.8 | 135.6 |
| Sumatriptan/Naproxen Sodium | 173.8 | 40.1 | 40.0 |
"Comparing number of migraine headache days from Baseline to Treatment Period Months 1, 2, and 3 in the Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm.~Comparing the number of migraine headache days reported from Baseline Period days 1-30 to number of migraine headache days reported in Treatment Period days Months 1(days 31-60), 2(days 61-90),and 3(days 91-120)in the Sumatriptan/Naproxen Sodium arm versus (vs.) Naproxen Sodium arm. Each treatment period month percent change was individually compared to Baseline. The following formula was used for each treatment period calculation.~e.g. percent change=[(total headache days during Treatment Period Month 3(days 91-120)-total headache days during Baseline(days 1-30)/total headache days during Baseline(days 1-30)]*100%)" (NCT01090050)
Timeframe: Baseline Period (days 1-30) collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121, respectively.
| Intervention | percent migraine headache days per month (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | -61.55 | -45.42 | -56.37 |
| Sumatriptan/Naproxen Sodium | -26.22 | -2.96 | -8.06 |
The primary objective for this study is to compare headache relief (defined as a reduction from moderate [Grade 2] or severe [Grade 3] pain to none [Grade 0] or mild [Grade 1] pain) at 120 minutes following a dose of 20 mg of OPTINOSE SUMATRIPTAN with placebo in the acute treatment of a single migraine attack. (NCT01462812)
Timeframe: 120 Minutes
| Intervention | participants (Number) |
|---|---|
| Matching Placebo | 47 |
| Sumatriptan | 73 |
The primary outcome was 2-hour headache relief; headache relief was defined as headache pain from moderate or severe pain to none or mild pain. Pain was assessed using a 4-point scale (none, mild, moderate, and severe) (NCT01807234)
Timeframe: 2 hours
| Intervention | percentage of participants (Number) |
|---|---|
| Ketorolac/ Placebo | 72.5 |
| Sumatriptan/ Placebo | 69.4 |
| Ketorolac Placebo/ Sumatriptan Placebo | 38.8 |
5) Absence of allodynia The presence of allodynia was assessed based on a series of 8 questions inquiring as to the presence of allodynia. Participants answering 2 or more questions positively were considered to have allodynia. (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 70.5 |
| Sumatriptan/ Placebo | 75.5 |
| Ketorolac Placebo/ Sumatriptan Placebo | 69.0 |
4) Defined as reduction of nausea to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe) (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 82.7 |
| Sumatriptan/ Placebo | 74.0 |
| Ketorolac Placebo/ Sumatriptan Placebo | 66.0 |
3) Defined as reduction of phonophobia to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe) (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 75.0 |
| Sumatriptan/Placebo | 66.0 |
| Ketorolac Placebo/ Sumatriptan Placebo | 56.0 |
2) Defined as reduction of photophobia to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe) (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 65.4 |
| Sumatriptan/ Placebo | 64.0 |
| Ketorolac Placebo/ Sumatriptan Placebo | 46.0 |
1) Pain Freedom: Pain Freedom at 2 hours is defined as being free of pain. Pain was assessed using a 4-point scale (none, mild, moderate, and severe). (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 43.1 |
| Sumatriptan/Placebo | 36.7 |
| Ketorolac Placebo/ Sumatriptan Placebo | 18.4 |
Participants' self-assessment of disability was assessed using 4-point scales (none, mild, moderate, and severe). A binary outcome variable was created grouping none and mild vs moderate to severe. . (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 1.9 |
| Sumatriptan/ Placebo | 8.1 |
| Ketorolac Placebo/ Sumatriptan Placebo | 10.2 |
8) 24 and 48 hours sustained pain freedom (SPF); Defined as the reduction of pain to none. Pain was assessed using a 4-point scale (none, mild, moderate, and severe). (NCT01807234)
Timeframe: 24 and 48 hours
| Intervention | percentage of patients (Number) | |
|---|---|---|
| 24 hour sustained pain freedom | 48 hour sustained pain freedom | |
| Ketorolac Placebo/ Sumatriptan Placebo | 12.2 | 12.2 |
| Ketorolac/ Placebo | 35.3 | 33.3 |
| Sumatriptan/ Placebo | 22.4 | 18.4 |
7) 24 and 48 hours sustained pain relief (SPR) Defined as the reduction of pain to none or mild from moderate or severe, on a 4-point scale (none, mild, moderate, and severe). (NCT01807234)
Timeframe: 24 and 48 hours
| Intervention | percentage of patients (Number) | |
|---|---|---|
| 24 hour sustained pain relief | 48 hour sustained pain relief | |
| Ketorolac Placebo/ Sumatriptan Placebo | 20.4 | 20.4 |
| Ketorolac/ Placebo | 49.0 | 49.0 |
| Sumatriptan/ Placebo | 40.8 | 30.6 |
9) The time, in minutes, will be measured from the time study drug is taken to the time when significant pain relief is first observed and maintained through 2 hours with no rescue medication use at or prior to this point. (NCT01807234)
Timeframe: following each treated migraine attack
| Intervention | percentage of patients (Number) | ||||
|---|---|---|---|---|---|
| 10 minutes | 15 minutes | 20 minutes | 30 minutes | 1 hour | |
| Ketorolac Placebo/ Sumatriptan Placebo | 12.2 | 14.3 | 22.4 | 26.5 | 32.6 |
| Ketorolac/ Placebo | 15.7 | 35.3 | 43.1 | 54.9 | 58.8 |
| Sumatriptan/ Placebo | 14.3 | 36.0 | 44.9 | 53.1 | 57.1 |
(NCT02571049)
Timeframe: 60 minutes post-treatment
| Intervention | Percentage of responders (Number) |
|---|---|
| Sumatriptan 3 mg | 50 |
| Sumatriptan 6 mg | 52.63 |
(NCT02279082)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| DFN-02 | 120 |
The Migraine-ACT is a 4-item scale with yes/no responses. A score of 3 or more is considered favorable. The primary efficacy dataset included the 37 patients that completed both phases of the study and uses the last observed headache. The Migraine-ACT is reported as a binary measure (3 or more positive responses). The outcome presented included the percentage with a score of 3 or more, and the Odds ratio comparing the two treatments. (NCT01086358)
Timeframe: 6 months
| Intervention | percentage of favorable responses (Mean) |
|---|---|
| Arm 1 - Triptan | 46 |
| Arm 2 - Sumatriptan/Naproxen Sodium (Treximet) Arm | 71 |
This outcome measure was lost activity time as measured by a variant of the Work Productivity and Activity Impairment Scale (WPAI) at 6 months.The primary efficacy dataset included the 37 patients that completed both phases of the study and uses the last observed headache. The primary efficacy dataset included the 37 patients that completed both phases of the study and uses the last observed headache. The unit of analysis is hours lost. The higher the score the greater impact on productivity. The range depends on the length of the attack, but in the sample among all observed attacks, lost work productivity ranged from 0-10.5 hours, while lost non-workplace activity time ranged from 0 to 8.95 hours. The total lost productivity is the sum of lost work productivity and lost non-workplace activity time. (NCT01086358)
Timeframe: 6 Months
| Intervention | hours (Mean) |
|---|---|
| Arm 1 - Triptan | 1.89 |
| Arm 2 - Sumatriptan/Naproxen Sodium (Treximet) Arm | 1.22 |
This outcome measure was lost workplace productivity as measured by a variant of the Work Productivity and Activity Impairment Scale (WPAI) at 6 months.The primary efficacy dataset included the 37 patients that completed both phases of the study and uses the last observed headache. The primary efficacy dataset included the 37 patients that completed both phases of the study and uses the last observed headache. The unit of analysis is hours lost. The higher the score the greater impact on productivity. The range depends on the length of the attack, but in the sample among all observed attacks, lost work productivity ranged from 0-10.5 hours, while lost non-workplace activity time ranged from 0 to 8.95 hours. The total lost productivity is the sum of lost work productivity and lost non-workplace activity time. (NCT01086358)
Timeframe: 6 months
| Intervention | hours (Mean) |
|---|---|
| Arm 1 - Triptan | 2.25 |
| Arm 2 - Sumatriptan/Naproxen Sodium (Treximet) Arm | 1.23 |
The primary outcome measure was lost productivity (workplace productivity + non-workplace activity time) as measured by a variant of the Work Productivity and Activity Impairment Scale (WPAI) at 6 months. The primary efficacy dataset included the 37 patients that completed both phases of the study and uses the last observed headache. The unit of analysis is hours lost. The higher the score the greater impact on productivity. The range depends on the length of the attack, but in the sample among all observed attacks, lost work productivity ranged from 0-10.5 hours, while lost non-workplace activity time ranged from 0 to 8.95 hours. The total lost productivity is the sum of lost work productivity and lost non-workplace activity time. (NCT01086358)
Timeframe: 6 months
| Intervention | hours (Mean) |
|---|---|
| Arm 1 - Triptan | 4.15 |
| Arm 2 - Sumatriptan/Naproxen Sodium (Treximet) Arm | 2.44 |
Participants rated their pain severity using a four point scale where 0=no pain, 1=mild pain, 2=moderate pain, and 3=severe pain. Pain-free was a rating of 0 (no pain) at the specified time. (NCT00382993)
Timeframe: 2 Hours Post-Dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 19 |
| Sumatriptan/Naproxen Sodium | 59 |
A rescue medication was defined as an additional medication taken for the treatment of migraine headache pain symptoms associated with the attack. Allowed were a single dose of either: sumatriptan (50mg or 100mg), OR naproxen sodium (max 550mg), OR, an over-the-counter pain-reliever (per label). (NCT00382993)
Timeframe: 0-24 Hours Post-Dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 72 |
| Sumatriptan/Naproxen Sodium | 29 |
Sustained Complete Pain/Symptom-Free was defined as completely symptom-free (migraine-free plus neck and sinus pain-free) at 2 hours and sustained from 2 to 24 hours without the use of rescue medication. (NCT00382993)
Timeframe: 2 - 24 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 7 |
| Sumatriptan/Naproxen Sodium | 30 |
Migraine-free was defined as pain-free with no traditional migraine-associated symptoms (i.e.,photophobia, phonophobia, nausea). Sustained migraine-free was defined as migraine-free at 2 hours and sustained from 2 to 24 hours post dose without the use of rescue medication. (NCT00382993)
Timeframe: 2 - 24 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 8 |
| Sumatriptan/Naproxen Sodium | 34 |
Sustained freedom from migraine pain was defined as having no pain at 2 hours post-dose without the use of rescue medication; and without the recurrence of any pain or the use of any rescue medication 2 to 24 hours post-dose. (NCT00382993)
Timeframe: 2 - 24 Hours Post-Dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 10 |
| Sumatriptan/Naproxen Sodium | 41 |
Sustained Freedom from Migraine-Associated Nausea was defined as the absence of nausea from 2 to 24 hours post-dose. (NCT00382993)
Timeframe: 2 - 24 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 38 |
| Sumatriptan/Naproxen Sodium | 79 |
Sustained Freedom from Migraine-Associated Neck Pain was defined as the absence of neck pain from 2 to 24 hours post-dose. (NCT00382993)
Timeframe: 2 - 24 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 29 |
| Sumatriptan/Naproxen Sodium | 65 |
Sustained Freedom from Migraine-Associated Phonophobia was defined as the absence of phonophobia (sensitivity to noise) from 2 to 24 hours post-dose. (NCT00382993)
Timeframe: 2 - 24 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 30 |
| Sumatriptan/Naproxen Sodium | 68 |
Sustained Freedom from Migraine-Associated Photophobia was defined as the absence of photophobia (sensitivity to light) from 2 to 24 hours post-dose. (NCT00382993)
Timeframe: 2 - 24 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 23 |
| Sumatriptan/Naproxen Sodium | 65 |
Sustained Freedom from Migraine-Associated Sinus Pain was defined as the absence of sinus pain from 2 to 24 hours post-dose. (NCT00382993)
Timeframe: 2 - 24 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 44 |
| Sumatriptan/Naproxen Sodium | 75 |
"Number of participants who were completely symptom-free (migraine-free plus neck and sinus pain-free) at time of assessment. Complete pain/symptom-free was defined as migraine-free, neck pain-free, and sinus pain free." (NCT00382993)
Timeframe: Baseline, 2, 4, and 8 hours post-dose
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Complete Pain/Symptom-Baseline | Complete Pain/Symptom-2 Hours Post-Dose | Complete Pain/Symptom-4 Hours Post-Dose | Complete Pain/Symptom-8 Hours Post-Dose | |
| Placebo | 132 | 121 | 114 | 106 |
| Sumatriptan/Naproxen Sodium | 134 | 94 | 70 | 58 |
Participants rated their pain severity using a four point scale where 0=no pain, 1=mild pain, 2=moderate pain, and 3=severe pain. Pain-free was a rating of 0 (no pain) at the specified time. (NCT00382993)
Timeframe: 0.5, 1, 4, and 8 Hours Post-Dose
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Pain Free at 0.5 Hour Post-Dose | Pain Free at 1 Hour Post-Dose | Pain Free at 4 Hours Post-Dose | Pain Free at 8 Hours Post-Dose | |
| Placebo | 3 | 12 | 23 | 32 |
| Sumatriptan/Naproxen Sodium | 3 | 33 | 83 | 88 |
Number of participants who had nausea at the time of assessment. Resolution of an associated symptom was defined as a migraine headache symptom that was present at the time of treatment that was not present post-dose. Symptom resolution was defined only among subjects who treated while their symptom was present. (NCT00382993)
Timeframe: Baseline, 2, 4, and 8 hours
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Migraine Associated Nausea at Baseline | Migraine Associated Nausea 2 Hours Post-Dose | Migraine Associated Nausea 4 Hours Post-Dose | Migraine Associated Nausea 8 Hours Post-Dose | |
| Placebo | 40 | 43 | 35 | 27 |
| Sumatriptan/Naproxen Sodium | 48 | 33 | 18 | 14 |
Number of Participants with neck pain at the time of assessment. (NCT00382993)
Timeframe: Baseline, 2, 4, and 8 hours post-dose
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Migraine-Assoc Neck Pain at Baseline | Migraine-Assoc Neck Pain at 2 Hours Post-Dose | Migraine-Assoc Neck Pain at 4 Hours Post-Dose | Migraine-Assoc Neck Pain at 8 Hours Post-Dose | |
| Placebo | 81 | 71 | 65 | 51 |
| Sumatriptan/Naproxen Sodium | 75 | 52 | 38 | 29 |
Number of participants who had phonophobia (sensitivity to noise) at the time of assessment. (NCT00382993)
Timeframe: Baseline, 2, 4, and 8 hours post-dose
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Migraine Assoc Phonophobia-Baseline | Migraine Assoc Phonophobia 2 Hours Post-Dose | Migraine Assoc Phonophobia 4 Hours Post-Dose | Migraine Assoc Phonophobia 8 Hours Post-Dose | |
| Placebo | 75 | 68 | 56 | 42 |
| Sumatriptan/Naproxen Sodium | 80 | 42 | 27 | 20 |
Number of participants who had photophobia (sensitivity to light) at the time of assessment. (NCT00382993)
Timeframe: Baseline, 2, 4, and 8 hours post-dose
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Migraine Assoc Photophobia-Baseline | Migraine Assoc Photophobia 2 Hours Post-Dose | Migraine Assoc Photophobia 4 Hours Post-Dose | Migraine Assoc Photophobia 8 Hours Post-Dose | |
| Placebo | 100 | 84 | 69 | 51 |
| Sumatriptan/Naproxen Sodium | 101 | 48 | 31 | 25 |
Number of participants who had sinus pain at the time of assessment. (NCT00382993)
Timeframe: Baseline, 2, 4, and 8 hours post-dose
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Migraine-Assoc Sinus Pain at Baseline | Migraine-Assoc Sinus Pain at 2 Hours Post-Dose | Migraine-Assoc Sinus Pain at 4 Hours Post-Dose | Migraine-Assoc Sinus Pain at 8 Hours Post-Dose | |
| Placebo | 47 | 40 | 36 | 27 |
| Sumatriptan/Naproxen Sodium | 56 | 41 | 27 | 20 |
Migraine-free was defined as pain-free with no traditional migraine-associated symptoms (i.e.,photophobia, phonophobia, nausea and vomiting) at the time of the assessment. (NCT00382993)
Timeframe: 2, 4 , and 8 hours post-dose
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Migraine-Free at 2 Hours Post-Dose | Migraine-Free at 4 Hours Post-Dose | Migraine-Free at 8 Hours Post-Dose | |
| Placebo | 15 | 20 | 30 |
| Sumatriptan/Naproxen Sodium | 46 | 76 | 83 |
Recurrence is defined as the return of any migraine headache pain during the specified post-dose period, following a pain-free response at 2 hours. (NCT00382993)
Timeframe: 24 hours and 48 hours
| Intervention | Participants (Number) | |
|---|---|---|
| Recurrence by 24 hours post-dose | Recurrence by 48 hours post-dose | |
| Placebo | 5 | 6 |
| Sumatriptan/Naproxen Sodium | 13 | 13 |
Participants rated their pain severity using a four point scale where 0=no pain, 1=mild pain, 2=moderate pain, and 3=severe pain. Pain-free was a rating of 0 (no pain) at the specified time. (NCT00383162)
Timeframe: 2 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 23 |
| Sumatriptan-Naproxen Sodium | 54 |
A rescue medication was defined as an additional medication taken for the treatment of migraine headache pain symptoms associated with the attack. Allowed were a single dose of either: sumatriptan (50mg or 100mg), OR naproxen sodium (max 550mg), OR, an over-the-counter pain-reliever (per label). (NCT00383162)
Timeframe: Dosing to 24 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 84 |
| Sumatriptan-Naproxen Sodium | 40 |
Sustained Complete Pain/Symptom-Free was defined as completely symptom-free (migraine-free plus neck and sinus pain-free) at 2 hours and sustained from 2 to 24 hours without the use of rescue medication. (NCT00383162)
Timeframe: 2 - 24 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 9 |
| Sumatriptan-Naproxen Sodium | 30 |
Migraine-free was defined as pain-free with no traditional migraine-associated symptoms (i.e.,photophobia, phonophobia, nausea). Sustained migraine-free was defined as migraine-free at 2 hours and sustained from 2 to 24 hours post dose without the use of rescue medication. (NCT00383162)
Timeframe: 2 - 24 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 11 |
| Sumatriptan-Naproxen Sodium | 32 |
Sustained freedom from migraine pain was defined as having no pain at 2 hours post-dose without the use of rescue medication; and without the recurrence of any pain or the use of any rescue medication 2 to 24 hours post-dose. (NCT00383162)
Timeframe: 2 - 24 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 10 |
| Sumatriptan-Naproxen Sodium | 36 |
Sustained Freedom from Migraine-Associated Nausea was defined as the absence of nausea from 2 to 24 hours post-dose. (NCT00383162)
Timeframe: 2 - 24 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 38 |
| Sumatriptan-Naproxen Sodium | 70 |
Sustained Freedom from Migraine-Associated Neck Pain was defined as the absence of neck pain from 2 to 24 hours post-dose. (NCT00383162)
Timeframe: 2 - 24 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 33 |
| Sumatriptan-Naproxen Sodium | 63 |
Sustained Freedom from Migraine-Associated Phonophobia was defined as the absence of phonophobia (sensitivity to noise) from 2 to 24 hours post-dose. (NCT00383162)
Timeframe: 2 - 24 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 31 |
| Sumatriptan-Naproxen Sodium | 66 |
Sustained Freedom from Migraine-Associated Photophobia was defined as the absence of photophobia (sensitivity to light) from 2 to 24 hours post-dose. (NCT00383162)
Timeframe: 2 - 24 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 23 |
| Sumatriptan-Naproxen Sodium | 59 |
Sustained Freedom from Migraine-Associated Sinus Pain was defined as the absence of sinus pain from 2 to 24 hours post-dose. (NCT00383162)
Timeframe: 2 - 24 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Placebo | 34 |
| Sumatriptan-Naproxen Sodium | 76 |
"Number of participants who were completely symptom-free (migraine-free plus neck and sinus pain-free) at time of assessment.Complete pain/symptom-free was defined as migraine-free, neck pain-free, and sinus pain free." (NCT00383162)
Timeframe: Baseline, 2, 4, and 8 hours post-dose
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Baseline | 2 hours post-dose | 4 hours post-dose | 8 hours post-dose | |
| Placebo | 133 | 117 | 107 | 106 |
| Sumatriptan-Naproxen Sodium | 136 | 92 | 73 | 62 |
Number of participants who had nausea at the time of assessment. Resolution of an associated symptom was defined as a migraine headache symptom that was present at the time of treatment that was not present post-dose. Symptom resolution was defined only among subjects who treated while their symptom was present. (NCT00383162)
Timeframe: Baseline, 2, 4, and 8 hours
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Baseline | 2 hours post-dose | 4 hours post-dose | 8 hours post-dose | |
| Placebo | 45 | 42 | 29 | 24 |
| Sumatriptan-Naproxen Sodium | 48 | 39 | 20 | 14 |
Number of Participants with neck pain at the time of assessment. (NCT00383162)
Timeframe: Baseline, 2, 4, and 8 hours post-dose
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Baseline | 2 hours post-dose | 4 hours post-dose | 8 hours post-dose | |
| Placebo | 65 | 54 | 46 | 37 |
| Sumatriptan-Naproxen Sodium | 82 | 54 | 40 | 31 |
Number of participants who had phonophobia (sensitivity to noise) at the time of assessment. (NCT00383162)
Timeframe: Baseline, 2, 4, and 8 hours post-dose
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Baseline | 2 hours post-dose | 4 hours post-dose | 8 hours post-dose | |
| Placebo | 82 | 73 | 56 | 44 |
| Sumatriptan-Naproxen Sodium | 86 | 47 | 31 | 24 |
Number of participants who had photophobia (sensitivity to light) at the time of assessment. (NCT00383162)
Timeframe: Baseline, 2, 4, and 8 hours post-dose
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Baseline | 2 hours post-dose | 4 hours post-dose | 8 hours post-dose | |
| Placebo | 98 | 86 | 65 | 48 |
| Sumatriptan-Naproxen Sodium | 95 | 57 | 33 | 27 |
Number of participants who had sinus pain at the time of assessment. (NCT00383162)
Timeframe: Baseline, 2, 4, and 8 hours post-dose
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Baseline | 2 hours post-dose | 4 hours post-dose | 8 hours post-dose | |
| Placebo | 58 | 52 | 39 | 35 |
| Sumatriptan-Naproxen Sodium | 61 | 31 | 20 | 19 |
Migraine-free was defined as pain-free with no traditional migraine-associated symptoms (i.e.,photophobia, phonophobia, nausea and vomiting) at the time of the assessment. (NCT00383162)
Timeframe: 2, 4 , and 8 hours post-dose
| Intervention | Participants (Number) | ||
|---|---|---|---|
| 2 hours post-dose | 4 hours post-dose | 8 hours post-dose | |
| Placebo | 19 | 30 | 29 |
| Sumatriptan-Naproxen Sodium | 47 | 72 | 80 |
Participants rated their pain severity using a four point scale where 0=no pain, 1=mild pain, 2=moderate pain, and 3=severe pain. Pain-free was a rating of 0 (no pain) at the specified time. (NCT00383162)
Timeframe: 1/2, 1, 4, and 8 hours post-dose
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| 1/2 hour post-dose | 1 hour post-dose | 4 hours post-dose | 8 hours post-dose | |
| Placebo | 2 | 13 | 30 | 32 |
| Sumatriptan-Naproxen Sodium | 6 | 26 | 80 | 88 |
Recurrence is defined as the return of any migraine headache pain during the specified post-dose period, following a pain-free response at 2 hours. (NCT00383162)
Timeframe: 24 hours and 48 hours
| Intervention | Participants (Number) | |
|---|---|---|
| Recurrence by 24 hours post-dose | Recurrence by 48 hours post-dose | |
| Placebo | 12 | 13 |
| Sumatriptan-Naproxen Sodium | 11 | 11 |
Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum anxiety. A change of 0 mm corresponds to no change in anxiety level, and a negative value indicates worsening of the anxiety after the medication. (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | mm (Mean) |
|---|---|
| Control Arm | 33.7 |
| Study Arm | 21.2 |
Reduction in 100 mm Visual Analog Scale (VAS) Score. Positive values represent a reduction in headache severity. The maximum possible change in VAS score is 100 mm, representing the complete relief of a maximally severe headache. A change of 0 mm corresponds to no change in headache severity, and a negative value indicates worsening of the headache after the medication. (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | mm (Mean) |
|---|---|
| Control Arm | 63.5 |
| Study Arm | 43.5 |
Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum nausea. A change of 0 mm corresponds to no change in nausea level, and a negative value indicates worsening of the nausea after the medication. (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | mm (Mean) |
|---|---|
| Control Arm | 38.9 |
| Study Arm | 22.9 |
Yes/No (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | participants (Number) |
|---|---|
| Control Arm | 2 |
| Study Arm | 3 |
Yes/No (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | participants (Number) |
|---|---|
| Control Arm | 3 |
| Study Arm | 3 |
Headache pain severity, relative to the administration of study medication, was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild pain), 2 (moderate pain), or 3 (severe pain). Pain freedom (PF) is defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 0 (no pain) post dose. (NCT00894556)
Timeframe: 2 hours post dose
| Intervention | attacks (Number) | |
|---|---|---|
| Resulting in PF at 2 hours post dose | Not resulting in PF at 2 hours post dose | |
| Placebo | 12 | 87 |
| Rizatriptan | 46 | 156 |
Pain severity was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild pain), 2 (moderate pain), or 3 (severe pain). Pain relief (PR) is defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 1/0 post dose. (NCT00894556)
Timeframe: 2 hours post dose
| Intervention | attacks (Number) | |
|---|---|---|
| Resulting in PR at 2 hours post dose | Not resulting in PR at 2 hours post dose | |
| Placebo | 21 | 78 |
| Rizatriptan | 102 | 100 |
The average number of headaches (non-migraine and migraine attacks), migraine attacks, and treated migraine attacks per month was calculated for each participant, based on their time in the study. The outcome measure represents the average of the mean number of the headaches, migraine headaches, and treated migraines per month of the study participants in the 6 Month, 12 Month, and ITT Populations. A treated attack is defined as a migraine treated with the Combination Tablet. (NCT00488514)
Timeframe: Baseline through End of Study (up to Month 12)
| Intervention | events (Mean) | ||
|---|---|---|---|
| Headaches | Migraines | Treated migraine attacks | |
| 12 Month Completer Population | 3.9 | 2.6 | 2.4 |
| 6 Month Completer Population | 3.3 | 2.2 | 1.9 |
| ITT Population | 3.0 | 1.8 | 1.5 |
At each visit, a participant's blood pressure was taken three times. The average of the three readings was then calculated for each participant at each visit (mean blood pressure). The outcome measure represents the average of the mean blood pressure of all of the study participants. SBP, systolic blood pressure; DBP, diastolic blood pressure. (NCT00488514)
Timeframe: Screening and Months 3, 6, 9, and 12
| Intervention | millimeters of mercury (mmHg) (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SBP, Screening, n=285, 337, 622 | SBP, Month 3, n=270, 308, 578 | SBP, Month 6, n=224, 249, 473 | SBP, Month 9, n=198, 221, 419 | SBP, Month 12, n=178, 198, 376 | DBP, Screening, n=285, 337, 622 | DBP, Month 3, n=270, 308, 578 | DBP, Month 6, n=224, 249, 473 | DBP, Month 9, n=198, 221, 419 | DBP, Month 12, n=178, 198, 376 | |
| 12-14 Years | 107.4 | 107.2 | 109.2 | 109.6 | 111.0 | 66.2 | 65.7 | 66.1 | 65.6 | 66.6 |
| 12-17 Years | 108.9 | 109.3 | 110.6 | 111.2 | 111.5 | 67.7 | 67.1 | 67.3 | 67.3 | 68.3 |
| 15-17 Years | 110.2 | 111.1 | 112.0 | 112.7 | 112.1 | 69.0 | 68.4 | 68.4 | 68.9 | 69.9 |
BMI = (Weight in kilograms)/(height in centimeters/100)^2 (NCT00488514)
Timeframe: Screening and Months 3, 6, 9, and 12
| Intervention | kilograms per meters squared (Mean) | ||||
|---|---|---|---|---|---|
| Screening, n=285, 337, 622 | Month 3, n=270, 306, 576 | Month 6, n=223, 248, 471 | Month 9, n= 197, 220, 417 | Month 12, n=178, 198, 376 | |
| 12-14 Years | 22.01 | 22.09 | 22.54 | 22.58 | 22.81 |
| 12-17 Years | 22.97 | 22.95 | 23.17 | 23.20 | 23.33 |
| 15-17 Years | 23.77 | 23.71 | 23.74 | 23.74 | 23.79 |
The MSQ-A consists of 14 items measuring how migraines affect QOL: Role Function (RF)-Restrictive (items 1-7) and RF-Preventative (items 8-11), examining the degree to which performance of daily activities is limited or interrupted, respectively, by migraine; RF-Emotional (items 12-14, examining frustration/helplessness due to migraine). Dimensions (dim.) are scored independently. The 14 items are reverse coded onto a 1-6 scale; dim. are then created by summing specific item scores and transforming raw total score onto a 0-100 scale. For each dim., higher scores indicate better health status. (NCT00488514)
Timeframe: Baseline and Months 3, 6, 9, and 12
| Intervention | points on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Role restrictive, Month 3, n=457, 160 | Role restrictive, Month 6, n=366, 160 | Role restrictive, Month 9, n=315, 148 | Role restrictive, Month 12, n=291, 153 | Role preventative, Month 3, n=457, 160 | Role preventative, Month 6, n=366, 160 | Role preventative, Month 9, n=315, 148 | Role preventative, Month 12, n=291, 153 | Role emotional , Month 3, n=457, 160 | Role emotional, Month 6, n=366, 160 | Role emotional, Month 9, n=315, 148 | Role emotional, Month 12, n=291, 153 | |
| 12 Month Completer Population | 9.0 | 8.2 | 9.0 | 11.5 | 9.6 | 8.3 | 8.2 | 8.4 | 7.9 | 7.2 | 9.0 | 7.1 |
| ITT Population | 10.1 | 10.5 | 13.7 | 15.7 | 7.9 | 6.8 | 9.4 | 9.8 | 7.1 | 6.6 | 10.5 | 11.4 |
A sitting heart rate was measured once for each participant at each visit. (NCT00488514)
Timeframe: Screening and Months 3, 6, 9, and 12
| Intervention | beats per minute (Mean) | ||||
|---|---|---|---|---|---|
| Screening, n=284, 336, 620 | Month 3, n=266, 305, 571 | Month 6, n=221, 247, 468 | Month 9, n=198, 221, 419 | Month 12, n=178, 198, 376 | |
| 12-14 Years | 75.8 | 76.9 | 77.5 | 76.9 | 76.8 |
| 12-17 Years | 7.43 | 76.2 | 76.4 | 76.1 | 75.7 |
| 15-17 Years | 73.0 | 75.6 | 75.4 | 75.4 | 74.7 |
(NCT00488514)
Timeframe: Screening and Months 3, 6, 9, and 12
| Intervention | centimeters (Mean) | ||||
|---|---|---|---|---|---|
| Screening, n=285, 337, 622 | Month 3, n=271, 308, 579 | Month 6, n=224, 249, 473 | Month 9, n=198, 221, 419 | Month 12, n=178, 198, 376 | |
| 12-14 Years | 160.2 | 161.3 | 162.6 | 163.8 | 165.3 |
| 12-17 Years | 163.9 | 164.5 | 165.1 | 165.8 | 166.7 |
| 15-17 Years | 167.0 | 167.3 | 167.3 | 167.6 | 167.9 |
(NCT00488514)
Timeframe: Screening and Months 3, 6, 9, and 12
| Intervention | kilograms (Mean) | ||||
|---|---|---|---|---|---|
| Screening, n=285, 337, 622 | Month 3, n=270, 306, 576 | Month 6, n=223, 248, 471 | Month 9, n=197, 220, 417 | Month 12, n=178, 198, 376 | |
| 12-14 Years | 57.02 | 58.01 | 60.20 | 61.24 | 62.92 |
| 12-17 Years | 62.19 | 62.58 | 63.57 | 64.23 | 65.25 |
| 15-17 Years | 66.57 | 66.61 | 66.61 | 66.90 | 67.35 |
The number of migraine attacks treated at the mild, moderate, or severe intensity were counted. Pain severity was assessed by participants based on a scale of 0-3: 0=no pain, 1=mild, 2= moderate, 3=severe. (NCT00488514)
Timeframe: Baseline through End of Study (up to Month 12)
| Intervention | treated migraine attacks (Number) | |||
|---|---|---|---|---|
| No pain | Mild | Moderate | Severe | |
| 12 Month Completer Population | 0 | 1009 | 2535 | 1686 |
| 6 Month Completer Population | 0 | 1373 | 3555 | 2385 |
| ITT Population | 0 | 1619 | 4132 | 2759 |
"The PPMQ-R is a fully validated 32-item questionnaire assessing participant satisfaction with acute migraine medication and includes 3 questions that assess satisfaction with respect to efficacy, side effects, and overall satisfaction (i.e., How effective the medication is overall, side effects of the medication, overall satisfaction with the medication). Each item is rated on a 7-point scale ranging from very satisfied (1) to very dissatisfied (7)." (NCT00488514)
Timeframe: End of Study/Month 12
| Intervention | participants (Number) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Efficacy, Very Satisfied | Overall Efficacy, Satisfied | Overall Efficacy, Somewhat Satisfied | Overall Efficacy, Neutral | Overall Efficacy, Somewhat Dissatisfied | Overall Efficacy, Dissatisfied | Overall Efficacy, Very Dissatisfied | Side Effects, Very Satisfied | Side Effects, Satisfied | Side Effects, Somewhat Satisfied | Side Effects, Neutral | Side Effects, Somewhat Dissatisfied | Side Effects, Dissatisfied | Side Effects, Very Dissatisfied | Overall Treatment Satisfaction, Very Satisfied | Overall Treatment Satisfaction, Satisfied | Overall Treatment Satisfaction, Somewhat Satisfied | Overall Treatment Satisfaction, Neutral | Treatment Satisfaction, Somewhat Dissatisfied | Overall Treatment Satisfaction, Dissatisfied | Overall Treatment Satisfaction, Very Dissatisfied | |
| 12 Month Completer Population | 48 | 46 | 12 | 3 | 1 | 0 | 0 | 42 | 40 | 14 | 6 | 3 | 3 | 2 | 51 | 47 | 6 | 2 | 3 | 0 | 1 |
| 6 Month Completer Population | 59 | 63 | 16 | 5 | 1 | 0 | 0 | 49 | 51 | 21 | 10 | 7 | 4 | 2 | 64 | 61 | 10 | 5 | 3 | 0 | 1 |
| ITT Population | 66 | 75 | 20 | 7 | 2 | 1 | 0 | 55 | 61 | 24 | 11 | 12 | 5 | 3 | 71 | 76 | 13 | 6 | 3 | 1 | 1 |
"The PPMQ-R is a fully validated 32-item questionnaire assessing participant satisfaction with acute migraine medication and includes 3 questions that assess satisfaction with respect to efficacy, side effects, and overall satisfaction (i.e., How effective the medication is overall, side effects of the medication, overall satisfaction with the medication). Each item is rated on a 7-point scale ranging from very satisfied (1) to very dissatisfied (7)." (NCT00488514)
Timeframe: Screening
| Intervention | participants (Number) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Efficacy, Very Satisfied | Overall Efficacy, Satisfied | Overall Efficacy, Somewhat Satisfied | Overall Efficacy, Neutral | Overall Efficacy, Somewhat Dissatisfied | Overall Efficacy, Dissatisfied | Overall Efficacy, Very Dissatisfied | Side Effects, Very Satisfied | Side Effects, Satisfied | Side Effects, Somewhat Satisfied | Side Effects, Neutral | Side Effects, Somewhat Dissatisfied | Side Effects, Dissatisfied | Side Effects, Very Dissatisfied | Overall Treatment Satisfaction, Very Satisfied | Overall Treatment Satisfaction, Satisfied | Overall Treatment Satisfaction, Somewhat Satisfied | Overall Treatment Satisfaction, Neutral | Treatment Satisfaction, Somewhat Dissatisfied | Overall Treatment Satisfaction, Dissatisfied | Overall Treatment Satisfaction, Very Dissatisfied | |
| 12 Month Completer Population | 11 | 54 | 72 | 15 | 12 | 8 | 2 | 50 | 50 | 26 | 36 | 6 | 2 | 4 | 11 | 70 | 56 | 16 | 9 | 9 | 3 |
| 6 Month Completer Population | 22 | 102 | 113 | 30 | 23 | 22 | 4 | 89 | 87 | 45 | 69 | 13 | 6 | 7 | 30 | 113 | 94 | 35 | 13 | 23 | 8 |
| ITT Population | 36 | 163 | 192 | 67 | 49 | 43 | 12 | 135 | 166 | 77 | 127 | 29 | 18 | 11 | 50 | 192 | 164 | 67 | 31 | 43 | 15 |
The number of participants with an electrocardiogram (ECG) status of normal, abnormal, clinically significant (CS), or not clinically significant (NCS), as determined by the Investigator, was reported. Specific definitions of ECG categorizations were not provided; investigators were expected to apply reasonable standards of clinical judgment. Normal, all ECG parameters within accepted normal ranges; abnormal, ECG finding(s) outside of normal ranges; CS, ECG with a CS abnormality that meets exclusion criteria; NCS, ECG with an abnormality not CS or meeting exclusion criteria per investigator. (NCT00488514)
Timeframe: Screening and Final Visit (up to Month 12)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Screening, normal, n=284, 337, 621 | Screening, abnormal, NCS, n=284, 337, 621 | Screening, abnormal, CS, n=284, 337, 621 | Final Visit, Normal, n=248, 294, 542 | Final Visit, abnormal, NCS, n=248, 294, 542 | Final Visit, abnormal, CS, n=248, 294, 542 | |
| 12-14 Years | 224 | 60 | 0 | 196 | 52 | 0 |
| 12-17 Years | 494 | 127 | 0 | 416 | 126 | 0 |
| 15-17 Years | 270 | 67 | 0 | 220 | 74 | 0 |
"A shift from normal to low, for example, indicates that a value was normal at baseline but low at the end of study visit. The value ranges were determined by the central laboratory. Reference ranges: ALT, 12 years old (y): 0-45 Units/liter (U/L), >13 y: 0-48 U/L; AST, 12 y: 0-42 U/L, >13 y 0-42 U/L; creatinine, 12 y: 27-88 micromoles/liter (UMOL/L), >13 y: 44-124 UMOL/L; potassium, 12 y: 3.5-5.5 millimoles/liter (MMOL/L), >13 y: 3.5-5.3 MMOL/L; BUN, 12-17 y: 24-101 milligrams (mg)/deciliter (dL)." (NCT00488514)
Timeframe: Baseline through End of Study (up to Month 12)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ALT, normal to high, n=330, 179, 565 | ALT, normal to low, n=330, 179, 565 | AST, normal to high, n=329, 179, 562 | AST, normal to low, n=329, 179, 562 | Creatinine, normal to high, n=330, 179, 565 | Creatinine, normal to low, n=330, 179, 565 | Potassium, normal to high, n=329, 179, 562 | Potassium, normal to low, n=329, 179, 562 | BUN, normal to high, n=330, 179, 565 | BUN, normal to low, n=330, 179, 565 | |
| 12 Month Completer Population | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 2 | 0 | 0 |
| 6 Month Completer Population | 2 | 0 | 1 | 0 | 0 | 2 | 1 | 3 | 0 | 2 |
| Safety Population | 3 | 0 | 3 | 0 | 0 | 2 | 4 | 6 | 1 | 9 |
The number of participants with any adverse event by age group (12-14 and 15-17 years) is recorded. (NCT00488514)
Timeframe: Baseline through End of Study (up to Month 12)
| Intervention | participants (Number) | |
|---|---|---|
| Ages 12-14 | Ages 15-17 | |
| 12 Month Completer Population | 57 | 73 |
| 6 Month Completer Population | 104 | 135 |
| Safety Population | 175 | 218 |
The number of participants with adverse events by gender is recorded. (NCT00488514)
Timeframe: Baseline through End of Study (up to Month 12)
| Intervention | participants (Number) | |
|---|---|---|
| Female | Male | |
| 85 mg Sumatriptan/500 mg Naproxen Sodium | 238 | 155 |
"The number of participants with any adverse event was categorized by race. The category Other captures : American Indian or Alaskan Native; Asian, Native Hawaiian, or Other Pacific Islander; African American/African Heritage and Asian; African American/African Heritage and White; and American Indian or Alaskan Native and White." (NCT00488514)
Timeframe: Baseline through End of Study (up to Month 12)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Caucasian | African American | Other | |
| 85 mg Sumatriptan/500 mg Naproxen Sodium | 344 | 35 | 14 |
The number of participants with at least one mild (an event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities), moderate (an event that is sufficiently discomforting to interfere with normal everyday activities), or severe adverse event (an event that prevents normal everyday activities) was recorded. (NCT00488514)
Timeframe: Baseline through End of Study (up to Month 12)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Mild | Moderate | Severe | |
| 12 Month Completer Population | 43 | 72 | 14 |
| 6 Month Completer Population | 74 | 140 | 24 |
| Safety Population | 127 | 220 | 44 |
The number of participants with an adverse event occurring in either the first six months of the study (months 0-6; <=194 days) or the second six months of the study (months 6-12; =>194 days until end of study) was recorded. (NCT00488514)
Timeframe: Baseline through End of Study (up to Month 12)
| Intervention | participants (Number) | |
|---|---|---|
| First six months of study | Second six months of study | |
| 12 Month Completer Population | 112 | 85 |
| 6 Month Completer Population | 208 | 143 |
| Safety Population | 348 | 191 |
The number of participants with adverse events that occurred within 3 or 5 days of their first dose of the Combination Tablet was recorded. (NCT00488514)
Timeframe: Baseline through End of Study (up to Month 12)
| Intervention | participants (Number) | |
|---|---|---|
| Within 3 days | Within 5 days | |
| 12 Month Completer Population | 35 | 35 |
| 6 Month Completer Population | 66 | 66 |
| Safety Population | 128 | 130 |
"A shift from normal to low, for example, indicates that a value was normal at baseline but low at the end of study visit. The value ranges were determined by the central laboratory. Reference ranges: hemoglobin, 12-17 years old (y): 120-160 grams (g)/L; hematocrit (expressed as the percentage of blood occupied by red blood cells), 12-17 y: 0.360-0.490." (NCT00488514)
Timeframe: Baseline through End of Study (up to Month 12)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Hemoglobin, normal to high, n=318,176, 546 | Hemoglobin, normal to low, n=318,176, 546 | Hematocrit, normal to high, n=318,176, 546 | Hematocrit, normal to low, n=318,176, 546 | |
| 12 Month Completer Population | 0 | 6 | 0 | 10 |
| 6 Month Completer Population | 6 | 10 | 2 | 17 |
| Safety Population | 9 | 20 | 4 | 29 |
The number of participants with a drug-related adverse event (AE). Frequency threshold for reporting a drug-related AE: >=2% participants recorded as having at least one occurrence of a reported drug-related AE. (NCT00488514)
Timeframe: Baseline through End of Study (up to Month 12)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| At least one drug-related adverse event | Nausea | Dizziness | Muscle tightness | Chest discomfort | Paresthesia | Throat tightness | Somnolence | Neck pain | Flushing | |
| 12 Month Completer Population | 46 | 11 | 3 | 5 | 3 | 2 | 6 | 2 | 3 | 2 |
| 6 Month Completer Population | 93 | 19 | 7 | 10 | 10 | 8 | 11 | 9 | 6 | 5 |
| Safety Population | 170 | 44 | 20 | 18 | 16 | 14 | 14 | 14 | 12 | 8 |
The number of events that occurred within 3 or 5 days of dosing with the combination tablet on a per tablet basis. A total of 8413, 5876, and 9989 tablets were taken by the 6 Month Completer, 12 Month Completer, and the Safety Populations, respectively. (NCT00488514)
Timeframe: Baseline through End of Study (up to Month 12)
| Intervention | tablets (Number) | |
|---|---|---|
| Number of tablets with an AE within 3 days | Number of tablets with an AE within 5 days | |
| 12 Month Completer Population | 667 | 706 |
| 6 Month Completer Population | 917 | 970 |
| Safety Population | 1116 | 1178 |
The total number of migraine headaches and the number of migraine headaches treated with the Combination Tablet during the study were summarized. (NCT00488514)
Timeframe: Baseline through End of Study (up to Month 12)
| Intervention | migraine attacks (Number) | |
|---|---|---|
| Total Migraines | Treated Migraines | |
| 12 Month Completer Population | 5851 | 5234 |
| 6 Month Completer Population | 8290 | 7318 |
| ITT Population | 9937 | 8517 |
The number of migraine attacks eligible for evaluation, not associated with rescue medication use, and not associated with either rescue medication use or prohibited medications were counted. Migraine Pain Free was defined as the migraine attack ending <= 24 hours after the participant was dosed with the Combination Tablet. (NCT00488514)
Timeframe: Baseline through End of Study (up to Month 12)
| Intervention | treated migraine attacks (Number) | ||
|---|---|---|---|
| All Migraines | Migraines Without Rescue Medication | Migraines Without Rescue or Prohibited Medication | |
| 85 mg Sumatriptan/500 mg Naproxen Sodium | 6400 | 6142 | 6052 |
The number of migraine attacks eligible for evaluation, not associated with rescue medication use, and not associated with either rescue medication use or prohibited medications were counted. Migraine Pain Free was defined as the migraine attack ending <= 4 hours after the participant was dosed with the Combination Tablet. (NCT00488514)
Timeframe: Baseline through End of Study (up to Month 12)
| Intervention | treated migraine attacks (Number) | ||
|---|---|---|---|
| All Migraines | Migraines Without Rescue Medication | Migraines Without Rescue or Prohibited Medication | |
| 85 mg Sumatriptan/500 mg Naproxen Sodium | 5076 | 5020 | 5017 |
The number of migraine attacks eligible for evaluation, not associated with rescue medication use, and not associated with either rescue medication use or prohibited medications were counted. Migraine Pain Free was defined as the migraine attack ending <= 4 hours after the participant was dosed with the Combination Tablet. (NCT00488514)
Timeframe: Baseline through End of Study (up to Month 12)
| Intervention | treated migraine attacks (Number) | ||
|---|---|---|---|
| All Migraines | Migraines Without Rescue Medication | Migraines Without Rescue or Prohibited Medication | |
| 85 mg Sumatriptan/500 mg Naproxen Sodium | 3623 | 3598 | 3596 |
The number of migraine attacks eligible for evaluation, not associated with rescue medication use, or prohibited medications, was summarized. Rescue medication was additional medication taken within 24 hours of Combination Tablet. Prohibited medications: ergot, opioid, barbiturate, 5-HT1 agonist, long-acting non-steroidal anti-inflammatory drug (NSAID), short-acting NSAID-containing compound, analgesic, anti-emetic, monoamine oxidase inhibitors, St. John's Wort, angiotensin-converting enzyme inhibitor, Angiotensin II receptor blockers, anti-coagulant, anti-platelet. (NCT00488514)
Timeframe: Baseline through End of Study (up to Month 12)
| Intervention | treated migraine attacks (Number) | ||
|---|---|---|---|
| All Migraines | Migraines Without Rescue Medication | Migraines Without Rescue or Prohibited Medication | |
| 85 mg Sumatriptan/500 mg Naproxen Sodium | 8517 | 7791 | 7657 |
The number of treated migraine attacks with the reported migraine-associated symptoms of photophobia, phonophobia, nausea, neck pain, sinus pain, and vomiting were counted. Photophobia: sensitivity to light; phonophobia: sensitivity to sound. (NCT00488514)
Timeframe: Baseline through End of Study (up to Month 12)
| Intervention | treated migraine attacks (Number) | |||||
|---|---|---|---|---|---|---|
| Photophobia | Phonophobia | Nausea | Neck pain | Sinus pain | Vomiting | |
| 12 Month Completer Population | 4064 | 3725 | 2173 | 2172 | 1424 | 375 |
| 6 Month Completer Population | 5608 | 5221 | 3120 | 3050 | 2052 | 555 |
| ITT Population | 6528 | 6063 | 3690 | 3540 | 2428 | 682 |
"Change from baseline in overall subject satisfaction with migraine treatments. Patient Perception of Migraine Questionnaire-Revised, question 3c Overall satisfaction was the measure. Baseline measured subjects satisfaction with past migraine treatments. End of study measured subject's satisfaction with migraine treatment by Sumavel DosePro. PPMQ-R scale (1-7 scale; 1=very satisfied)is transformed to a 0-100 scale (100=very satisfied)" (NCT01016834)
Timeframe: After 4 migraines or 60 days
| Intervention | Scale of 0-100; 100= very satisfied (Mean) |
|---|---|
| Sumavel DosePro | 73.7 |
Number of subjects who indicated they were confident or very confident in treating repeated migraine attacks with Sumavel DosePro at end of treatment. (NCT01016834)
Timeframe: After 4 migraines or 60 days
| Intervention | participants (Number) |
|---|---|
| Sumavel DosePro | 136 |
Number of subjects preferring Sumavel DosePro compared to their pre-study migraine treatment (Prefer Sumavel DosePro vs. No Preference or Prefer Other Treatment). (NCT01016834)
Timeframe: After 4 migraines or 60 days
| Intervention | participants (Number) |
|---|---|
| Sumavel DosePro | 74 |
The PPMQ-R questionnaire was used to assess participant satisfaction with migraine medication; the answers are used to generate a total score and 4 subscales scores for efficacy, functionality, ease-of-use and bothersomeness-of-side effects. The total score was calculated as the average of the efficacy, functionality and ease-of-use subscores. Subscores could range from 0 to 100; higher scores indicate greater satisfaction. (NCT00573170)
Timeframe: At 24 hours after dosing for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | scores on a scale (Mean) |
|---|---|
| Placebo | 88 |
| Treximet | 86 |
| Butalbital-containing Combination Medication | 89 |
The PPMQ-R questionnaire was used to assess participant satisfaction with migraine medication; the answers are used to generate a total score and 4 subscales scores for efficacy, functionality, ease-of-use and bothersomeness-of-side effects. The total score was calculated as the average of the efficacy, functionality and ease-of-use subscores. Subscores could range from 0 to 100; higher scores indicate greater satisfaction. (NCT00573170)
Timeframe: At 24 hours after dosing for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | scores on a scale (Mean) |
|---|---|
| Placebo | 79 |
| Treximet | 82 |
| Butalbital-containing Combination Medication | 78 |
The PPMQ-R questionnaire was used to assess participant satisfaction with migraine medication; the answers are used to generate a total score and 4 subscales scores for efficacy, functionality, ease-of-use and bothersomeness-of-side effects. The total score was calculated as the average of the efficacy, functionality and ease-of-use subscores. Subscores could range from 0 to 100; higher scores indicate greater satisfaction. (NCT00573170)
Timeframe: At 24 hours after dosing for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | scores on a scale (Mean) |
|---|---|
| Placebo | 55 |
| Treximet | 62 |
| Butalbital-containing Combination Medication | 56 |
The PPMQ-R questionnaire was used to assess participant satisfaction with migraine medication; the answers are used to generate a total score and 4 subscales scores for efficacy, functionality, ease-of-use and bothersomeness-of-side effects. The total score was calculated as the average of the efficacy, functionality and ease-of-use subscores. Subscores could range from 0 to 100; higher scores indicate greater satisfaction. (NCT00573170)
Timeframe: At 24 hours after dosing for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | scores on a scale (Mean) |
|---|---|
| Placebo | 55 |
| Treximet | 61 |
| Butalbital-containing Combination Medication | 56 |
Average time until participants took any medication to treat their migraine pain or symptoms within 48 hours after they took the first dose of study medication (placebo, Treximet, or butalbital-containing combination medication) for the first migraine attack treated. Participants were asked not to take rescue for at least 2 hours after they took the study medication (placebo, Treximet, or butalbital-containing combination medication) for that attack. Participants took rescue medication if they felt they needed it. (NCT00573170)
Timeframe: From dose time through 48 hours post-dose for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | hours (Mean) |
|---|---|
| Placebo | 12.00 |
| Treximet | 17.07 |
| Butalbital-containing Combination Medication | 20.15 |
Average time until participants took any medication to treat their migraine pain or symptoms within 48 hours after they took the first dose of study medication (placebo, Treximet, or butalbital-containing combination medication) for their second migraine attack treated in the study. Participants were asked not to take rescue for at least 2 hours after they took the study medication (placebo, Treximet, or butalbital-containing combination medication) for that attack. Participants took rescue medication if they felt they needed it. (NCT00573170)
Timeframe: From dose time through 48 hours post-dose for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | hours (Mean) |
|---|---|
| Placebo | 8.29 |
| Treximet | 20.90 |
| Butalbital-containing Combination Medication | 16.70 |
Average time until participants took any medication to treat their migraine pain or symptoms within 48 hours after they took the first dose of study medication (placebo, Treximet, or butalbital-containing combination medication) for their third migraine attack treated in the study. Participants were asked not to take rescue for at least 2 hours after they took the study medication (placebo, Treximet, or butalbital-containing combination medication) for that attack. Participants took rescue medication if they felt they needed it. (NCT00573170)
Timeframe: From dose time through 48 hours post-dose for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | hours (Mean) |
|---|---|
| Placebo | 6.69 |
| Treximet | 20.77 |
| Butalbital-containing Combination Medication | 9.44 |
SPF 2-24 hours is defined for all participants as having no pain at 2 hours post-dose and without the return of any pain or the use of any rescue medication (any medication taken after the first dose of study medication for any migraine pain or symptoms) from 2-24 hours. (NCT00573170)
Timeframe: From 2 to 24 hours post-dose. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | participants (Number) |
|---|---|
| Placebo | 10 |
| Treximet | 26 |
| Butalbital-containing Combination Medication | 18 |
The PPMQ-R questionnaire was used to assess participant satisfaction with migraine medication; the answers are used to generate a total score and 4 subscales scores for efficacy, functionality, ease-of-use and bothersomeness-of-side effects. The total score was calculated as the average of the efficacy, functionality and ease-of-use subscores. Subscores could range from 0 to 100; higher scores indicate greater satisfaction. (NCT00573170)
Timeframe: At 24 hours after dosing for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | scores on a scale (Mean) |
|---|---|
| Placebo | 63 |
| Treximet | 68 |
| Butalbital-containing Combination Medication | 63 |
"Clinical disability for each participant was assessed using the CDQ. This scale uses one question to assess ability to perform normal or usual activities. Responses are recorded on a 5-point scale, where 1 is normal/not impaired, 2 is mildly impaired, 3 is moderately impaired, 4 is severely impaired, and 5 is 'required bedrest." (NCT00573170)
Timeframe: At dosing and at 2, 4, 6 and 8 hours after dosing of each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| At dose time | 2 hours | 4 hours | 6 hours | 8 hours | |
| Butalbital-containing Combination Medication | 10 | 29 | 50 | 60 | 60 |
| Placebo | 9 | 19 | 59 | 76 | 77 |
| Treximet | 8 | 33 | 62 | 77 | 83 |
Overall cognition was assessed with a composite score (range 0-9) called the Performance Index, as derived from the number of correct responses per minute on subtests of the Mental Efficiency Workload Test (MEWT) cognitive battery. For a particular participant, lower scores indicate a negative impact, or worsened, general cognition; higher scores indicate improved cognition. (NCT00573170)
Timeframe: At time of dosing, and at 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | scores on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Dose time | 2 hours | 4 hours | 6 hours | 8 hours | 24 hours | 48 hours | |
| Butalbital-containing Combination Medication | 7.30 | 7.27 | 7.38 | 7.34 | 7.33 | 7.61 | 7.69 |
| Placebo | 7.36 | 7.33 | 7.44 | 7.38 | 7.45 | 7.66 | 7.78 |
| Treximet | 7.29 | 7.37 | 7.50 | 7.43 | 7.33 | 7.82 | 7.88 |
"Participant alertness was evaluated with the 7-point modified SS scale, where 1 is feeling active, vital, alert, wide awake, 2 is still functioning at high levels, but not peak; able to concentrate, 3 is awake, but relaxed; responsive but not fully alert, 4 is somewhat foggy, let down, 5 is foggy, losing interest in remaining awake, 6 is sleepy, woozy, fighting sleep, prefer to lie down, and 7 is no longer fighting sleep, sleep onset soon, having dream like thoughts." (NCT00573170)
Timeframe: Dose time, 2, 4, 6, 8, 24 and 48 hours post-dose. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Dose time, n=318, 316, 304 | 2 hours, n=275, 268, 251 | 4 hours, n=249, 240, 234 | 6 hours, n=215, 219, 210 | 8 hours, n=195, 195, 186 | 24 hours, n=252, 258, 241 | 48 hours, n=215, 240, 218 | |
| Butalbital-containing Combination Medication | 4.00 | 3.88 | 3.91 | 3.82 | 3.91 | 2.78 | 2.60 |
| Placebo | 3.94 | 3.88 | 3.75 | 3.78 | 3.85 | 2.73 | 2.56 |
| Treximet | 3.97 | 3.87 | 3.67 | 3.75 | 3.81 | 2.80 | 2.72 |
Number of participants who took any medication to treat their migraine pain or symptoms within 48 hours after they took the first dose of study medication (placebo, Treximet, or butalbital-containing combination medication) for that attack. Participants were asked not to take rescue for at least 2 hours after they took the study medication (placebo, Treximet, or butalbital-containing combination medication) for that attack. Participants took rescue medication if they felt they needed it. (NCT00573170)
Timeframe: From dose time through 48 hours post-dose for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Use of 1st rescue < 2 hours post-dose | Use of 1st rescue (investigational medication) | Use of 2nd rescue (investigational medication) | Use of other rescue (not investigational med.) | |
| Butalbital-containing Combination Medication | 25 | 203 | 121 | 8 |
| Placebo | 25 | 234 | 114 | 6 |
| Treximet | 19 | 158 | 79 | 5 |
Complete symptom-free is defined as migraine-free, neck pain-free, and sinus pain-free without the use of any rescue medication prior to the defined time point. (NCT00573170)
Timeframe: At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| 2 hours | 4 hours | 6 hours | 8 hours | 24 hours | 48 hours | |
| Butalbital-containing Combination Medication | 21 | 36 | 38 | 38 | 74 | 62 |
| Placebo | 13 | 19 | 27 | 29 | 43 | 47 |
| Treximet | 29 | 68 | 67 | 68 | 95 | 86 |
Migraine-free is defined as pain-free with no migraine-associated symptoms (nausea, vomiting, photophobia [sensitivity to light], and phonophobia [sensitivity to sound]) with use of any rescue medication before the defined time point. (NCT00573170)
Timeframe: At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| 2 hours | 4 hours | 6 hours | 8 hours | 24 hours | 48 hours | |
| Butalbital-containing Combination Medication | 22 | 37 | 39 | 40 | 75 | 65 |
| Placebo | 14 | 20 | 28 | 29 | 46 | 48 |
| Treximet | 33 | 74 | 70 | 73 | 101 | 90 |
Pain-Free is defined as having no pain and without the use of any rescue medication from the time of the initial dose of study medication for a particular migraine attack until the defined time point at 2, 4, 6, 8, 24 or 48 hours post-dose. (NCT00573170)
Timeframe: At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| 2 hours post-dose | 4 hours post-dose | 6 hours post-dose | 8 hours post-dose | 24 hours post-dose | 48 hours post-dose | |
| Butalbital-containing Combination Medication | 26 | 39 | 40 | 42 | 78 | 66 |
| Placebo | 16 | 21 | 29 | 30 | 48 | 51 |
| Treximet | 45 | 86 | 78 | 79 | 104 | 93 |
Pain relief is defined as having no or mild pain and no use of rescue medication after dosing in those participants who had moderate or severe pain at dosing. (NCT00573170)
Timeframe: At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| 2 hours post-dose | 4 hours post-dose | 6 hours post-dose | 8 hours post-dose | 24 hours post-dose | 48 hours post-dose | |
| Butalbital-containing Combination Medication | 114 | 90 | 66 | 61 | 88 | 71 |
| Placebo | 76 | 51 | 48 | 46 | 62 | 54 |
| Treximet | 148 | 124 | 107 | 97 | 127 | 99 |
The number of participants with no pain and relief of nausea in those participants for whom nausea was present at dose time. Participants using rescue medication were removed from the participants with relief group for all subsequent timed assessments, regardless of pain and associated symptom evaluations at the specified time point. (NCT00573170)
Timeframe: At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| 2 hrs post-dose | 4 hrs post-dose | 6 hrs post-dose | 8 hrs post-dose | 24 hrs post-dose | 48 hrs post-dose | |
| Butalbital-containing Combination Medication | 8 | 8 | 8 | 9 | 30 | 28 |
| Placebo | 5 | 6 | 8 | 9 | 15 | 20 |
| Treximet | 13 | 28 | 32 | 29 | 39 | 41 |
The number of participants with no pain and relief of phonophobia in those participants for whom phonophobia was present at dose time. Participants using rescue medication were removed from the participants with relief group for all subsequent timed assessments, regardless of pain and associated symptom evaluations at the specified time point. (NCT00573170)
Timeframe: At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| 2 hrs post-dose | 4 hrs post-dose | 6 hrs post-dose | 8 hrs post-dose | 24 hrs post-dose | 48 hrs post-dose | |
| Butalbital-containing Combination Medication | 15 | 24 | 30 | 30 | 61 | 52 |
| Placebo | 11 | 15 | 21 | 21 | 33 | 34 |
| Treximet | 25 | 57 | 49 | 57 | 79 | 71 |
The number of participants with no pain and relief of photophobia in those participants for whom photophobia was present at dose time. Participants using rescue medication were removed from the participants with relief group for all subsequent timed assessments, regardless of pain and associated symptom evaluations at the specified time point. (NCT00573170)
Timeframe: At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| 2 hrs post-dose | 4 hrs post-dose | 6 hrs post-dose | 8 hrs post-dose | 24 hrs post-dose | 48 hrs post-dose | |
| Butalbital-containing Combination Medication | 16 | 23 | 27 | 32 | 24 | 20 |
| Placebo | 11 | 16 | 22 | 21 | 35 | 38 |
| Treximet | 30 | 64 | 54 | 61 | 84 | 81 |
The number of participants with no pain and relief of vomiting in those participants for whom vomiting was present at dose time. Participants using rescue medication were removed from the participants with relief group for all subsequent timed assessments, regardless of pain and associated symptom evaluations at the specified time point. (NCT00573170)
Timeframe: At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| 2 hrs post-dose | 4 hrs post-dose | 6 hrs post-dose | 8 hrs post-dose | 24 hrs post-dose | 48 hrs post-dose | |
| Butalbital-containing Combination Medication | 0 | 0 | 1 | 1 | 3 | 2 |
| Placebo | 1 | 1 | 1 | 0 | 3 | 3 |
| Treximet | 0 | 1 | 2 | 1 | 3 | 2 |
The number of participants with no pain and relief of neck pain in those participants for whom neck pain was present at dose time. Participants using rescue medication were removed from the participants with relief group for all subsequent timed assessments, regardless of pain and associated symptom evaluations at the specified time point. (NCT00573170)
Timeframe: At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| 2 hrs post-dose | 4 hrs post-dose | 6 hrs post-dose | 8 hrs post-dose | 24 hrs post-dose | 48 hrs post-dose | |
| Butalbital-containing Combination Medication | 14 | 22 | 19 | 29 | 44 | 37 |
| Placebo | 4 | 7 | 12 | 16 | 20 | 26 |
| Treximet | 19 | 43 | 39 | 38 | 51 | 46 |
The number of participants with no pain and relief of sinus/facial pain in those participants for whom sinus/facial pain was present at dose time. Participants using rescue medication were removed from the participants with relief group for all subsequent timed assessments, regardless of pain and associated symptom evaluations at the specified time point. (NCT00573170)
Timeframe: At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migraine attacks were to have been treated within 19 weeks of randomization (when study medication was dispensed).
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| 2 hrs post-dose | 4 hrs post-dose | 6 hrs post-dose | 8 hrs post-dose | 24 hrs post-dose | 48 hrs post-dose | |
| Butalbital-containing Combination Medication | 9 | 17 | 15 | 16 | 30 | 24 |
| Placebo | 5 | 4 | 10 | 8 | 13 | 15 |
| Treximet | 14 | 35 | 29 | 28 | 38 | 40 |
The number of participants with any valid two-day consecutive average diastolic blood pressure measurement of >=90 mmHg was calculated. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine. (NCT00792636)
Timeframe: Baseline to End of Study (6-month study duration)
| Intervention | participants (Number) |
|---|---|
| Sumatriptan/Naproxen | 10 |
| Sumatriptan | 11 |
| Naproxen | 11 |
The number of participants with any valid two-day consecutive average systolic blood pressure measurement of >=140 mmHg was calculated. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine. (NCT00792636)
Timeframe: Baseline to End of Study (6-month study duration)
| Intervention | participants (Number) |
|---|---|
| Sumatriptan/Naproxen | 2 |
| Sumatriptan | 2 |
| Naproxen | 3 |
The number of participants with an increase of >=3 mmHg from the baseline diastolic blood pressure for the average of any given two-day consecutive collection of valid blood pressure measurements during the study were summarized. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine. (NCT00792636)
Timeframe: Baseline to End of Study (6-month study duration)
| Intervention | participants (Number) |
|---|---|
| Sumatriptan/Naproxen | 72 |
| Sumatriptan | 65 |
| Naproxen | 77 |
The number of participants with an increase of >=5 mmHg from the baseline systolic blood pressure for the average of any given two-day consecutive collection of valid blood pressure measurements during the study were summarized. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine. (NCT00792636)
Timeframe: Baseline to End of Study (6-month study duration)
| Intervention | participants (Number) |
|---|---|
| Sumatriptan/Naproxen | 53 |
| Sumatriptan | 57 |
| Naproxen | 63 |
The number of participants withdrawn from the study due to protocol-defined blood pressure changes were summarized for each treatment group. Defined blood pressure changes included (1) monthly average BP ≥140 mmHg systolic or >=90 mmHg diastolic and confirmed in clinic, (2) monthly average BP increase of >=30 mmHg systolic or >=20 mmHg from in-clinic screening and confirmed in clinic, and (3) systolic >=140 mmHg or diastolic >=90 mmHg on consecutive clinic visits >=2 weeks apart. (NCT00792636)
Timeframe: Baseline to End of Study (6-month study duration)
| Intervention | participants (Number) |
|---|---|
| Sumatriptan/Naproxen | 1 |
| Sumatriptan | 0 |
| Naproxen | 0 |
Kaplan-Meier curves for the distribution of time to the first day with an average diastolic BP increase of >=3 mmHg from the baseline diastolic BP during each calendar day were calculated and graphed for each treatment group. Only valid BP measurements were included and were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine. (NCT00792636)
Timeframe: Baseline to End of Study (6-month study duration)
| Intervention | days (Median) |
|---|---|
| Sumatriptan/Naproxen | 51 |
| Sumatriptan | 50.5 |
| Naproxen | 26 |
Kaplan-Meier curves for the distribution of time to the first day with an average diastolic BP increase of >=3 mmHg from the baseline diastolic BP during each calendar day were calculated and graphed for each treatment group. Only valid BP measurements were included and were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine. (NCT00792636)
Timeframe: Baseline to End of Study (6-month study duration)
| Intervention | days (Median) |
|---|---|
| Sumatriptan/Naproxen | 42.5 |
| Sumatriptan | 32.5 |
| Naproxen | 18.5 |
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM). (NCT00792636)
Timeframe: Baseline and Month 6
| Intervention | mmHg (Mean) | |||||
|---|---|---|---|---|---|---|
| Systolic, Baseline, n=109, 115 | Systolic, Month 6, n=42, 37 | Systolic, Change from Baseline, n=41, 36 | Diastolic, Baseline, n=109, 115 | Diastolic, Month 6, n=42, 37 | Diastolic, Change from Baseline, n=41, 36 | |
| Naproxen | 110.1 | 108.2 | -1.8 | 74.7 | 74.3 | -0.6 |
| Sumatriptan | 110.8 | 109.4 | -2.8 | 75.7 | 73.9 | -1.6 |
The calculation of baseline and post-baseline mean blood pressure (BP) (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM). (NCT00792636)
Timeframe: Baseline and Month 6
| Intervention | millimeters of mercury (mmHg) (Mean) | |||||
|---|---|---|---|---|---|---|
| Systolic, Baseline, n=120 | Systolic, Month 6, n=48 | Systolic, Change from Baseline, n=47 | Diastolic, Baseline, n=120 | Diastolic, Month 6, n=48 | Diastolic, Change from Baseline, n=47 | |
| Sumatriptan/Naproxen | 111.7 | 107.1 | -2.9 | 76.0 | 73.0 | -2.1 |
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis. Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals (CIs) were based on MMRM analysis. LSMeans and CIs were not calculated for the 60-90 and the >90 total dose groups due to lack of convergence. (NCT00792636)
Timeframe: Baseline and Month 6
| Intervention | mmHg (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Systolic, <30 total doses | Systolic, 30-60 total doses | Systolic, >=30 total doses | Diastolic, <30 total doses | Diastolic, 30-60 total doses | Diastolic, >=30 total doses | |
| Sumatriptan/Naproxen | -1.2 | -3.4 | -3.7 | -0.6 | -3.3 | -3.6 |
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis.Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals were based on MMRM analysis. (NCT00792636)
Timeframe: Baseline and Month 6
| Intervention | mmHg (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Systolic, <1.3 doses per migraine | Systolic, 1.3-1.7 doses per migraine | Systolic, >1.7 doses per migraine | Diastolic, <1.3 doses per migraine | Diastolic, 1.3-1.7 doses per migraines | Diastolic, >1.7 doses per migraine | |
| Sumatriptan/Naproxen | -0.3 | -2.7 | -3.8 | -0.4 | -0.9 | -3.2 |
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis.Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals were based on MMRM analysis. LSMeans and corresponding confidence intervals were not calculated for > 6 migraines/month group due to lack of convergence. (NCT00792636)
Timeframe: Baseline and Month 6
| Intervention | mmHg (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Systolic, <4 migraines per month | Systolic, 4-6 migraines per month | Systolic, >=4 migraines per month | Diastolic, <4 migraines per month | Diastolic, 4-6 migraines per month | Diastolic, >=4 migraines per month | |
| Sumatriptan/Naproxen | -2.0 | -3.3 | -3.7 | -1.2 | -5.3 | -4.1 |
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis. Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals (CIs) were based on MMRM analysis. LSMeans and CIs were not calculated for the 10-14 and the >14 doses/month groups due to lack of convergence. (NCT00792636)
Timeframe: Baseline and Month 6
| Intervention | mmHg (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Systolic,<6 doses per month | Systolic, 6-10 doses per month | Systolic, >=6 doses per month | Diastolic,<6 doses per month | Diastolic, 6-10 doses per month | Diastolic, >=6 doses per month | |
| Sumatriptan/Naproxen | -1.6 | -4.6 | -4.3 | -1.0 | -3.7 | -3.5 |
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM). (NCT00792636)
Timeframe: Baseline and Month 6
| Intervention | mmHg (Mean) | |||||
|---|---|---|---|---|---|---|
| Systolic, Baseline, n=120, 115 | Systolic, Month 6, n=48, 37 | Systolic, Change from Baseline, n=47, 36 | Diastolic, Baseline, n=120, 115 | Diastolic, Month 6, n=48, 37 | Diastolic, Change from Baseline, n=47, 36 | |
| Naproxen | 110.1 | 108.2 | -1.8 | 74.7 | 74.3 | -0.6 |
| Sumatriptan/Naproxen | 111.7 | 107.1 | -2.9 | 76.0 | 73.0 | -2.1 |
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM). (NCT00792636)
Timeframe: Baseline and Month 6
| Intervention | mmHg (Mean) | |||||
|---|---|---|---|---|---|---|
| Systolic, Baseline, n=120, 109 | Systolic, Month 6, n=48, 42 | Systolic, Change from Baseline, n=47, 41 | Diastolic, Baseline, n=120, 109 | Diastolic, Month 6, n=48, 42 | Diastolic, Change from Baseline, n=47, 41 | |
| Sumatriptan | 110.8 | 109.4 | -2.8 | 75.7 | 73.9 | -1.6 |
| Sumatriptan/Naproxen | 111.7 | 107.1 | -2.9 | 76.0 | 73.0 | -2.1 |
Nausea free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours
| Intervention | participants (Number) |
|---|---|
| NP101 | 143 |
Headache pain relief (no pain or mild headache pain) at two hours post activation of NP101. (NCT00792103)
Timeframe: 2 hours
| Intervention | participants (Number) |
|---|---|
| NP101 | 105 |
Phonophobia free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours
| Intervention | participants (Number) |
|---|---|
| NP101 | 109 |
Photophobia free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours
| Intervention | participant (Number) |
|---|---|
| NP101 | 97 |
For each patch application, subjects performed a self-examination of skin irritation using a 5-point scale (0=no redness; 1=minimal skin redness; 2=moderate skin redness with sharp borders; 3=intense skin redness with or without swelling; 4=intense skin redness with blisters or broken skin). (NCT00792103)
Timeframe: 24 hours post patch activation
| Intervention | scores on a scale (Mean) |
|---|---|
| NP101 | 1.0 |
The mean age of participants at baseline was calculated for all participants in the 12 to 14 year and 15 to 17 year age groups. (NCT00843024)
Timeframe: Baseline
| Intervention | Years (Mean) |
|---|---|
| 12 to 14 Years Age Group | 13.1 |
| 15 to 17 Years Age Group | 16.1 |
The mean body mass index of participants at baseline was calculated for all participants in the 12 to 14 year and 15 to 17 year age groups. Body mass index is calculated as: weight (kilograms [kg]) divided by height (meters [m]^2). (NCT00843024)
Timeframe: Baseline
| Intervention | Kilograms per meters squared (kg/m^2) (Mean) |
|---|---|
| 12 to 14 Years Age Group | 22.6 |
| 15 to 17 Years Age Group | 24.6 |
The mean weight of participants at baseline was calculated for all participants in the 12 to 14 year and 15 to 17 year age groups. (NCT00843024)
Timeframe: Baseline
| Intervention | Kilograms (kg) (Mean) |
|---|---|
| 12 to 14 Years Age Group | 58.7 |
| 15 to 17 Years Age Group | 69.6 |
The gender of participants at baseline was reported for all participants in the 12 to 14 year and 15 to 17 year age groups. (NCT00843024)
Timeframe: Baseline
| Intervention | Participants (Number) | |
|---|---|---|
| Female | Male | |
| 12 to 14 Years Age Group | 114 | 111 |
| 15 to 17 Years Age Group | 173 | 92 |
The number of participants who did not have nausea at 2 hours post dose was analzyed. (NCT00843024)
Timeframe: 2 hours after single dose of double-blind treatment (Randomization through Week 13)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Total Population, n=144, 95, 96, 151 | 12-14 years, n=71, 43, 46, 65 | 15-17 years, n=73, 52, 50, 86 | |
| Placebo | 101 | 55 | 46 |
| Sumatriptan 10 mg/ Naproxen 60 mg | 78 | 36 | 42 |
| Sumatriptan 30 mg/ Naproxen 180 mg | 74 | 38 | 36 |
| Sumatriptan 85 mg/ Naproxen 500 mg | 106 | 47 | 59 |
The race of participants at baseline was reported for all participants in the 12 to 14 year and 15 to 17 year age groups. (NCT00843024)
Timeframe: Baseline
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| African American/African Heritage | American Indian or Alaska Native | Asian | Native Hawaiian or other Pacific Islander | White | African American/African Heritage and White | American Indian or Alaska Native and White | Asian and Native Hawaiian/other Pacific Islander | Asian and White | Native Hawaiian/ other Pacific Islander and White | Missing | |
| 12 to 14 Years Age Group | 31 | 1 | 2 | 1 | 181 | 2 | 4 | 0 | 2 | 0 | 1 |
| 15 to 17 Years Age Group | 32 | 0 | 2 | 0 | 216 | 4 | 4 | 1 | 3 | 2 | 1 |
Participants with a pain-free response at 1 hour post-dose were considered as those who had a reduction in migraine headache pain from moderate (a score of 2) or severe (a score of 3) at baseline to none (a score of 0) post-treatment, without the use of rescue medication prior to or at 1 hour post dose. (NCT00843024)
Timeframe: 1 hour after single dose of double-blind treatment (Randomization through Week 13)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Total Population, n=142, 96, 97, 150 | 12-14 years, n=70, 43, 46, 65 | 15-17 years, n=72, 53, 51, 85 | |
| Placebo | 6 | 4 | 2 |
| Sumatriptan 10 mg/ Naproxen 60 mg | 9 | 7 | 2 |
| Sumatriptan 30 mg/ Naproxen 180 mg | 6 | 2 | 4 |
| Sumatriptan 85 mg/ Naproxen 500 mg | 11 | 4 | 7 |
The number of participants who did not have phonophobia (sensitivity to sound) at 2 hours post dose was analzyed. (NCT00843024)
Timeframe: 2 hours after single dose of double-blind treatment (Randomization through Week 13)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Total Population, n=144, 96, 96, 151 | 12-14 years, n=71, 43, 46, 65 | 15-17 years, n=73, 53, 50, 86 | |
| Placebo | 60 | 34 | 26 |
| Sumatriptan 10 mg/ Naproxen 60 mg | 59 | 32 | 47 |
| Sumatriptan 30 mg/ Naproxen 180 mg | 55 | 33 | 22 |
| Sumatriptan 85 mg/ Naproxen 500 mg | 90 | 41 | 49 |
The number of participants who did not have photophobia (sensitivity to light) at 2 hours post dose was analyzed. (NCT00843024)
Timeframe: 2 hours after single dose of double-blind treatment (Randomization through Week 13)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Total Population, n=144, 96, 96, 151 | 12-14 years, n=71, 43, 46, 65 | 15-17 years, n=73, 53, 50, 86 | |
| Placebo | 59 | 33 | 26 |
| Sumatriptan 10 mg/ Naproxen 60 mg | 57 | 29 | 28 |
| Sumatriptan 30 mg/ Naproxen 180 mg | 47 | 24 | 23 |
| Sumatriptan 85 mg/ Naproxen 500 mg | 89 | 41 | 48 |
The number of participants receiving double-blind treatment were reported according to age. (NCT00843024)
Timeframe: Baseline
| Intervention | Participants (Number) | |
|---|---|---|
| 12-14 years | 15-17 years | |
| Placebo | 71 | 74 |
| Sumatriptan 10 mg/ Naproxen 60 mg | 43 | 53 |
| Sumatriptan 30 mg/ Naproxen 180 mg | 46 | 51 |
| Sumatriptan 85 mg/ Naproxen 500 mg | 65 | 87 |
Participants with sustained freedom from nausea were those with an absence of nausea from 2 to 24 hours post-dose without the use of rescue medication. (NCT00843024)
Timeframe: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Total Population, n=144, 95, 96, 151 | 12-14 years, n=71, 43, 46, 65 | 15-17 years, n=73, 52, 50, 86 | |
| Placebo | 68 | 39 | 29 |
| Sumatriptan 10 mg/ Naproxen 60 mg | 67 | 31 | 36 |
| Sumatriptan 30 mg/ Naproxen 180 mg | 64 | 33 | 31 |
| Sumatriptan 85 mg/ Naproxen 500 mg | 94 | 43 | 51 |
Participants with sustained pain-freedom were defined as those with pain-freedom at 2 hours post-dose that was maintained up to 24 hours post-treatment without the use of rescue medication. (NCT00843024)
Timeframe: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Total Population, n=142, 96, 97, 150 | 12-14 years, n=70, 43, 46, 65 | 15-17 years, n=72, 53, 51, 85 | |
| Placebo | 13 | 10 | 3 |
| Sumatriptan 10 mg/ Naproxen 60 mg | 23 | 14 | 9 |
| Sumatriptan 30 mg/ Naproxen 180 mg | 24 | 12 | 12 |
| Sumatriptan 85 mg/ Naproxen 500 mg | 35 | 17 | 18 |
Participants with sustained freedom from phonophobia were those with an absence of phonophobia (sensitivity to sound) from 2 to 24 hours post-dose without the use of rescue medication. (NCT00843024)
Timeframe: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Total Population, n=144, 96, 96, 151 | 12-14 years, n=71, 43, 46, 65 | 15-17 years, n=73, 53, 50, 86 | |
| Placebo | 47 | 27 | 20 |
| Sumatriptan 10 mg/ Naproxen 60 mg | 48 | 24 | 24 |
| Sumatriptan 30 mg/ Naproxen 180 mg | 51 | 31 | 20 |
| Sumatriptan 85 mg/ Naproxen 500 mg | 79 | 36 | 43 |
Participants with sustained freedom from photophobia were those with an absence of photophobia (sensitivity to light) from 2 to 24 hours post-dose without the use of rescue medication. (NCT00843024)
Timeframe: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Total Population, n=144, 96, 96, 151 | 12-14 years, n=71, 43, 46, 65 | 15-17 years, n=73, 53, 50, 86 | |
| Placebo | 44 | 25 | 19 |
| Sumatriptan 10 mg/ Naproxen 60 mg | 48 | 21 | 27 |
| Sumatriptan 30 mg/ Naproxen 180 mg | 43 | 21 | 22 |
| Sumatriptan 85 mg/ Naproxen 500 mg | 75 | 35 | 40 |
Rescue medication was defined as an additional medication taken by participants for the treatment of migraine pain or associated symptoms within 24 hours of dosing with investigational product. Permitted rescue medications included oral naproxen sodium (maximum 15 mg/kg), oral over-the-counter pain reliever, and anti-emetics. This outcome measure included only participants who rescued from 2 to 24 hours post-dose, inclusive. (NCT00843024)
Timeframe: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Total Population, n=145, 96, 97, 152 | 12-14 years, n=71, 43, 46, 65 | 15-17 years, n=74, 53, 51, 87 | |
| Placebo | 47 | 21 | 26 |
| Sumatriptan 10 mg/ Naproxen 60 mg | 14 | 5 | 9 |
| Sumatriptan 30 mg/ Naproxen 180 mg | 16 | 6 | 10 |
| Sumatriptan 85 mg/ Naproxen 500 mg | 21 | 10 | 11 |
Rescue medication was defined as an additional medication taken by participants for the treatment of migraine pain or associated symptoms within 24 hours of dosing with double-blind treatment. In addition to participants who rescued from 2 to 24 hours post-dose, inclusive, this outcome measure also included nine protocol violators who rescued < 2 hours post-treatment. (NCT00843024)
Timeframe: Dosing to 24 hours after single dose of double-blind treatment (Randomization through Week 13)
| Intervention | participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Population, 1 hour, n=145, 96, 96, 152 | Total Population, 2 hours, n=145, 96, 96, 152 | Total Population, 3 hours, n=145, 96, 96, 152 | Total Population, 4 hours, n=145, 96, 96, 152 | Total Population, 8 hours, n=145, 96, 96, 152 | Total Population, 12 hours, n=145, 96, 96, 152 | Total Population, 18 hours, n=145, 96, 96, 152 | Total Population, 24 hours, n=145, 96, 96, 152 | 12-14 years, 1 hour, n=71, 43, 46, 65 | 12-14 years, 2 hours, n=71, 43, 46, 65 | 12-14 years, 3 hours, n=71, 43, 46, 65 | 12-14 years, 4 hours, n=71, 43, 46, 65 | 12-14 years, 8 hours, n=71, 43, 46, 65 | 12-14 years, 12 hours, n=71, 43, 46, 65 | 12-14 years, 18 hours, n=71, 43, 46, 65 | 12-14 years, 24 hours, n=71, 43, 46, 65 | 15-17 years, 1 hour, n=74, 53, 50, 87 | 15-17 years, 2 hours, n=74, 53, 50, 87 | 15-17 years, 3 hours, n=74, 53, 50, 87 | 15-17 years, 4 hours, n=74, 53, 50, 87 | 15-17 years, 8 hours, n=74, 53, 50, 87 | 15-17 years, 12 hours, n=74, 53, 50, 87 | 15-17 years, 18 hours, n=74, 53, 50, 87 | 15-17 years, 24 hours, n=74, 53, 50, 87 | |
| Placebo | 2 | 10 | 29 | 34 | 45 | 48 | 50 | 52 | 1 | 4 | 11 | 14 | 20 | 10 | 21 | 22 | 1 | 6 | 18 | 20 | 25 | 28 | 29 | 30 |
| Sumatriptan 10 mg/ Naproxen 60 mg | 0 | 0 | 6 | 6 | 9 | 11 | 13 | 14 | 0 | 0 | 1 | 1 | 4 | 4 | 4 | 5 | 0 | 0 | 5 | 5 | 5 | 7 | 9 | 9 |
| Sumatriptan 30 mg/ Naproxen 180 mg | 0 | 6 | 11 | 13 | 15 | 15 | 15 | 17 | 0 | 1 | 2 | 4 | 4 | 4 | 4 | 6 | 0 | 5 | 9 | 9 | 11 | 11 | 11 | 11 |
| Sumatriptan 85 mg/ Naproxen 500 mg | 2 | 3 | 15 | 16 | 20 | 20 | 22 | 23 | 0 | 1 | 7 | 8 | 10 | 10 | 10 | 10 | 2 | 2 | 8 | 8 | 10 | 10 | 12 | 13 |
Participants were evaluated (self-assessment) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe. Participants with pain-free response were considered as those who had a reduction in migraine headache pain from moderate (score=2) or severe (score=3) at baseline to none (score=0) post-treatment, without the use of rescue medication (additional medication taken by participants for the treatment of migraine pain or associated symptoms) prior to or at 2 hours post-dose. (NCT00843024)
Timeframe: 2 hours after single dose of double-blind treatment (Randomization through Week 13)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Total Population, n=142, 96, 97, 150 | 12-14 years, n=70, 43, 46, 65 | 15-17 years, n=72, 53, 51, 85 | |
| Placebo | 14 | 10 | 4 |
| Sumatriptan 10 mg/ Naproxen 60 mg | 28 | 18 | 10 |
| Sumatriptan 30 mg/ Naproxen 180 mg | 26 | 13 | 13 |
| Sumatriptan 85 mg/ Naproxen 500 mg | 36 | 17 | 19 |
Number of subjects who were nausea free and who had not received any rescue medication before their two-hour assessment. (NCT00724815)
Timeframe: 2 hours post patch activation
| Intervention | participants (Number) |
|---|---|
| NP101 Patch | 189 |
| Placebo Patch | 144 |
Subjects whose headache severity score equaled zero (0) two hours post patch activation and who had not received any rescue medication before their two-hour assessment. (NCT00724815)
Timeframe: 2 hours post patch activation
| Intervention | participants (Number) |
|---|---|
| NP101 Patch | 40 |
| Placebo Patch | 21 |
Subjects who were phonophobia free and who had not received any rescue medication before their two-hour assessment. (NCT00724815)
Timeframe: 2 hours post patch activation
| Intervention | participants (Number) |
|---|---|
| NP101 Patch | 125 |
| Placebo Patch | 89 |
Subjects who were photophobia free and who had not received any rescue medication before their two-hour assessment. (NCT00724815)
Timeframe: 2 hours post patch activation
| Intervention | participants (Number) |
|---|---|
| NP101 Patch | 116 |
| Placebo Patch | 83 |
"CORS scores for Pain (0-4), Associated Symptoms (0-4), Limbic/Affective Symptoms (0-5), and Speed of Return to Functionality (1-5), represent outcome measures that are relevant to patients. Higher scores represent better treatment efficacy.~The analysis compares CORS scores for usual triptan (pre-study) versus (vs.) Treximet (study medication)." (NCT00893737)
Timeframe: Visit 1 (screening) and Visit 2 (study completion following 2-month treatment period)
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Pain Score | Associated Symptoms Score | Limbic Symptoms Score | Functionality Score | |
| Treximet | 0.17 | 0.07 | 0.03 | 0.10 |
Scores calculated for (1) Efficacy (2) Functionality (3) Ease of use (4) Cost. Higher score represents better treatment satisfaction. (NCT00893737)
Timeframe: Visit 1 (screening) and Visit 2 (study completion following 2-month treatment period)
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Efficacy | Functionality | Ease of Use | Cost | |
| Treximet | 8.61 | 13.86 | 2.76 | 7.28 |
CORS completed at Visit 1 regarding participant pre-study triptan and at Visit 2 regarding Treximet taken in study. Areas of therapeutic advantage evaluated: How often does 1 dose completely relieve (1) headache pain (2) neck/shoulder pain (3) nausea (4) light sensitivity (5) sound sensitivity (6) irritability. How quickly can/do you (1) concentrate or think clearly (2) resume normal activities (3) function normally (4) feel completely normal. How confident are you that (1) one dose will completely relieve migraine within 2 hours (2) once relieved, migraine will not return within 24 hours. (NCT00893737)
Timeframe: Visit 1 (screening) and Visit 2 (study completion following 2-month treatment period)
| Intervention | Percent of Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| How often 1 dose relieves headache pain | How often 1 dose relieves neck/shoulder pain | How often 1 dose relieves nausea | How often 1 dose relieves light sensitivity | How often 1 dose relieves sound sensitivity | How often 1 dose relieves irritability | How quickly can you concentrate or think clearly | How quickly can you resume normal activities | How quickly can you function normally | How quickly do you feel completely normal | Confidence 1 dose will relieve migraine in 2 hours | Confidence migraine will not return in 24 hours | |
| Treximet | 42 | 52 | 43 | 42 | 45 | 36 | 31 | 32 | 32 | 36 | 33 | 38 |
"Number of subjects either pain free or mild at 2 hours then pain level increases within 24 hours following treatment with Treximet versus (vs.) Placebo for 1 menstrual migraine.~0-3 pain scale with 0=No Pain, 1=Mild, 2=Moderate,and 3=Severe." (NCT01329562)
Timeframe: From onset of a single menstrual migraine episode to 24 hours post menstrual migraine treatment.
| Intervention | participants (Number) |
|---|---|
| Placebo | 0 |
| Treximet | 2 |
"Number of subjects either pain-free or mild at 2 hours then pain level increases within 24 hours following treatment in Treximet vs. Placebo arm for 1 menstrual migraine headache with Treximet vs. Placebo in responders* vs. non-responders.~0-3 Pain Scale with 0=No Pain, 1=Mild, 2=Moderate, and 3=Severe~*A responder is defined as those who at the time of two hours post treatment reported mild or no pain. Additionally, these subjects could not have taken a rescue medication or have a pain level increase within 24 hours post treatment.~A non-responder is one that fails to meet the responder criteria." (NCT01329562)
Timeframe: From the onset of 1 menstrual migraine until 24 hours post treatment.
| Intervention | participants (Number) |
|---|---|
| Placebo | 1 |
| Treximet Responder | 2 |
| Treximet Non-Responder | 0 |
"Duration of 1 menstrual migraine from time of treatment at menstrual migraine headache onset until pain free in Treximet vs. Placebo arms.~0-3 pain scale with 0=No Pain, 1=Mild, 2=Moderate, and 3=Severe." (NCT01329562)
Timeframe: From onset of 1 menstrual migraine headache until pain free.
| Intervention | hours (Mean) |
|---|---|
| Placebo | 7.64 |
| Treximet | 3.90 |
"Duration of time from treatment at menstrual migraine headache onset until pain-free in Treximet vs. Placebo arms in responders* vs. non-responders for 1 menstrual migraine.~0-3 Pain Scale, with 0=No Pain, 1=Mild, 2=Moderate, and 3=Severe.~*A responder is defined as those who at the time of two hours post treatment reported mild or no pain. Additionally, these subjects could not have taken a rescue medication or have a pain level increase within 24 hours post treatment.~A non-responder is one that fails to meet the responder criteria." (NCT01329562)
Timeframe: From the onset of 1 menstrual migraine headache until pain-free.
| Intervention | hours (Mean) |
|---|---|
| Placebo | 7.64 |
| Treximet Responder | 3.13 |
| Treximet Non-Responder | 4.68 |
"Vasoactive Intestinal Peptide (VIP), Prostaglandin E2 (PGE2), Cortisol, Prostaglandin I2 (PGI2), Estradiol, and β-endorphin** levels collected at Baseline, Menstrual Migraine Headache Onset, and 2 Hours Post Treatment in Treximet vs. Placebo arms for 1 menstrual migraine headache * This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure. Calcitonin Gene-Related Peptide (CGRP) and α-amylase both have their own outcome measure reported individually.~**β-endorphin levels were not assayed due to limitations on saliva sample volumes." (NCT01329562)
Timeframe: From Baseline until 2 hours post treatment of 1 menstrual migraine headache
| Intervention | pg/mL (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIP Baseline (n=10, 14) | VIP Migraine Onset (n=10, 13) | VIP 2 Hours Post Treatment (n=9, 13) | PGE2 Baseline (n=10, 14) | PGE2 Migraine Onset (n=10, 13) | PGE2 2 Hours Post Treatment (n=9, 14) | Cortisol Baseline (n=10, 13) | Cortisol Migraine Onset (n=8, 13) | Cortisol 2 Hours Post Treatment (n=8, 10) | PGI2 Baseline (n=10, 14) | PGI2 Migraine Onset (n=10, 13) | PGI2 2 Hours Post Treatment (n=9, 14) | Estradiol Baseline (n=10, 13) | Estradiol Migraine Onset (n=9, 13) | Estradiol 2 Hours Post Treatment (n=9,14) | |
| Placebo | 763.6 | 1052.8 | 1130.44 | 9.25 | 7.56 | 8.29 | 1064.14 | 1084.85 | 2011.45 | 109.51 | 108.23 | 97.58 | 63.37 | 41.68 | 54.07 |
| Treximet | 1149.5 | 1111.31 | 933.77 | 12.65 | 13.02 | 7.99 | 1040.49 | 1209.34 | 418.48 | 160.27 | 158.29 | 201.60 | 62.61 | 43.93 | 41.66 |
"VIP, PGE2, Cortisol, PGI2, Estradiol, and β-endorphin** levels collected for 1 menstrual migraine headache at Baseline, Menstrual Migraine Headache Onset, and 2 Hours Post Treatment in Treximet vs. Placebo arms in responders vs. non-responders***.~*This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same unit of measure. CGRP and α-amylase both have their own outcome measure reported individually.~**β-endorphin levels were not assayed due to limitations on saliva sample volumes.~***A responder is defined as those who at the time of two hours post treatment reported mild or no pain. Additionally, these subjects could not have taken a rescue medication or have a pain level increase within 24 hours post treatment.~A non-responder is one that fails to meet the responder criteria." (NCT01329562)
Timeframe: From Baseline until 2 Hours post menstrual migraine treatment for 1 menstrual migraine headache.
| Intervention | pg/mL (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIP Baseline (n=10,7,7) | VIP Migraine Onset (n=10,7,6) | VIP 2 Hours Post Treatment (n=9,7,6,) | PGE2 Baseline (n=10,7,7) | PGE2 Migraine Onset (n=10,7,6) | PGE2 2 Hours Post Treatment (n=9,7,7) | Cortisol Baseline (n=10,6,7) | Cortisol Migraine Onset (n=8,7,6) | Cortisol 2 Hours Post Treatment (n=8,6,4) | PGI2 Baseline (n=10,7,7) | PGI2 Migraine Onset (n=10,7,6) | PGI2 2 Hours Post Treatment (n=9,7,7) | Estradiol Baseline (n=9,7,6) | Estradiol Migraine Onset (n=8,7,6) | Estradiol 2 Hours Post Treatment (n=8,7,7) | |
| Placebo | 763.6 | 1052.8 | 1130.44 | 9.25 | 7.56 | 8.29 | 1064.14 | 1084.5 | 2011.45 | 109.51 | 108.23 | 97.58 | 63.37 | 37.05 | 54.07 |
| Treximet Non-Responder | 885.0 | 948.17 | 414.0 | 11.01 | 11.72 | 9.15 | 1254.53 | 1508.97 | 322.72 | 177.54 | 186.17 | 247.63 | 66.68 | 42.81 | 46.68 |
| Treximet Responder | 1414.0 | 1251.14 | 1320.14 | 14.29 | 14.13 | 6.83 | 790.77 | 952.52 | 482.32 | 142.99 | 134.40 | 155.56 | 49.60 | 44.89 | 36.64 |
"VIP, PGE2, Cortisol, PGI2, Estradiol, and β-endorphin** levels collected for 1 menstrual migraine headache at Menstrual Migraine Headache Onset, Migraine Headache Free, and 24 Hours Migraine Headache Free in Responders vs Non-Responders***.~*This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure. CGRP and α-amylase both have their own outcome measure reported individually.~**β-endorphin levels were not assayed due to limitations on saliva sample volumes.~***A responder is defined as those who at the time of two hours post treatment reported mild or no pain. Additionally, these subjects could not have taken a rescue medication or have a pain level increase within 24 hours post treatment. A non-responder is one that fails to meet the responder criteria." (NCT01329562)
Timeframe: From Baseline for the duration of 1 menstrual migraine headache, an estimated 7 days
| Intervention | pg/mL (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIP Migraine Onset (n=10,7,6) | VIP Migraine Headache Free (n=9,4,6) | VIP 24 Hours Migraine Headache Free (n=10,7,5) | PGE2 Migraine Onset (n=10,7,6) | PGE2 Migraine Headache Free (n=10,4,6) | PGE2 24 Hours Migraine Headache Free (n=10,7,7) | Cortisol Migraine Onset (n=8,7,6) | Cortisol Migraine Headache Free (n=10,3,5) | Cortisol 24 Hours Migraine Headache Free(n=10,6,6) | PGI2 Migraine Onset (n=10,7,6) | PGI2 Migraine Headache Free (n=10,4,6) | PGI2 24 Hours Migraine Headache Free (n=10,7,7) | Estradiol Migraine Onset (n=9,7,6) | Estradiol Migraine Headache Free (n=9,5,4) | Estradiol 24 Hours Migraine Headache Free(n=6,7,6) | |
| Placebo | 105.28 | 964.4 | 1059.9 | 7.56 | 8.35 | 10.46 | 1084.5 | 1490.92 | 1031.16 | 108.23 | 115.63 | 97.69 | 37.75 | 48.83 | 21.34 |
| Treximet Non-Responder | 948.97 | 643.0 | 1174.2 | 11.72 | 10.21 | 12.65 | 1508.97 | 2042.87 | 1621.38 | 186.17 | 176.37 | 295.07 | 42.81 | 26.58 | 81.38 |
| Treximet Responder | 1251.14 | 1409.75 | 1480.79 | 14.13 | 7.87 | 13.43 | 952.52 | 592.35 | 863.09 | 134.40 | 154.16 | 154.10 | 44.89 | 56.59 | 34.86 |
"VIP, PGE2, Cortisol, PGI2, Estradiol, and β-endorphin** levels collected at Menstrual Migraine Headache Onset, Migraine Headache Free and 24 Hours Migraine Headache Free in Treximet vs. Placebo arm for 1 menstrual migraine headache.~* This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure. CGRP and α-amylase both have their own outcome measure reported individually.~**β-endorphin levels were not assayed due to limitations on saliva sample volumes." (NCT01329562)
Timeframe: From baseline to 24 hours post headache gone for 1 menstrual migraine headache.
| Intervention | pg/mL (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIP Migraine Onset (n=10,7,6) | VIP Migraine Headache Free (n=9,4,7) | VIP 24 Hours Migraine Headache Free (n=10,7,6) | PGE2 Migraine Onset (n=10,7,6) | PGE2 Migraine Headache Free (n=10,4,6,) | PGE2 24 Hours Migraine Headache Free (n=10,7,7) | Cortisol Migraine Onset (n=8,7,6) | Cortisol Migraine Headache Free (n=10,3,6) | Cortisol 24 Hours Migraine Headache Free(n=10,6,6) | PGI2 Migraine Onset (n=10,7,6) | PGI2 Migraine Headache Free (n=10,4,6) | PGI2 24 Hours Migraine Headache Free (n=10,7,7) | Estradiol Migraine Onset (n=9,7,6) | Estradiol Migraine Headache Free (n=9,4,5,) | Estradiol 24 Hours Migraine Headache Free(n=6,7,5) | |
| Placebo | 1052.8 | 964.4 | 1059.9 | 7.56 | 8.35 | 10.46 | 1084.5 | 1490.92 | 1031.16 | 108.23 | 115.63 | 97.69 | 37.05 | 48.83 | 21.34 |
| Treximet | 1111.31 | 949.7 | 1353.04 | 13.02 | 9.27 | 13.04 | 1209.34 | 1498.92 | 1271.4 | 158.29 | 167.48 | 224.58 | 43.93 | 39.92 | 56.33 |
"CGRP levels collected at Baseline, Menstrual Migraine Headache Onset, and 2 Hours Post Treatment in Treximet vs. Placebo arms for 1 menstrual migraine headache~* This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure." (NCT01329562)
Timeframe: From Baseline until 2 hours post treatment for 1 menstrual migraine headache
| Intervention | pmol/mg (Mean) | ||
|---|---|---|---|
| CGRP Baseline (n=10, 14) | CGRP Migraine Onset (n=10, 13) | CGRP 2 Hours Post Treatment (n=9, 14) | |
| Placebo | 18.55 | 22.28 | 14.92 |
| Treximet | 15.03 | 27.82 | 21.38 |
"CGRP levels collected for 1 menstrual migraine headache at Baseline, Menstrual Migraine Headache Onset, and 2 Hours Post-Treatment in Responders vs Non-Responders**.~*This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure.~**A responder is defined as those who at the time of two hours post treatment reported mild or no pain. Additionally, these subjects could not have taken a rescue medication or have a pain level increase within 24 hours post treatment.~A non-responder is one that fails to meet the responder criteria." (NCT01329562)
Timeframe: From Baseline until 2 Hours post menstrual migraine treatment for 1 menstrual migraine headache.
| Intervention | pmol/mg (Mean) | ||
|---|---|---|---|
| CGRP Baseline (n=10,7,7) | CGRP Migraine Onset (n=10,7,6) | CGRP 2 Hours Post Treatment (n=9,7,7) | |
| Placebo | 18.55 | 22.28 | 14.92 |
| Treximet Non-Responder | 17.80 | 33.76 | 21.67 |
| Treximet Responder | 12.27 | 22.74 | 21.08 |
"CGRP levels collected at Menstrual Migraine Headache Onset, Migraine Headache Free, and 24 Hours Migraine Headache Free in Treximet vs. Placebo arm for 1 menstrual migraine headache.~* This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure." (NCT01329562)
Timeframe: From baseline to 24 hours post headache gone for 1 menstrual migraine headache
| Intervention | pmol/mg (Mean) | ||
|---|---|---|---|
| CGRP Migraine Onset (n=10,7,6) | CGRP Migraine Headache Free (n=9,4,6) | CGRP 24 Hours Migraine Headache Free (n=9,7,7) | |
| Placebo | 22.28 | 22.55 | 29.37 |
| Treximet | 28.82 | 32.26 | 32.15 |
"CGRP levels collected for 1 menstrual migraine headache at Menstrual Migraine Headache Onset, Migraine Headache Free, and 24 Hours Migraine Headache Free in Responders vs Non-Responders**.~*This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure.~**A responder is defined as those who at the time of two hours post treatment reported mild or no pain. Additionally, these subjects could not have taken a rescue medication or have a pain level increase within 24 hours post treatment.~A non-responder is one that fails to meet the responder criteria." (NCT01329562)
Timeframe: From Baseline to 24 hours post headache gone for 1 menstrual migraine.
| Intervention | pmol/mg (Mean) | ||
|---|---|---|---|
| CGRP Migraine Onset (n=10,7,6) | CGRP Migraine Headache Free (n=9,4,6) | CGRP 24 Hours Migraine Headache Free (n=9,7,7) | |
| Placebo | 22.28 | 22.55 | 29.37 |
| Treximet Non-Responder | 33.76 | 20.78 | 35.87 |
| Treximet Responder | 22.74 | 49.48 | 28.43 |
"Correlation of mean estrogen levels in saliva and urine estradiol at mid luteal, menstrual migraine headache onset*, and at migraine headache free following treatment with Treximet vs. Placebo for 1 menstrual migraine headache~*Urine estradiol levels were not collected at migraine onset, therefore; correlations could not be completed for that time point." (NCT01329562)
Timeframe: From mid luteal phase and for the duration of 1 menstrual migraine headache and until headache free
| Intervention | pg/mL (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Urine Pre-Cycle Day 1 (n=3, 6) | Urine Pre-Cycle Day 2 (n=6, 8) | Urine Pre-Cycle Day 3 (n=8, 6) | Urine Pre-Cycle Day 4 (n=9, 10) | Urine Migraine Headache Free (n=11, 13 | Saliva Pre-Cycle Day 1 (n=1, 4) | Saliva Pre-Cycle Day 2 (n=2, 6) | Saliva Pre-Cycle Day 3 (n=8, 10) | Saliva Pre-Cycle Day 4 (n=6, 9) | Saliva Migraine Headache Free (n=8, 6) | |
| Placebo | 2442.44 | 4333.92 | 3582.92 | 3232.10 | 2398.55 | 41.75 | 63.45 | 46.47 | 55.86 | 54.93 |
| Treximet | 3090.92 | 2616.64 | 5089.63 | 3141.51 | 2989.72 | 43.33 | 41.87 | 73.08 | 41.72 | 51.32 |
"Correlation of mean estrogen levels in saliva and urine estradiol at mid-luteal, menstrual migraine headache onset* and at migraine headache free following treatment in responders vs. non-responders**.~*Urine estradiol levels were not collected at migraine onset, therefore; correlations could not be completed for that time point.~***A responder is defined as those who at the time of two hours post treatment reported mild or no pain. Additionally, these subjects could not have taken a rescue medication or have a pain level increase within 24 hours post treatment.~A non-responder is one that fails to meet the responder criteria." (NCT01329562)
Timeframe: From mid luteal phase and for the duration of 1 menstrual migraine until headache free.
| Intervention | pg/mL (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Urine Pre-Cycle Day 1 (n=3,2,4) | Urine Pre-Cycle Day 2 (n=6,3,5) | Urine Pre-Cycle Day 3 (n=8,2,5) | Urine Pre-Cycle Day 4 (n=9,5,5) | Urine Migraine Headache Free (n=10,7,7) | Saliva Pre-Cycle Day 1 (n=1,0,4) | Saliva Pre-Cycle Day 2 (n=2,2,4) | Saliva Pre-Cycle Day 3 (n=8,4,7) | Saliva Pre-Cycle Day 4 (n=8,5,4) | Saliva Migraine Headache Free (n=8,3,4) | |
| Placebo | 2442.44 | 4333.92 | 3582.92 | 3232.10 | 2398.55 | 41.75 | 63.45 | 46.47 | 55.86 | 54.93 |
| Treximet Non-Responder | 3687.07 | 3661.52 | 5629.71 | 4266.02 | 3373.40 | 43.33 | 47.36 | 67.76 | 54.22 | 33.22 |
| Treximet Responder | 1898.63 | 875.34 | 3739.44 | 2016.99 | 2542.09 | NA | 30.89 | 81.05 | 31.71 | 75.45 |
"α-Amylase levels collected at Baseline, Menstrual Migraine Headache Onset, and 2 Hours Post Treatment in Treximet vs. Placebo arm for 1 menstrual migraine headache~* This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure." (NCT01329562)
Timeframe: From Baseline until 2 hours post treatment for 1 menstrual migraine headache
| Intervention | U/L (Mean) | ||
|---|---|---|---|
| α-Amylase Baseline (n=10, 14) | α-Amylase Migraine Onset (n=10, 13) | α-Amylase 2 Hours Post Treatment (n=9, 14) | |
| Placebo | 109280.50 | 100956.70 | 102449.80 |
| Treximet | 99626.61 | 98853.32 | 103594.90 |
"α-Amylase levels collected at Baseline, Menstrual Migraine Headache Onset, and 2 Hours Post Treatment in Responders vs Non-Responders*.~*A responder is defined as those who at the time of two hours post treatment reported mild or no pain. Additionally, these subjects could not have taken a rescue medication or have a pain level increase within 24 hours post treatment.~A non-responder is one that fails to meet the responder criteria." (NCT01329562)
Timeframe: From Baseline until 2 hours post treatment of 1 menstrual migraine headache.
| Intervention | U/L (Mean) | ||
|---|---|---|---|
| α-Amylase Baseline (n=10,7,7) | α-Amylase Migraine Onset (n=10,7,6) | α-Amylase 2 Hours Post Treatment (n=9,7,7) | |
| Placebo | 109280.50 | 100956.7 | 102449.88 |
| Treximet Non-Responder | 101250.54 | 93456.77 | 103662.4 |
| Treximet Responder | 98002.68 | 103478.94 | 103527.5 |
"α-Amylase levels collected at Menstrual Migraine Headache Onset, Migraine Headache Free, and 24 Hours Migraine Headache Free in Treximet vs. Placebo arm for 1 menstrual migraine headache~* This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure." (NCT01329562)
Timeframe: From baseline to 24 hours post headache gone for 1 menstrual migraine headache
| Intervention | U/L (Mean) | ||
|---|---|---|---|
| α-Amylase Migraine Onset (n=10,7,6) | α-Amylase Migraine Headache Free (n=10,4,6) | α-Amylase 24 Hours Migraine Headache Free(n=10,7,7 | |
| Placebo | 100956.70 | 102908.61 | 100354.00 |
| Treximet | 98853.32 | 101307.25 | 102017.80 |
"α-Amylase levels collected for 1 menstrual migraine at Menstrual Migraine Headache Onset, Migraine Headache Free, and 24 Hours Migraine Headache Free in Responders vs Non-Responders**.~*This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure.~**A responder is defined as those who at the time of two hours post treatment reported mild or no pain. Additionally, these subjects could not have taken a rescue medication or have a pain level increase within 24 hours post treatment.~A non-responder is one that fails to meet the responder criteria." (NCT01329562)
Timeframe: From Baseline from 24 hours post migraine gone for 1 menstrual migraine.
| Intervention | U/L (Mean) | ||
|---|---|---|---|
| α-amylase Migraine Onset (n=10,7,6) | α-amylase Migraine Headache Free (n=9,7,7) | α-amylase 24 Hours Migraine Headache Free(n=10,4,6 | |
| Placebo | 100956.7 | 102908.61 | 100354.3 |
| Treximet Non-Responder | 93456.77 | 103031.44 | 101559.9 |
| Treximet Responder | 103478.94 | 98720.95 | 102475.8 |
Baseline number of headache days per month collected historically at screening. Post-treatment number of headache days collected per month via diary. (NCT01071096)
Timeframe: Baseline (collected historically at screening) versus (vs.) Month (Mo) 1, Mo 2, Mo 3, Mo 4, Mo 5, Mo 6, and Mo 7
| Intervention | days (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline vs. Month 1 | Baseline vs. Month 2 | Baseline vs. Month 3 | Baseline vs. Month 4 | Baseline vs. Month 5 | Baseline vs. Month 6 | Baseline vs. Month 7 | |
| Group A | -7.61 | -9.72 | -10.06 | -9.50 | -8.94 | -9.50 | -6.50 |
| Group B | -6.67 | -5.22 | -5.22 | -6.89 | -6.33 | -9.22 | -4.56 |
Baseline number of headache days per month collected historically at screening. Post-treatment number of headache days collected per month via diary. (NCT01071096)
Timeframe: Baseline (collected historically at screening) vs. Mo 1, Mo 1 vs. Mo 2, Mo 2 vs. Mo 3, Mo 3 vs. Mo 4, Mo 4 vs. Mo 5, Mo 5 vs. Mo 6, and Mo 6 vs. Mo 7
| Intervention | days (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline vs. Mo 1 | Mo 1 vs. Mo 2 | Mo 2 vs. Mo 3 | Mo 3 vs. Mo 4 | Mo 4 vs. Mo 5 | Mo 5 vs. Mo 6 | Mo 6 vs. M 7 | |
| Group A | -7.61 | -2.11 | -0.33 | 0.56 | 0.56 | -0.56 | 3.00 |
| Group B | -6.67 | 1.44 | 0.00 | -1.67 | 0.56 | -2.89 | 4.67 |
Only cytokines with a mean densimetric value 1.65 times the background grey value in a minimum of 3 patients were considered detectable. These are reported below. Values normalized to positive control array spots after background subtraction: C5/C5a, CD40 Ligand, Granulocyte Colony Stimulating Factor (G-CSF), Growth Regulated Oncogene(GRO)-alpha, Soluble Intercellular Adhesion Molecule (sICAM)-1, Interferon gamma (IFN-y), Interleukin(IL)-1alpha, 1beta, 1ra, 8, 16, 17E, & 23, Interferon Gamma-Induced Protein 10 (IP-10), Interferon-inducible T cell alpha chemoattractant (I-TAC), Macrophage Migration Inhibitory Factor (MIF), Serpin E1, and Regulated Upon Activation Normal T-cell Expressed (RANTES) (NCT01071096)
Timeframe: For OnabotulinumtoxinA and Saline treatment months 1, 2 and 3 at Baseline level (inter-ictal) and at onset of headache that is one degree worse than Baseline level and that will be treated with acute therapy
| Intervention | Florescent Units (FU) (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C5/C5a | CD40 Ligand | G-CSF | GROa | sICAM-1 | IFN-y | IL-1alpha | IL-1beta | IL-1ra | IL-8 | IL-16 | IL-17E | IL-23 | IP-10 | I-TAC | MIF | Serpin E1 | RANTES | |
| Month 1 vs. Month 3 Non-Responders | 3.26 | 1.22 | 1.34 | 0.73 | 1.51 | 1.63 | 0.81 | 1.03 | 1.30 | 2.28 | 1.10 | 1.45 | 2.61 | 3.11 | 3.65 | 1.24 | 3.16 | 1.24 |
| Month 1 vs. Month 3 Responders | 1.03 | 0.91 | 1.07 | 1.05 | 3.99 | 0.91 | 0.86 | 1.15 | 0.88 | 4.38 | 0.98 | 1.28 | 0.93 | 1.55 | 0.67 | 0.80 | 0.76 | 1.14 |
| Month 1 vs. Saline Non-Responders | 1.01 | 1.26 | 0.93 | 3.18 | 0.61 | 0.80 | 2.88 | 1.12 | 2.02 | 1.70 | 2.07 | 1.02 | 1.80 | 0.95 | 0.28 | 9.55 | 0.70 | 0.77 |
| Month 1 vs. Saline Responders | 1.38 | 1.09 | 0.92 | 1.34 | 2.60 | 1.29 | 2.30 | 1.63 | 1.13 | 1.61 | 0.91 | 0.86 | 2.45 | 1.32 | 1.40 | 3.71 | 0.98 | 0.95 |
| Month 3 vs. Saline Non-Responders | 1.61 | 1.31 | 0.99 | 1.81 | 2.00 | 1.92 | 2.14 | 0.51 | 1.90 | 1.22 | 1.97 | 0.42 | 1.69 | 2.76 | 0.94 | 8.66 | 0.90 | 0.91 |
| Month 3 vs. Saline Responders | 1.39 | 0.98 | 0.85 | 1.40 | 5.99 | 1.29 | 1.50 | 1.38 | 0.96 | 2.71 | 0.75 | 1.59 | 1.06 | 0.86 | 1.01 | 2.71 | 0.70 | 0.93 |
CGRP Level collected each month when subject did not have a headache or was at lowest pain level of headache that month. (NCT01071096)
Timeframe: Baseline levels collected for OnabotulinumtoxinA and Saline treatment during Months 1 through 7
| Intervention | pmol/mg total protein (Mean) | ||
|---|---|---|---|
| Treatment Month 1 | Treatment Month 2 | Treatment Month 3 | |
| OnabotulinumtoxinA | 39.64 | 28.37 | 26.14 |
| Saline | 40.79 | 39.14 | 50.63 |
Saliva samples collected at Baseline (at no headache or lowest level of headache), at headache attack directly before taking rescue medication and 2 hours after treating with rescue medication. (NCT01071096)
Timeframe: For OnabotulinumtoxinA and Saline treatment months 1, 2 and 3
| Intervention | pmol/mg total protein (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Treatment Month 1 - Baseline | Treatment Month 1 - Attack | Treatment Month 1 - 2 Hours Post | Treatment Month 2 - Baseline | Treatment Month 2 - Attack | Treatment Month 2 - 2 Hours Post | Treatment Month 3 - Baseline | Treatment Month 3 - Attack | Treatment Month 3 - 2 Hours Post | |
| OnabotulinumtoxinA Non-Responders | 29.36 | 22.36 | 23.66 | 28.66 | 32.65 | 22.35 | 32.61 | 30.17 | 19.11 |
| OnabotulinumtoxinA Responders | 52.36 | 27.94 | 61.55 | 59.89 | 60.14 | 39.13 | 51.33 | 73.18 | 54.04 |
| Saline | 70.46 | 36.23 | 39.76 | 44.12 | 33.05 | 33.93 | 58.74 | 46.16 | 49.39 |
Self-assessed grade of compliance with lifestyle modification changes (where A=1, B=2, C=3, D=4, and F=5; lower scores represent better outcomes) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. (NCT01300546)
Timeframe: Day 121
| Intervention | scores on a scale (Mean) |
|---|---|
| Sumatriptan/Naproxen Sodium | 2.33 |
| Naproxen Sodium | 2.43 |
Comparing the number of migraine headache days during Baseline Period Days 1-30 to number or migraine headache days reported in Treatment Period Days 91-120 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. Percent change=[ (total headache days during Treatment Period Month 3 (Days 91-120)-total headache days during Baseline (Days 1-30)/total headache days during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Day 121 (following 30 day Baseline Period and Treatment Period Days 91-120)
| Intervention | percent change of headache days (Mean) |
|---|---|
| Sumatriptan/Naproxen Sodium | -13.50 |
| Naproxen Sodium | -36.50 |
Total number of doses of study medication reported taken per participant in Treatment Period Months 1, 2, and 3 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. (NCT01300546)
Timeframe: Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | doses of study medication (Mean) | ||
|---|---|---|---|
| Treatment Period Month 1 | Treatment Period Month 2 | Treatment Period Month 3 | |
| Naproxen Sodium | 9.36 | 8.86 | 8.50 |
| Sumatriptan/Naproxen Sodium | 11.00 | 10.28 | 10.28 |
Number of subjects with at least a 50% reduction in number of headache days reported in Baseline versus Treatment period Months 1, 2, and 3 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | participants (Number) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | 3 | 3 | 6 |
| Sumatriptan/Naproxen Sodium | 1 | 2 | 3 |
Comparing the number of migraine attacks reported from Baseline to the number of migraine attacks reported in Treatment Period Months 1(Days 31-60), 2(Days 61-90), and 3(Days 91-120) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. Each treatment month percent change was individually compared to Baseline. The following formula was used for each treatment period calculation. e.g.,Percent change=[ (total migraine attacks days during Treatment Period Month 3 (Days 91-120)-total migraine attacks during Baseline (Days 1-30)/total migraine attacks during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine attacks (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | -12.23 | -9.03 | -39.12 |
| Sumatriptan/Naproxen Sodium | -4.35 | -2.88 | -8.63 |
Number of subjects with at least a 50% reduction in number of migraine attacks reported in Baseline versus Treatment period Months 1, 2, and 3 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | participants (Number) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | 1 | 0 | 6 |
| Sumatriptan/Naproxen Sodium | 3 | 2 | 4 |
"Change in MIDAS total score from end of Baseline (Day 31) to end Treatment Period month 3 (Day 121) in the Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm.~Total score of disability ranges:~0 to 5, MIDAS Grade I, Little or no disability~6 to 10, MIDAS Grade II, Mild disability~11 to 20, MIDAS Grade III, Moderate disability~21+, MIDAS Grade IV, Severe disability No subscales are present." (NCT01300546)
Timeframe: Baseline MIDAS collected at Day 31, Post final dose study medication MIDAS collected at Day 121.
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Baseline Day 31 | Day 121 | |
| Naproxen Sodium | 22.6 | 24.1 |
| Sumatriptan/Naproxen Sodium | 28.7 | 27.9 |
Comparing mean migraine duration from onset to painfree from Baseline(Days 1-30) to each month: Treatment Period Months 1 (Days 31-60), 2(Days 61-90), and 3(Days 91-120) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. Percent change was calculated by determining percent change in each subject, from Treatment Period Month 3 and Baseline, then comparing the average change between each arm. The following formula was used for each treatment period calculation. e.g.,Percent change=[(mean duration from onset to painfree during Treatment Period Month 3 (Days 91-120)- mean duration from onset to painfree during Baseline (Days 1-30)/mean duration from onset to painfree during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine duration (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | -14.92 | -26.35 | 70.84 |
| Sumatriptan/Naproxen Sodium | 72.04 | 35.86 | 61.96 |
"% change from Baseline in mean migraine duration from time of treatment to pain free reported in Treatment Period Months 1, 2, and 3 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm.~Percent change=[(mean duration from treatment to painfree during Treatment Period Month 3 (Days 91-120)- mean duration from treatment to painfree during Baseline (Days 1-30)/mean duration from treatment to painfree during Baseline (Days 1-30)]*100%)." (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine duration (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | -14.91 | -25.52 | 73.42 |
| Sumatriptan/Naproxen Sodium | 150.10 | 92.73 | 114.10 |
Comparing migraine severity 2 hours after treatment from Baseline(Days 1-30) to migraine severity reported 2 hours after treatment in Treatment Period Months 1 (Days 31-60), 2(Days 61-90), and 3(Days 91-120) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. Percent change was calculated by determining percent change in each subject, from Treatment Period Month 3 and Baseline, then comparing the average change between each arm. The following formula was used for each treatment period calculation. e.g.,Percent change=[ (mean migraine severity during Treatment Period Month 3 (Days 91-120)- mean migraine severity during Baseline (Days 1-30)/mean migraine severity during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine severity (Mean) | ||
|---|---|---|---|
| 2 hours after treatment for Baseline to Month 1 | 2 hours after treatment for Baseline to Month 2 | 2 hours after treatment for Baseline to Month 3 | |
| Naproxen Sodium | 11.78 | 0.33 | 32.62 |
| Sumatriptan/Naproxen Sodium | -17.84 | -36.71 | -55.60 |
Comparing the number of migraine headache days during Baseline Period Days 1-30 to number or migraine headache days reported in Treatment Period Month 1 (Days 31-60), Treatment Period Month 2 (Days 61-90), and Treatment Period Month 3 (Days 91-120) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. e.g., Percent change=[ (total headache days during Treatment Period Month 3 (Days 91-120)-total headache days during Baseline (Days 1-30)/total headache days during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine headache days (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | -26.86 | -21.44 | -36.50 |
| Sumatriptan/Naproxen Sodium | -1.70 | -4.39 | -13.50 |
% change in number of doses during Baseline of triptans (Group A) and non-steroidal anti-inflammatory drugs(NSAIDs) (Group B) vs. doses during Treatment Period Months 1, 2, and 3 of study medication in the Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. e.g.,Percent change=[(number of doses during Treatment Period Month 3 (Days 91-120)- number of doses during Baseline (Days 1-30)/number of doses during Baseline (Days 1-30)]*100%). The total number of subjects used in this analysis is different than the total number of subjects as the analysis is only looking at those subjects that were taking one of the study medications during Baseline. (NCT01300546)
Timeframe: Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of study medication (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | 160.8 | 76.4 | 112.7 |
| Sumatriptan/Naproxen Sodium | 130.8 | 114.9 | 96.1 |
335 reviews available for sumatriptan and Abdominal Migraine
| Article | Year |
|---|---|
Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
Topics: Amino Acid Sequence; Animals; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Recep | 2014 |
[Sumatriptan 3 mg subcutaneous : Clinical relevance of acute treatment of migraine despite dose reduction].
Topics: Drug Tapering; Humans; Migraine Disorders; Pain; Quality of Life; Sumatriptan; Tryptamines | 2022 |
Harnessing Intranasal Delivery Systems of Sumatriptan for the Treatment of Migraine.
Topics: Administration, Intranasal; Administration, Oral; Drug Delivery Systems; Humans; Migraine Disorders; | 2022 |
Efficacy of ketorolac in the treatment of acute migraine attack: A systematic review and meta-analysis.
Topics: Caffeine; Dexamethasone; Diclofenac; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Pain; Ph | 2022 |
Post-COVID Headache: A Literature Review.
Topics: COVID-19; Epilepsy; Female; Headache; Humans; Migraine Disorders; Sumatriptan | 2022 |
Sumatriptan as a First-Line Treatment for Headache in the Pediatric Emergency Department.
Topics: Child; Emergency Service, Hospital; Female; Headache; Humans; Male; Migraine Disorders; Retrospectiv | 2023 |
The Efficacy of Different Triptans for the Treatment of Acute Headache in Pediatric Migraine: A Systematic Review.
Topics: Adolescent; Child; Headache; Humans; Migraine Disorders; Naproxen; Sumatriptan; Tryptamines | 2023 |
The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials.
Topics: Chlorpromazine; Granisetron; Headache; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Nausea | 2023 |
Comparative efficacy of different treatments for menstrual migraine: a systematic review and network meta-analysis.
Topics: Humans; Migraine Disorders; Network Meta-Analysis; Sumatriptan; Tryptamines | 2023 |
[Sumatriptan-naproxen sodium fix-dose combination for acute migraine treatment, a review].
Topics: Double-Blind Method; Drug Therapy, Combination; Headache; Humans; Migraine Disorders; Naproxen; Qual | 2023 |
Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.
Topics: Academies and Institutes; Adolescent; Child; Drug Combinations; Headache; Humans; Migraine Disorders | 2019 |
Onset of action in placebo-controlled migraine attacks trials: A literature review and recommendation.
Topics: Humans; Migraine Disorders; Pain; Pharmaceutical Preparations; Randomized Controlled Trials as Topic | 2021 |
Beyond its anti-migraine properties, sumatriptan is an anti-inflammatory agent: A systematic review.
Topics: Anti-Inflammatory Agents; Humans; Inflammation; Migraine Disorders; Sumatriptan; Tumor Necrosis Fact | 2021 |
Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review.
Topics: Animals; Migraine Disorders; Piperidines; Randomized Controlled Trials as Topic; Serotonin Receptor | 2021 |
AVP-825: a novel intranasal delivery system for low-dose sumatriptan powder in the treatment of acute migraine.
Topics: Administration, Intranasal; Adult; Dose-Response Relationship, Drug; Drug Delivery Systems; Humans; | 2017 |
Intranasal sumatriptan for acute migraine attacks: a systematic review and meta-analysis.
Topics: Acute Disease; Administration, Intranasal; Humans; Migraine Disorders; Pain Management; Randomized C | 2018 |
A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine.
Topics: Administration, Intranasal; Administration, Oral; Adult; Drug Delivery Systems; Exhalation; Humans; | 2018 |
Menstrual migraine: a review of current and developing pharmacotherapies for women.
Topics: Acute Disease; Calcitonin Gene-Related Peptide; Female; Fructose; Humans; Menstruation; Migraine Dis | 2018 |
Is subcutaneous sumatriptan an effective treatment for adults presenting to the emergency department with acute migraine headache?
Topics: Adult; Emergency Medicine; Emergency Service, Hospital; Female; Humans; Injections, Subcutaneous; Ma | 2013 |
What's new in the migraine attack treatment.
Topics: Analgesics; Calcitonin Gene-Related Peptide Receptor Antagonists; Dihydroergotamine; Humans; Migrain | 2013 |
Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults.
Topics: Acetaminophen; Acute Disease; Adult; Analgesics, Non-Narcotic; Antiemetics; Drug Therapy, Combinatio | 2013 |
Aspirin with or without an antiemetic for acute migraine headaches in adults.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Aspirin; Drug Therapy, Combination; Hum | 2013 |
Diclofenac with or without an antiemetic for acute migraine headaches in adults.
Topics: Acute Disease; Adult; Analgesics; Antiemetics; Diclofenac; Drug Therapy, Combination; Female; Humans | 2013 |
The efficacy of triptans in childhood and adolescence migraine.
Topics: Adolescent; Analgesics; Child; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, C | 2013 |
Sumatriptan : treatment across the full spectrum of migraine.
Topics: Animals; Humans; Migraine Disorders; Sumatriptan; Treatment Outcome | 2013 |
Clinical implications for breath-powered powder sumatriptan intranasal treatment.
Topics: Administration, Intranasal; Animals; Dry Powder Inhalers; Humans; Migraine Disorders; Respiration; S | 2013 |
Primary headache disorders.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anticonvulsants; Chronic Disease; Cluster Headache; Cycloox | 2013 |
Sumatriptan iontophoretic transdermal system: a review of its use in patients with acute migraine.
Topics: Acute Pain; Administration, Cutaneous; Adult; Drug Delivery Systems; Drug Eruptions; Humans; Iontoph | 2013 |
Sumatriptan/naproxen sodium: a review of its use in adult patients with migraine.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Drug The | 2013 |
A review of needle-free sumatriptan injection for rapid control of migraine.
Topics: Animals; Chemistry, Pharmaceutical; Drug Delivery Systems; Humans; Injections, Subcutaneous; Migrain | 2013 |
Sumatriptan iontophoretic transdermal system: history, study results, and use in clinical practice.
Topics: Administration, Cutaneous; Animals; Clinical Trials as Topic; Drug Delivery Systems; Humans; Iontoph | 2013 |
Naproxen with or without an antiemetic for acute migraine headaches in adults.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Drug Therapy, Combination; Humans; Migr | 2013 |
Sumatriptan plus naproxen for acute migraine attacks in adults.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Drug Therapy, Comb | 2013 |
Animal migraine models for drug development: status and future perspectives.
Topics: Animals; Animals, Genetically Modified; Disease Models, Animal; Drug Discovery; Forecasting; Humans; | 2013 |
Daily triptan use for intractable migraine.
Topics: Drug Administration Schedule; Female; Humans; Middle Aged; Migraine Disorders; Retrospective Studies | 2014 |
Chronic migraine in women.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Botulinum Toxins, Type A; Female; Fructose; Humans; | 2014 |
Sumatriptan iontophoretic transdermal system for the acute treatment of migraine.
Topics: Administration, Cutaneous; Humans; Iontophoresis; Migraine Disorders; Randomized Controlled Trials a | 2014 |
Adiponectin and migraine: systematic review of clinical evidence.
Topics: Adiponectin; Adult; Comorbidity; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Migrain | 2014 |
Red flags and comfort signs for ominous secondary headaches.
Topics: Adult; Cooperative Behavior; Diagnosis, Differential; Diagnostic Imaging; Female; Headache Disorders | 2014 |
Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews.
Topics: Acute Disease; Adult; Drug Administration Routes; Humans; Migraine Disorders; Numbers Needed To Trea | 2014 |
Pharmacokinetics and safety of a new aspirin formulation for the acute treatment of primary headaches.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Headache; Humans | 2014 |
Sumatriptan iontophoretic patch for migraine.
Topics: Humans; Iontophoresis; Migraine Disorders; Serotonin 5-HT1 Receptor Agonists; Sumatriptan; Transderm | 2014 |
Migraine and pregnancy. Choice of treatment.
Topics: Abnormalities, Drug-Induced; Female; Fetus; Gestational Age; Humans; Migraine Disorders; Patient Sel | 2014 |
A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine.
Topics: Administration, Intranasal; Drug Delivery Systems; Humans; Migraine Disorders; Nose; Powders; Random | 2015 |
The pharmacokinetics and clinical efficacy of AVP-825: a potential advancement for acute treatment of migraine.
Topics: Administration, Intranasal; Drugs, Investigational; Humans; Migraine Disorders; Randomized Controlle | 2015 |
Sumatriptan/Naproxen Sodium: A Review in Migraine.
Topics: Drug Combinations; Humans; Migraine Disorders; Naproxen; Sumatriptan | 2016 |
[Update on Current Care Guideline: Migraine].
Topics: Acetaminophen; Adrenergic beta-Antagonists; Amitriptyline; Analgesics, Non-Narcotic; Analgesics, Opi | 2015 |
Headache research in 2015: progress in migraine treatment.
Topics: Analgesics; Antibodies, Monoclonal; Biomedical Research; Headache; Humans; Migraine Disorders; Sumat | 2016 |
Systematic review: Is Metoclopramide more effective than Sumatriptan in relieving pain from migraine in adults in the Emergency Department (ED) setting?
Topics: Adult; Analgesics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Migraine Disor | 2016 |
Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Drug Therapy, Comb | 2016 |
The efficacy and safety of sumatriptan intranasal powder in adults with acute migraine.
Topics: Administration, Intranasal; Adult; Humans; Migraine Disorders; Powders; Serotonin Receptor Agonists; | 2016 |
Comparative tolerability of treatments for acute migraine: A network meta-analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Drug Therapy, Comb | 2017 |
Sumatriptan Nasal Powder: A Review in Acute Treatment of Migraine.
Topics: Administration, Intranasal; Clinical Trials, Phase III as Topic; Humans; Migraine Disorders; Powders | 2016 |
Network meta-analysis of migraine disorder treatment by NSAIDs and triptans.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Ibuprofen; Migraine Disorders; Oxazolidinones; Pyrr | 2016 |
The specific treatment of migraine: a story about one triptan.
Topics: Humans; Migraine Disorders; Sumatriptan; Vasoconstrictor Agents | 2007 |
Sumatriptan/naproxen sodium combination for the treatment of migraine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Drug Combinations; Humans; Migrai | 2008 |
Cutaneous allodynia and migraine: another view.
Topics: Humans; Hyperalgesia; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan | 2006 |
What can be learned from the history of recurrence in migraine? A comment.
Topics: Clinical Trials as Topic; Humans; Migraine Disorders; Recurrence; Sumatriptan; Vasoconstrictor Agent | 2009 |
Does sumatriptan cross the blood-brain barrier in animals and man?
Topics: Animals; Blood-Brain Barrier; Central Nervous System; Dose-Response Relationship, Drug; Humans; Migr | 2010 |
Question: What are the best pharmacological options for treating the symptoms of migraine headaches in children?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Decision Making; Humans; Ibuprofen; Migraine Disorde | 2010 |
Efficacy and tolerability of rizatriptan 10 mg compared with sumatriptan 100 mg: an evidence-based analysis.
Topics: Double-Blind Method; Evidence-Based Medicine; Humans; Meta-Analysis as Topic; Migraine Disorders; Pa | 2010 |
Therapeutic windows.
Topics: History, 19th Century; History, 20th Century; History, 21st Century; Humans; Migraine Disorders; Ser | 2010 |
Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal.
Topics: Clinical Trials as Topic; Drug Combinations; Humans; Migraine Disorders; Naproxen; Sumatriptan | 2010 |
Aspirin with or without an antiemetic for acute migraine headaches in adults.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Aspirin; Drug Therapy, Combination; Hum | 2010 |
Meeting acute migraine treatment needs through novel treatment formulations.
Topics: Analgesics, Non-Narcotic; Diclofenac; Dihydroergotamine; Drug Administration Routes; Drug Delivery S | 2010 |
Transdermal delivery of sumatriptan for the treatment of acute migraine.
Topics: Acute Disease; Administration, Cutaneous; Animals; Clinical Trials, Phase III as Topic; Drug Evaluat | 2010 |
Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: Results of a new analysis of data from five previously published studies.
Topics: Acute Disease; Carbazoles; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Dose-Respon | 2010 |
A sumatriptan needle-free injection for migraine.
Topics: Chemistry, Pharmaceutical; Drug Delivery Systems; Humans; Injections, Subcutaneous; Migraine Disorde | 2010 |
Triptan therapy in migraine.
Topics: Female; Humans; Migraine Disorders; Practice Guidelines as Topic; Serotonin Receptor Agonists; Sumat | 2010 |
Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine.
Topics: Clinical Trials as Topic; Drug Administration Routes; Female; Gastroparesis; Humans; Iontophoresis; | 2010 |
Sumatriptan therapy for headache and acute myocardial infarction.
Topics: Adolescent; Adult; Animals; Coronary Vasospasm; Female; Humans; Male; Middle Aged; Migraine Disorder | 2010 |
Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Antiemetics; Drug Therapy, Combination; Humans; Hype | 2010 |
Emerging migraine treatments and drug targets.
Topics: Benzamides; Benzopyrans; Botulinum Toxins, Type A; Calcitonin Gene-Related Peptide Receptor Antagoni | 2011 |
Sumatriptan needle-free subcutaneous (Sumavel(®) DosePro™) approved for the acute treatment of migraine, with or without aura, and cluster headaches.
Topics: Cluster Headache; Drug Administration Routes; Drug Delivery Systems; Female; Humans; Injections, Sub | 2011 |
Evaluation of the use of sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea.
Topics: Dysmenorrhea; Female; Humans; Menstrual Cycle; Migraine Disorders; Naproxen; Prostaglandins; Seroton | 2011 |
Needle-free subcutaneous sumatriptan: in the acute treatment of migraine attacks or cluster headache episodes.
Topics: Clinical Trials, Phase IV as Topic; Cluster Headache; Drug Delivery Systems; Humans; Infusions, Subc | 2011 |
Pharmacological synergy: the next frontier on therapeutic advancement for migraine.
Topics: Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxygenas | 2012 |
WITHDRAWN: Oral sumatriptan for acute migraine.
Topics: Acute Disease; Administration, Oral; Adult; Humans; Migraine Disorders; Randomized Controlled Trials | 2012 |
Sumatriptan (oral route of administration) for acute migraine attacks in adults.
Topics: Acute Disease; Administration, Oral; Adult; Analgesics; Humans; Migraine Disorders; Randomized Contr | 2012 |
Diclofenac with or without an antiemetic for acute migraine headaches in adults.
Topics: Acute Disease; Adult; Analgesics; Antiemetics; Diclofenac; Drug Therapy, Combination; Humans; Hypera | 2012 |
Sumatriptan (intranasal route of administration) for acute migraine attacks in adults.
Topics: Acute Disease; Administration, Intranasal; Adult; Dihydroergotamine; Female; Humans; Male; Migraine | 2012 |
Sumatriptan (rectal route of administration) for acute migraine attacks in adults.
Topics: Acute Disease; Administration, Rectal; Adult; Caffeine; Ergotamine; Female; Humans; Male; Migraine D | 2012 |
Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults.
Topics: Acute Disease; Adult; Humans; Injections, Subcutaneous; Migraine Disorders; Pain Management; Randomi | 2012 |
Therapeutic applications for subcutaneous triptans in the acute treatment of migraine.
Topics: Humans; Injections, Subcutaneous; Migraine Disorders; Nausea; Sumatriptan; Treatment Outcome | 2012 |
Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment.
Topics: Animals; Dihydroergotamine; Ergotamine; Humans; Methysergide; Migraine Disorders; Sumatriptan; Treat | 2012 |
An update in the treatment of neurologic disorders during pregnancy--focus on migraines and seizures.
Topics: Animals; Anticonvulsants; Female; Humans; Migraine Disorders; Nervous System Diseases; Pregnancy; Pr | 2012 |
Treatment of perimenstrual migraine with triptans: an update.
Topics: Female; Humans; Migraine Disorders; Premenstrual Syndrome; Randomized Controlled Trials as Topic; Su | 2012 |
Aspirin for acute migraine headaches in adults.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Aspirin; Dopamine Antagonists; Drug Therapy, C | 2013 |
Sumatriptan succinate : pharmacokinetics of different formulations in clinical practice.
Topics: Animals; Cluster Headache; Humans; Migraine Disorders; Serotonin 5-HT1 Receptor Agonists; Sumatripta | 2012 |
Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison.
Topics: Acute Disease; Administration, Oral; Adult; Comparative Effectiveness Research; Cost-Benefit Analysi | 2012 |
QT prolongation, Torsade de Pointes, myocardial ischemia from coronary vasospasm, and headache medications. Part 1: review of serotonergic cardiac adverse events with a triptan case.
Topics: Coronary Vasospasm; Electrocardiography; Female; Humans; Middle Aged; Migraine Disorders; Myocardial | 2013 |
Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine.
Topics: Animals; Humans; Migraine Disorders; Randomized Controlled Trials as Topic; Serotonin 5-HT1 Receptor | 2013 |
Mechanisms of action of the 5-HT1B/1D receptor agonists.
Topics: Carbazoles; Humans; Indoles; Migraine Disorders; Oxazolidinones; Piperidines; Pyrrolidines; Receptor | 2002 |
[Treatment of migraine in patients with hypertension and ischemic heart disease].
Topics: Adjuvants, Pharmaceutic; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Carbazol | 2002 |
Clinical pharmacokinetics of intranasal sumatriptan.
Topics: Administration, Intranasal; Adolescent; Adult; Animals; Child; Clinical Trials as Topic; Dose-Respon | 2002 |
[How do sumatriptan and co. work? The action mechanisms of triptans].
Topics: Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Vasodilator Agents | 2002 |
[Which triptan is best? Rating of triptans in migraine treatment].
Topics: Animals; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Vasodilator Agents | 2002 |
Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.
Topics: Administration, Oral; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Migraine D | 2002 |
An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy.
Topics: Animals; Carotid Arteries; Cerebrovascular Circulation; Craniotomy; Ergotamine; History, 20th Centur | 2002 |
Medication overuse headache.
Topics: Analgesics; Ergot Alkaloids; Headache; Humans; Migraine Disorders; Narcotics; Serotonin Receptor Ago | 2001 |
Ergotamine, dihydroergotamine: current uses and problems.
Topics: Analgesics, Non-Narcotic; Dihydroergotamine; Ergotamine; Humans; Migraine Disorders; Serotonin Recep | 2001 |
Sumatriptan: pharmacological basis and clinical results.
Topics: Administration, Inhalation; Headache; Humans; Injections; Migraine Disorders; Patient Satisfaction; | 2001 |
Zolmitriptan: differences from sumatriptan.
Topics: Cluster Headache; Humans; Migraine Disorders; Oxazolidinones; Serotonin Receptor Agonists; Sumatript | 2001 |
Rizatriptan: pharmacological differences from sumatriptan and clinical results.
Topics: Administration, Oral; Humans; Migraine Disorders; Patient Satisfaction; Recurrence; Serotonin Recept | 2001 |
Eletriptan: pharmacological differences and clinical results.
Topics: Humans; Indoles; Migraine Disorders; Pyrrolidines; Serotonin Receptor Agonists; Sumatriptan; Tryptam | 2001 |
Almotriptan: pharmacological differences and clinical results.
Topics: Administration, Oral; Humans; Indoles; Migraine Disorders; Recurrence; Serotonin Receptor Agonists; | 2001 |
Safety of sumatriptan in pregnancy: a review of the data so far.
Topics: Animals; Female; Humans; Migraine Disorders; Pregnancy; Pregnancy Complications; Pregnancy Outcome; | 2003 |
Sumatriptan nasal spray for migraine: a review of studies in patients aged 17 years and younger.
Topics: Administration, Intranasal; Adolescent; Adult; Child; Child, Preschool; Dose-Response Relationship, | 2002 |
[The problems of migraine headache treatment].
Topics: Aged; Analgesics; Analgesics, Non-Narcotic; Aspirin; Dihydroergotamine; Female; Humans; Male; Methys | 2002 |
Ergotamine and dihydroergotamine: a review.
Topics: Dihydroergotamine; Dose-Response Relationship, Drug; Ergotamine; Humans; Migraine Disorders; Randomi | 2003 |
Tolerability of the triptans: clinical implications.
Topics: Brain; Cardiovascular System; Drug Interactions; Female; Fetus; Humans; Migraine Disorders; Pregnanc | 2003 |
The triptan formulations : how to match patients and products.
Topics: Dose-Response Relationship, Drug; Drug Administration Routes; Drug Delivery Systems; Drug Prescripti | 2003 |
5-HT(1)-like receptor agonists and the pathophysiology of migraine.
Topics: Animals; Brain; Cats; Dogs; Humans; Indoles; Migraine Disorders; Receptors, Serotonin; Serotonin Rec | 1989 |
Comparative aspects of triptans in treating migraine.
Topics: Carbazoles; Cardiovascular Diseases; Humans; Indoles; Migraine Disorders; Oxazolidinones; Patient Sa | 2001 |
Sumatriptan versus eletriptan: which is best?
Topics: Clinical Trials as Topic; Humans; Indoles; Migraine Disorders; Pyrrolidines; Serotonin Receptor Agon | 2002 |
The link between glutamate and migraine.
Topics: Glutamic Acid; Humans; Migraine Disorders; Sumatriptan; Trigeminal Ganglion; Vasoconstrictor Agents | 2003 |
Oral sumatriptan for acute migraine.
Topics: Administration, Oral; Adult; Humans; Migraine Disorders; Randomized Controlled Trials as Topic; Sero | 2003 |
Clinical applications of new therapeutic deliveries in migraine.
Topics: Administration, Intranasal; Administration, Oral; Adult; Clinical Trials as Topic; Dysgeusia; Female | 2003 |
Triptans for treatment of acute pediatric migraine: a systematic literature review.
Topics: Acute Disease; Administration, Intranasal; Administration, Oral; Child; Clinical Trials as Topic; Hu | 2003 |
Serotonin syndrome and the use of SSRIs.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Therapy, Combination; Fem | 2004 |
Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials.
Topics: Dose-Response Relationship, Drug; Humans; Indoles; Migraine Disorders; Oxazolidinones; Piperidines; | 2004 |
[Recent progress in therapy for migraine headache].
Topics: Anticonvulsants; Botulinum Toxins; Calcitonin Gene-Related Peptide; Central Nervous System; Clinical | 2004 |
Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a review.
Topics: Administration, Oral; Analgesics; Double-Blind Method; Humans; Indoles; Migraine Disorders; Oxazolid | 2004 |
Managing migraine in children.
Topics: Adolescent; Analgesics; Antiemetics; Child; Humans; Migraine Disorders; Narcotics; Phytotherapy; Ran | 2004 |
[Pitfall in migraine treatment].
Topics: Contraindications; Headache Disorders; Humans; Meta-Analysis as Topic; Migraine Disorders; Randomize | 2003 |
Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms.
Topics: Animals; Central Nervous System Diseases; Humans; Migraine Disorders; Serotonin Receptor Agonists; S | 2004 |
Intranasal medications for the treatment of migraine and cluster headache.
Topics: Administration, Intranasal; Analgesics; Capsaicin; Cluster Headache; Humans; Migraine Disorders; Oxa | 2004 |
Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine.
Topics: Carbazoles; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Menstruatio | 2004 |
Treatment of migraine headaches with sumatriptan in pregnancy.
Topics: Abnormalities, Drug-Induced; Clinical Trials as Topic; Female; Humans; Migraine Disorders; Pregnancy | 2004 |
Migraine: pathophysiology, pharmacology, treatment and future trends.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; History, 17th Century; History, 19th Cent | 2003 |
[Treatment and prophylaxis of an acute migraine attack].
Topics: Acupuncture Therapy; Acute Disease; Administration, Oral; Adrenergic beta-Antagonists; Analgesics; A | 2004 |
Acute drug treatment of migraine attack.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Clinical Trials as Topic; Contr | 2004 |
Update on menstrual migraine: from clinical aspects to therapeutical strategies.
Topics: Female; Humans; Menstruation; Migraine Disorders; Migraine without Aura; Serotonin Receptor Agonists | 2004 |
[Triptans in migraine: a comparative review of pharmacology, pharmacokinetics].
Topics: Animals; Biological Availability; Cardiovascular System; Dose-Response Relationship, Drug; Humans; I | 2004 |
[Triptans in migraine: from clinical view].
Topics: Drug Administration Schedule; Humans; Indoles; Migraine Disorders; Oxazolidinones; Pyrrolidines; Rec | 2004 |
[Meta-analysis of triptan treatment in migraine].
Topics: Carbazoles; Evidence-Based Medicine; Humans; Indoles; Migraine Disorders; Oxazolidinones; Piperidine | 2004 |
[Side effects of triptans].
Topics: Central Nervous System; Dose-Response Relationship, Drug; Humans; Indoles; Migraine Disorders; Nause | 2004 |
Migraine headache.
Topics: Acute Disease; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Dicl | 2003 |
Diagnosis and management of migraine headaches.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Half-Life; Humans; Male; Middle Aged; Migrai | 2004 |
[Therapeutic recommendations for migraine].
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Anxiety Disorders; Biofeedback, Psychology; Com | 2004 |
[Mechanism based prevention and treatment of migraine].
Topics: Humans; Migraine Disorders; Sumatriptan; Vasoconstrictor Agents | 2004 |
Migraine headache.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Ergotamine; Humans; Ibuprofen; Indoles; Migrain | 2004 |
[Pharmacologic treatment of acute migraine attack in children].
Topics: Acetaminophen; Acute Disease; Administration, Intranasal; Administration, Oral; Adolescent; Age Fact | 2005 |
Intranasal sumatriptan: in adolescents with migraine.
Topics: Administration, Intranasal; Adolescent; Humans; Migraine Disorders; Sumatriptan | 2005 |
Oral serotonin receptor agonists: a review of their cost effectiveness in migraine.
Topics: Cost-Benefit Analysis; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan | 2005 |
Where do triptans act in the treatment of migraine?
Topics: Animals; Brain; Humans; Migraine Disorders; Receptors, Serotonin, 5-HT1; Serotonin 5-HT1 Receptor Ag | 2005 |
Evaluating the triptans.
Topics: Administration, Oral; Clinical Trials as Topic; Humans; Migraine Disorders; Patient Satisfaction; Pr | 2005 |
Sumatriptan: a decade of use and experience in the treatment of migraine.
Topics: Clinical Trials as Topic; Humans; Migraine Disorders; Sumatriptan | 2004 |
Pharmacokinetic opportunities for combination therapy in migraine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Humans; Migraine Disorders; Seco | 2005 |
Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine.
Topics: Caffeine; Cost-Benefit Analysis; Drug Combinations; Drug Therapy, Combination; Economics, Pharmaceut | 2005 |
Pharmacologic treatment of migraine. Comparison of guidelines.
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Ergotamines; Humans; | 2005 |
The treatment of pediatric migraine.
Topics: Adrenergic beta-Antagonists; Anticonvulsants; Antidepressive Agents; Antiemetics; Biofeedback, Psych | 2005 |
Symptomatic treatment of migraine in children: a systematic review of medication trials.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; Child, Preschool; Controlled Clinical Tr | 2005 |
Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain--results of a model-based meta-analysis that accounts for encapsulation.
Topics: Capsules; Dose-Response Relationship, Drug; Humans; Indoles; Migraine Disorders; Models, Statistical | 2005 |
[Positron emission tomographic studies of migraine].
Topics: Cerebrovascular Circulation; Humans; Migraine Disorders; Migraine with Aura; Muscle Tonus; Positron- | 2005 |
The treatment of acute migraine.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Calcitonin Gene-Related Peptide Receptor Ant | 2005 |
Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; | 2005 |
Infrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials.
Topics: Administration, Oral; Clinical Trials as Topic; Humans; Migraine Disorders; Outcome Assessment, Heal | 2006 |
Polytherapy in the preventive and acute treatment of migraine: fundamentals for changing the approach.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Schedule; Drug Therapy, Com | 2006 |
[Triptanes in the treatment of migraine. A review based on three Cochrane reviews].
Topics: Acute Disease; Administration, Oral; Dose-Response Relationship, Drug; Humans; Migraine Disorders; P | 2006 |
Functional neuroimaging of primary headache disorders.
Topics: Blood Flow Velocity; Brain; Cerebrovascular Circulation; Headache Disorders, Primary; Hemiplegia; Hu | 2006 |
Migraine: emerging treatment options for preventive and acute attack therapy.
Topics: Acute Disease; Analgesics; Animals; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatri | 2006 |
Migraine headache in children.
Topics: Adolescent; Adrenergic beta-Antagonists; Child; Humans; Migraine Disorders; Propranolol; Serotonin A | 2006 |
[Medication-overuse headache].
Topics: Acute Disease; Analgesics; Analgesics, Non-Narcotic; Chronic Disease; Ergotamine; Female; Headache; | 2006 |
Migraine headaches: a historical prospective, a glimpse into the future, and migraine epidemiology.
Topics: Benzamides; Benzopyrans; Calcitonin Gene-Related Peptide; Drug Therapy, Combination; Ergotamine; Glo | 2006 |
[Self-medication of migraine and headache].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Caffeine; | 2006 |
Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relatio | 2007 |
[Acute and chronic headaches].
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspir | 2006 |
Major therapeutic advances in the past 25 years.
Topics: Adrenergic beta-Antagonists; Anticonvulsants; Antidepressive Agents, Tricyclic; Calcitonin Gene-Rela | 2007 |
Sumatriptan nasal spray in the acute treatment of migraine in adolescents and children.
Topics: Administration, Intranasal; Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Humans; M | 2007 |
Sumatriptan fast-disintegrating/rapid-release tablets in the acute treatment of migraine.
Topics: Animals; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Humans; Migraine Disorder | 2007 |
Acute treatment of paediatric migraine: a meta-analysis of efficacy.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; | 2008 |
Over-the-counter triptans for migraine : what are the implications?
Topics: Germany; Humans; Migraine Disorders; Nonprescription Drugs; Piperidines; Serotonin Receptor Agonists | 2007 |
Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment.
Topics: Administration, Oral; Biological Availability; Humans; Infusions, Parenteral; Injections, Subcutaneo | 2007 |
[Current diagnosis and treatment of migraine].
Topics: Acupuncture Therapy; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Analgesics; Behavior Ther | 2008 |
Acute treatment and prevention of menstrually related migraine headache: evidence-based review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Double-Blind Method; Estrogens; Evidence-Based | 2008 |
[Sumatriptan ++ in the treatment of migraine and cluster headache].
Topics: Adolescent; Adult; Aged; Blood Proteins; Brain; Cluster Headache; Female; Humans; Kidney; Liver; Mal | 1995 |
[Treatment of the acute migraine attack].
Topics: Acute Disease; Dihydroergotamine; Ergotamine; Humans; Migraine Disorders; Serotonin Receptor Agonist | 1995 |
[Status migrainosus].
Topics: Brain; Dihydroergotamine; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Vaso | 1995 |
[Therapeutic strategies in menstrual migraine].
Topics: Brain; Ergotamine; Estradiol; Female; Hormones; Humans; Menopause; Menstrual Cycle; Menstruation; Mi | 1995 |
Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache.
Topics: Administration, Oral; Animals; Cluster Headache; Humans; Injections, Subcutaneous; Migraine Disorder | 1994 |
Treatment of cluster headache and its variants.
Topics: Cluster Headache; Humans; Hyperbaric Oxygenation; Injections, Subcutaneous; Migraine Disorders; Sero | 1995 |
Acute treatment of migraine attacks.
Topics: Adolescent; Adult; Analgesics; Child; Dihydroergotamine; Female; Humans; Male; Migraine Disorders; P | 1995 |
The mode of action of sumatriptan is vascular? A debate.
Topics: Animals; Cerebrovascular Circulation; Humans; Migraine Disorders; Nerve Endings; Sumatriptan; Trigem | 1994 |
[New serotonin-receptor drugs for migraine and nausea].
Topics: Humans; Migraine Disorders; Nausea; Serotonin Antagonists; Sumatriptan | 1993 |
[Sumatriptan ++].
Topics: Humans; Migraine Disorders; Sumatriptan | 1994 |
A review of current treatments for migraine.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Ergot Alkaloids; Humans; Migraine Disorders; Su | 1994 |
The clinical profile of sumatriptan: efficacy in migraine.
Topics: Administration, Oral; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administratio | 1994 |
The clinical profile of sumatriptan: safety and tolerability.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Drug Monitoring; Electrocardiography, Ambula | 1994 |
Sumatriptan clinical pharmacokinetics.
Topics: Animals; Biological Availability; Dose-Response Relationship, Drug; Drug Interactions; Half-Life; Hu | 1994 |
[Drug therapy of migraine--a review of the literature].
Topics: Adrenergic beta-Antagonists; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Calci | 1995 |
Migraine: a pharmacologic review with newer options and delivery modalities.
Topics: Administration, Intranasal; Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Bu | 1994 |
[Present problems of migraine and similar headaches].
Topics: Brain; Cranial Nerves; Humans; Migraine Disorders; Neurotransmitter Agents; Stress, Psychological; S | 1994 |
Migraine treatment: the British perspective.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Dihydroergotamine; Ergotamine; Humans; Migra | 1994 |
Overview of diagnosis and treatment of migraine.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antidepressiv | 1994 |
Headache.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ergotamine; Headache; Humans; Migraine Disorders; Sumatript | 1994 |
Clinical experiences from Sweden on the use of subcutaneously administered sumatriptan in migraine and cluster headache.
Topics: Cardiovascular Diseases; Central Nervous System Diseases; Cluster Headache; Humans; Injections, Subc | 1994 |
[Therapy of migraine with special reference to sumatriptan].
Topics: Cluster Headache; Drug Interactions; Humans; Migraine Disorders; Receptors, Serotonin; Sumatriptan | 1994 |
[Migraine--summary of diagnostic and therapeutic strategies].
Topics: Humans; International Cooperation; Migraine Disorders; Risk Factors; Sumatriptan | 1994 |
Recent advances in the acute management of migraine and cluster headaches.
Topics: Analgesics; Butorphanol; Capsaicin; Cluster Headache; Dihydroergotamine; Humans; Ketorolac; Metoclop | 1994 |
Sumatriptan.
Topics: Administration, Oral; Clinical Trials as Topic; Humans; Indoles; Injections, Subcutaneous; Migraine | 1993 |
Drug therapy of migraine.
Topics: Adrenergic alpha-Antagonists; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel B | 1993 |
[Sumatriptan and cardiac complaints. Careful cardiac anamnesis is needed prior to treatment].
Topics: Cardiovascular Diseases; Coronary Disease; Humans; Migraine Disorders; Sumatriptan | 1994 |
[Treatment of acute migraine with sumatriptan. Clinical experiences with advantages and disadvantages].
Topics: Acute Disease; Humans; Injections, Subcutaneous; Migraine Disorders; Serotonin Antagonists; Sumatrip | 1993 |
[Treatment of migraine attacks with sumatriptan].
Topics: Administration, Oral; Humans; Injections, Subcutaneous; Migraine Disorders; Sumatriptan | 1993 |
Sumatriptan: a novel therapy for the management of acute migraine.
Topics: Acute Disease; Humans; Migraine Disorders; Randomized Controlled Trials as Topic; Sumatriptan | 1993 |
Recent advances in migraine management.
Topics: Analgesics; Ergotamine; Humans; Indoles; Migraine Disorders; Serotonin Receptor Agonists; Sulfonamid | 1993 |
Sumatriptan in the acute treatment of migraine.
Topics: Acute Disease; Humans; Indoles; Migraine Disorders; Serotonin Receptor Agonists; Sulfonamides; Sumat | 1993 |
Sumatriptan: a new serotonin agonist for the treatment of migraine headache.
Topics: Humans; Indoles; Migraine Disorders; Serotonin Receptor Agonists; Sulfonamides; Sumatriptan | 1993 |
[Sumatriptan in the treatment of acute migraine attacks].
Topics: Administration, Oral; Humans; Indoles; Injections, Subcutaneous; Long-Term Care; Migraine Disorders; | 1993 |
Therapeutic advances in migraine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dihydroergotamine; Female; Humans; Indoles; Male; Migraine | 1993 |
SUMATRIPTAN: a receptor-targeted treatment for migraine.
Topics: Clinical Trials as Topic; Humans; Indoles; Migraine Disorders; Serotonin Receptor Agonists; Sulfonam | 1993 |
The therapeutics of migraine.
Topics: Brain; Humans; Indoles; Migraine Disorders; Neurons; Serotonin Receptor Agonists; Sulfonamides; Suma | 1993 |
[Sumatriptan in clinical practice].
Topics: Adolescent; Adult; Child; Cluster Headache; Humans; Indoles; Migraine Disorders; Myocardial Ischemia | 1993 |
Neurogenic inflammation in the pathophysiology and treatment of migraine.
Topics: Blood Proteins; Gene Expression; Genes, fos; Humans; Indoles; Inflammation; Migraine Disorders; Sero | 1993 |
Acute and prophylactic treatment of migraine: practical approaches and pharmacologic rationale.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dihydroergotamine; Ergotamine; Humans; Indoles; Migraine Di | 1993 |
5-Hydroxytryptamine receptor subtypes and the pharmacology of migraine.
Topics: Adenylyl Cyclases; Dihydroergotamine; Humans; Indoles; Migraine Disorders; Receptors, Serotonin; Ser | 1993 |
Sumatriptan in the treatment of migraine.
Topics: Humans; Indoles; Migraine Disorders; Serotonin Receptor Agonists; Sulfonamides; Sumatriptan | 1993 |
Clinical and experimental effects of sumatriptan in humans.
Topics: Animals; Humans; Indoles; Migraine Disorders; Muscle, Smooth, Vascular; Serotonin Receptor Agonists; | 1993 |
On serotonin and migraine: a clinical and pharmacological review.
Topics: Blood Platelets; Humans; Indoles; Migraine Disorders; Receptors, Serotonin; Serotonin; Serotonin Rec | 1993 |
Sumatriptan for the treatment of migraine attacks--a review of controlled clinical trials.
Topics: Humans; Indoles; Migraine Disorders; Randomized Controlled Trials as Topic; Serotonin Receptor Agoni | 1993 |
Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience.
Topics: Clinical Trials as Topic; Cluster Headache; Humans; Migraine Disorders; Serotonin Receptor Agonists; | 1995 |
Pharmacologic treatment of recurrent pediatric headache.
Topics: Acetaminophen; Adolescent; Adrenal Cortex Hormones; Analgesics; Aspirin; Child; Child, Preschool; Er | 1995 |
Approach to the patient with migraine.
Topics: Analgesics, Non-Narcotic; Antipyrine; Chloral Hydrate; Drug Combinations; Drug Therapy, Combination; | 1996 |
Mechanisms and functions of serotonin neuronal systems: opportunities for neuropeptide interactions.
Topics: Animals; Central Nervous System; Corticotropin-Releasing Hormone; Female; Mental Disorders; Migraine | 1996 |
[Drug treatment of migraine attacks. Pharmacological considerations].
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Ergotamines; Humans; Migraine Disorders; Seroto | 1996 |
Drug treatment of migraine: acute treatment and migraine prophylaxis.
Topics: Humans; Migraine Disorders; Sumatriptan; Time Factors | 1996 |
Emergency treatment of migraine. Insights into current options.
Topics: Acute Disease; Analgesics; Diagnosis, Differential; Emergency Service, Hospital; Ergotamine; Humans; | 1997 |
Serotonin 1D (5-HT1D) agonists and other agents in acute migraine.
Topics: Acute Disease; Analgesics, Non-Narcotic; Cluster Headache; Dihydroergotamine; Drug Interactions; Hum | 1997 |
Increasing the options for effective migraine management.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Ergotamine; Humans; Migraine Disorders; Oxazol | 1997 |
Evolution of the measurement of quality of life in migraine.
Topics: Attitude to Health; Emotions; Headache; Health Status; Humans; Mental Health; Migraine Disorders; Pa | 1997 |
Acute migraine therapy: the newer drugs.
Topics: Acute Disease; Animals; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan | 1997 |
Sumatriptan relieves migrainelike headaches associated with carbon monoxide exposure.
Topics: Carbon Monoxide Poisoning; Environmental Exposure; Female; Humans; Middle Aged; Migraine Disorders; | 1997 |
Diagnosis, prophylaxis, and treatment of headaches in the athlete.
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Tricyclic; | 1997 |
[Physiopathology of migraine].
Topics: Brain; Humans; Migraine Disorders; Serotonin; Serotonin Receptor Agonists; Sumatriptan | 1998 |
Quality of life in migraine.
Topics: Chronic Disease; Humans; Migraine Disorders; Quality of Life; Reproducibility of Results; Serotonin | 1998 |
Migraine.
Topics: Ergot Alkaloids; Humans; Migraine Disorders; Sumatriptan; Vasoconstrictor Agents | 1998 |
[Migraine and neurotransmitters].
Topics: GABA Agents; Indoles; Isoindoles; Migraine Disorders; Neurokinin-1 Receptor Antagonists; Neurotransm | 1998 |
Sumatriptan. An updated review of its use in migraine.
Topics: Administration, Intranasal; Administration, Oral; Administration, Rectal; Cerebrovascular Circulatio | 1998 |
Cardiac effects of sumatriptan: findings of Holter monitoring and review of the literature.
Topics: Adult; Aged; Arrhythmias, Cardiac; Cluster Headache; Electrocardiography, Ambulatory; Female; Humans | 1998 |
Migraine. More than a headache.
Topics: Humans; Migraine Disorders; Sumatriptan | 1998 |
Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types.
Topics: Administration, Intranasal; Adult; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Mult | 1998 |
Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat.
Topics: Administration, Intranasal; Administration, Oral; Double-Blind Method; Humans; Injections, Subcutane | 1998 |
[New triptan preparations can help the migraine patient. Pharmacodynamic and pharmacokinetic progresses].
Topics: Analgesics; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Migraine Disorders; Serotonin | 1998 |
[Clinical efficacy of zolmitriptan in migraine].
Topics: Adolescent; Adult; Aged; Humans; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Serotoni | 1998 |
Appropriate migraine therapy for children and adolescents.
Topics: Adolescent; Adult; Analgesics; Child; Clinical Trials as Topic; Female; Humans; Male; Migraine Disor | 1999 |
Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses.
Topics: Female; Humans; Menstruation Disturbances; Migraine Disorders; Prospective Studies; Randomized Contr | 1999 |
Current concepts of migraine and its treatment.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Serotonin Receptor A | 1999 |
Sumatriptan. A pharmacoeconomic review of its use in migraine.
Topics: Economics, Pharmaceutical; Humans; Migraine Disorders; Sumatriptan | 1997 |
[Anti-migraine treatment: present and future].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Forecasting; Humans; Injections, Subc | 1999 |
Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents.
Topics: Acute Disease; Animals; Clinical Trials as Topic; Coronary Circulation; Coronary Vasospasm; Drug Des | 1999 |
Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy.
Topics: Animals; Disease Models, Animal; Forecasting; Headache; Humans; Migraine Disorders; Models, Biologic | 1999 |
[The role of agonists of serotonin receptor 5HT1B/D in pathogenesis and treatment of migraine attacks].
Topics: Humans; Migraine Disorders; Receptors, Serotonin; Serotonin Receptor Agonists; Sumatriptan | 1999 |
[New therapies in neurology, but who benefits?].
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antiviral Agents; Carbamates; Humans; Interferon-b | 1999 |
Acute management of migraine: triptans and beyond.
Topics: Humans; Indoles; Migraine Disorders; Oxazoles; Oxazolidinones; Piperidines; Serotonin Receptor Agoni | 1999 |
Rizatriptan: a review of its efficacy in the management of migraine.
Topics: Administration, Oral; Clinical Trials as Topic; Humans; Migraine Disorders; Serotonin Receptor Agoni | 1999 |
The biology of serotonin receptors: focus on migraine pathophysiology and treatment.
Topics: Brain; Humans; Migraine Disorders; Receptors, Serotonin; Serotonin Receptor Agonists; Sumatriptan | 1999 |
The scientific basis of medication choice in symptomatic migraine treatment.
Topics: Acute Disease; Choice Behavior; Dose-Response Relationship, Drug; Humans; Indoles; Migraine Disorder | 1999 |
Migraine management. New approaches focus on serotonin receptors.
Topics: Adult; Brain Chemistry; Female; Humans; Male; Migraine Disorders; Nurse Practitioners; Receptors, Se | 1999 |
Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies.
Topics: Administration, Inhalation; Controlled Clinical Trials as Topic; Humans; Migraine Disorders; Sumatri | 1999 |
Newer intranasal migraine medications.
Topics: Administration, Intranasal; Administration, Oral; Analgesics, Non-Narcotic; Clinical Trials as Topic | 2000 |
Defining optimal dosing for sumatriptan tablets in the acute treatment of migraine.
Topics: Acute Disease; Administration, Oral; Clinical Trials as Topic; Dose-Response Relationship, Drug; Hum | 1999 |
Triptans. A support to the central link between serotonin and acetylcholine in migraine.
Topics: Acetylcholine; Analgesia; Analgesics; Animals; Brain; Humans; Migraine Disorders; Serotonin; Seroton | 1999 |
Are the triptans for migraine therapy worth the cost?
Topics: Cost-Benefit Analysis; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan | 2000 |
[Cardiovascular side-effects of triptanes in migraine exist but are rare. 5-HT receptor mediated extracranial vasoconstriction is the most common cause].
Topics: Contraindications; Coronary Disease; Humans; Migraine Disorders; Myocardial Infarction; Risk Assessm | 2000 |
Childhood migraine.
Topics: Analgesics; Antiemetics; Behavior Therapy; Child; Ergotamines; Female; Humans; Life Style; Male; Mig | 2000 |
Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Humans; Migraine Disorders; Pain; Placebos; R | 2000 |
Treatment of acute migraine attacks.
Topics: Analgesics; Ergotamine; Humans; Indoles; Migraine Disorders; Piperidines; Serotonin Receptor Agonist | 2000 |
[Role of serotonin and other neuroactive molecules in the physiopathogenesis of migraine. Current hypotheses].
Topics: Animals; Humans; Migraine Disorders; Neuropeptides; Neurotransmitter Agents; Polymorphism, Genetic; | 2000 |
[Emergency treatment of migraine attacks with particular reference to agonists of 5-HT1B/1D receptor].
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Emergency Treatment; E | 1999 |
[Clinical pharmacology of triptans].
Topics: Diagnosis, Differential; Drug Interactions; Humans; Indoles; Migraine Disorders; Pharmacies; Seroton | 2000 |
New abortive agents for the treatment of migraine.
Topics: Clinical Trials as Topic; Female; Humans; Indoles; Male; Migraine Disorders; Oxazolidinones; Piperid | 2001 |
[Migraine, ten years of progress].
Topics: Brain; Headache; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan | 2000 |
Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.
Topics: Animals; Biological Availability; Cardiovascular System; Dose-Response Relationship, Drug; Humans; M | 2000 |
Tolerability of sumatriptan: clinical trials and post-marketing experience.
Topics: Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Migraine Disor | 2000 |
The impact of pharmacogenetics for migraine.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Calcium Channels; Chromo | 2001 |
Rational migraine management: optimising treatment with the triptans.
Topics: Humans; Migraine Disorders; Randomized Controlled Trials as Topic; Serotonin Receptor Agonists; Suma | 2000 |
The effectiveness of combined oral lysine acetylsalicylate and metoclopramide (Migpriv) in the treatment of migraine attacks. Comparison with placebo and oral sumatriptan.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dopamine Antagonists; Drug Combinations; Humans; L | 2000 |
Drug comparisons: why are they so difficult?
Topics: Clinical Trials as Topic; Humans; Migraine Disorders; Sumatriptan | 2000 |
Evidence-based analysis of a migraine treatment drug comparison trial.
Topics: Adult; Clinical Trials as Topic; Evidence-Based Medicine; Female; Humans; Migraine Disorders; Sumatr | 2000 |
A systematic review of the use of triptans in acute migraine.
Topics: Acute Disease; Drug Interactions; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatript | 2001 |
Cluster headache: review of the literature.
Topics: Anticonvulsants; Clinical Protocols; Cluster Headache; Diagnosis, Differential; Humans; Migraine Dis | 2001 |
Neurogenic inflammation in the context of migraine.
Topics: Animals; Blood Proteins; Bosentan; Calcitonin Gene-Related Peptide; Capillary Permeability; Dihydroe | 2001 |
Complicated migraine and migraine variants.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Diagnosis, Differential; Dihydroergotami | 2001 |
Managing migraine: strategies for successful patient outcomes.
Topics: Acute Disease; Attitude to Health; Diagnosis, Differential; Information Services; Internet; Migraine | 2001 |
[Migraine: selection of therapeutic agents to be applied during its attack].
Topics: Analgesics; Antiemetics; Dihydroergotamine; Ergotamine; Humans; Migraine Disorders; Sumatriptan | 2001 |
[Migraine: sumatriptan].
Topics: Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Vasoconstrictor Agents | 2001 |
[Current topics: expectation for new triptans].
Topics: Humans; Indoles; Migraine Disorders; Oxazolidinones; Piperidines; Pyrrolidines; Serotonin Receptor A | 2001 |
[Anti-migraine drug sumatriptan succinate, a 5-HT1B/1D-receptor agonist].
Topics: Animals; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Vasoconstrictor Agent | 2001 |
Establishing a standard of speed for assessing the efficacy of the serotonin(1B/1D) agonists (triptans).
Topics: Analgesics, Non-Narcotic; Carbazoles; Clinical Trials as Topic; Humans; Indoles; Migraine Disorders; | 2001 |
Have the triptans fulfilled their promise?
Topics: Humans; Indoles; Migraine Disorders; Oxazolidinones; Piperidines; Serotonin Receptor Agonists; Sumat | 2001 |
Have the triptans fulfilled their promise?
Topics: Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan | 2001 |
Have the triptans fulfilled their promise?
Topics: Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan | 2001 |
What matters is not the differences between triptans, but the differences between patients.
Topics: Humans; Migraine Disorders; Oxazolidinones; Serotonin Receptor Agonists; Sumatriptan; Triazoles; Try | 2001 |
Efficacy of sumatriptan in the treatment of migraine: a review of the literature.
Topics: Adult; Child; Clinical Trials as Topic; Humans; Migraine Disorders; Sumatriptan; Treatment Outcome | 2001 |
Comparison of rizatriptan and other triptans on stringent measures of efficacy.
Topics: Administration, Oral; Humans; Indoles; Migraine Disorders; Oxazolidinones; Patient Satisfaction; Pip | 2001 |
Clinical efficacy and tolerability of sumatriptan tablet and suppository in the acute treatment of migraine: a review of data from clinical trials.
Topics: Acute Disease; Administration, Oral; Clinical Trials as Topic; Humans; Migraine Disorders; Sumatript | 2001 |
The sumatriptan nasal spray: a review of clinical trials.
Topics: Administration, Intranasal; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Migr | 2001 |
Patient satisfaction with rizatriptan versus other triptans: direct head-to-head comparisons.
Topics: Adolescent; Adult; Aged; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Humans; M | 2001 |
[Treatment of idiopathic headache in childhood - recommendations of the German Migraine and Headache Society (DMKG)].
Topics: Acetaminophen; Adrenergic beta-Antagonists; Age Factors; Analgesics, Non-Narcotic; Biofeedback, Psyc | 2002 |
Almotriptan versus sumatriptan in migraine treatment: direct medical costs of managing adverse chest symptoms.
Topics: Chest Pain; Drug Costs; Electrocardiography; Humans; Indoles; Migraine Disorders; Serotonin Receptor | 2002 |
Pharmacoeconomic evidence and considerations for triptan treatment of migraine.
Topics: Cost of Illness; Drug Costs; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan | 2002 |
Acute treatment of migraine and the role of triptans.
Topics: Acute Disease; Blood Flow Velocity; Carbazoles; Clinical Trials as Topic; Drug Administration Routes | 2001 |
Almotriptan reduces the incidence of migraine-associated symptoms: a pooled analysis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Clinical Trials, Phase III as Topic; Female; Humans; | 2002 |
Is there a preferred triptan?
Topics: Humans; Migraine Disorders; Patient Acceptance of Health Care; Serotonin Receptor Agonists; Sumatrip | 2002 |
Practical approaches to migraine management.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Analgesics, Opioid; Anesthetics, Local; Anti | 2002 |
Integrating the triptans into clinical practice.
Topics: Consumer Behavior; Drug Administration Routes; Drug Tolerance; Humans; Migraine Disorders; Nausea; S | 2002 |
[The latest in headache treatment].
Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics; Analgesics, Non-Narcotic; Angiotensin-Converting | 2002 |
Sumatriptan: a selective 5-hydroxytryptamine receptor agonist for the acute treatment of migraine.
Topics: Clinical Trials as Topic; Drug Interactions; Female; Humans; Indoles; Migraine Disorders; Pregnancy; | 1992 |
Headache and migraine.
Topics: Arousal; Brain; Electroencephalography; Headache; Humans; Indoles; Migraine Disorders; Regional Bloo | 1992 |
Clinical effects and mechanism of action of sumatriptan in migraine.
Topics: Animals; Brain; Cluster Headache; Dose-Response Relationship, Drug; Humans; Indoles; Migraine Disord | 1992 |
[Migraine: new aspects on physiopathology and research].
Topics: Calcitonin Gene-Related Peptide; Cerebrovascular Circulation; Humans; Indoles; Migraine Disorders; R | 1992 |
[Management of migraine].
Topics: Adolescent; Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Con | 1992 |
[Current treatment of migraine].
Topics: Adult; Child; Dihydroergotamine; Ergotamine; Female; Humans; Indoles; Male; Methysergide; Metoclopra | 1992 |
From serotonin receptor classification to the antimigraine drug sumatriptan.
Topics: Animals; Dogs; Drug Design; History, 20th Century; Humans; Indoles; Migraine Disorders; Receptors, S | 1992 |
Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine.
Topics: Ergot Alkaloids; Humans; Indoles; Migraine Disorders; Pain; Proto-Oncogene Proteins c-fos; Serotonin | 1992 |
Sumatriptan: a new approach to migraine.
Topics: Animals; Humans; Indoles; Migraine Disorders; Serotonin Receptor Agonists; Sulfonamides; Sumatriptan | 1992 |
Management of headache.
Topics: Diagnosis, Differential; Headache; Humans; Indoles; Migraine Disorders; Sulfonamides; Sumatriptan; V | 1992 |
Sumatriptan: a new drug for vascular headache.
Topics: Cluster Headache; Humans; Indoles; Migraine Disorders; Serotonin Receptor Agonists; Sulfonamides; Su | 1992 |
Sumatriptan: efficacy and contribution to migraine mechanisms.
Topics: Administration, Oral; Animals; Brain; Humans; Indoles; Injections, Subcutaneous; Migraine Disorders; | 1992 |
[The role of serotonin in the pathophysiology of migraine].
Topics: Animals; Blood Platelets; Humans; Indoles; Migraine Disorders; Serotonin; Serotonin Receptor Agonist | 1992 |
[Sumatriptan and its use in treatment of migraine and cluster headaches].
Topics: Cluster Headache; Humans; Indoles; Migraine Disorders; Serotonin Receptor Agonists; Sulfonamides; Su | 1992 |
[Sumatriptan--future development, alternative features and potential new indications].
Topics: Administration, Oral; Cluster Headache; Humans; Indoles; Injections, Subcutaneous; Migraine Disorder | 1992 |
[Serotonin agonists and antagonists in migraine].
Topics: Benzoxepins; Contraindications; Cyproheptadine; Dihydroergotamine; Ergotamine; Histamine H1 Antagoni | 1992 |
Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache.
Topics: Acute Disease; Animals; Cluster Headache; Humans; Indoles; Migraine Disorders; Serotonin; Sulfonamid | 1992 |
The trigemino-vascular system and migraine.
Topics: Blood Proteins; Calcitonin Gene-Related Peptide; Cerebrovascular Disorders; Cranial Nerve Diseases; | 1992 |
The pathophysiology of migraine: a tentative synthesis.
Topics: Brain Stem; Calcitonin Gene-Related Peptide; Cerebrovascular Circulation; Cerebrovascular Disorders; | 1992 |
Rationale for the use of 5-HT1-like agonists in the treatment of migraine.
Topics: Animals; Blood Proteins; Carotid Arteries; Humans; Indoles; Migraine Disorders; Receptors, Serotonin | 1991 |
Pharmacology of antimigraine drugs.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Ergot Alkaloids; Humans; Indoles; | 1991 |
Preclinical studies on the anti-migraine drug, sumatriptan.
Topics: Animals; Drug Evaluation, Preclinical; Hemodynamics; Indoles; Migraine Disorders; Receptors, Seroton | 1991 |
[Migraine crisis: current physiopathological and therapeutic aspects].
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Cerebrovascular Circulation; Drug | 1991 |
Serotonin receptor subtypes and neuropsychiatric diseases: focus on 5-HT1D and 5-HT3 receptor agents.
Topics: Animals; Humans; Indoles; Migraine Disorders; Models, Molecular; Receptors, Serotonin; Serotonin Ant | 1991 |
Mode of action of the anti-migraine drug sumatriptan.
Topics: Animals; Cerebral Arteries; Humans; Indoles; Migraine Disorders; Sulfonamides; Sumatriptan; Vasocons | 1991 |
The pharmacology of current anti-migraine drugs.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Humans; Indoles; Migraine Disorders; Receptor | 1990 |
Sumatriptan in acute migraine: pharmacology and review of world experience.
Topics: Acute Disease; Administration, Oral; Animals; Cluster Headache; Humans; Indoles; Injections, Subcuta | 1990 |
296 trials available for sumatriptan and Abdominal Migraine
| Article | Year |
|---|---|
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain.
Topics: Adult; Double-Blind Method; Humans; Migraine Disorders; Pain; Pyridines; Sumatriptan; Treatment Outc | 2022 |
Sumatriptan prevents central sensitization specifically in the trigeminal dermatome in humans.
Topics: Capsaicin; Central Nervous System Sensitization; Headache; Humans; Hyperalgesia; Migraine Disorders; | 2022 |
Sumatriptan Does Not Antagonize CGRP-Induced Symptoms in Healthy Volunteers.
Topics: Adult; Calcitonin Gene-Related Peptide; Cross-Over Studies; Double-Blind Method; Female; Healthy Vol | 2020 |
[The efficacy of the second generation triptan migrepam in the treatment of migraine attacks: results of the comparative study].
Topics: Adolescent; Adult; Aged; Humans; Middle Aged; Migraine Disorders; Prospective Studies; Quality of Li | 2019 |
Subcutaneous sumatriptan reduces cilostazol induced headache in migraine patients.
Topics: Adult; Cilostazol; Cross-Over Studies; Double-Blind Method; Female; Humans; Injections, Subcutaneous | 2020 |
Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans.
Topics: Adult; Calcitonin Gene-Related Peptide Receptor Antagonists; Cross-Over Studies; Drug Interactions; | 2020 |
Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial.
Topics: Adolescent; Adult; Cross-Over Studies; Double-Blind Method; Humans; Incidence; Middle Aged; Migraine | 2021 |
Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Aged; Comparative Effectiveness | 2017 |
Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the CO
Topics: Administration, Intranasal; Administration, Oral; Adult; Cross-Over Studies; Disability Evaluation; | 2017 |
AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial.
Topics: Administration, Intranasal; Adult; Antiemetics; Cross-Over Studies; Double-Blind Method; Female; Hum | 2018 |
Cilostazol induced migraine does not respond to sumatriptan in a double blind trial.
Topics: Adult; Cilostazol; Cross-Over Studies; Cyclic AMP; Double-Blind Method; Female; Humans; Male; Middle | 2018 |
Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers.
Topics: Adult; Antibodies, Monoclonal, Humanized; Blood Pressure; Calcitonin Gene-Related Peptide Receptor A | 2019 |
DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
Topics: Acute Disease; Adult; Double-Blind Method; Excipients; Female; Humans; Male; Maltose; Middle Aged; M | 2018 |
Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Migraine Di | 2018 |
Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study.
Topics: Adolescent; Adult; Double-Blind Method; Female; Humans; Hyperacusis; Injections, Subcutaneous; Male; | 2018 |
Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers.
Topics: Adult; Cilostazol; Cross-Over Studies; Double-Blind Method; Female; Headache; Healthy Volunteers; Hu | 2018 |
Meningeal contribution to migraine pain: a magnetic resonance angiography study.
Topics: Adolescent; Adult; Carotid Arteries; Cilostazol; Female; Headache; Humans; Magnetic Resonance Angiog | 2019 |
Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity.
Topics: Adolescent; Adult; Aspirin; Double-Blind Method; Humans; Hyperalgesia; Middle Aged; Migraine Disorde | 2019 |
DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; | 2019 |
Evaluating Mean Level and Within-Person Consistency in Migraine Pain Intensity and Migraine-Related Disability for AVP-825 vs Oral Sumatriptan: Results from the COMPASS Study, A Randomized Trial.
Topics: Acute Disease; Administration, Intranasal; Administration, Oral; Adult; Cross-Over Studies; Double-B | 2019 |
Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging.
Topics: Adult; Animals; Brain; Cilostazol; Dextrans; Female; Humans; Inflammation; Macrophages; Magnetic Res | 2019 |
Evaluation of sumatriptan-naproxen in the treatment of acute migraine: a placebo-controlled, double-blind, cross-over study assessing cognitive function.
Topics: Adult; Analgesics; Cognition; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle A | 2013 |
Ictal adiponectin levels in episodic migraineurs: a randomized pilot trial.
Topics: Adiponectin; Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Body Composition; Choles | 2013 |
Efficacy endpoints in migraine clinical trials: the importance of assessing freedom from pain.
Topics: Humans; Migraine Disorders; Pain; Pain Management; Pain Measurement; Patient Satisfaction; Research | 2013 |
Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: results from a randomized study in patients with migraine.
Topics: Adult; Analgesics; Azepines; Blood Pressure; Calcitonin Gene-Related Peptide Receptor Antagonists; C | 2013 |
Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks.
Topics: Acute Disease; Adult; Anticonvulsants; Double-Blind Method; Female; Humans; Male; Middle Aged; Migra | 2014 |
BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Pep | 2014 |
Treatment of chronic migraine: a 3-month comparator study of naproxen sodium vs SumaRT/Nap.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Double-Blind Meth | 2014 |
SumaRT/Nap vs naproxen sodium in treatment and disease modification of migraine: a pilot study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Female; Follow- | 2014 |
Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination.
Topics: Adult; Analgesics; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Male; | 2014 |
Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study.
Topics: Administration, Oral; Adolescent; Child; Double-Blind Method; Female; Humans; Japan; Male; Migraine | 2014 |
Promethazine plus sumatriptan in the treatment of migraine: a randomized clinical trial.
Topics: Adult; Double-Blind Method; Drug Therapy, Combination; Female; Histamine H1 Antagonists; Humans; Mal | 2014 |
Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Double-Blind Method; Drug Admini | 2014 |
The Efficacy of Propofol vs. Subcutaneous Sumatriptan for Treatment of Acute Migraine Headaches in the Emergency Department: A Double-Blinded Clinical Trial.
Topics: Adult; Aged; Anesthetics, Intravenous; Double-Blind Method; Emergency Service, Hospital; Female; Hum | 2015 |
A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Chemistry, Pharmaceutical; Double-Blind Method; | 2015 |
Theory-based analysis of clinical efficacy of triptans using receptor occupancy.
Topics: Humans; Migraine Disorders; Oxazolidinones; Piperidines; Pyrrolidines; Serotonin 5-HT1 Receptor Agon | 2014 |
Ictal adipokines are associated with pain severity and treatment response in episodic migraine.
Topics: Adipokines; Adult; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Combinations; Female; Humans | 2015 |
Consistency of response to sumatriptan/naproxen sodium in a randomized placebo-controlled, cross-over study for the acute treatment of migraine in adolescence.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Cross-Over Studies; Double-Blind Method; | 2015 |
Toward a pragmatic migraine model for drug testing: I. Cilostazol in healthy volunteers.
Topics: Adolescent; Adult; Cilostazol; Cross-Over Studies; Double-Blind Method; Female; Healthy Volunteers; | 2016 |
AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
Topics: Administration, Intranasal; Administration, Oral; Adult; Cross-Over Studies; Double-Blind Method; Dr | 2015 |
Sumatriptan Iontophoretic Transdermal System Reduces Treatment-Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline - Results From a Randomized Controlled Trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Incidence; | 2015 |
Intravenous Valproate versus Subcutaneous Sumatriptan in Acute Migraine Attack.
Topics: Adult; Female; Humans; Male; Middle Aged; Migraine Disorders; Nausea; Recurrence; Sumatriptan; Valpr | 2015 |
A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Disability Evaluation; Double-Bl | 2016 |
Towards a pragmatic human migraine model for drug testing: 2. Isosorbide-5-mononitrate in healthy individuals.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Healthy Volunteers; Humans; Isosorbide Dinit | 2017 |
A human trigeminovascular biomarker for antimigraine drugs: A randomised, double-blind, placebo-controlled, crossover trial with sumatriptan.
Topics: Adult; Analgesics; Biomarkers; Blood Flow Velocity; Calcitonin Gene-Related Peptide; Cross-Over Stud | 2017 |
A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients.
Topics: Administration, Cutaneous; Adolescent; Adult; Area Under Curve; Child; Cross-Over Studies; Female; H | 2016 |
Acute migraine medication adherence, migraine disability and patient satisfaction: A naturalistic daily diary study.
Topics: Adult; Analgesics, Opioid; Disability Evaluation; Female; Humans; Male; Medical Records; Medication | 2017 |
Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorder | 2017 |
A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine.
Topics: Administration, Intranasal; Adult; Drug Combinations; Female; Humans; Male; Maltose; Middle Aged; Mi | 2017 |
Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine.
Topics: Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Migr | 2008 |
Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Cyclooxygenase Inhibitors; Female; Humans; Incidence; M | 2009 |
Zelrix: a novel transdermal formulation of sumatriptan.
Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Adult; Cross-Over Studi | 2009 |
Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine.
Topics: Adult; Cross-Over Studies; Female; Humans; Male; Migraine Disorders; Pain Measurement; Pain Threshol | 2009 |
Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 2009 |
Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 2009 |
Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 2009 |
Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 2009 |
Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 2009 |
Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 2009 |
Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 2009 |
Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 2009 |
Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 2009 |
Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 2009 |
Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 2009 |
Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 2009 |
Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 2009 |
Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 2009 |
Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 2009 |
Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 2009 |
Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials.
Topics: Administration, Oral; Adult; Double-Blind Method; Drug Combinations; Dysmenorrhea; Female; Humans; M | 2009 |
Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials.
Topics: Administration, Oral; Adult; Double-Blind Method; Drug Combinations; Dysmenorrhea; Female; Humans; M | 2009 |
Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials.
Topics: Administration, Oral; Adult; Double-Blind Method; Drug Combinations; Dysmenorrhea; Female; Humans; M | 2009 |
Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials.
Topics: Administration, Oral; Adult; Double-Blind Method; Drug Combinations; Dysmenorrhea; Female; Humans; M | 2009 |
Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device.
Topics: Absorption; Administration, Intranasal; Adult; Drug Delivery Systems; Electroencephalography; Female | 2009 |
Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study.
Topics: Adult; Analgesics; Benzamides; Benzopyrans; Double-Blind Method; Female; Humans; Male; Migraine Diso | 2009 |
Subcutaneous sumatriptan pharmacokinetics: delimiting the monoamine oxidase inhibitor effect.
Topics: Brain; Computer Simulation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions | 2010 |
[Trimigren in stopping migraine attacks: an open prospective multicenter comparative study of rectal suppository and tablet forms of sumatriptan].
Topics: Administration, Oral; Administration, Rectal; Adult; Aged; Disease Progression; Dose-Response Relati | 2009 |
A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department.
Topics: Adult; Akathisia, Drug-Induced; Analgesics; Conscious Sedation; Diphenhydramine; Double-Blind Method | 2010 |
A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department.
Topics: Adult; Akathisia, Drug-Induced; Analgesics; Conscious Sedation; Diphenhydramine; Double-Blind Method | 2010 |
A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department.
Topics: Adult; Akathisia, Drug-Induced; Analgesics; Conscious Sedation; Diphenhydramine; Double-Blind Method | 2010 |
A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department.
Topics: Adult; Akathisia, Drug-Induced; Analgesics; Conscious Sedation; Diphenhydramine; Double-Blind Method | 2010 |
Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine.
Topics: Acute Disease; Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biological Avai | 2010 |
Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan.
Topics: Adult; Analgesics; Double-Blind Method; Emergency Service, Hospital; Female; Headache; Humans; Male; | 2010 |
Changes in salivary prostaglandin levels during menstrual migraine with associated dysmenorrhea.
Topics: Adult; Double-Blind Method; Dysmenorrhea; Female; Humans; Middle Aged; Migraine Disorders; Naproxen; | 2010 |
Changes in salivary prostaglandin levels during menstrual migraine with associated dysmenorrhea.
Topics: Adult; Double-Blind Method; Dysmenorrhea; Female; Humans; Middle Aged; Migraine Disorders; Naproxen; | 2010 |
Changes in salivary prostaglandin levels during menstrual migraine with associated dysmenorrhea.
Topics: Adult; Double-Blind Method; Dysmenorrhea; Female; Humans; Middle Aged; Migraine Disorders; Naproxen; | 2010 |
Changes in salivary prostaglandin levels during menstrual migraine with associated dysmenorrhea.
Topics: Adult; Double-Blind Method; Dysmenorrhea; Female; Humans; Middle Aged; Migraine Disorders; Naproxen; | 2010 |
Migraine recurrence is not associated with depressive or anxiety symptoms. Results of a randomized controlled trial.
Topics: Adult; Anxiety; Cross-Over Studies; Depression; Double-Blind Method; Female; Humans; Male; Middle Ag | 2010 |
Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study.
Topics: Administration, Inhalation; Administration, Intranasal; Adult; Female; Humans; Male; Middle Aged; Mi | 2010 |
Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Di | 2011 |
Migraine headaches in chronic fatigue syndrome (CFS): comparison of two prospective cross-sectional studies.
Topics: Adult; Comorbidity; Cross-Sectional Studies; Fatigue Syndrome, Chronic; Female; Fibromyalgia; Humans | 2011 |
Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes.
Topics: Adult; Analgesics; Double-Blind Method; Drug Combinations; Dysmenorrhea; Female; Humans; Migraine Di | 2011 |
Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes.
Topics: Adult; Analgesics; Double-Blind Method; Drug Combinations; Dysmenorrhea; Female; Humans; Migraine Di | 2011 |
Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes.
Topics: Adult; Analgesics; Double-Blind Method; Drug Combinations; Dysmenorrhea; Female; Humans; Migraine Di | 2011 |
Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes.
Topics: Adult; Analgesics; Double-Blind Method; Drug Combinations; Dysmenorrhea; Female; Humans; Migraine Di | 2011 |
Long-term evaluation of sumatriptan and naproxen sodium for the acute treatment of migraine in adolescents.
Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Drug Therapy, Combination | 2011 |
Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptans.
Topics: Adolescent; Adult; Aged; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Migraine Disor | 2011 |
Sumatriptan-naproxen migraine efficacy in allodynic patients: early intervention.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Disability Evaluation; Drug Therap | 2012 |
Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidence.
Topics: Adolescent; Adult; Aged; Drug Administration Routes; Drug Delivery Systems; Female; Humans; Male; Mi | 2011 |
Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
Topics: Adolescent; Adult; Aged; Barbiturates; Cross-Over Studies; Double-Blind Method; Drug Combinations; F | 2012 |
Evaluation of the migraine treatment sumatriptan/naproxen sodium on blood pressure following long-term administration.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Confidence Intervals; Double-Blind M | 2011 |
Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind M | 2012 |
Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Chemistry, Pharmaceutical; Female; Follow-Up Stu | 2012 |
Oral sumatriptan and almotriptan--delimiting the MAOI effect.
Topics: Administration, Oral; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Fem | 2012 |
Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine.
Topics: Adolescent; Child; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; | 2012 |
A sumatriptan iontophoretic transdermal system for the acute treatment of migraine.
Topics: Adult; Analgesics; Double-Blind Method; Female; Humans; Iontophoresis; Male; Migraine Disorders; Sum | 2012 |
A randomized controlled trial of a comprehensive migraine intervention prior to discharge from an emergency department.
Topics: Adult; Emergency Service, Hospital; Female; Headache; Humans; Male; Middle Aged; Migraine Disorders; | 2012 |
Comparison of tolerability and efficacy of a combination of paracetamol + caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Caffeine; Double-Blind Method; Drug Therapy, Combina | 2012 |
Efficacy, end points and eventualities: sumatriptan/naproxen versus butalbital/paracetamol/caffeine in the treatment of migraine.
Topics: Acetaminophen; Barbiturates; Caffeine; Double-Blind Method; Drug Combinations; Drug Therapy, Combina | 2012 |
An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan.
Topics: Adult; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Migraine Disorders; Sumatriptan; | 2013 |
Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Indoles; Male; M | 2002 |
Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study.
Topics: Adult; Double-Blind Method; Female; Humans; Indoles; Logistic Models; Male; Middle Aged; Migraine Di | 2002 |
Acupuncture versus placebo versus sumatriptan for early treatment of migraine attacks: a randomized controlled trial.
Topics: Acupuncture Therapy; Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorde | 2003 |
Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg.
Topics: Acute Disease; Adolescent; Adult; Double-Blind Method; Female; Humans; Indoles; Male; Middle Aged; M | 2003 |
Effect of autogenic training on drug consumption in patients with primary headache: an 8-month follow-up study.
Topics: Adolescent; Adult; Analgesics; Autogenic Training; Behavior Therapy; Combined Modality Therapy; Fema | 2003 |
Efficacy of sumatriptan nasal spray in recurrent migrainous headache: an open prospective study.
Topics: Administration, Inhalation; Adult; Female; Headache Disorders; Humans; Male; Migraine Disorders; Pro | 2003 |
Sumatriptan in migraine with unilateral cranial autonomic symptoms: an open study.
Topics: Adult; Autonomic Nervous System; Female; Humans; Male; Migraine Disorders; Reflex; Serotonin Recepto | 2003 |
Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan.
Topics: Administration, Oral; Adult; Aged; Double-Blind Method; Drug Tolerance; Female; Humans; Indoles; Mal | 2003 |
A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine.
Topics: Administration, Intranasal; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind | 2003 |
Pharmacokinetics of sumatriptan nasal spray in adolescents.
Topics: Administration, Intranasal; Adolescent; Age Factors; Area Under Curve; Body Weight; Chromatography, | 2003 |
Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Caffeine; Central Nervou | 2003 |
Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cross-Over Studies; Female; Humans; Male; Middle Aged | 2003 |
Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; M | 2003 |
Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine.
Topics: Administration, Oral; Adolescent; Adult; Aged; Double-Blind Method; Drug Administration Schedule; Fe | 2003 |
Onset of effect of 5-HT1B/1D agonists: a model with pharmacokinetic validation.
Topics: Dose-Response Relationship, Drug; Humans; Migraine Disorders; Models, Biological; Reproducibility of | 2004 |
Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial.
Topics: Administration, Intranasal; Adolescent; Child; Cross-Over Studies; Dose-Response Relationship, Drug; | 2004 |
Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study.
Topics: Adult; Female; Humans; Male; Migraine Disorders; Randomized Controlled Trials as Topic; Severity of | 2004 |
Pharmacokinetics of sumatriptan nasal spray in children.
Topics: Administration, Intranasal; Area Under Curve; Child; Female; Humans; Male; Metabolic Clearance Rate; | 2004 |
Almotriptan improves response rates when treatment is within 1 hour of migraine onset.
Topics: Acute Disease; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Indoles; Male; Middle A | 2004 |
Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Sumatripta | 2004 |
Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms.
Topics: Adolescent; Adult; Aged; Aspirin; Demography; Double-Blind Method; Female; Follow-Up Studies; Humans | 2004 |
Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database.
Topics: Adolescent; Adult; Analgesics, Non-Narcotic; Clinical Trials as Topic; Databases, Factual; Double-Bl | 2004 |
Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan.
Topics: Adolescent; Adult; Aged; Chi-Square Distribution; Confidence Intervals; Drug Administration Schedule | 2004 |
Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks.
Topics: Adult; Aspirin; Chemistry, Pharmaceutical; Chi-Square Distribution; Confidence Intervals; Cross-Over | 2004 |
Sumatriptan (5-HT1B/1D-agonist) causes a transient allodynia.
Topics: Adult; Cold Temperature; Cross-Sectional Studies; Female; Hot Temperature; Humans; Hyperalgesia; Mal | 2004 |
Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine.
Topics: Adolescent; Adult; Aged; Dizziness; Double-Blind Method; Fatigue; Female; Humans; Menstrual Cycle; M | 2004 |
Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan.
Topics: Administration, Oral; Adolescent; Adult; Cross-Over Studies; Female; Humans; Indoles; Injections, Su | 2005 |
Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Double-Blind Method; Drug Tolerance; Female; Hu | 2005 |
A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines.
Topics: Adult; Akathisia, Drug-Induced; Anti-Inflammatory Agents, Non-Steroidal; Diphenhydramine; Dizziness; | 2005 |
Effects of a fast disintegrating/rapid release oral formulation of sumatriptan on functional ability in patients with migraine.
Topics: Adult; Chemistry, Pharmaceutical; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine D | 2004 |
Pilot study evaluating preference for 3-mg versus 6-mg subcutaneous sumatriptan.
Topics: Adult; Aged; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Injections, Subcu | 2005 |
Anti-migraine action of triptans is preceded by transient aggravation of headache caused by activation of meningeal nociceptors.
Topics: Action Potentials; Adolescent; Adult; Animals; Dose-Response Relationship, Drug; Female; Humans; Mal | 2005 |
Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.
Topics: Adolescent; Adult; Aged; Female; Humans; Indoles; Male; Middle Aged; Migraine Disorders; Serotonin R | 2005 |
Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
Topics: Adult; Area Under Curve; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Double-Blind M | 2005 |
Multiple attack study on the available triptans in Italy versus placebo.
Topics: Adult; Female; Humans; Indoles; Italy; Male; Middle Aged; Migraine Disorders; Oxazolidinones; Pyrrol | 2005 |
Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Analysis of Variance; Anti-Inflammatory Agents, Non- | 2005 |
Sumatriptan and naproxen sodium for the acute treatment of migraine.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Synergism; | 2005 |
Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Tolerance; Female; H | 2005 |
Managing migraine headaches experienced by patients who self-report with menstrually related migraine: a prospective, placebo-controlled study with oral sumatriptan.
Topics: Administration, Oral; Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Luteal Phase; | 2005 |
Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients.
Topics: Administration, Oral; Adult; Adverse Drug Reaction Reporting Systems; Female; Humans; Injections, Su | 2005 |
Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study.
Topics: Acute Disease; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Migr | 2006 |
Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack.
Topics: Adult; Cross-Over Studies; Female; Headache; Humans; Injections, Subcutaneous; Male; Middle Aged; Mi | 2006 |
Intensive community pharmacy intervention had little impact on triptan consumption: a randomized controlled trial.
Topics: Adult; Denmark; Drug Prescriptions; Drug Utilization; Education, Pharmacy, Continuing; Female; Heada | 2006 |
Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study.
Topics: Acute Disease; Administration, Inhalation; Administration, Intranasal; Adolescent; Dose-Response Rel | 2006 |
Does earlier headache response equate to earlier return to functioning in patients suffering from migraine?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Comorbidity; Double-Blind Method; Female; Headache; Huma | 2006 |
Pain free efficacy of sumatriptan in the early treatment of migraine.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Pain; Serotonin R | 2006 |
The natural course of migraine attacks. A prospective analysis of untreated attacks compared with attacks treated with a triptan.
Topics: Adult; Aged; Comorbidity; Cross-Over Studies; Disease Progression; Female; Humans; Hyperacusis; Inci | 2006 |
A clinical trial of trimethobenzamide/diphenhydramine versus sumatriptan for acute migraines.
Topics: Acute Disease; Adult; Antiemetics; Benzamides; Diphenhydramine; Drug Combinations; Female; Humans; I | 2006 |
A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults.
Topics: Adolescent; Adult; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; | 2006 |
Prevalence of migraine and response to sumatriptan in patients self-reporting tension/stress headache.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Patient Selection; P | 2006 |
The impact of different antimigraine compounds on platelet and erythrocyte aggregation.
Topics: Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Over Studie | 2006 |
Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; | 2006 |
Sumatriptan 6 mg subcutaneous as an effective migraine treatment in patients with cutaneous allodynia who historically fail to respond to oral triptans.
Topics: Administration, Oral; Adult; Drug Tolerance; Female; Humans; Hyperesthesia; Injections, Subcutaneous | 2007 |
Sumatriptan and corneal reflexes in headache-free migraine patients: a randomized and placebo-controlled crossover study.
Topics: Adult; Area Under Curve; Blinking; Cornea; Cross-Over Studies; Female; Humans; Male; Migraine Disord | 2007 |
Twelve-month tolerability and safety of sumatriptan-naproxen sodium for the treatment of acute migraine.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; | 2007 |
Clarification of developing and established clinical allodynia and pain-free outcomes.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Female; Health Surveys; Humans; Hyperalgesia; Male; Mid | 2007 |
Intranasal sumatriptan study with high placebo response in Taiwanese patients with migraine.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Midd | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Combinations; Female; Huma | 2007 |
Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Migraine Dis | 2007 |
Sumatriptan/Naproxen sodium for migraine: efficacy, health related quality of life, and satisfaction outcomes.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; | 2007 |
The phe-124-Cys and A-161T variants of the human 5-HT1B receptor gene are not major determinants of the clinical response to sumatriptan.
Topics: Adult; Aged; Cysteine; DNA Mutational Analysis; Female; Gene Frequency; Genetic Variation; Humans; M | 2007 |
A unique iontophoretic patch for optimal transdermal delivery of sumatriptan.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Chemistry, Pharmaceutical; Drug Delivery Sys | 2007 |
Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, mu
Topics: Administration, Oral; Adolescent; Adult; Analgesics; Caffeine; Double-Blind Method; Drug Combination | 2007 |
Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomes.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Double-Blind Method; Drug Combinat | 2007 |
Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomes.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Double-Blind Method; Drug Combinat | 2007 |
Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomes.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Double-Blind Method; Drug Combinat | 2007 |
Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomes.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Double-Blind Method; Drug Combinat | 2007 |
Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis.
Topics: Adult; Brain; Brain Chemistry; Carbon Radioisotopes; Cerebral Cortex; Feedback, Physiological; Femal | 2008 |
The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group.
Topics: Adult; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Menstruation; Middle Aged; Mig | 1995 |
The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine.
Topics: Administration, Oral; Adolescent; Adult; Analgesics; Aspirin; Dopamine Antagonists; Double-Blind Met | 1995 |
Efficacy and tolerability of oral sumatriptan in the treatment of acute migraine.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Drug Tolerance; Female; Humans; Middle Aged; | 1995 |
Patient preferences for migraine therapy: subcutaneous sumatriptan compared with other medications.
Topics: Adult; Aged; Analgesics; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Migraine Disor | 1995 |
Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; | 1995 |
Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method | 1995 |
Oral sumatriptan for the long-term treatment of migraine: clinical findings.
Topics: Administration, Oral; Adolescent; Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Lo | 1995 |
Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; | 1995 |
[Sumatriptan treatment of migraine in general practice. A randomized, double-blind, placebo-controlled cross-over study].
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind Method; Family Practice; Female; Humans; I | 1995 |
Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Double-Blind Method; Emergency Service, Hospital; | 1995 |
Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences.
Topics: Administration, Oral; Adult; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male | 1994 |
Cerebral blood flow during migraine attacks without aura and effect of sumatriptan.
Topics: Adult; Aged; Brain; Double-Blind Method; Female; Hallucinations; Humans; Male; Middle Aged; Migraine | 1995 |
[Sumatriptan in the treatment of cluster headache and migraine attacks].
Topics: Adult; Chronic Disease; Cluster Headache; Humans; Injections, Subcutaneous; Male; Middle Aged; Migra | 1994 |
Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group.
Topics: Adult; Double-Blind Method; Female; Hallucinations; Humans; Injections, Subcutaneous; Male; Middle A | 1994 |
A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Male; Midd | 1994 |
Intranasal sumatriptan for the acute treatment of migraine. International Intranasal Sumatriptan Study Group.
Topics: Acute Disease; Administration, Intranasal; Adult; Double-Blind Method; Drug Tolerance; Female; Heada | 1994 |
Oral sumatriptan in the treatment of recurrent headache.
Topics: Administration, Oral; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Injections, Subc | 1994 |
[Sumatriptan in the treatment of migraine in general practice].
Topics: Adolescent; Adult; Aged; Double-Blind Method; Family Practice; Female; Humans; Male; Middle Aged; Mi | 1994 |
[Sumatriptan in the treatment of acute migraine: its role in primary health care].
Topics: Acute Disease; Administration, Oral; Algorithms; Aspirin; Caffeine; Double-Blind Method; Drug Therap | 1994 |
Sumatriptan.
Topics: Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Sumatriptan | 1994 |
Exteroceptive suppression of temporalis muscle activity during migraine attack and migraine interval before and after treatment with sumatriptan.
Topics: Adult; Double-Blind Method; Electromyography; Female; Humans; Middle Aged; Migraine Disorders; React | 1994 |
Oral sumatriptan compared with placebo in the acute treatment of migraine.
Topics: Acute Disease; Administration, Oral; Adult; Double-Blind Method; Female; Fever; Humans; Hypesthesia; | 1994 |
Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study.
Topics: Acute Disease; Adolescent; Adult; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antieme | 1994 |
Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. French Migraine Network Bordeaux-Lyon-Grenoble.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Dihydroergotamine; Double-Blind Method | 1993 |
Subcutaneous sumatriptan in acute treatment of migraine: a multicentre New Zealand trial.
Topics: Adult; Double-Blind Method; Female; Humans; Indoles; Injections, Subcutaneous; Male; Middle Aged; Mi | 1993 |
Efficacy of subcutaneous sumatriptan in repeated episodes of migraine.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Indoles; Injections, Subcutaneous; Mal | 1993 |
Familial occurrence of migraine without aura and migraine with aura.
Topics: Adult; Child; Child, Preschool; Double-Blind Method; Female; Humans; Indoles; Male; Middle Aged; Mig | 1993 |
Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. Early-Morning Migraine Sumatriptan Study Group.
Topics: Adult; Double-Blind Method; Female; Humans; Indoles; Injections, Subcutaneous; Male; Middle Aged; Mi | 1993 |
Long-term experience with sumatriptan in the treatment of migraine.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Mo | 1993 |
Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Menstruation | 1993 |
Health-related quality of life under six months' treatment of migraine--an open clinic-based longitudinal study.
Topics: Adrenergic beta-Antagonists; Adult; Female; Humans; Longitudinal Studies; Male; Medical Records; Mig | 1995 |
Introduction of a novel self-injector for sumatriptan. A controlled clinical trial in general practice.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Male | 1995 |
Comparison of subcutaneous sumatriptan with usual acute treatments for migraine. French Sumatriptan Study Group.
Topics: Adolescent; Adult; Aged; Analgesics; Cross-Over Studies; Double-Blind Method; Female; Humans; Inject | 1995 |
A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine.
Topics: Acute Disease; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Dihydroergotamine; Double-Blind Me | 1996 |
Response measures in the acute treatment of migraine.
Topics: Adult; Aged; Computer Simulation; Double-Blind Method; Humans; Middle Aged; Migraine Disorders; Pain | 1995 |
[Evaluation of the efficacy of oral sumatriptan in the management of migraine attacks. Clinical results].
Topics: Acute Disease; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Met | 1995 |
Moral crisis.
Topics: Acute Disease; Adolescent; Adult; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Migra | 1996 |
Treatment of acute migraine with sumatriptan--response in 40 consecutive patients.
Topics: Acute Disease; Adolescent; Adult; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Migra | 1996 |
A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine.
Topics: Administration, Intranasal; Adult; Dihydroergotamine; Double-Blind Method; Female; Humans; Injection | 1996 |
Changes in cerebral blood flow velocity after treatment with sumatriptan or placebo and implications for the pathophysiology of migraine.
Topics: Adult; Autonomic Nervous System Diseases; Blood Flow Velocity; Cerebrovascular Circulation; Cross-Ov | 1996 |
Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response.
Topics: Adolescent; Adult; Aged; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Mig | 1996 |
Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic, and clinical consequences.
Topics: Adolescent; Adult; Aged; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Inject | 1996 |
Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Mig | 1996 |
Oral sumatriptan in the acute treatment of migraine and migraine recurrence in general practice.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Double-Blind Method; Drug Administrati | 1996 |
Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine.
Topics: Activities of Daily Living; Adult; Efficiency; Employee Performance Appraisal; Female; Georgia; Huma | 1996 |
Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine.
Topics: Activities of Daily Living; Adult; Efficiency; Employee Performance Appraisal; Female; Georgia; Huma | 1996 |
Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine.
Topics: Activities of Daily Living; Adult; Efficiency; Employee Performance Appraisal; Female; Georgia; Huma | 1996 |
Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine.
Topics: Activities of Daily Living; Adult; Efficiency; Employee Performance Appraisal; Female; Georgia; Huma | 1996 |
A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine in general practice.
Topics: Acute Disease; Administration, Oral; Adult; Cross-Over Studies; Family Practice; Female; Humans; Inj | 1997 |
Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist.
Topics: Administration, Oral; Adult; Analysis of Variance; Blood Pressure; Double-Blind Method; Heart Rate; | 1997 |
Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults?
Topics: Administration, Oral; Adolescent; Child; Cross-Over Studies; Double-Blind Method; Female; Humans; Ma | 1997 |
[Zolmitriptan: new perspectives in migraine therapy. Satellite symposium of the 11th Migraine Trust International Symposium, London, 10 September 1996].
Topics: Blood-Brain Barrier; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Sumatriptan; Tryptamines | 1997 |
The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache.
Topics: Adolescent; Adult; Age of Onset; Aged; Double-Blind Method; Female; Humans; Injections, Subcutaneous | 1997 |
A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using 13NH3 positron emission tomography.
Topics: Adult; Aged; Analysis of Variance; Angina Pectoris; Coronary Circulation; Cross-Over Studies; Double | 1997 |
Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
Topics: Administration, Intranasal; Adolescent; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; | 1997 |
Intravenous chlorpromazine versus intramuscular sumatriptan for acute migraine.
Topics: Adolescent; Adult; Aged; Australia; Chlorpromazine; Cross-Over Studies; Dopamine Antagonists; Emerge | 1997 |
Oral and subcutaneous sumatriptan in the acute treatment of migraine: an open randomized cross-over study.
Topics: Administration, Oral; Adult; Cross-Over Studies; Female; Humans; Injections, Subcutaneous; Male; Mid | 1997 |
Responsiveness of non-IHS migraine and tension-type headache to sumatriptan.
Topics: Adult; Female; Humans; Longitudinal Studies; Male; Migraine Disorders; Serotonin Receptor Agonists; | 1997 |
Studies to assess if pizotifen prophylaxis improves migraine beyond the benefit offered by acute sumatriptan therapy alone.
Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Double-Blind Method; Drug Therapy, Combination; F | 1997 |
Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies.
Topics: Acute Disease; Administration, Intranasal; Adolescent; Adult; Aged; Disability Evaluation; Double-Bl | 1997 |
Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy.
Topics: Adolescent; Adult; Aged; Child; Dose-Response Relationship, Drug; Female; Humans; Menstruation; Midd | 1997 |
The way to serotonergic use and abuse in migraine.
Topics: Adult; Behavior; Double-Blind Method; Ergotamine; Female; Humans; Male; Methysergide; Middle Aged; M | 1997 |
[Treatment of acute attack of migraine with sumatriptan].
Topics: Acute Disease; Adolescent; Adult; Age Distribution; Double-Blind Method; Female; Humans; Male; Migra | 1997 |
Monitoring of acute migraine attacks: placebo response and safety data.
Topics: Acute Disease; Adult; Double-Blind Method; Electrocardiography, Ambulatory; Female; Humans; Male; Mi | 1998 |
Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male | 1998 |
Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study.
Topics: Acute Disease; Adult; Dosage Forms; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine | 1998 |
Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial.
Topics: Adult; Double-Blind Method; Efficiency; Female; Humans; Male; Migraine Disorders; Recurrence; Self A | 1998 |
[Evaluation of efficacy and tolerance sumatriptan at a dose of 50 mg in treatment of migraine attack].
Topics: Administration, Oral; Adult; Female; Humans; Male; Middle Aged; Migraine Disorders; Remission Induct | 1998 |
A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine.
Topics: Adult; Female; Humans; Menstruation Disturbances; Middle Aged; Migraine Disorders; Pilot Projects; S | 1998 |
Effect of operationalized computer diagnosis on the therapeutic results of sumatriptan in general practice.
Topics: Adolescent; Adult; Algorithms; Diagnosis, Computer-Assisted; Family Practice; Female; Humans; Male; | 1998 |
Succinate sumatriptan evaluation by Doppler echocardiography in patients with migraine.
Topics: Adult; Blood Pressure; Double-Blind Method; Drug Evaluation; Echocardiography, Doppler; Female; Hear | 1998 |
Safety trial with the 5HT1B/1D agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/or pain in the chest, neck, and/or throat following sumatriptan.
Topics: Adult; Chest Pain; Diagnosis, Differential; Electrocardiography; Electrocardiography, Ambulatory; Fe | 1998 |
Subcutaneous sumatriptan compared with usual acute treatments for migraine: clinical and pharmacoeconomic evaluation.
Topics: Absenteeism; Adolescent; Adult; Analgesics; Cost-Benefit Analysis; Drug Costs; Female; Humans; Injec | 1998 |
The pharmacodynamics of sumatriptan in nitroglycerin-induced headache.
Topics: Adult; Analysis of Variance; Area Under Curve; Brain; Cerebral Arteries; Electrocardiography; Headac | 1999 |
Effect of subcutaneous sumatriptan on head temperature in migraines.
Topics: Adult; Analysis of Variance; Blood Pressure; Body Temperature; Double-Blind Method; Electrocardiogra | 1998 |
Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine. A retrospective cost-efficacy analysis.
Topics: Adolescent; Adult; Aged; Cost-Benefit Analysis; Dihydroergotamine; Humans; Middle Aged; Migraine Dis | 1996 |
A multinational investigation of the impact of subcutaneous sumatriptan. I: Design, methods and clinical findings.
Topics: Adolescent; Adult; Aged; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Migraine Disor | 1997 |
A multinational investigation of the impact of subcutaneous sumatriptan. II: Health-related quality of life.
Topics: Adolescent; Adult; Aged; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Migraine Disor | 1997 |
A multinational investigation of the impact of subcutaneous sumatriptan. III: Workplace productivity and non-workplace activity.
Topics: Adolescent; Adult; Aged; Efficiency; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Mi | 1997 |
A multinational investigation of the impact of subcutaneous sumatriptan. IV: Patient satisfaction.
Topics: Adolescent; Adult; Aged; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Migraine Disor | 1997 |
Sumatriptan nasal spray: a dose-ranging study in the acute treatment of migraine.
Topics: Adult; Aerosols; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart; Humans; Hyper | 1999 |
Intranasal sumatriptan for the acute treatment of migraine in children.
Topics: Administration, Intranasal; Child; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Su | 1999 |
Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alcohol Drinking; Cardiovascular Diseases; Cerebrovascul | 1999 |
Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Dicl | 1999 |
Altered oesophageal motility following the administration of the 5-HT1 agonist, sumatriptan.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Esophageal Motility Disorders; Female; Humans; Male; | 1999 |
Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG St
Topics: Adult; Analgesics; Aspirin; Double-Blind Method; Female; Humans; Infusions, Intravenous; Injections, | 1999 |
[The efficacy of subcutaneous sumatriptan for the treatment of migraine attack].
Topics: Acute Disease; Adult; Dose-Response Relationship, Drug; Female; Humans; Injections, Subcutaneous; Ma | 1999 |
How to assess patient preference of migraine treatments.
Topics: Adult; Analgesics; Cross-Over Studies; Female; Humans; Male; Middle Aged; Migraine Disorders; Migrai | 1999 |
Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Analysis of Variance; Computer Simulation; Data Inter | 1999 |
Unbalanced randomization influences placebo response: scientific versus ethical issues around the use of placebo in migraine trials.
Topics: Double-Blind Method; Ethics, Medical; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Placebos | 1999 |
Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.
Topics: Acute Disease; Administration, Oral; Adult; Double-Blind Method; Female; Humans; Indoles; Male; Midd | 2000 |
No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Huma | 2000 |
Efficacy and safety of sumatriptan 50 mg in patients not responding to standard care, in the treatment of mild to moderate migraine. The Sumatriptan 50 mg Italian Study Group.
Topics: Adolescent; Adult; Aged; Analgesics; Double-Blind Method; Drug Resistance; Humans; Italy; Middle Age | 1999 |
A double-blind placebo-controlled study assessing the efficacy and tolerability of 50 mg sumatriptan tablets in the acute treatment of migraine. Sumatriptan Tablets S2CM07 Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Migr | 1999 |
Patient preference for oral sumatriptan 25 mg, 50 mg, or 100 mg in the acute treatment of migraine: a double-blind, randomized, crossover study. Sumatriptan Tablets S2CM11 Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind Metho | 1999 |
A dose-defining study of sumatriptan suppositories in the acute treatment of migraine.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male | 1999 |
A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; M | 2000 |
Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; | 2000 |
Effects of the anti-migraine drug sumatriptan on muscle energy metabolism: relationship to side-effects.
Topics: Adenosine Triphosphate; Adult; Creatine Kinase; Energy Metabolism; Female; Humans; Magnetic Resonanc | 2000 |
Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial.
Topics: Administration, Oral; Cross-Over Studies; Drug Resistance; Humans; Migraine Disorders; Oxazoles; Oxa | 2000 |
[Sumatriptan nasal spray 20mg: efficacy, tolerance and quality of life in migraine patients].
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Migraine Dis | 2000 |
Naproxen sodium decreases migraine recurrence when administered with sumatriptan.
Topics: Acute Disease; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug | 2000 |
Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial.
Topics: Adult; Cost-Benefit Analysis; Double-Blind Method; Efficiency; Female; Humans; Injections, Subcutane | 2000 |
A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine.
Topics: Adult; Aged; Belgium; Cross-Over Studies; Dihydroergotamine; Double-Blind Method; Female; France; Hu | 2000 |
Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Indoles; Middle Ag | 2000 |
Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Humans; Migraine Disorders; Pain; Placebos; R | 2000 |
Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches.
Topics: Adult; Analysis of Variance; Blood Flow Velocity; Blood Pressure; Brachial Artery; Carotid Artery, C | 2000 |
A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents.
Topics: Acute Disease; Administration, Intranasal; Adolescent; Adult; Age Factors; Child; Double-Blind Metho | 2000 |
One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study.
Topics: Administration, Intranasal; Adolescent; Child; Dose-Response Relationship, Drug; Female; Humans; Mal | 2000 |
The effectiveness of combined oral lysine acetylsalicylate and metoclopramide (Migpriv) in the treatment of migraine attacks. Comparison with placebo and oral sumatriptan.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dopamine Antagonists; Drug Combinations; Humans; L | 2000 |
Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Indoles; Male; Middle Aged; Migraine D | 2001 |
Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; | 2000 |
Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine.
Topics: Adult; Cross-Over Studies; Female; Humans; Intestinal Absorption; Male; Middle Aged; Migraine Disord | 2001 |
Efficacy, tolerability, and patient satisfaction with 50- and 100-mg sumatriptan tablets in those initially dissatisfied with the efficacy of 50-mg sumatriptan tablets.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Pain Measurement; Patient Sati | 2001 |
Sumatriptan nasal spray and cognitive function during migraine: results of an open-label study.
Topics: Acute Disease; Administration, Intranasal; Adult; Cognition; Cognition Disorders; Female; Humans; Me | 2001 |
Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine.
Topics: Acetaminophen; Adult; Analgesics; Antipyrine; Capsules; Chloral Hydrate; Double-Blind Method; Drug C | 2001 |
Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double-blind, international study.
Topics: Administration, Oral; Adult; Double-Blind Method; Female; Humans; International Cooperation; Male; M | 2001 |
Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cross-Over Studies; Female; Humans; Male; Middle Aged | 2001 |
Neuroendocrine effects of subcutaneous sumatriptan in patients with migraine.
Topics: Adrenocorticotropic Hormone; Adult; Female; Humans; Hydrocortisone; Male; Migraine Disorders; Placeb | 2001 |
A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; | 2001 |
The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adolescent; Adult; Analysis of Variance; Benzopyrans; Dose-Response Relationship, Dru | 2001 |
Preference comparison of rizatriptan ODT 10-mg and sumatriptan 50-mg tablet in migraine.
Topics: Adult; Cross-Over Studies; Female; Humans; Male; Migraine Disorders; Serotonin Receptor Agonists; Su | 2001 |
Mixing sumatriptan: a prospective study of stratified care using multiple formulations.
Topics: Aerosols; Humans; Injections, Subcutaneous; Migraine Disorders; Prospective Studies; Salvage Therapy | 2001 |
Efficacy and tolerability of subcutaneous sumatriptan for acute migraine: a comparison between ethnic groups.
Topics: Acute Disease; Black People; Cross-Over Studies; Double-Blind Method; Hispanic or Latino; Humans; In | 2001 |
Migraine and tension-type headache reduction through pericranial muscular suppression: a preliminary report.
Topics: Analgesics; Dental Occlusion, Centric; Device Approval; Equipment Design; Equipment Safety; Female; | 2001 |
Sumatriptan challenge in bipolar patients with and without migraine: a neuroendocrine study of 5-HT1D receptor function.
Topics: Adult; Bipolar Disorder; Female; Human Growth Hormone; Humans; Hydrocortisone; Male; Middle Aged; Mi | 2002 |
Almotriptan versus sumatriptan in migraine treatment: direct medical costs of managing adverse chest symptoms.
Topics: Chest Pain; Drug Costs; Electrocardiography; Humans; Indoles; Migraine Disorders; Serotonin Receptor | 2002 |
Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials.
Topics: Acute Disease; Adult; Female; Humans; Indoles; Male; Middle Aged; Migraine Disorders; Palliative Car | 2002 |
Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan.
Topics: Acute Disease; Adult; Carbazoles; Clinical Trials as Topic; Dizziness; Dose-Response Relationship, D | 2002 |
Sumatriptan in the treatment of acute migraine with aura.
Topics: Acute Disease; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Indoles; Male; Middle A | 1992 |
A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aspirin; Double-Blind Method; Drug Therapy, Combinati | 1992 |
Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks.
Topics: Adolescent; Adult; Aged; Blood Flow Velocity; Blood Pressure; Cerebral Arteries; Cerebrovascular Cir | 1992 |
Sumatriptan injection is superior to placebo in the acute treatment of migraine--with regard to both efficacy and general well-being.
Topics: Acute Disease; Adult; Aged; Double-Blind Method; Female; Humans; Indoles; Injections, Subcutaneous; | 1992 |
Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indoles; I | 1992 |
Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group.
Topics: Adult; Double-Blind Method; Female; Humans; Indoles; Male; Middle Aged; Migraine Disorders; Placebos | 1992 |
Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man.
Topics: Adult; Double-Blind Method; Fats; Gamma Cameras; Gastric Emptying; Half-Life; Humans; Indoles; Infus | 1992 |
Migraine.
Topics: Humans; Indoles; Migraine Disorders; Research Design; Sulfonamides; Sumatriptan; Time Factors; Vasoc | 1992 |
Sumatriptan and recurrence of migraine.
Topics: Double-Blind Method; Drug Administration Schedule; Humans; Indoles; Migraine Disorders; Recurrence; | 1992 |
Subcutaneous sumatriptan in the acute treatment of migraine. Sumatriptan International Study Group.
Topics: Adult; Double-Blind Method; Humans; Indoles; Injections, Subcutaneous; Middle Aged; Migraine Disorde | 1991 |
Subcutaneous sumatriptan in the treatment of headache during withdrawal from drug-induced headache.
Topics: Adult; Cerebral Arteries; Cerebrovascular Circulation; Double-Blind Method; Ergotamine; Female; Head | 1991 |
Treatment of migraine attacks with sumatriptan.
Topics: Adolescent; Adult; Aged; Consumer Behavior; Double-Blind Method; Drug Tolerance; Female; Humans; Ind | 1991 |
Sumatriptan--an oral dose-defining study. The Oral Sumatriptan Dose-Defining Study Group.
Topics: Administration, Oral; Adult; Consumer Behavior; Double-Blind Method; Female; Humans; Indoles; Male; | 1991 |
Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. The Oral Sumatriptan International Multiple-Dose Study Group.
Topics: Adult; Aged; Consumer Behavior; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up | 1991 |
A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group.
Topics: Administration, Oral; Adult; Aged; Caffeine; Double-Blind Method; Drug Combinations; Electrocardiogr | 1991 |
Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. The Sumatriptan Auto-Injector Study Group.
Topics: Adult; Aged; Consumer Behavior; Double-Blind Method; Female; Humans; Indoles; Injections, Subcutaneo | 1991 |
A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group.
Topics: Absorption; Administration, Intranasal; Adult; Disability Evaluation; Double-Blind Method; Female; H | 1991 |
The safety and tolerability of sumatriptan: an overview.
Topics: Adult; Aged; Electrocardiography; Female; Humans; Indoles; Male; Middle Aged; Migraine Disorders; Mo | 1991 |
Oral sumatriptan in acute migraine.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Double-Blind Method; Drug Evaluation; Female | 1991 |
Treatment of acute migraine with subcutaneous sumatriptan.
Topics: Acute Disease; Adult; Double-Blind Method; Female; Humans; Indoles; Injections, Subcutaneous; Male; | 1991 |
The pharmacology of current anti-migraine drugs.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Humans; Indoles; Migraine Disorders; Receptor | 1990 |
Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine.
Topics: Adult; Clinical Trials as Topic; Female; Humans; Indoles; Infusions, Intravenous; Male; Middle Aged; | 1988 |
586 other studies available for sumatriptan and Abdominal Migraine
| Article | Year |
|---|---|
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
Topics: Animals; Aorta; Computer-Aided Design; Drug Design; Haplorhini; In Vitro Techniques; Migraine Disord | 1995 |
Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamin
Topics: Animals; Benzopyrans; Cattle; Cloning, Molecular; Glioma; HeLa Cells; Humans; Mice; Migraine Disorde | 1996 |
Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.
Topics: Administration, Oral; Animals; Biological Availability; Migraine Disorders; Receptor, Serotonin, 5-H | 1997 |
Isochroman-6-carboxamides as highly selective 5-HT1D agonists: potential new treatment for migraine without cardiovascular side effects.
Topics: Animals; Benzopyrans; Biological Availability; Blood Pressure; Brain; Capillary Permeability; Caroti | 1998 |
Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
Topics: Administration, Oral; Animals; Biological Availability; CHO Cells; Cricetinae; Humans; Indoles; Migr | 1999 |
3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents.
Topics: Administration, Oral; Animals; Biological Availability; CHO Cells; Cricetinae; Indoles; Male; Migrai | 1999 |
5-Thienyltryptamine derivatives as serotonin 5-HT1B/1D receptor agonists: potential treatments for migraine.
Topics: Cloning, Molecular; Humans; Indicators and Reagents; Migraine Disorders; Receptor, Serotonin, 5-HT1B | 2000 |
Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.
Topics: Administration, Oral; Animals; Binding, Competitive; Biological Availability; Brain; Capillary Perme | 2001 |
N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy.
Topics: Animals; Benzamides; Cell Line; Dura Mater; Guinea Pigs; Humans; In Vitro Techniques; Indoles; Infla | 2001 |
Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migr
Topics: Administration, Intranasal; Amides; Animals; Caco-2 Cells; Calcitonin Gene-Related Peptide Receptor | 2013 |
Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headache.
Topics: Allosteric Regulation; Animals; Dogs; Dose-Response Relationship, Drug; Drug Discovery; Humans; Migr | 2017 |
Design, synthesis and biological evaluation of pyridinylmethylenepiperidine derivatives as potent 5-HT
Topics: Animals; Body Weight; Dose-Response Relationship, Drug; Drug Design; Eating; Female; Haplorhini; HEK | 2021 |
A prolactin-dependent sexually dimorphic mechanism of migraine chronification.
Topics: Animals; Female; Headache Disorders, Secondary; Humans; Hyperalgesia; Male; Mice; Migraine Disorders | 2022 |
Evaluation of sex differences in the pharmacokinetics of oral sumatriptan in healthy Korean subjects using population pharmacokinetic modeling.
Topics: Female; Humans; Male; Migraine Disorders; Republic of Korea; Serotonin Receptor Agonists; Sex Charac | 2022 |
Sumatriptan dose increase-induced acute angle closure glaucoma in chronic migraine sufferer.
Topics: Glaucoma, Angle-Closure; Humans; Intraocular Pressure; Migraine Disorders; Sumatriptan | 2022 |
The implementation of transcranial Doppler ultrasonography for preclinical study of migraine.
Topics: Animals; Blood Flow Velocity; Cerebrovascular Circulation; Humans; Migraine Disorders; Rats; Reprodu | 2022 |
Development of Optimized Sumatriptan-Prochlorperazine Combined Orodispersible Films Without Disintegrant: in vitro, ex vivo and in vivo Characterization.
Topics: Excipients; Humans; Migraine Disorders; Nausea; Prochlorperazine; Sumatriptan; Vomiting | 2022 |
Triptan medication use among patients with migraine with contraindications in the US.
Topics: Contraindications; Humans; Migraine Disorders; Retrospective Studies; Serotonin 5-HT1 Receptor Agoni | 2022 |
PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine.
Topics: Animals; Calcitonin Gene-Related Peptide; Cromakalim; Disease Models, Animal; Drug Hypersensitivity; | 2022 |
PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine.
Topics: Animals; Calcitonin Gene-Related Peptide; Cromakalim; Disease Models, Animal; Drug Hypersensitivity; | 2022 |
PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine.
Topics: Animals; Calcitonin Gene-Related Peptide; Cromakalim; Disease Models, Animal; Drug Hypersensitivity; | 2022 |
PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine.
Topics: Animals; Calcitonin Gene-Related Peptide; Cromakalim; Disease Models, Animal; Drug Hypersensitivity; | 2022 |
[Integrating new migraine treatments into clinical practice (part 1) : management of acute migraine attack].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Belgium; Humans; Migraine Disorders; Sumatriptan; Tryptamin | 2023 |
Duality in response of intracranial vessels to nitroglycerin revealed in rats by imaging photoplethysmography.
Topics: Animals; Migraine Disorders; Nitroglycerin; Photoplethysmography; Rats; Sumatriptan; Vasodilator Age | 2023 |
Multi-omic analyses of triptan-treated migraine attacks gives insight into molecular mechanisms.
Topics: Fatty Acids; Glutamine; Humans; Migraine Disorders; Multiomics; Serotonin 5-HT1 Receptor Agonists; S | 2023 |
Quality by design for sumatriptan loaded nano-ethosomal mucoadhesive gel for the therapeutic management of nitroglycerin induced migraine.
Topics: Administration, Intranasal; Humans; Migraine Disorders; Nasal Mucosa; Nitroglycerin; Sumatriptan | 2023 |
Contribution of intraganglionic CGRP to migraine-like responses in male and female rats.
Topics: Animals; Calcitonin Gene-Related Peptide; Female; Hyperalgesia; Male; Migraine Disorders; Rats; Rats | 2020 |
Orofacial Pain and Menstrually Related Migraine.
Topics: Adult; Facial Pain; Female; Headache; Humans; Middle Aged; Migraine Disorders; Sumatriptan | 2019 |
Low-dose interleukin-2 reverses behavioral sensitization in multiple mouse models of headache disorders.
Topics: Animals; Headache Disorders; Interleukin-2; Mice; Migraine Disorders; Nitroglycerin; Sumatriptan | 2020 |
[Paediatric extensiv cerebral venous sinus thrombosis with benign course].
Topics: Adolescent; Delayed Diagnosis; Factor V; Female; Heparin; Humans; Migraine Disorders; Mutation; Sinu | 2020 |
Repetitive stress in mice causes migraine-like behaviors and calcitonin gene-related peptide-dependent hyperalgesic priming to a migraine trigger.
Topics: Animals; Calcitonin Gene-Related Peptide; Female; Humans; Hyperalgesia; Male; Mice; Migraine Disorde | 2020 |
Vasospasm induced myocardial ischaemia secondary to sumatriptan use.
Topics: Coronary Angiography; Coronary Vasospasm; Electrocardiography; Humans; Male; Middle Aged; Migraine D | 2020 |
A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.
Topics: Animals; Calcitonin Gene-Related Peptide; Disease Models, Animal; Female; Hyperalgesia; Male; Mice; | 2021 |
Subcutaneous sumatriptans for acute migraine attacks in adults.
Topics: Adult; Double-Blind Method; Humans; Injections, Subcutaneous; Migraine Disorders; Sumatriptan; Treat | 2021 |
Twenty-five years of triptans - a nationwide population study.
Topics: Cohort Studies; Denmark; Female; Humans; Male; Migraine Disorders; Population Surveillance; Serotoni | 2021 |
Sumatriptan dose increase-induced acute angle closure glaucoma in chronic migraine sufferer.
Topics: Acute Disease; Female; Glaucoma, Angle-Closure; Humans; Middle Aged; Migraine Disorders; Sumatriptan | 2021 |
Advantages of imaging photoplethysmography for migraine modeling: new optical markers of trigemino-vascular activation in rats.
Topics: Animals; Electric Stimulation; Heart Rate; Male; Migraine Disorders; Photoplethysmography; Rats; Rat | 2021 |
Are 5-HT
Topics: Humans; Migraine Disorders; Pharmaceutical Preparations; Serotonin; Serotonin 5-HT1 Receptor Agonist | 2021 |
Changes in the gene expression profile during spontaneous migraine attacks.
Topics: Adolescent; Adult; Aged; Epistasis, Genetic; Female; Humans; Male; Middle Aged; Migraine Disorders; | 2021 |
Sumatriptan-induced angle-closure glaucoma: A case report.
Topics: Adult; Diagnosis, Differential; Female; Glaucoma, Angle-Closure; Humans; Migraine Disorders; Sumatri | 2017 |
Recurrent administration of the nitric oxide donor, isosorbide dinitrate, induces a persistent cephalic cutaneous hypersensitivity: A model for migraine progression.
Topics: Animals; Central Nervous System Sensitization; Dipeptides; Disease Models, Animal; Hyperalgesia; Iso | 2018 |
Soluble guanylyl cyclase is a critical regulator of migraine-associated pain.
Topics: Adrenergic beta-Antagonists; Allosteric Regulation; Animals; Anticonvulsants; Calcitonin Gene-Relate | 2018 |
Clinical characteristics and overuse patterns of medication overuse headache: Retrospective case-series study.
Topics: Adult; Analgesics; Analgesics, Opioid; Female; Headache Disorders; Headache Disorders, Secondary; Hu | 2017 |
Induction of chronic migraine phenotypes in a rat model after environmental irritant exposure.
Topics: Acrolein; Analysis of Variance; Animals; Chronic Disease; Disease Models, Animal; Exploratory Behavi | 2018 |
Use and overuse of triptans in Austria - a survey based on nationwide healthcare claims data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Austria; Databases, Factual; Drug Utilization; Female; H | 2018 |
Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Cross-Sectiona | 2018 |
The effect of intravenous administration of liposomal curcumin in addition to sumatriptan treatment in an experimental migraine model in rats.
Topics: Administration, Intravenous; Animals; Curcumin; Disease Models, Animal; Liposomes; Male; Malondialde | 2018 |
Characterization of dural afferent neurons innervating cranial blood vessels within the dura in rats.
Topics: Animals; Calcium Channels; Capsaicin; Dura Mater; Female; Ganglia, Spinal; Male; Mechanoreceptors; M | 2018 |
[In process].
Topics: Adolescent; Adrenergic beta-Antagonists; Age Factors; Analgesics; Behavior Therapy; Child; Flunarizi | 2016 |
The use of focused ultrasound for the treatment of cutaneous allodynia associated with chronic migraine.
Topics: Animals; Disease Models, Animal; Hyperalgesia; Male; Migraine Disorders; Pain Threshold; Peripheral | 2018 |
Use of existing electronic health care databases to evaluate medication safety in pregnancy: Triptan exposure in pregnancy as a case study.
Topics: Abnormalities, Drug-Induced; Administrative Claims, Healthcare; Adolescent; Adult; Databases, Factua | 2018 |
Midface migraine with concomitant dental disease: A report of two cases.
Topics: Adult; Combined Modality Therapy; Female; Humans; Middle Aged; Migraine Disorders; Root Canal Therap | 2018 |
Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache.
Topics: Analgesics; Analgesics, Opioid; Animals; Headache Disorders, Secondary; Hyperalgesia; Male; Migraine | 2019 |
Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process.
Topics: Adverse Drug Reaction Reporting Systems; Burns, Chemical; Cicatrix; Clinical Trials as Topic; Drug A | 2018 |
Recurrent Headache Increases Blood-Brain Barrier Permeability and VEGF Expression in Rats.
Topics: Animals; Blood-Brain Barrier; Capillary Permeability; Headache; Hyperalgesia; Inflammation; Male; Mi | 2018 |
Cost-Effectiveness of Reclassifying Triptans in Australia: Application of an Economic Evaluation Approach to Regulatory Decisions.
Topics: Australia; Cost-Benefit Analysis; Drug and Narcotic Control; General Practitioners; Humans; Migraine | 2019 |
Modulation of brain networks by sumatriptan-naproxen in the inflammatory soup migraine model.
Topics: Animals; Brain; Drug Combinations; Infusions, Intraventricular; Magnetic Resonance Imaging; Male; Mi | 2019 |
The efficacy of transdermal sumatriptan is too low for general use in migraine.
Topics: Analgesics; Female; Humans; Male; Migraine Disorders; Sumatriptan | 2013 |
Characterization of a novel model of chronic migraine.
Topics: Animals; Chronic Disease; Disease Models, Animal; Female; Freund's Adjuvant; Hyperalgesia; Male; Mic | 2014 |
Oral sumatriptan for the acute treatment of migraine in children and adolescents: yet another failed study.
Topics: Female; Humans; Male; Migraine Disorders; Sumatriptan; Vasoconstrictor Agents | 2014 |
Sumatriptan in clinical practice: effectiveness in migraine and the problem of psychiatric comorbidity.
Topics: Antidepressive Agents; Drug Interactions; Humans; Mental Disorders; Migraine Disorders; Monoamine Ox | 2014 |
The efficacy of transdermal sumatriptan is too low for general use - a response.
Topics: Administration, Cutaneous; Dose-Response Relationship, Drug; Humans; Migraine Disorders; Sumatriptan | 2014 |
ACP Journal Club. Review: Sumatriptan plus naproxen improves acute migraine more than placebo, sumatriptan, or naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Migraine Disorders; Naproxen; Serotonin 5-HT1 Recep | 2014 |
Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium.
Topics: Adolescent; Adult; Analgesics; Drug Combinations; Dysmenorrhea; Female; Humans; Logistic Models; Mig | 2014 |
Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium.
Topics: Adolescent; Adult; Analgesics; Drug Combinations; Dysmenorrhea; Female; Humans; Logistic Models; Mig | 2014 |
Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium.
Topics: Adolescent; Adult; Analgesics; Drug Combinations; Dysmenorrhea; Female; Humans; Logistic Models; Mig | 2014 |
Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium.
Topics: Adolescent; Adult; Analgesics; Drug Combinations; Dysmenorrhea; Female; Humans; Logistic Models; Mig | 2014 |
5-HT7 receptors are involved in neurogenic dural vasodilatation in an experimental model of migraine.
Topics: Animals; Dura Mater; Male; Meningeal Arteries; Migraine Disorders; Phenols; Rats; Rats, Sprague-Dawl | 2014 |
Sumatriptan transdermal system can be correctly assembled and applied during migraine attacks.
Topics: Adolescent; Adult; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Iontophoresis; Male; Mi | 2014 |
Comparison of the vasodilator responses of isolated human and rat middle meningeal arteries to migraine related compounds.
Topics: Animals; Humans; Male; Meningeal Arteries; Migraine Disorders; Piperazines; Purines; Rats; Rats, Spr | 2014 |
Treatment adherence among new triptan users: a 2-year cohort study in Taiwan.
Topics: Adult; Drug Prescriptions; Female; Humans; Male; Medication Adherence; Middle Aged; Migraine Disorde | 2014 |
[Sumatriptan plus naproxen for acute migraine attacks in adults].
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Humans; Migraine D | 2014 |
Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
Topics: Administration, Oral; Adolescent; Adult; Drug Combinations; Female; Health Care Costs; Humans; Male; | 2015 |
Pharmacological trials in migraine: it's time to reappraise where the headache is and what the pain is like.
Topics: Acetylcholine Release Inhibitors; Botulinum Toxins; Humans; Migraine Disorders; Pain; Serotonin 5-HT | 2015 |
Application of design of experiment for polyox and xanthan gum coated floating pulsatile delivery of sumatriptan succinate in migraine treatment.
Topics: Biological Availability; Chemistry, Pharmaceutical; Drug Chronotherapy; Drug Delivery Systems; Drug | 2014 |
Improvement of transdermal delivery of sumatriptan succinate using a novel self-dissolving microneedle array fabricated from sodium hyaluronate in rats.
Topics: Administration, Cutaneous; Animals; Biological Availability; Chemistry, Pharmaceutical; Drug Carrier | 2015 |
Prescribing patterns of anti-migraine medicines in South Africa using a claims database.
Topics: Adult; Clonidine; Databases, Factual; Drugs, Generic; Female; Humans; Insurance, Health, Reimburseme | 2015 |
Triptans: beware of vasoconstrictive effects.
Topics: Adult; Female; Humans; Male; Migraine Disorders; Patient Selection; Pregnancy; Risk Assessment; Risk | 2014 |
Intranasal sumatriptan for migraine in children.
Topics: Administration, Intranasal; Adolescent; Child; Humans; Migraine Disorders; Serotonin 5-HT1 Receptor | 2015 |
An in silico approach helped to identify the best experimental design, population, and outcome for future randomized clinical trials.
Topics: Computer Simulation; Cross-Over Studies; Forecasting; Humans; Migraine Disorders; Randomized Control | 2016 |
Sumatriptan succinate loaded chitosan solid lipid nanoparticles for enhanced anti-migraine potential.
Topics: Animals; Behavior, Animal; Brain; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Chi | 2015 |
Predictive validity of endpoints used in electrophysiological modelling of migraine in the trigeminovascular system.
Topics: Action Potentials; Animals; Blood Pressure; Disease Models, Animal; Electric Stimulation; Fructose; | 2015 |
A sumatriptan patch (Zecuity) for migraine.
Topics: Adult; Double-Blind Method; Humans; Migraine Disorders; Randomized Controlled Trials as Topic; Serot | 2015 |
ST-Elevation Myocardial Infarction After Sumitriptan Ingestion in Patient with Normal Coronary Arteries.
Topics: Electrocardiography; Emergency Service, Hospital; Female; Humans; Middle Aged; Migraine Disorders; M | 2015 |
OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics.
Topics: Alleles; Biological Availability; Cell Membrane Permeability; Enzyme Inhibitors; Genotype; HEK293 Ce | 2016 |
The effects of acute and preventive migraine therapies in a mouse model of chronic migraine.
Topics: Acute Disease; Amiloride; Animals; Anticonvulsants; Disease Models, Animal; Drug Evaluation, Preclin | 2016 |
A Comparative Study of Orally Delivered PBCA and ApoE Coupled BSA Nanoparticles for Brain Targeting of Sumatriptan Succinate in Therapeutic Management of Migraine.
Topics: Administration, Oral; Animals; Apolipoprotein E3; Brain; Delayed-Action Preparations; Drug Carriers; | 2016 |
Sumatriptan iontophoretic transdermal system for acute treatment of episodic migraine.
Topics: Europe; Female; Humans; Iontophoresis; Migraine Disorders; Nausea; Sumatriptan | 2016 |
Breath-Powered Intranasal Sumatriptan Dry Powder.
Topics: Administration, Intranasal; Humans; Migraine Disorders; Powders; Serotonin 5-HT1 Receptor Agonists; | 2016 |
Clinically relevant behavioral endpoints in a recurrent nitroglycerin migraine model in rats.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Male; Migraine Disorders; Motor Activity; Nitrogl | 2016 |
New migraine therapies promise prevention: A new generation of drugs could avert migraine attacks rather than merely relieve symptoms.
Topics: Antibodies, Monoclonal; Calcitonin Gene-Related Peptide; Humans; Immunologic Factors; Migraine Disor | 2016 |
Onzetra Xsail--sumatriptan nasal powder.
Topics: Administration, Intranasal; Aerosols; Drug Administration Schedule; Drug Interactions; Humans; Migra | 2016 |
Sumatriptan Patch is Temporarily Suspended.
Topics: Administration, Cutaneous; Burns; Drug-Related Side Effects and Adverse Reactions; Humans; Migraine | 2016 |
Critical neural targets for (the level of) human consciousness: Arousal arrest and unconsciousness after sumatriptan administration.
Topics: Adolescent; Arousal; Diffusion Tensor Imaging; Humans; Image Processing, Computer-Assisted; Magnetic | 2016 |
Pharmacology of reflex blinks in the rat: a novel model for headache research.
Topics: Animals; Blinking; Disease Models, Animal; Electromyography; Male; Migraine Disorders; Nitric Oxide | 2016 |
Triptans and third nerve paresis: a case series of three patients.
Topics: Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Oculomotor Nerve Diseases; Paresis; Sum | 2017 |
Induction of Migraine-Like Photophobic Behavior in Mice by Both Peripheral and Central CGRP Mechanisms.
Topics: Animals; Anxiety; Calcitonin Gene-Related Peptide; Darkness; Female; Injections, Intraperitoneal; Li | 2017 |
Nitroglycerin enhances the propagation of cortical spreading depression: comparative studies with sumatriptan and novel kynurenic acid analogues.
Topics: Cortical Spreading Depression; Dose-Response Relationship, Drug; Humans; Injections, Intraperitoneal | 2017 |
Sumatriptan, an Antimigraine Drug, Inhibits Pentylenetetrazol-induced Seizures in NMRI Mice.
Topics: Animals; Anticonvulsants; Male; Mice; Migraine Disorders; Pentylenetetrazole; Seizures; Sumatriptan; | 2017 |
Depression of home cage wheel running: a reliable and clinically relevant method to assess migraine pain in rats.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Female; Isothiocyanates; Migraine Disorders; Rats | 2017 |
Maximum effect of triptans in migraine? A comment.
Topics: Dose-Response Relationship, Drug; Humans; Injections, Subcutaneous; Migraine Disorders; Pain Measure | 2008 |
Images from headache: a costly attack of migraine.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Brain; Drug Therapy, Combination; Electrocardiograph | 2008 |
A fixed-dose combination of sumatriptan and naproxen for migraine.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Humans; Migraine D | 2008 |
Comparison of rizatriptan and sumatriptan.
Topics: Humans; Migraine Disorders; Patient Satisfaction; Serotonin Receptor Agonists; Sumatriptan; Time Fac | 1999 |
Investigation of the immunoreactivities of NOS enzymes and the effect of sumatriptan in adolescent rats using an experimental model of migraine.
Topics: Analysis of Variance; Animals; Brain; Disease Models, Animal; Male; Migraine Disorders; Nitric Oxide | 2008 |
Goshuyuto, a traditional Japanese medicine for migraine, inhibits platelet aggregation in guinea-pig whole blood.
Topics: Animals; Collagen; Drugs, Chinese Herbal; Guinea Pigs; Indicators and Reagents; Male; Migraine Disor | 2008 |
New therapies may ease headache symptoms. A two-drug combo and two kinds of oxygen therapy show promise for relieving migraine and cluster headache pain.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cluster Headache; Drug Therapy, C | 2008 |
Frovatriptan and data publication.
Topics: Carbazoles; Double-Blind Method; Humans; Migraine Disorders; Periodicals as Topic; Randomized Contro | 2008 |
Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Patient Satisfaction | 2008 |
Analysis of the relationship between age and treatment response in migraine.
Topics: Adolescent; Adult; Age Factors; Clinical Trials as Topic; Humans; Markov Chains; Migraine Disorders; | 2009 |
Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Drug Costs; Drugs, Generi | 2009 |
Gaze-evoked and rebound nystagmus in a case of migrainous vertigo.
Topics: Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Middle Aged; Migraine Disorders; | 2009 |
Margaritas... not science.
Topics: Biomedical Research; Causality; Cerebrovascular Circulation; Clinical Trials as Topic; Drug Design; | 2009 |
Revisiting the level of evidence in randomized controlled clinical trials: A simulation approach.
Topics: Double-Blind Method; Evidence-Based Medicine; Humans; Migraine Disorders; Models, Statistical; Monte | 2009 |
Evaluating the efficacy of migraine therapy.
Topics: Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Time Factors; Treatment Outcom | 2000 |
The central analgesia induced by antimigraine drugs is independent from Gi proteins: superiority of a fixed combination of indomethacin, prochlorperazine and caffeine, compared to sumatriptan, in an in vivo model.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Caffeine; Central Nervous Syste | 2009 |
Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs.
Topics: Animals; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Cath | 2009 |
Unpublished clinical trials with sumatriptan.
Topics: Drug Industry; Ergotamine; Europe; Humans; Migraine Disorders; Publication Bias; Randomized Controll | 2009 |
Formulation and evaluation of nasal mucoadhesive microspheres of sumatriptan succinate.
Topics: Adhesiveness; Administration, Intranasal; Hypromellose Derivatives; Methylcellulose; Microspheres; M | 2009 |
Pharmacological management for the adult migraine sufferer.
Topics: Acute Disease; Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Chemoprevention; Chronic | 2009 |
Drug dependence associated with triptans and ergot derivatives: a case/non-case study.
Topics: Claviceps; Dihydroergotamine; Ergotamine; Humans; Migraine Disorders; Oxazolidinones; Piperidines; P | 2010 |
Development and evaluation of occlusive systems employing polyvinyl alcohol for transdermal delivery of sumatriptan succinate.
Topics: Administration, Cutaneous; Antihypertensive Agents; Azepines; Chemistry, Pharmaceutical; Drug Carrie | 2010 |
Standardizing emergency department-based migraine research: an analysis of commonly used clinical trial outcome measures.
Topics: Antiemetics; Benzamides; Clinical Trials as Topic; Diphenhydramine; Dopamine Antagonists; Drug Combi | 2010 |
Abdominal migraine associated with ecchymosis of the legs and buttocks: does the symptom imply an unknown mechanism of migraine?
Topics: Abdominal Pain; Buttocks; Child; Ecchymosis; Female; Humans; Leg; Migraine Disorders; Serotonin Rece | 2010 |
Injectable sumatriptan: now needle-based or needle-free.
Topics: Contraindications; Drug Administration Routes; Drug Delivery Systems; Humans; Injections, Subcutaneo | 2010 |
In vitro dissolution profile comparison of an anti-migraine combinational drug in dosage form.
Topics: Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Compounding; Migraine Disorder | 2010 |
Safety of triptans for migraine headaches during pregnancy and breastfeeding.
Topics: Breast Feeding; Female; Humans; Migraine Disorders; Piperidines; Pregnancy; Pregnancy Complications; | 2010 |
Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers.
Topics: Animals; Calcitonin Gene-Related Peptide; Dura Mater; Enzyme Inhibitors; Male; Migraine Disorders; N | 2010 |
NerveCenter: Sumatriptan's evolution from brand drug to best buy of 2010.
Topics: Humans; Migraine Disorders; Pharmaceutical Preparations; Pharmacies; Sumatriptan; Vasoconstrictor Ag | 2010 |
Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled cross-over study.
Topics: Conflict of Interest; Cross-Over Studies; Cyclooxygenase Inhibitors; Humans; Migraine Disorders; Nap | 2010 |
Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled cross-over study.
Topics: Conflict of Interest; Cross-Over Studies; Cyclooxygenase Inhibitors; Humans; Migraine Disorders; Nap | 2010 |
Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled cross-over study.
Topics: Conflict of Interest; Cross-Over Studies; Cyclooxygenase Inhibitors; Humans; Migraine Disorders; Nap | 2010 |
Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled cross-over study.
Topics: Conflict of Interest; Cross-Over Studies; Cyclooxygenase Inhibitors; Humans; Migraine Disorders; Nap | 2010 |
Triptan therapy in migraine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Indomethacin; Injections, Intravenous; Ket | 2010 |
Triptan therapy in migraine.
Topics: Adult; Coronary Artery Disease; Electrocardiography; Female; Humans; Injections, Subcutaneous; Migra | 2010 |
Low efficacy of transdermal sumatriptan in migraine.
Topics: Humans; Migraine Disorders; Randomized Controlled Trials as Topic; Sumatriptan; Transdermal Patch; T | 2011 |
Subcutaneous sumatriptan: results of a peculiar, unpublished, comparative, double-blind, randomised, and controlled trial.
Topics: Double-Blind Method; France; History, 20th Century; Humans; Injections, Subcutaneous; Migraine Disor | 2011 |
Commentary.
Topics: Clinical Trials as Topic; Dihydroergotamine; Humans; Migraine Disorders; Serotonin 5-HT1 Receptor Ag | 2011 |
Evolution of paediatric off-label use after new significant medicines become available for adults: a study on triptans in Finnish children 1994-2007.
Topics: Adolescent; Adult; Age Factors; Child; Drug Approval; Female; Finland; Humans; Male; Migraine Disord | 2011 |
Basilar artery occlusion in migraine-like headache: a possible triggering effect of sumatriptan.
Topics: Adult; Brain Stem Infarctions; Female; Humans; Migraine Disorders; Serotonin 5-HT1 Receptor Agonists | 2012 |
Formulation and optimization of orally disintegrating tablets of sumatriptan succinate.
Topics: Administration, Oral; Adult; Chemistry, Pharmaceutical; Drug Compounding; Drug Stability; Excipients | 2011 |
[A comparative analysis on the efficacy of sumamigren in treatment menstrual and non-menstrual migraine attacks].
Topics: Adult; Female; Humans; Male; Menstruation; Middle Aged; Migraine Disorders; Premenstrual Syndrome; S | 2011 |
Talking about migraine.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Diet; Humans; Migraine Disorders; Phytotherapy; Ser | 2012 |
Headache currents commentary.
Topics: Analgesics; Animals; Dihydroergotamine; Ergotamine; Headache; Humans; Methysergide; Migraine Disorde | 2012 |
Headache in three new cases of Harlequin syndrome with accompanying pharmacological comparison with migraine.
Topics: Adult; Aged; Autonomic Nervous System Diseases; Diagnosis, Differential; Dihydroergotamine; Ergotami | 2012 |
Question 2: Does intranasal sumatriptan use relieve migraine in children and young people?
Topics: Administration, Intranasal; Adolescent; Child; Humans; Male; Migraine Disorders; Serotonin 5-HT1 Rec | 2013 |
Effects of sumatriptan on cerebral blood flow under normo- and hypercapnia in rats.
Topics: Animals; Cerebrovascular Circulation; Corpus Striatum; Hypercapnia; Male; Migraine Disorders; Muscle | 2002 |
Sumatriptan-induced chest symptoms in Japanese.
Topics: Chest Pain; Humans; Japan; Migraine Disorders; Myocardial Ischemia; Serotonin Receptor Agonists; Sum | 2002 |
Evidence against strong correlation between chest symptoms and ischemic coronary changes after subcutaneous sumatriptan injection.
Topics: Adolescent; Adult; Chest Pain; Female; Humans; Injections, Subcutaneous; Japan; Male; Middle Aged; M | 2002 |
The comparative clinical and economic benefits of drugs should be established and discussed as part of any formulary decision process.
Topics: Adolescent; Adult; Chest Pain; Child; Cost-Benefit Analysis; Female; Formularies as Topic; Humans; M | 2002 |
Treatment of migraine.
Topics: Analgesics; Aspirin; Humans; Lysine; Metoclopramide; Migraine Disorders; Riboflavin; Serotonin Recep | 2002 |
Sumatriptan-associated ischemic colitis.
Topics: Colitis, Ischemic; Female; Humans; Middle Aged; Migraine Disorders; Serotonin Receptor Agonists; Sum | 2002 |
Restoring migraine sufferers' ability to function normally: a comparison of rizatriptan and other triptans in randomized trials.
Topics: Administration, Oral; Adolescent; Adult; Aged; Female; Humans; Indoles; Male; Middle Aged; Migraine | 2002 |
Sumatriptan scavenges superoxide, hydroxyl, and nitric oxide radicals: in vitro electron spin resonance study.
Topics: Electron Spin Resonance Spectroscopy; Free Radical Scavengers; Free Radicals; Humans; Hydroxyl Radic | 2002 |
Triptans versus analgesics.
Topics: Adolescent; Adult; Analgesics; Humans; Middle Aged; Migraine Disorders; Multicenter Studies as Topic | 2002 |
The hazards of medication refills by telephone.
Topics: Drug Prescriptions; Female; Humans; Middle Aged; Migraine Disorders; Myocardial Infarction; Serotoni | 2002 |
The antimigraine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain.
Topics: Animals; Dihydroergotamine; Disease Models, Animal; Male; Migraine Disorders; Oxazolidinones; Pain; | 2002 |
Preclinical studies characterizing the anti-migraine and cardiovascular effects of the selective 5-HT1D receptor agonist PNU-142633.
Topics: Analgesics; Animals; Cardiovascular System; Cats; CHO Cells; Chromans; Cricetinae; Dogs; Drug Evalua | 2002 |
Single use of sumatriptan: a patient interview study.
Topics: Adult; Aged; Female; Humans; Interviews as Topic; Male; Middle Aged; Migraine Disorders; Netherlands | 2003 |
Stimulation of the calcitonin gene-related peptide enhancer by mitogen-activated protein kinases and repression by an antimigraine drug in trigeminal ganglia neurons.
Topics: Animals; Calcitonin Gene-Related Peptide; Calcium; Cells, Cultured; Enhancer Elements, Genetic; Gene | 2003 |
Relief for menstruation-related migraines.
Topics: Female; Humans; Menstruation Disturbances; Migraine Disorders; Serotonin Receptor Agonists; Sumatrip | 2002 |
Migraine preventive medication reduces resource utilization.
Topics: Amitriptyline; Cohort Studies; Health Resources; Humans; Migraine Disorders; Practice Guidelines as | 2003 |
Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study.
Topics: Area Under Curve; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blin | 2003 |
The truth about frovatriptan.
Topics: Carbazoles; Clinical Trials as Topic; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumat | 2003 |
Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment.
Topics: Adolescent; Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy; Drug-Related S | 2003 |
Misdiagnosis of migraine.
Topics: Adult; Diagnostic Errors; Headache; Humans; Male; Migraine Disorders; Practice Guidelines as Topic; | 2003 |
Unilateral time-delayed encapsulation does not make for a fair race.
Topics: Capsules; Delayed-Action Preparations; Double-Blind Method; Humans; Indoles; Migraine Disorders; Pyr | 2003 |
Investigation of the effects of naratriptan, rizatriptan, and sumatriptan on jugular venous oxygen saturation in anesthetized pigs: implications for their mechanism of acute antimigraine action.
Topics: Anesthesia; Animals; Blood Gas Analysis; Hemodynamics; Indoles; Jugular Veins; Male; Migraine Disord | 2003 |
[Strong and sustained-acting triptan. Therewith migraine does not return soon].
Topics: Administration, Oral; Clinical Trials as Topic; Humans; Indoles; Migraine Disorders; Placebos; Pyrro | 2003 |
Musing on Mathew et al.
Topics: Capsules; Clinical Trials as Topic; Double-Blind Method; Humans; Indoles; Migraine Disorders; Prospe | 2003 |
Incidence and determinants of antidepressant drug use in migraine patients.
Topics: Adult; Analgesics; Antidepressive Agents; Databases, Factual; Drug Utilization; Ergotamine; Female; | 2003 |
[Improved pharmacokinetics. Fast tryptan with sustained response].
Topics: Administration, Oral; Controlled Clinical Trials as Topic; Delayed-Action Preparations; Female; Head | 2003 |
[Highly selective beginning. Associated symptoms and side effects in retrospect].
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indoles; Migraine D | 2003 |
A fluorescence-based method to assess plasma protein extravasation in rat dura mater using confocal laser scanning microscopy.
Topics: Animals; Biological Assay; Blood Proteins; Disease Models, Animal; Dose-Response Relationship, Drug; | 2003 |
Hemicrania continua with contralateral episodic cluster headache: a case report.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cluster Headache; Functional Laterality; Humans; Ind | 2003 |
The responsiveness of headache impact scales scored using 'classical' and 'modern' psychometric methods: a re-analysis of three clinical trials.
Topics: Adult; Clinical Trials as Topic; Female; Humans; Male; Migraine Disorders; Psychometrics; Quality of | 2003 |
Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain.
Topics: Animals; Brain; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Infusions, Parentera | 2004 |
Parental satisfaction with sumatriptan nasal spray in childhood migraine.
Topics: Administration, Intranasal; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Human | 2003 |
Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization.
Topics: Animals; Brain Mapping; Disease Models, Animal; Electrophysiology; Male; Migraine Disorders; Neurons | 2004 |
Defeating migraine pain with triptans: a race against the development of cutaneous allodynia.
Topics: Administration, Oral; Adolescent; Adult; Humans; Injections; Middle Aged; Migraine Disorders; Oxazol | 2004 |
The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg.
Topics: Adolescent; Adult; Aged; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method | 2004 |
Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Cardiovascular Diseases; Cause | 2004 |
Use and misuse of triptans in France: data from the GRIM2000 population survey.
Topics: Adult; Chi-Square Distribution; Female; France; Headache Disorders; Health Surveys; Humans; Male; Mi | 2004 |
Revised estimates for probability of successful outcome of pregnancy after sumatriptan exposure.
Topics: Abnormalities, Drug-Induced; Female; Humans; Infant, Newborn; Migraine Disorders; Pregnancy; Pregnan | 2004 |
Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists.
Topics: Animals; Mice; Migraine Disorders; Neurons; Receptors, Cytoplasmic and Nuclear; Serotonin Receptor A | 2004 |
The disparity in access to new medication by type of health insurance: lessons from Germany.
Topics: Adolescent; Adult; Aged; Drug Prescriptions; Female; Germany; Health Services Accessibility; Health | 2004 |
Effective treatment of migraine. Terminating acute attacks, reducing their frequency.
Topics: Acute Disease; Adrenergic beta-Antagonists; Anticonvulsants; Antidepressive Agents, Tricyclic; Calci | 2004 |
Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet.
Topics: Humans; Migraine Disorders; Oxazolidinones; Patient Satisfaction; Serotonin Receptor Agonists; Sumat | 2004 |
Quantifying delay in access to new medical treatment: an application of risk advancement period methodology.
Topics: Adult; Aged; Confidence Intervals; Female; Germany; Health Status Indicators; Humans; Male; Middle A | 2004 |
Headaches that could spell trouble.
Topics: Dihydroergotamine; Headache; Humans; Migraine Disorders; Sumatriptan | 2004 |
Metoclopramide and sumatriptan.
Topics: Dopamine Antagonists; Drug Interactions; Drug Therapy, Combination; Humans; Metoclopramide; Migraine | 2004 |
Thyrotoxicosis, sumatriptan and coronary artery spasm.
Topics: Coronary Angiography; Coronary Vasospasm; Female; Heart Arrest; Humans; Middle Aged; Migraine Disord | 2004 |
The anti-migraine agent sumatriptan induces a calcium-dependent discharge in meningeal sensory neurons.
Topics: Animals; Calcium; Electrophysiology; Evoked Potentials; Male; Membrane Potentials; Meninges; Migrain | 2004 |
The sumatriptan/naratriptan aggregated patient (SNAP) database: aggregation, validation and application.
Topics: Clinical Trials as Topic; Data Collection; Databases, Factual; Humans; Indoles; Logistic Models; Mig | 2004 |
Triptan therapy impacts health and productivity.
Topics: Adolescent; Adult; Aged; Child; Efficiency; Female; Humans; Male; Middle Aged; Migraine Disorders; O | 2004 |
Effects of sumatriptan on capsaicin-induced carotid haemodynamic changes and CGRP release in anaesthetized pigs.
Topics: Animals; Calcitonin Gene-Related Peptide; Capsaicin; Carotid Arteries; Dose-Response Relationship, D | 2004 |
Treatment of primary headache in the emergency department.
Topics: Anesthetics, Local; Bupivacaine; Emergency Service, Hospital; Headache; Humans; Injections, Intramus | 2004 |
[Use of triptanes according to indications. Risk of infarct is not increased].
Topics: Cerebral Infarction; Clinical Trials as Topic; Coronary Circulation; Humans; Indoles; Injections, In | 2004 |
Switching patients with migraine from sumatriptan to other triptans increases primary care costs.
Topics: Adult; Cost-Benefit Analysis; Costs and Cost Analysis; Family Practice; Humans; Middle Aged; Migrain | 2004 |
Indomethacin, alone and combined with prochlorperazine and caffeine, but not sumatriptan, abolishes peripheral and central sensitization in in vivo models of migraine.
Topics: Animals; Caffeine; Disease Models, Animal; Drug Therapy, Combination; Indomethacin; Male; Mice; Migr | 2004 |
Cerebral vasospasm from sumatriptan.
Topics: Adult; Cerebral Angiography; Female; Hemiplegia; Humans; Migraine Disorders; Serotonin Receptor Agon | 2004 |
Daily sumatriptan for detoxification from rebound.
Topics: Administration, Oral; Headache; Humans; Inactivation, Metabolic; Migraine Disorders; Sumatriptan | 1998 |
Correlation between lipophilicity and triptan outcomes.
Topics: Central Nervous System Diseases; Chemical Phenomena; Chemistry, Physical; Humans; Indoles; Migraine | 2005 |
Evaluation of the anti-emetic potential of anti-migraine drugs to prevent resiniferatoxin-induced emesis in Suncus murinus (house musk shrew).
Topics: Animals; Antiemetics; Butanols; Capsaicin; Cyclooxygenase Inhibitors; Dihydroergotamine; Diphenhydra | 2005 |
[Therapeutic management of migraines in children].
Topics: Adolescent; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Child; Combined Modality Therapy; H | 2005 |
Nasal sumatriptan: new dosage. For adolescents with migraine: too little benefit.
Topics: Administration, Intranasal; Adolescent; Clinical Trials as Topic; Cost-Benefit Analysis; France; Hum | 2005 |
Acute migraine attack, angina-like chest pain with documented ST-segment elevation and slow coronary flow.
Topics: Acute Disease; Angina Pectoris; Coronary Angiography; Coronary Circulation; Electrocardiography; Fem | 2005 |
A group sequential adaptive treatment assignment design for proof of concept and dose selection in headache trials.
Topics: Clinical Trials, Phase II as Topic; Computer Simulation; Controlled Clinical Trials as Topic; Humans | 2005 |
Accessing a new medication in Germany: a novel approach to assess a health insurance-related barrier.
Topics: Adolescent; Adult; Aged; Cohort Studies; Decision Making; Female; Germany; Health Policy; Health Ser | 2005 |
[Therapy of severe migraine attacks: practical tips].
Topics: Analgesics; Antiemetics; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administr | 2005 |
Biochemical evidence of the placebo effect during the treatment of menstrual migraines.
Topics: Female; Humans; Menstrual Cycle; Migraine Disorders; Placebo Effect; Serotonin; Serotonin Receptor A | 2005 |
Donitriptan decreases jugular venous oxygen saturation in rats in the absence of cranial vasoconstriction: an overlooked mechanism of antimigraine action?
Topics: Animals; Blood Gas Analysis; Cerebrovascular Circulation; Hemodynamics; Jugular Veins; Male; Migrain | 2005 |
Open label study of intranasal sumatriptan (Imigran) for footballer's headache.
Topics: Administration, Intranasal; Headache; Humans; Migraine Disorders; Migraine without Aura; Pain Measur | 2005 |
Over-the-counter triptans--making the switch.
Topics: Drug and Narcotic Control; Drug Approval; Drug Interactions; Humans; Migraine Disorders; Nonprescrip | 2005 |
Uncertainty analysis in pharmacokinetics and pharmacodynamics: application to naratriptan.
Topics: Algorithms; Analgesics; Female; Humans; Male; Migraine Disorders; Models, Biological; Piperidines; S | 2005 |
A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines.
Topics: Anesthetics, Local; Clinical Trials as Topic; Diphenhydramine; Dopamine Antagonists; Drug Administra | 2005 |
A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines.
Topics: Anesthetics, Local; Clinical Trials as Topic; Diphenhydramine; Dopamine Antagonists; Dose-Response R | 2005 |
The effect of early intervention with sumatriptan tablets on migraine-associated productivity loss.
Topics: Adult; Clinical Trials as Topic; Female; Humans; Male; Migraine Disorders; Pain; Retrospective Studi | 2005 |
Increased expression of endothelial and neuronal nitric oxide synthase in dura and pia mater after air stress.
Topics: Air Movements; Animals; Blotting, Western; Corticosterone; Dura Mater; Gene Expression Regulation, E | 2006 |
Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients.
Topics: Adolescent; Adult; Calcitonin Gene-Related Peptide; Ephedrine; Female; Humans; Male; Middle Aged; Mi | 2006 |
Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients.
Topics: Adolescent; Adult; Calcitonin Gene-Related Peptide; Ephedrine; Female; Humans; Male; Middle Aged; Mi | 2006 |
Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients.
Topics: Adolescent; Adult; Calcitonin Gene-Related Peptide; Ephedrine; Female; Humans; Male; Middle Aged; Mi | 2006 |
Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients.
Topics: Adolescent; Adult; Calcitonin Gene-Related Peptide; Ephedrine; Female; Humans; Male; Middle Aged; Mi | 2006 |
The risks of sumatriptan administration in patients with unrecognized subarachnoid haemorrhage (SAH).
Topics: Adult; Diagnostic Errors; Female; Humans; Male; Migraine Disorders; Pain; Serotonin Receptor Agonist | 2006 |
Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial--a comment.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Caffeine; | 2006 |
A comment on acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Caffeine; | 2006 |
[Medical treatment of migraine attacks in the child].
Topics: Acetaminophen; Age Factors; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Child; Ergot Alkalo | 2006 |
Prediction of headache response in migraine treatment.
Topics: Comorbidity; Computer Simulation; Decision Support Systems, Clinical; Dose-Response Relationship, Dr | 2006 |
A case of sumatriptan-induced intestinal ischemia.
Topics: Adult; Female; Humans; Intestine, Small; Ischemia; Migraine Disorders; Serotonin Receptor Agonists; | 2006 |
Assessment of clinical, service, and cost outcomes of a conversion program of sumatriptan to rizatriptan ODT in primary care patients with migraine headaches.
Topics: Female; Health Maintenance Organizations; Humans; Male; Medical Records Systems, Computerized; Middl | 2006 |
Influence of sumatriptan on the autonomic system during migraine attacks.
Topics: Autonomic Nervous System; Humans; Migraine Disorders; Sumatriptan; Vasoconstrictor Agents | 2006 |
[First generic triptan approved].
Topics: Administration, Oral; Dose-Response Relationship, Drug; Drug Approval; Drugs, Generic; Humans; Migra | 2006 |
Sumatriptan fast-disintegrating/rapid-release tablets.
Topics: Adult; Area Under Curve; Clinical Trials, Phase III as Topic; Female; Humans; Male; Middle Aged; Mig | 2006 |
Sumatriptan fast-disintegrating/rapid-release tablets: viewpoints.
Topics: Biological Availability; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Table | 2006 |
Spontaneous splenic infarction associated with sumatriptan use.
Topics: Causality; Cerebral Arteries; Female; Humans; Middle Aged; Migraine Disorders; Muscle, Smooth, Vascu | 2006 |
Intravital microscopy on a closed cranial window in mice: a model to study trigeminovascular mechanisms involved in migraine.
Topics: Animals; Arteries; Calcitonin Gene-Related Peptide; Capsaicin; Disease Models, Animal; Dura Mater; E | 2006 |
A model-based approach to treatment comparison in acute migraine.
Topics: Dose-Response Relationship, Drug; Humans; Markov Chains; Migraine Disorders; Models, Biological; Pip | 2006 |
Sumatriptan for the treatment of undifferentiated primary headaches in the ED.
Topics: Adult; Emergency Service, Hospital; Female; Headache; Humans; Male; Migraine Disorders; Minnesota; P | 2007 |
Benign or sinister? Distinguishing migraine from subarachnoid hemorrhage.
Topics: Adult; Diagnosis, Differential; Female; Humans; Migraine Disorders; Subarachnoid Hemorrhage; Sumatri | 2007 |
Analysis of responses in migraine modelling using hidden Markov models.
Topics: Biometry; Clinical Trials as Topic; Confidence Intervals; Humans; Markov Chains; Migraine Disorders; | 2007 |
Patient information regarding subcutaneous self-administration of sumatriptan (imitrex).
Topics: Guidelines as Topic; Humans; Injections, Subcutaneous; Migraine Disorders; Self Administration; Sero | 2007 |
Dark green blood in the operating theatre.
Topics: Adult; Compartment Syndromes; Humans; Male; Migraine Disorders; Sulfhemoglobinemia; Sumatriptan; Vas | 2007 |
[Bonus-malus regulations in the framework of the AVWG guideline-suitable migraine therapy are possible].
Topics: Clinical Trials as Topic; Cross-Over Studies; Drug and Narcotic Control; Germany; Humans; Migraine D | 2007 |
Sumatriptan succinate transdermal delivery systems for the treatment of migraine.
Topics: Administration, Cutaneous; Animals; Azepines; Chemistry, Pharmaceutical; Diffusion Chambers, Culture | 2008 |
Combination of sumatriptan and naproxen for migraine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Drug Therapy, Combination; Humans; Migra | 2007 |
[Acute migraine. Sumatriptan-naproxen combination tablets work better than a single substance].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Humans; Migraine Disorder | 2007 |
Diagnosis of menstrual headache and an open-label study among those with previously undiagnosed menstrually related migraine to evaluate the efficacy of sumatriptan 100 mg.
Topics: Adult; Female; Humans; Menstruation; Migraine Disorders; Sumatriptan; Vasoconstrictor Agents | 2007 |
Relevance of absorption rate and lag time to the onset of action in migraine.
Topics: Administration, Oral; Biological Availability; Clinical Trials as Topic; Computer Simulation; Databa | 2008 |
Migraine-like headache in intracranial haemorrhage is alleviated by sumatriptan and almotriptan.
Topics: Adult; Diagnosis, Differential; Drug Therapy, Combination; Headache; Humans; Intracranial Hemorrhage | 2008 |
Predictors of migraine headache recurrence: a pooled analysis from the eletriptan database.
Topics: Adolescent; Adult; Age Factors; Aged; Clinical Trials as Topic; Databases, Factual; Dose-Response Re | 2008 |
Triptans: actions and reactions.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Analgesics, Non-Narcotic; Dihydroergotamine; | 2008 |
[Efficacy of sumamigren at early and late stages of migraine attack].
Topics: Adult; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Migraine Disorders | 2007 |
An adult case of cyclic vomiting syndrome successfully responding to valproic acid.
Topics: Anti-Anxiety Agents; Anticonvulsants; Antiemetics; Consciousness Disorders; Diazepam; Female; Humans | 2008 |
The discovery and development of the triptans, a major therapeutic breakthrough.
Topics: History, 20th Century; History, 21st Century; Humans; Migraine Disorders; Receptors, Serotonin; Sero | 2008 |
[Stabilization treatments of migraine].
Topics: Analgesics; Antiemetics; Drug Therapy, Combination; Female; Humans; Male; Medical History Taking; Mi | 1995 |
[Therapeutic strategies in migraine: introduction].
Topics: Brain; Ergotamines; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Vasoconstr | 1995 |
What to suggest for migraine headache.
Topics: Administration, Oral; Humans; Migraine Disorders; Patient Education as Topic; Serotonin Receptor Ago | 1995 |
Angioedema associated with sumatriptan administration.
Topics: Adult; Angioedema; Female; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan | 1995 |
Function of the peripheral serotoninergic pathways in migraine: a proposal for an experimental model.
Topics: Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Binding, Competitive; Female; Flow C | 1994 |
Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan.
Topics: Acute Disease; Adult; Cerebellar Diseases; Cerebral Infarction; Fatal Outcome; Humans; Ischemic Atta | 1995 |
Brain stem activation in spontaneous human migraine attacks.
Topics: Adult; Auditory Cortex; Brain Stem; Cerebrovascular Circulation; Female; Gyrus Cinguli; Humans; Male | 1995 |
Migraine to the year 2000.
Topics: Humans; Migraine Disorders; Receptors, Serotonin; Serotonin; Sumatriptan | 1995 |
Assessment of peripheral vascular effects of antimigraine drugs in humans.
Topics: Adult; Dose-Response Relationship, Drug; Fingers; Forearm; Humans; Migraine Disorders; Plethysmograp | 1995 |
Quality of life assessment among migraine patients treated with sumatriptan.
Topics: Health Status; Humans; Migraine Disorders; Pain; Pain Measurement; Quality of Life; Serotonin Recept | 1995 |
Lack of an interaction between sumatriptan and selective serotonin reuptake inhibitors.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Drug Interactions; Female; Humans; Male | 1995 |
Sumatriptan prophylaxis for postelectroconvulsive therapy headaches.
Topics: Adult; Depressive Disorder; Electroconvulsive Therapy; Female; Humans; Migraine Disorders; Premedica | 1995 |
Understanding the biologic basis of migraine.
Topics: Brain; Female; Humans; Male; Migraine Disorders; Regional Blood Flow; Sumatriptan | 1994 |
Advances in migraine therapy: focus on oral sumatriptan.
Topics: Administration, Oral; Contraindications; Humans; Migraine Disorders; Sumatriptan | 1995 |
[Migraine in 1994].
Topics: Adult; Female; France; Humans; Male; Migraine Disorders; Prevalence; Sumatriptan | 1994 |
Upregulated expression of peripheral serotonergic receptors in migraine and cluster headache by sumatriptan.
Topics: Adult; Analysis of Variance; Binding, Competitive; Cluster Headache; Ergotamine; Female; Flow Cytome | 1994 |
Sumatriptan: a clinical standard?
Topics: Drug Costs; Emergency Service, Hospital; Humans; Migraine Disorders; Sumatriptan | 1995 |
Recurrent depression after sumatriptan administration for treatment of migraine.
Topics: Depressive Disorder; Female; Humans; Middle Aged; Migraine Disorders; Recurrence; Sumatriptan | 1995 |
[Sumatriptan].
Topics: Humans; Migraine Disorders; Sumatriptan | 1995 |
Winning a sweepstakes does not cure migraine.
Topics: Female; Humans; Life Change Events; Middle Aged; Migraine Disorders; Sumatriptan | 1995 |
Extra care urged in use of sumatriptan.
Topics: Adult; Diagnostic Errors; Drug Labeling; Female; Humans; Male; Migraine Disorders; Product Surveilla | 1995 |
[The migraine remedy sumatriptan (Imigran) and coronary heart disease].
Topics: Adult; Angina Pectoris; Coronary Disease; Female; Humans; Migraine Disorders; Risk Factors; Sumatrip | 1995 |
The safety of concomitant use of sumatriptan and antidepressant treatments.
Topics: Administration, Oral; Adult; Antidepressive Agents; Contraindications; Depressive Disorder; Drug The | 1995 |
The use of sumatriptan in patients on monoamine oxidase inhibitors.
Topics: Female; Humans; Middle Aged; Migraine Disorders; Monoamine Oxidase Inhibitors; Sumatriptan | 1995 |
Cardiac arrest following use of sumatriptan.
Topics: Adult; Coronary Disease; Female; Heart Arrest; Humans; Migraine Disorders; Sumatriptan | 1995 |
Unstable angina pectoris associated with Imitrex therapy.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Coronary Vasospasm; Electrocardiography; Female; H | 1995 |
[Headache caused by analgesics].
Topics: Acetaminophen; Adult; Female; Headache; Humans; Middle Aged; Migraine Disorders; Sumatriptan | 1994 |
Coronary angiography in migraine patient after subcutaneous sumatriptan.
Topics: Coronary Angiography; Coronary Vessels; Female; Humans; Injections, Subcutaneous; Middle Aged; Migra | 1995 |
Fluoxetine and sumatriptan: possibly a counterproductive combination.
Topics: Acute Disease; Adult; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Female; Flu | 1995 |
Dystonic reaction associated with sumatriptan.
Topics: Acute Disease; Adult; Benztropine; Drug Interactions; Dystonia; Female; Humans; Injections, Intramus | 1994 |
Sumatriptan in acute migraine therapy.
Topics: Acute Disease; Humans; Migraine Disorders; Sumatriptan | 1994 |
Drugs for migraine.
Topics: Adrenergic beta-Antagonists; Analgesics; Dihydroergotamine; Humans; Migraine Disorders; Sumatriptan | 1995 |
Abnormal photoreactivity in ictal migraine: reversal by sumatriptan.
Topics: Adolescent; Adult; Blood Flow Velocity; Cerebral Cortex; Female; Fourier Analysis; Humans; Injection | 1993 |
Sumatriptan-induced stroke in sagittal sinus thrombosis.
Topics: Adult; Cerebrovascular Disorders; Diagnostic Errors; Female; Hemiplegia; Humans; Injections, Subcuta | 1994 |
Sumatriptan-induced [correction of Sumatripan] stroke in sagittal sinus thrombosis.
Topics: Cerebrovascular Disorders; Diagnosis, Differential; Humans; Migraine Disorders; Sinus Thrombosis, In | 1994 |
[Use of sumatriptan (Imigran) in a female patient with coronary spasm].
Topics: Adult; Coronary Angiography; Coronary Vasospasm; Ergotamine; Female; Humans; Migraine Disorders; Sum | 1994 |
Acute myocardial infarction in a young female migraineur: sumatriptan suspected, but found not guilty.
Topics: Acute Disease; Adult; Female; Humans; Migraine Disorders; Myocardial Infarction; Sumatriptan | 1994 |
Sumatriptan for high-altitude headache.
Topics: Adult; Altitude Sickness; Female; Headache; Humans; Male; Middle Aged; Migraine Disorders; Sumatript | 1994 |
Sumatriptan offers rapid relief of acute migraines.
Topics: Acute Disease; Adult; Female; Humans; Migraine Disorders; Patient Education as Topic; Sumatriptan | 1994 |
Migraine in doctors: work loss and consumption of medication.
Topics: Adult; Aged; Analgesics; Ergotamine; Female; Humans; Male; Middle Aged; Migraine Disorders; Physicia | 1994 |
[Diagnosis and therapy of migraine].
Topics: Humans; Migraine Disorders; Naproxen; Stress, Psychological; Sumatriptan | 1994 |
[Sumatriptan and general practice].
Topics: Drug Costs; Drug Utilization; Family Practice; Humans; Migraine Disorders; Norway; Sumatriptan | 1994 |
Comparison between venoconstrictor effects of sumatriptan and ergotamine in migraine patients.
Topics: Adult; Ergotamine; Female; Hand; Humans; Middle Aged; Migraine Disorders; Sumatriptan; Vasoconstrict | 1994 |
Ischemic optic neuropathy after sumatriptan in a migraine with aura patient.
Topics: Female; Humans; Ischemia; Middle Aged; Migraine Disorders; Optic Nerve; Sensation Disorders; Sumatri | 1994 |
Adverse reactions associated with sumatriptan.
Topics: Adult; Female; Hemiplegia; Humans; Indoles; Injections, Subcutaneous; Male; Middle Aged; Migraine Di | 1993 |
[Multiple value of sumatriptan above that of ergot alkaloids still not proven].
Topics: Ergotamine; Humans; Migraine Disorders; Sumatriptan | 1994 |
Long term use of sumatriptan.
Topics: Humans; Long-Term Care; Migraine Disorders; Sumatriptan | 1994 |
Subcutaneous sumatriptan in a clinical setting: the first 100 consecutive patients with acute migraine in a tertiary care center.
Topics: Acute Disease; Adolescent; Adult; Aged; Ambulatory Care Facilities; Female; Humans; Injections, Subc | 1994 |
Is there a problem with long-term use of sumatriptan in migraine.
Topics: Humans; Male; Middle Aged; Migraine Disorders; Substance-Related Disorders; Sumatriptan | 1994 |
Recommendations for the emergency treatment of migraine headache.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Dexamethasone; Dihydroergotamine; Emergency Me | 1994 |
Treatment of migraine with sumatriptan in the ED.
Topics: Emergency Service, Hospital; Female; Humans; Male; Middle Aged; Migraine Disorders; Sumatriptan | 1994 |
Sumatriptan for migraine.
Topics: Dose-Response Relationship, Drug; Humans; Migraine Disorders; Sumatriptan | 1994 |
New drugs. In the realm of the brain.
Topics: Central Nervous System Agents; Depression; Humans; Hypnotics and Sedatives; Migraine Disorders; Paro | 1993 |
[Greater value of sumatriptan over ergot alkaloids still not proven].
Topics: Adult; Ergot Alkaloids; Ergotamine; Humans; Middle Aged; Migraine Disorders; Sumatriptan | 1993 |
Sumatriptan--a new treatment of migraine.
Topics: Adult; Drug Tolerance; Female; Humans; Male; Migraine Disorders; Receptors, Serotonin; Sumatriptan; | 1993 |
[Migraine: what is new?].
Topics: Central Nervous System; Dura Mater; Ergotamines; Humans; Migraine Disorders; Serotonin Antagonists; | 1993 |
Skin sensitivity to sumatriptan.
Topics: Adult; Drug Eruptions; Female; Humans; Migraine Disorders; Skin Tests; Sumatriptan | 1994 |
Migraine following the use of a 5-hydroxytryptamine antagonist.
Topics: Ergotamine; Female; Humans; Middle Aged; Migraine Disorders; Oligodendroglioma; Ondansetron; Sumatri | 1993 |
Effects of sumatriptan on the cerebral intraparenchymal microcirculation in the cat.
Topics: Animals; Blood Volume; Cats; Cerebrovascular Circulation; Female; Male; Microcirculation; Migraine D | 1993 |
Amplifying effect of sumatriptan on noradrenaline venoconstriction in migraine patients.
Topics: Adolescent; Adult; Drug Interactions; Hand; Humans; Injections, Intravenous; Injections, Subcutaneou | 1993 |
[Sumatriptan (Imigran) and migraine with aura--is the price still too high?].
Topics: Drug Costs; Humans; Indoles; Migraine Disorders; Sulfonamides; Sumatriptan; Vasoconstrictor Agents | 1993 |
From the Food and Drug Administration.
Topics: Cholesterol; Consumer Product Safety; Drug-Related Side Effects and Adverse Reactions; Equipment and | 1993 |
Sumatriptan relieves and prevents peri-operative migraine attacks.
Topics: Adult; Anesthesia, General; Female; Humans; Indoles; Middle Aged; Migraine Disorders; Postoperative | 1993 |
Psychological status during migraine attack and interval before and after treatment with a selective 5-HT1-agonist.
Topics: Adult; Double-Blind Method; Female; Humans; Indoles; Middle Aged; Migraine Disorders; Psychological | 1993 |
Effect of sumatriptan on visual aura symptoms in migraine.
Topics: Female; Humans; Indoles; Middle Aged; Migraine Disorders; Serotonin Receptor Agonists; Sulfonamides; | 1993 |
[Improper equalization of sumatriptan with ergotamine and dihydroergotamine in the Drug Equivalency System].
Topics: Dihydroergotamine; Ergotamine; Humans; Indoles; Migraine Disorders; Serotonin Receptor Agonists; Sul | 1993 |
The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats.
Topics: Adolescent; Adult; Animals; Blood Vessels; Cats; Cerebrovascular Circulation; Dihydroergotamine; Fem | 1993 |
Subcutaneous sumatriptan does not abort attacks of chronic paroxysmal hemicrania (CPH).
Topics: Adult; Humans; Indoles; Male; Migraine Disorders; Serotonin Receptor Agonists; Sulfonamides; Sumatri | 1993 |
The challenge of unexplained disease: migraine.
Topics: Blood Flow Velocity; Humans; Indoles; Migraine Disorders; Serotonin Receptor Agonists; Sulfonamides; | 1993 |
Battle against migraine.
Topics: Electric Stimulation Therapy; Humans; Indoles; Migraine Disorders; Serotonin Antagonists; Sulfonamid | 1993 |
[Unjustified equalization of sumatriptan with ergotamine and dihydroergotamine in the Drug Equivalency System].
Topics: Dihydroergotamine; Ergotamine; Humans; Indoles; Migraine Disorders; Serotonin Receptor Agonists; Sul | 1993 |
Intracranial hypertension and sumatriptan efficacy in a case of chronic paroxysmal hemicrania which became bilateral. (The mechanism of indomethacin in CPH).
Topics: Adult; Brain; Female; Functional Laterality; Humans; Indoles; Indomethacin; Intracranial Pressure; M | 1993 |
Sumatriptan: new relief for migraine headaches.
Topics: Humans; Indoles; Migraine Disorders; Serotonin Receptor Agonists; Sulfonamides; Sumatriptan; Vasodil | 1993 |
Expression of mRNA for the serotonin 5-hydroxytryptamine1D beta receptor subtype in human and bovine cerebral arteries.
Topics: Animals; Base Sequence; Blotting, Northern; Cattle; Cerebral Arteries; Humans; Indoles; Migraine Dis | 1993 |
Cortical spreading depression does not result in the release of calcitonin gene-related peptide into the external jugular vein of the cat: relevance to human migraine.
Topics: Animals; Brain; Calcitonin Gene-Related Peptide; Cats; Cerebrovascular Circulation; Cortical Spreadi | 1993 |
The safety of sumatriptan in asthmatic migraineurs.
Topics: Asthma; Clinical Trials as Topic; Databases, Factual; Humans; Indoles; Migraine Disorders; Serotonin | 1993 |
Sumatriptan for the treatment of acute migraine headache.
Topics: Humans; Indoles; Migraine Disorders; Sulfonamides; Sumatriptan; United States; United States Food an | 1993 |
[Migraine and sumatriptan].
Topics: Humans; Indoles; Migraine Disorders; Sulfonamides; Sumatriptan; Vasoconstrictor Agents | 1993 |
Headache.
Topics: Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Vasoconstrictor Agents | 1995 |
Improvements in health-related quality of life with sumatriptan treatment for migraine.
Topics: Acute Disease; Adolescent; Adult; Aged; Disabled Persons; Efficiency; Female; Health Status; Humans; | 1996 |
Subcutaneous sumatriptan and the migraine aura.
Topics: Humans; Injections, Subcutaneous; Migraine Disorders; Sumatriptan | 1996 |
[Sumatriptan--side effects and problems in routine clinical practice].
Topics: Adult; Cluster Headache; Contraindications; Dose-Response Relationship, Drug; Drug Administration Sc | 1995 |
Sumatriptan and migraine.
Topics: Cost-Benefit Analysis; Humans; Migraine Disorders; Sumatriptan; Vasoconstrictor Agents | 1996 |
Coexistence of migraine and idiopathic intracranial hypertension without papilledema.
Topics: Acetazolamide; Adolescent; Adult; Dihydroergotamine; Diuretics; Ergotamine; Female; Follow-Up Studie | 1996 |
Vasospasm-induced myocardial infarction with sumatriptan.
Topics: Coronary Vasospasm; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Migraine Disorders; | 1996 |
Sumatriptan in clinical practice: a 2-year review of 453 migraine patients.
Topics: Adult; Female; Humans; Male; Middle Aged; Migraine Disorders; Netherlands; Recurrence; Sumatriptan | 1996 |
[Migraine].
Topics: Adolescent; Adult; Age Factors; Age of Onset; Aged; Brain; Child; Child, Preschool; Diagnosis, Diffe | 1996 |
Is overuse of sumatriptan a problem? A population-based study.
Topics: Adult; Analgesics; Denmark; Drug Prescriptions; Drug Utilization; Female; Humans; Male; Middle Aged; | 1996 |
Effects of antimigraine drugs on retinal spreading depression.
Topics: Acetaminophen; Adrenergic beta-Antagonists; Adrenochrome; Analgesics, Non-Narcotic; Animals; Aspirin | 1996 |
EEG and topographic frequency analysis in migraine attack before and after sumatriptan infusion.
Topics: Adult; Electroencephalography; Female; Humans; Injections, Subcutaneous; Male; Migraine Disorders; N | 1996 |
How does sumatriptan perform in clinical practice?
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; In | 1995 |
Oral sumatriptan.
Topics: Administration, Oral; Humans; Migraine Disorders; Sumatriptan | 1996 |
[18 months long-term analysis of effectiveness, safety and tolerance of sumatriptan s.c. in acute therapy of migraine attacks].
Topics: Adult; Drug Tolerance; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Long-Term Care; | 1996 |
Delayed urticaria with sumatriptan.
Topics: Adult; Humans; Male; Migraine Disorders; Sumatriptan; Urticaria | 1996 |
Sumatriptan use in a large group-model health maintenance organization.
Topics: Adolescent; Adult; Drug Utilization Review; Female; Formularies as Topic; Health Maintenance Organiz | 1996 |
Sumatriptan-nonresponders: a survey in 366 migraine patients.
Topics: Administration, Oral; Adult; Body Mass Index; Female; Humans; Injections, Subcutaneous; Male; Middle | 1996 |
Pattern of sumatriptan use and overuse in general practice.
Topics: Administration, Oral; Adult; Cluster Headache; Cohort Studies; Drug Utilization; Family Practice; Fe | 1996 |
Use of sumatriptan in post-ictal migraine headache.
Topics: Adult; Epilepsy; Female; Humans; Male; Middle Aged; Migraine Disorders; Sumatriptan | 1996 |
Distribution and excretion of sumatriptan in human milk.
Topics: Adult; Female; Humans; Migraine Disorders; Milk, Human; Sumatriptan | 1996 |
Distribution of [3H]-sumatriptan binding sites in human brain.
Topics: Blood-Brain Barrier; Brain Chemistry; Brain Stem; Humans; Migraine Disorders; Receptor, Serotonin, 5 | 1996 |
Serotonin syndrome complicating migraine pharmacotherapy.
Topics: Adult; Autonomic Nervous System Diseases; Dihydroergotamine; Drug Synergism; Female; Gastrointestina | 1996 |
Autoradiographic distribution of [3H]sumatriptan-binding sites in post-mortem human brain.
Topics: Adult; Animals; Antiemetics; Blood-Brain Barrier; Brain; Brain Chemistry; Brain Mapping; Guinea Pigs | 1996 |
Sumatriptan and panic-like symptoms.
Topics: Chest Pain; Cluster Headache; Humans; Migraine Disorders; Panic Disorder; Serotonin Receptor Agonist | 1996 |
Investigations with GMC2021 in experimental models predictive of antimigraine activity and coronary side-effect potential.
Topics: Animals; Carotid Arteries; Coronary Vessels; Hemodynamics; Humans; Migraine Disorders; Sumatriptan; | 1996 |
Effect of antimigraine drugs on dural blood flows and resistances and the responses to trigeminal stimulation.
Topics: Animals; Blood Pressure; Carotid Arteries; Cats; Dihydroergotamine; Dose-Response Relationship, Drug | 1996 |
Sumatriptan and episodic pain syndromes other than migraine.
Topics: Humans; Migraine Disorders; Pain; Palliative Care; Periodicity; Sumatriptan; Syndrome | 1996 |
Effects of S20749, a close analogue of sumatriptan, on porcine carotid haemodynamics and human isolated coronary artery.
Topics: Animals; Arteriovenous Anastomosis; Capillaries; Carotid Arteries; Coronary Vessels; Dose-Response R | 1996 |
Nitroglycerin-induced headache.
Topics: Arteriovenous Anastomosis; Dose-Response Relationship, Drug; Head; Headache; Humans; Migraine Disord | 1996 |
Prescribing practices for the management of headache in Newfoundland and Labrador.
Topics: Analgesics; Cohort Studies; Drug Prescriptions; Headache; Humans; Migraine Disorders; Newfoundland a | 1996 |
Impact of sumatriptan on clinic utilization and costs of care in migraineurs.
Topics: Adult; Aged; Chronic Disease; Female; Health Care Costs; Humans; Male; Middle Aged; Migraine Disorde | 1996 |
[Sumatriptan in treatment of migraine and its efficacy and tolerance in self-assessment by patients].
Topics: Adult; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Migraine Disorders; Patient Part | 1996 |
The central cholinergic system has a role in the antinociception induced in rodents and guinea pigs by the antimigraine drug sumatriptan.
Topics: Acetylcholine; Analgesics, Non-Narcotic; Animals; Brain; Dose-Response Relationship, Drug; Female; G | 1996 |
Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism.
Topics: Afferent Pathways; Animals; Cats; Electric Stimulation; Migraine Disorders; Proto-Oncogene Proteins | 1996 |
Subcutaneous dihydroergotamine vs subcutaneous sumatriptan.
Topics: Dihydroergotamine; Humans; Injections, Subcutaneous; Migraine Disorders; Sumatriptan | 1996 |
Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients.
Topics: Adult; Angina Pectoris; Chest Pain; Female; Humans; Male; Middle Aged; Migraine Disorders; Retrospec | 1996 |
Cognitive processing in primary headache: a study on event-related potentials.
Topics: Adolescent; Adult; Aged; Cluster Headache; Cognition; Evoked Potentials; Female; Habituation, Psycho | 1997 |
Effects of avitriptan, a new 5-HT 1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential.
Topics: Animals; Arteriovenous Anastomosis; Blood Pressure; Carotid Arteries; Coronary Vessels; Head; Heart | 1997 |
Sumatriptan prophylaxis for intractable migraine.
Topics: Female; Humans; Middle Aged; Migraine Disorders; Pain, Intractable; Serotonin Receptor Agonists; Sum | 1997 |
History lessons. This incident underscored the importance of a fundamental nursing activity: history-taking.
Topics: Caffeine; Contraindications; Drug Combinations; Drug Interactions; Drug Therapy; Ergotamine; Female; | 1997 |
Sumatriptan-associated myocardial infarction: report of case with attention to potential risk factors.
Topics: Female; Humans; Middle Aged; Migraine Disorders; Myocardial Infarction; Risk Factors; Serotonin Rece | 1997 |
Sumatriptan treatment of acute migraine attacks in a Saudi population.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Dose-Response Relationship, Drug; Drug Monit | 1997 |
The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Dura Mater; Electric Stimulation; | 1997 |
[Cluster headache: misjudged because unknown].
Topics: Adult; Analgesics; Calcium Channel Blockers; Cluster Headache; Diagnosis, Differential; Humans; Male | 1997 |
[Migraine--diagnosis, differential diagnosis and therapy].
Topics: Adrenergic beta-Antagonists; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Calc | 1997 |
Use of sumatriptan in Denmark in 1994-5: an epidemiological analysis of nationwide prescription data.
Topics: Adolescent; Adult; Aging; Analgesics, Non-Narcotic; Cohort Studies; Denmark; Drug Prescriptions; Dru | 1997 |
[The treatment of migraine].
Topics: Adrenergic beta-Antagonists; Amitriptyline; Calcium Channel Blockers; Dihydroergotamine; Ergotamine; | 1997 |
Efficacy of antimigrainous therapy in the treatment of migraine-associated dizziness.
Topics: Adolescent; Adult; Aged; Dizziness; Drug Therapy; Female; Humans; Male; Middle Aged; Migraine Disord | 1997 |
Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model.
Topics: Animals; Blood-Brain Barrier; Calcitonin Gene-Related Peptide; Disease Models, Animal; Dura Mater; E | 1997 |
The site of common side effects of sumatriptan.
Topics: Adult; Cluster Headache; Humans; Male; Migraine Disorders; Paresthesia; Sumatriptan; Vasoconstrictor | 1997 |
Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzopyrans; Binding, Competitive; Cell Membrane; C | 1997 |
Would any acute treatment for migraine demonstrate recurrence?
Topics: Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Recurrence; Serotonin Receptor Agonists; Sumat | 1997 |
What is lacking in the treatment of paediatric and adolescent migraine?
Topics: Adolescent; Adult; Analgesics; Child; Child, Preschool; Clinical Trials as Topic; Humans; Migraine D | 1997 |
Recurrent neck pain as a variant of migraine: description of four cases.
Topics: Adult; Carotid Arteries; Female; Humans; Magnetic Resonance Imaging; Migraine Disorders; Neck; Pain; | 1997 |
After sumatriptan-the flood.
Topics: Humans; Migraine Disorders; Sumatriptan | 1997 |
Co-administration of fluoxetine and sumatriptan: the Canadian experience.
Topics: Canada; Depression; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Migraine Disor | 1997 |
Stability of sumatriptan succinate in extemporaneously prepared oral liquids.
Topics: Administration, Oral; Chromatography, High Pressure Liquid; Drug Stability; Drug Storage; Humans; Hy | 1997 |
Responsiveness of non-IHS migraine and tension-type headache to sumatriptan.
Topics: Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Tension-Type Headache | 1997 |
Cost benefit of sumatriptan to an employer.
Topics: Absenteeism; Cost of Illness; Cost-Benefit Analysis; Humans; Interviews as Topic; Migraine Disorders | 1997 |
Migraine research methods.
Topics: Analgesics, Opioid; Butorphanol; Chlorpromazine; Dopamine Antagonists; Humans; Migraine Disorders; R | 1997 |
The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine.
Topics: Animals; Binding, Competitive; Cats; Cerebral Arteries; Cyclic AMP; Disease Models, Animal; Guinea P | 1997 |
Migraine relief.
Topics: GABA Agents; Humans; Migraine Disorders; Sumatriptan; Valproic Acid; Vasoconstrictor Agents | 1997 |
Trigeminal ganglion elicited increases in nucleus trigeminal caudalis blood flow: a novel migraine model.
Topics: Animals; Cats; Disease Models, Animal; Electric Stimulation; Electrophysiology; Female; Male; Migrai | 1997 |
[Drug-clinics. The drug of the month. Imitrex nasal spray (sumatriptan)].
Topics: Administration, Intranasal; Administration, Oral; Cluster Headache; Humans; Injections, Subcutaneous | 1997 |
A triptan too far?
Topics: Acute Disease; Clinical Trials as Topic; Humans; Indoles; Migraine Disorders; Oxazoles; Oxazolidinon | 1998 |
Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat.
Topics: Animals; Cats; Cerebrovascular Circulation; Cranial Sinuses; Electric Stimulation; Gene Expression R | 1998 |
[Treatment of migraine attacks and migraine prophylaxis: recommendations of the German Migraine and Headache Society].
Topics: Adult; Analgesics; Antiemetics; Child; Clinical Protocols; Germany; Humans; Metoprolol; Migraine Dis | 1998 |
[Critical evaluation of "guidelines"].
Topics: Adult; Dihydroergotamine; Female; Humans; Migraine Disorders; Practice Guidelines as Topic; Quality | 1998 |
A 27-year-old woman with migraine headaches, 1 year later.
Topics: Adult; Female; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan | 1998 |
Relief for migraine sufferers.
Topics: GABA Agents; Humans; Migraine Disorders; Sumatriptan; Valproic Acid; Vasoconstrictor Agents | 1998 |
Practicability and acceptance of subcutaneous self-administration of the selective serotonin agonist sumatriptan.
Topics: Adult; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Migraine Disorders; Patient Acce | 1998 |
5-HT1B receptor polymorphism and clinical response to sumatriptan.
Topics: Adult; Aged; Alleles; Female; Gene Frequency; Humans; Male; Middle Aged; Migraine Disorders; Polymor | 1998 |
Neurogenic vs vascular mechanisms of sumatriptan and ergot alkaloids in migraine.
Topics: Arteries; Brain; Dura Mater; Ergot Alkaloids; Humans; Migraine Disorders; Receptor, Serotonin, 5-HT1 | 1998 |
Migraine-like symptoms triggered by occipital lobe seizures: response to sumatriptan.
Topics: Adult; Electroencephalography; Epilepsy; Female; Humans; Magnetic Resonance Imaging; Male; Migraine | 1998 |
It never hurts to check. Taking the time to read a label benefited this migraine sufferer.
Topics: Adult; Contraindications; Drug Labeling; Female; Humans; Medication Errors; Migraine Disorders; Oxaz | 1998 |
Dosing of oral sumatriptan: a review of our first 104 patients.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Humans; Injections, Subcutaneous; Migraine D | 1998 |
Chromosomal localization of the 5-HT1F receptor gene: no evidence for involvement in response to sumatriptan in migraine patients.
Topics: Adult; Aged; Chromosome Mapping; Chromosomes, Human, Pair 3; Female; Humans; Male; Middle Aged; Migr | 1998 |
Multiple intracerebral hemorrhages and vasospasm following antimigrainous drug abuse.
Topics: Acute Disease; Adult; Analgesics, Non-Narcotic; Cerebral Hemorrhage; Ergotamine; Female; Humans; Isc | 1998 |
Coronary side-effect potential of current and prospective antimigraine drugs.
Topics: Adolescent; Adult; Aged; Angina Pectoris; Child; Coronary Vessels; Dihydroergotamine; Ergotamine; Fe | 1998 |
[Effect of KB-2796, a novel calcium channel blocker, on spreading depression in rat hippocampal slices].
Topics: Animals; Calcium Channel Blockers; Cortical Spreading Depression; Flunarizine; Hippocampus; Histamin | 1998 |
How does sumatriptan nasal spray perform in clinical practice?
Topics: Administration, Intranasal; Adult; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Pati | 1998 |
Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine.
Topics: Adult; Aged; Animals; Blood Vessels; Capillary Permeability; Choroid; Electric Stimulation; Female; | 1998 |
A fluorescence-based method for assessing dural protein extravasation induced by trigeminal ganglion stimulation.
Topics: Animals; Biological Transport; Dura Mater; Electric Stimulation; Evans Blue; Extravasation of Diagno | 1998 |
BMS-181885, a 5-HT1B/1D receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential.
Topics: Animals; Arteriovenous Anastomosis; Carotid Arteries; Coronary Vessels; Hemodynamics; Humans; In Vit | 1998 |
A case of chronic paroxysmal hemicrania responding to subcutaneous sumatriptan.
Topics: Adult; Chronic Disease; Cluster Headache; Female; Humans; Injections, Subcutaneous; Migraine Disorde | 1998 |
When the migraine rx isn't working.
Topics: Administration, Oral; Adult; Contraindications; Female; Humans; Indoles; Migraine Disorders; Patient | 1998 |
Ischemic colitis and sumatriptan use.
Topics: Adult; Colitis, Ischemic; Female; Humans; Male; Middle Aged; Migraine Disorders; Serotonin Receptor | 1998 |
Sumatriptan is not the only analgesic used inappropriately.
Topics: Analgesics; Health Services Misuse; Humans; Migraine Disorders; Substance-Related Disorders; Sumatri | 1998 |
New "triptans" and other drugs for migraine.
Topics: Adrenergic beta-Antagonists; Amitriptyline; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive | 1998 |
What's causing angina in this headache patient?
Topics: Adult; Angina Pectoris; Coronary Vasospasm; Humans; Male; Migraine Disorders; Sumatriptan; Vasoconst | 1998 |
Imitrex.
Topics: Adolescent; Drug Hypersensitivity; Female; Humans; Injections, Subcutaneous; Migraine Disorders; Sum | 1998 |
Level of nitric oxide-dependent cGMP in patients with migraine.
Topics: Adult; Cyclic GMP; Female; Humans; Male; Middle Aged; Migraine Disorders; Nitric Oxide; Serotonin Re | 1998 |
[Zolmitriptan].
Topics: Chemistry, Pharmaceutical; Humans; Indoles; Migraine Disorders; Oxazoles; Oxazolidinones; Piperidine | 1998 |
Reduction of labor costs associated with treating migraine in the workplace.
Topics: Efficiency; Humans; Injections, Subcutaneous; Migraine Disorders; Sumatriptan; United States; Vasoco | 1999 |
Identification of (-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-benzoylamino)- 3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3S-ol as a potential antimigraine agent.
Topics: Animals; Benzamides; Benzopyrans; Dose-Response Relationship, Drug; Methylcellulose; Mice; Migraine | 1999 |
Adult abdominal migraine and sumatriptan: a case report.
Topics: Abdominal Pain; Adult; Diagnosis, Differential; Female; Humans; Middle Aged; Migraine Disorders; Ser | 1998 |
Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes.
Topics: Adult; Cost of Illness; Efficiency; Female; Health Maintenance Organizations; Health Services; Human | 1999 |
Development and implementation of practice guidelines (Part 1).
Topics: Acquired Immunodeficiency Syndrome; Colony-Stimulating Factors; Drug Utilization; Hospital Bed Capac | 1994 |
Cost-effectiveness of sumatriptan in a managed care population.
Topics: Cost of Illness; Cost-Benefit Analysis; Drug Costs; Health Expenditures; Humans; Independent Practic | 1997 |
Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine.
Topics: Administration, Oral; Caffeine; Cost-Benefit Analysis; Ergotamine; Migraine Disorders; Sensitivity a | 1997 |
The inhibition of nicotine-evoked relaxation of the guinea-pig isolated basilar artery by some analgesic drugs and progesterone.
Topics: Analgesics; Animals; Aspirin; Basilar Artery; Capsaicin; Dinoprost; Guinea Pigs; In Vitro Techniques | 1999 |
A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine.
Topics: Administration, Oral; Female; Humans; Menstruation; Migraine Disorders; Pilot Projects; Sumatriptan | 1999 |
Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective.
Topics: Activities of Daily Living; Adolescent; Adult; Efficiency; Female; Health Resources; Humans; Male; M | 1999 |
Tolfenamic acid decreases migraine recurrence when used with sumatriptan.
Topics: Adult; Analgesics; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Migraine Disorders; | 1999 |
Sumatriptan and sensory neuropeptide activity in subarachnoid haemorrhage: an hypothesis.
Topics: Animals; Calcitonin Gene-Related Peptide; Humans; Migraine Disorders; Subarachnoid Hemorrhage; Subst | 1995 |
Issues relating to the assessment of migraine recurrence following triptan therapy.
Topics: Humans; Migraine Disorders; Recurrence; Serotonin Receptor Agonists; Sumatriptan | 1999 |
Prolonged migraine aura without headache arrested by sumatriptan. A case report with further considerations.
Topics: Adult; Female; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Time Factors; T | 1999 |
Zolmitriptan.
Topics: Drug Interactions; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists | 1999 |
Migraine: which triptan?
Topics: Drug Administration Routes; Drug Costs; Family Practice; Humans; Migraine Disorders; Recurrence; Ser | 1999 |
Vasoconstrictive properties of the 5HT1B/1D agonists: response to Dahlöf and Mathew.
Topics: Humans; Indoles; Migraine Disorders; Piperidines; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, | 1999 |
Interictal and postictal cognitive changes in migraine.
Topics: Adult; Attention; Cognition Disorders; Female; Humans; Male; Migraine Disorders; Neurocognitive Diso | 1999 |
Headache medication-use among primary care headache patients in a health maintenance organization.
Topics: Adolescent; Adult; Aged; Analgesics; Analgesics, Opioid; Drug Therapy, Combination; Drug Utilization | 1999 |
Pharmacological evidence that alpha1-and alpha2-adrenoceptors mediate vasoconstriction of carotid arteriovenous anastomoses in anaesthetized pigs.
Topics: Anesthesia; Animals; Arteriovenous Anastomosis; Azepines; Carotid Arteries; Hemodynamics; Migraine D | 1999 |
Primary care in a health maintenance organization.
Topics: Analgesics; Drug Utilization; Health Maintenance Organizations; Humans; Injections, Subcutaneous; Mi | 1999 |
Efficacy of 5HT in migraine.
Topics: Action Potentials; Animals; Cats; Cranial Sinuses; Electric Stimulation; Humans; Migraine Disorders; | 1999 |
Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-As | 1999 |
Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Analgesics; Antiemetics; Calcium Channel Block | 1999 |
Effects of sumatriptan on nitric oxide and superoxide balance during glyceryl trinitrate infusion in the rat. Implications for antimigraine mechanisms.
Topics: Animals; Blood Flow Velocity; Blood Pressure; Cerebrovascular Circulation; Dose-Response Relationshi | 1999 |
Managed migraine.
Topics: Humans; Migraine Disorders; Sumatriptan; Vasoconstrictor Agents | 1999 |
HMO direct costs and health care resources use after implementation of a monthly limit on sumatriptan.
Topics: Drug Costs; Female; Health Care Costs; Health Maintenance Organizations; Humans; Longitudinal Studie | 1999 |
Use and overuse of sumatriptan. Pharmacoepidemiological studies based on prescription register and interview data.
Topics: Cluster Headache; Denmark; Drug Prescriptions; Female; Humans; Interviews as Topic; Male; Migraine D | 1999 |
Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry.
Topics: Bufotenin; Chromatography, High Pressure Liquid; Humans; Indoles; Mass Spectrometry; Migraine Disord | 2000 |
Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288.
Topics: Animals; Calcitonin Gene-Related Peptide; Cats; Cerebral Arteries; Cerebrovascular Circulation; Cran | 1999 |
Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370.
Topics: Animals; Benzamides; Cerebral Arteries; Decerebrate State; Electric Stimulation; Humans; Hyperalgesi | 1999 |
Patient-selected dosing in a six-month open-label study evaluating oral sumatriptan in the acute treatment of migraine. Sumatriptan Tablets S2CM10 Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Analgesia; Female; Humans; Male; Middl | 1999 |
Intranasal sumatriptan for the acute treatment of migraine in children.
Topics: Administration, Intranasal; Child; Humans; Migraine Disorders; Sumatriptan | 2000 |
Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study.
Topics: Abortion, Spontaneous; Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Middle Aged; Migr | 1999 |
Triptans and migraine.
Topics: Humans; Migraine Disorders; Randomized Controlled Trials as Topic; Serotonin; Serotonin Receptor Ago | 2000 |
Pregnancy outcome following prescription for sumatriptan.
Topics: Adult; Drug Prescriptions; Female; Humans; Infant, Low Birth Weight; Infant, Newborn; Maternal Expos | 2000 |
Decision making in migraine patients taking sumatriptan: an exploratory study.
Topics: Adult; Decision Support Techniques; Female; Humans; Male; Middle Aged; Migraine Disorders; Models, P | 2000 |
Acquired transient stuttering during a migraine attack.
Topics: Adult; Female; Humans; Migraine Disorders; Serotonin Receptor Agonists; Stuttering; Sumatriptan | 2000 |
Transient global amnesia, migraine, thalamic infarct, dihydroergotamine, and sumatriptan.
Topics: Amnesia, Transient Global; Brain Infarction; Dihydroergotamine; Female; Humans; Injections, Subcutan | 2000 |
Zolmitriptan: new product. Similar to sumatriptan.
Topics: Clinical Trials as Topic; Drug Interactions; Humans; Migraine Disorders; Oxazoles; Placebos; Recurre | 1999 |
Sumatriptan modifies cortical free radical release during cortical spreading depression. A novel antimigraine action for sumatriptan?
Topics: Animals; Cats; Cerebral Cortex; Cortical Spreading Depression; Free Radicals; Male; Membrane Potenti | 2000 |
Migraine revolution and sumatriptan.
Topics: Capsules; Humans; Indoles; Migraine Disorders; Pyrrolidines; Serotonin Receptor Agonists; Sumatripta | 2000 |
Zolmitriptan reverses blink reflex changes induced during the migraine attack in humans.
Topics: Adolescent; Adult; Blinking; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazol | 2000 |
Triptans to the rescue: effective therapy for migraine headaches in the workplace.
Topics: Absenteeism; Adult; Cost-Benefit Analysis; Efficiency; Female; Humans; Indoles; Injections, Subcutan | 2000 |
Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies.
Topics: Dihydroergotamine; Humans; Migraine Disorders; Nebulizers and Vaporizers; Sumatriptan; Vasoconstrict | 2000 |
A pilot study to measure cognitive efficiency during migraine.
Topics: Cognition; Migraine Disorders; Neuropsychological Tests; Pilot Projects; Reference Values; Serotonin | 2000 |
Is it migraine or cluster?
Topics: Adult; Calcium Channel Blockers; Cluster Headache; Diagnosis, Differential; Female; Humans; Migraine | 2000 |
Electriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan.
Topics: Double-Blind Method; Humans; Indoles; Migraine Disorders; Pyrrolidines; Randomized Controlled Trials | 2000 |
Effects of subcutaneous sumatriptan on plasma growth hormone concentrations in migraine patients.
Topics: Adult; Analysis of Variance; Area Under Curve; Case-Control Studies; Double-Blind Method; Female; Hu | 2000 |
Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan.
Topics: Acute Disease; Double-Blind Method; Humans; Indoles; Migraine Disorders; Pyrrolidines; Randomized Co | 2000 |
Treatment options for acute migraine.
Topics: Acute Disease; Adult; Female; Humans; Migraine Disorders; Oxazolidinones; Patient Selection; Practic | 2000 |
Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model.
Topics: Animals; Axons; Brain; Calcitonin Gene-Related Peptide; Disease Models, Animal; Dura Mater; Female; | 2000 |
Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine.
Topics: Absenteeism; Cost of Illness; Cost-Benefit Analysis; Decision Trees; Double-Blind Method; Female; Hu | 2000 |
Oral therapy for migraine: comparisons between rizatriptan and sumatriptan. A review of four randomized, double-blind clinical trials.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Migraine Disord | 2000 |
Rizatriptan versus usual care in long-term treatment of migraine.
Topics: Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Time Factors; Triazoles; Trypt | 2000 |
The (suma)triptan history revisited.
Topics: Animals; History, 20th Century; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan | 2000 |
[Effect of migraine medications on monocyte chemotaxis] .
Topics: Adult; Analgesics; Aspirin; Chemotaxis, Leukocyte; Dihydroergotamine; Humans; Immune Tolerance; Male | 2000 |
Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine.
Topics: Animals; Cattle; Colforsin; Cyclic AMP; Dogs; Dose-Response Relationship, Drug; HeLa Cells; Humans; | 2000 |
Functional profile of almotriptan in animal models predictive of antimigraine activity.
Topics: Animals; Arteriovenous Anastomosis; Carotid Arteries; Cats; Dogs; Dose-Response Relationship, Drug; | 2000 |
Cardiovascular safety profile of almotriptan, a new indolic derivative for the treatment of migraine.
Topics: Animals; Blood Pressure; Cardiovascular System; Cats; Coronary Circulation; Coronary Vessels; Dogs; | 2000 |
Cortical spreading depression produces increased cGMP levels in cortex and brain stem that is inhibited by tonabersat (SB-220453) but not sumatriptan.
Topics: Analgesics; Animals; Benzamides; Benzopyrans; Brain Stem; Cerebral Cortex; Cortical Spreading Depres | 2001 |
Are triptans with enhanced lipophilicity used for the acute treatment of migraine associated with an increased consulting rate for depressive illness?
Topics: Cohort Studies; Depression; Female; Humans; Indoles; Male; Migraine Disorders; Oxazolidinones; Piper | 2000 |
Migraine-like headache in bacterial meningitis.
Topics: Adult; Female; Humans; Male; Meningitis, Bacterial; Migraine Disorders; Serotonin Receptor Agonists; | 2000 |
Effect of sumatriptan on health care resource use among patients with migraine.
Topics: Adult; Drug Utilization Review; Female; Health Resources; Humans; Idaho; Insurance Claim Review; Mal | 2001 |
Pharmacology and efficacy of eletriptan for the treatment of migraine attacks.
Topics: Double-Blind Method; Female; Humans; Indoles; Male; Migraine Disorders; Pyrrolidines; Randomized Con | 2000 |
Sumatriptan: what do we know about fetal risks?
Topics: Denmark; Female; Humans; Infant, Newborn; Infant, Premature; Maternal Exposure; Migraine Disorders; | 2001 |
Butterscotch masks the bitter taste of sumatriptan nasal spray.
Topics: Acute Disease; Administration, Intranasal; Aerosols; Candy; Humans; Migraine Disorders; Serotonin Re | 2001 |
Zolmitriptan versus sumatriptan comparison trial.
Topics: Acute Disease; Clinical Trials as Topic; Communication; Humans; Migraine Disorders; Oxazolidinones; | 2001 |
Economic implications of early treatment of migraine with sumatriptan tablets.
Topics: Cost Control; Drug Costs; Migraine Disorders; Pain; Retrospective Studies; Sumatriptan; Vasoconstric | 2001 |
Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis.
Topics: Canada; Costs and Cost Analysis; Humans; Migraine Disorders; Models, Economic; Serotonin Receptor Ag | 2001 |
Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model.
Topics: Animals; Capillaries; Dura Mater; Electric Stimulation; Female; Immunohistochemistry; Indoles; Male; | 2001 |
Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan.
Topics: Adult; Congenital Abnormalities; Delivery, Obstetric; Female; Humans; Infant, Newborn; Middle Aged; | 2001 |
Sumatriptin vs dihydroergotamine: patient preference.
Topics: Administration, Inhalation; Analgesics, Non-Narcotic; Dihydroergotamine; Humans; Migraine Disorders; | 2001 |
An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calcitonin Gene-Related Peptide; Disease | 2001 |
Status migrainosus in children and adolescents.
Topics: Adolescent; Child; Diagnosis, Differential; Dihydroergotamine; Drug Therapy, Combination; Female; Fo | 2001 |
Intracranial hemorrhages associated with sumatriptan.
Topics: Adult; Angiography, Digital Subtraction; Female; Humans; Intracranial Hemorrhages; Middle Aged; Migr | 2001 |
[Aspirin, triptan tablet, nasal spray, injection. Even the most severe migraine capitulates].
Topics: Administration, Intranasal; Aspirin; Cluster Headache; Humans; Injections, Intravenous; Injections, | 2001 |
Effect of rizatriptan in the spectrum of headache.
Topics: Clinical Trials as Topic; Humans; Migraine Disorders; Retrospective Studies; Serotonin Receptor Agon | 2001 |
[Diagnosis and recent treatment of migraine].
Topics: Adolescent; Adult; Aged; Female; Humans; Japan; Male; Medical Records; Middle Aged; Migraine Disorde | 2000 |
Patterns of ergotamine and sumatriptan use in the Netherlands from 1991 to 1997.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Caffeine; Cohort Studies; Cycl | 2001 |
[New potent serotonin receptor agonist. Helps migraine patients even when other triptans fail].
Topics: Clinical Trials as Topic; Humans; Indoles; Migraine Disorders; Pyrrolidines; Serotonin Receptor Agon | 2001 |
[Migraine headache. Severe attacks: triptans are essential].
Topics: Clinical Trials as Topic; Humans; Indoles; Migraine Disorders; Serotonin Receptor Agonists; Sumatrip | 2001 |
A systematic review of the use of triptans in acute migraine.
Topics: Humans; Migraine Disorders; Research Design; Serotonin Receptor Agonists; Sumatriptan | 2001 |
[Effect of sumatriptan on cerebral blood flow during migraine headache: measurement by sequential SPECT used 99mTc-ECD background subtraction method].
Topics: Adolescent; Adult; Brain; Cerebrovascular Circulation; Cysteine; Humans; Middle Aged; Migraine Disor | 2001 |
When should triptans be taken during a migraine attack?
Topics: Humans; Migraine Disorders; Sumatriptan; Time Factors; Vasoconstrictor Agents | 2001 |
An open preference study with sumatriptan 50 mg and zolmitriptan 2.5 mg in 100 migraine patients.
Topics: Adult; Chi-Square Distribution; Confidence Intervals; Cross-Over Studies; Female; Humans; Male; Midd | 2001 |
Migraine treatment.
Topics: Adolescent; Dose-Response Relationship, Drug; Humans; Migraine Disorders; Sumatriptan | 2001 |
Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis.
Topics: Administration, Oral; Adult; Double-Blind Method; Humans; Indoles; Migraine Disorders; Nausea; Oxazo | 2001 |
Immunological aspects in migraine: increase of IL-10 plasma levels during attack.
Topics: Adult; Female; Humans; Interferon-gamma; Interleukin-10; Interleukin-4; Interleukin-5; Male; Middle | 2001 |
Reduction in the intensity of abortive migraine drug use during coumarin therapy.
Topics: Anticoagulants; Aspirin; Coumarins; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erg | 2001 |
Effects of medication use on health state in postictal migraineurs.
Topics: Adult; Affect; Female; Health Status; Humans; Interpersonal Relations; Male; Migraine Disorders; Per | 2001 |
Dexamethasone decreases migraine recurrence observed after treatment with a triptan combined with a nonsteroidal anti-inflammatory drug.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Dexamethasone; | 2001 |
Safety profile of almotriptan, a new antimigraine agent. Effects on central nervous system, renal function and respiratory dynamics.
Topics: Animals; Behavior, Animal; Central Nervous System; Dogs; Drug Interactions; Guinea Pigs; Indoles; Ki | 2001 |
How it started.
Topics: Dose-Response Relationship, Drug; Ergotamine; Humans; Migraine Disorders; Sumatriptan; Vasoconstrict | 2001 |
Sumatriptan by injection.
Topics: Clinical Trials as Topic; Dihydroergotamine; Dose-Response Relationship, Drug; Humans; Injections, S | 2001 |
The sumatriptan difference.
Topics: Administration, Intranasal; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Meta | 2001 |
Sumatriptan and naratriptan tolerability and safety: an update of post-marketing experience.
Topics: Contraindications; Coronary Circulation; Dose-Response Relationship, Drug; Humans; Indoles; Injectio | 2001 |
Sumatriptan in paediatric and adolescent migraine.
Topics: Acute Disease; Administration, Intranasal; Adolescent; Child; Clinical Trials as Topic; Dose-Respons | 2001 |
Bringing sumatriptan to primary care.
Topics: Humans; Migraine Disorders; Patient Care Team; Patient Satisfaction; Primary Health Care; Sumatripta | 2001 |
Looking forward: the expanding utility of sumatriptan and naratriptan.
Topics: Headache Disorders; Humans; Indoles; Migraine Disorders; Piperidines; Primary Health Care; Serotonin | 2001 |
Building on the sumatriptan experience: the development of naratriptan.
Topics: Administration, Oral; Biological Availability; Clinical Trials as Topic; Dose-Response Relationship, | 2001 |
Different approaches to valuing the lost productivity of patients with migraine.
Topics: Absenteeism; Cost of Illness; Humans; Migraine Disorders; Occupations; Patient Satisfaction; Pennsyl | 2001 |
Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine.
Topics: Absenteeism; Acute Disease; Administration, Oral; Adult; Cost of Illness; Cost-Benefit Analysis; Eco | 2001 |
Migraine, eating disorders, and triptans: an unrecognized risk?
Topics: Feeding and Eating Disorders; Humans; Migraine Disorders; Risk Factors; Sumatriptan; Vasoconstrictor | 2001 |
Assessing patient preference in migraine treatment.
Topics: Clinical Trials as Topic; Humans; Migraine Disorders; Oxazolidinones; Patient Satisfaction; Research | 2001 |
Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries.
Topics: Arteries; Basilar Artery; Carotid Artery, Internal; Coronary Vessels; Humans; In Vitro Techniques; I | 2001 |
Tolerability of sumatriptan: clinical trials and postmarketing experience.
Topics: Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Vasoconstrictor Agents | 2001 |
Intracranial hemorrhages associated with sumatriptan.
Topics: Cerebral Hemorrhage; Humans; Migraine Disorders; Sumatriptan | 2001 |
Sumatriptan responsiveness and clinical, psychiatric and psychologic features in migraine patients.
Topics: Adult; Female; Humans; Male; Menstrual Cycle; Mental Disorders; Middle Aged; Migraine Disorders; Neu | 2001 |
Intracranial hemorrhages associated with sumatriptan.
Topics: Cerebral Hemorrhage; Humans; Migraine Disorders; Sumatriptan | 2001 |
[Migraine and facial pain].
Topics: Adult; Analgesics; Analgesics, Non-Narcotic; Carbamazepine; Child; Diagnosis, Differential; Dihydroe | 2001 |
[Migraine therapy. NSAID are included as first choice].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Humans; Migraine Disorders | 2001 |
Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model.
Topics: Brain; Caudate Nucleus; Cerebrovascular Circulation; Cortical Spreading Depression; Functional Later | 2002 |
[Choice of triptan in migraine].
Topics: Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Vasoconstrictor Agents | 2001 |
Sumatriptan use in patients with migraine.
Topics: Absenteeism; Adult; Bias; Comorbidity; Contraceptives, Oral; Drug Interactions; Female; Humans; Migr | 2002 |
Cost savings in migraine associated with less chest pain on new triptan therapy.
Topics: Chest Pain; Cohort Studies; Cost Savings; Cost-Benefit Analysis; Data Collection; Female; Humans; In | 2002 |
[New triptanes in control of migraine attacks. More rapid onset of action--more efficient reduction of pain].
Topics: Clinical Trials as Topic; Humans; Indoles; Migraine Disorders; Pyrrolidines; Serotonin Receptor Agon | 2002 |
Successful treatment of threatening limb loss ischemia of the upper limb caused by ergotamine. A case report and review of the literature.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Angiography; Arm; Arterial Occlusive Diseases; E | 2002 |
[Migraine has to be treated. Otherwise a stroke threatens].
Topics: Humans; Indoles; Migraine Disorders; Pyrrolidines; Risk Factors; Serotonin Receptor Agonists; Stroke | 2002 |
Evidence-based migraine therapy.
Topics: Evidence-Based Medicine; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Triaz | 2001 |
Imigran: Ten years of improving the lives of migraine patients. Rome, 24 March 2000. Proceedings of a conference.
Topics: Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Vasoconstrictor Agents | 2001 |
Triptan medications to treat acute migraine.
Topics: Acute Disease; Clinical Trials as Topic; Humans; Indoles; Meta-Analysis as Topic; Migraine Disorders | 2002 |
Triptan medications to treat acute migraine.
Topics: Acute Disease; Humans; Indoles; Meta-Analysis as Topic; Migraine Disorders; Serotonin Receptor Agoni | 2002 |
Triptan medications to treat acute migraine.
Topics: Acute Disease; Humans; Indoles; Meta-Analysis as Topic; Migraine Disorders; Serotonin Receptor Agoni | 2002 |
Clinical benefits of early triptan therapy for migraine.
Topics: Acute Disease; Dose-Response Relationship, Drug; Early Diagnosis; Humans; Migraine Disorders; Recurr | 2002 |
Tripstar: a comprehensive patient-based approach to compare triptans.
Topics: Acute Disease; Decision Support Techniques; Endpoint Determination; Humans; Meta-Analysis as Topic; | 2002 |
Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan.
Topics: Adolescent; Adult; Chest Pain; Cohort Studies; Cost Savings; Cost-Benefit Analysis; Drug Costs; Elec | 2002 |
[Triptanes are still effective in the middle of a migraine attack. Best effect before reaching high point].
Topics: Drug Administration Schedule; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; | 2002 |
Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain.
Topics: Female; Humans; Indoles; Male; Migraine Disorders; Oxazolidinones; Piperidines; Prospective Studies; | 2002 |
Migraine, Midrin, and Imitrex.
Topics: Acetaminophen; Antipyrine; Chloral Hydrate; Drug Combinations; Humans; Methylamines; Migraine Disord | 2002 |
Mixing sumatriptan.
Topics: Acute Disease; Drug Therapy, Combination; Humans; Injections, Subcutaneous; Migraine Disorders; Salv | 2002 |
The name of a drug used for the treatment of migraine.
Topics: Education, Medical, Undergraduate; Health Knowledge, Attitudes, Practice; Humans; Migraine Disorders | 2002 |
Management of migraine.
Topics: Adrenal Cortex Hormones; Aspirin; Clonidine; Humans; Indoles; Migraine Disorders; Propranolol; Sulfo | 1992 |
Sumatriptan and cerebral perfusion in healthy volunteers.
Topics: Adult; Cerebrovascular Circulation; Humans; Indoles; Male; Middle Aged; Migraine Disorders; Sulfonam | 1992 |
Sumatriptan.
Topics: Humans; Indoles; Migraine Disorders; Sulfonamides; Sumatriptan; Vasoconstrictor Agents | 1992 |
Sumatriptan for migraine.
Topics: Administration, Oral; Clinical Trials as Topic; Humans; Indoles; Injections, Subcutaneous; Migraine | 1992 |
Sumatriptan.
Topics: History, 20th Century; Humans; Indoles; Male; Migraine Disorders; Receptors, Serotonin; Sulfonamides | 1992 |
Sumatriptan arrests migraine aura.
Topics: Adult; Humans; Indoles; Male; Migraine Disorders; Sulfonamides; Sumatriptan | 1992 |
Cardiorespiratory distress after sumatriptan given by injection.
Topics: Adult; Aged; Arrhythmias, Cardiac; Female; Humans; Indoles; Male; Migraine Disorders; Sulfonamides; | 1992 |
Cardiorespiratory distress after sumatriptan given by injection.
Topics: Heart; Humans; Indoles; Migraine Disorders; Sulfonamides; Sumatriptan; Vasoconstrictor Agents | 1992 |
[Sumatriptan (Imigran) to patients with hemiplegic migraine?].
Topics: Humans; Indoles; Migraine Disorders; Serotonin Receptor Agonists; Sulfonamides; Sumatriptan; Vasocon | 1992 |
Lack of effect of the antimigraine drugs, sumatriptan, ergotamine and dihydroergotamine on arteriovenous anastomotic shunting in the dura mater of the pig.
Topics: Animals; Arteriovenous Anastomosis; Dihydroergotamine; Dura Mater; Ergotamine; Hemodynamics; Indoles | 1992 |
[Sumatriptan (Imigran) and migraine with aura--is the price too high?].
Topics: Denmark; Drug Costs; Humans; Indoles; Migraine Disorders; Sulfonamides; Sumatriptan | 1992 |
Sumatriptan, serotonin, migraine, and money.
Topics: Acute Disease; Costs and Cost Analysis; Humans; Indoles; Migraine Disorders; Recurrence; Serotonin; | 1992 |
Headache recurrence after subcutaneous sumatriptan.
Topics: Adult; Female; Humans; Indoles; Injections, Subcutaneous; Male; Middle Aged; Migraine Disorders; Rec | 1992 |
Migraine.
Topics: Coronary Disease; Humans; Indoles; Migraine Disorders; Sulfonamides; Sumatriptan; Vasoconstrictor Ag | 1992 |
Cost of sumatriptan.
Topics: Fees, Pharmaceutical; Humans; Indoles; Migraine Disorders; Sulfonamides; Sumatriptan | 1992 |
Sumatriptan and other drugs used in migraine treatment.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Tricycl | 1992 |
Sumatriptan and recurrence of migraine.
Topics: Humans; Indoles; Migraine Disorders; Recurrence; Sulfonamides; Sumatriptan; Vasoconstrictor Agents | 1992 |
5-Hydroxtryptamine1D receptor agonism predicts antimigraine efficacy.
Topics: Adenylyl Cyclase Inhibitors; Amitriptyline; Animals; Cattle; Caudate Nucleus; Dihydroergotamine; Erg | 1991 |
Serotonin receptors and headache.
Topics: Cluster Headache; Headache; Humans; Indoles; Migraine Disorders; Receptors, Serotonin; Sulfonamides; | 1991 |
Sumatriptan. From molecule to man. An official session at the 8th Migraine Trust International Symposium. London, UK, 28 September 1990. Proceedings.
Topics: Humans; Indoles; Migraine Disorders; Sulfonamides; Sumatriptan; Vasoconstrictor Agents | 1991 |
The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan.
Topics: Aged; Aged, 80 and over; Biological Availability; Drug Administration Schedule; Drug Interactions; F | 1991 |
Methodology of clinical trials of sumatriptan in migraine and cluster headache.
Topics: Cluster Headache; Double-Blind Method; Female; Humans; Indoles; Male; Migraine Disorders; Multicente | 1991 |
Ergotamine, flunarizine and sumatriptan do not change cerebral blood flow velocity in normal subjects and migraneurs.
Topics: Adult; Blood Flow Velocity; Cardiovascular Agents; Cerebrovascular Circulation; Ergotamine; Female; | 1991 |
[Sumatriptan in migraine and cluster headache].
Topics: Cluster Headache; Contraindications; Humans; Indoles; Migraine Disorders; Sulfonamides; Sumatriptan; | 1991 |
Subcutaneous sumatriptan in acute migraine.
Topics: Acute Disease; Humans; Indoles; Injections, Subcutaneous; Migraine Disorders; Sulfonamides; Sumatrip | 1991 |
Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine.
Topics: Animals; Blood Proteins; Calcitonin Gene-Related Peptide; Capillary Permeability; Cerebrovascular Ci | 1991 |
The hospital management of severe migrainous headache.
Topics: Adolescent; Adult; Aged; Child; Dihydroergotamine; Drug Therapy, Combination; Female; Humans; Indole | 1991 |
Sumatriptan in migraine.
Topics: Indoles; Migraine Disorders; Sulfonamides; Sumatriptan; Vasoconstrictor Agents | 1991 |
Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan.
Topics: Adult; Aged; Blood Flow Velocity; Cerebral Arteries; Cerebrovascular Circulation; Dilatation, Pathol | 1991 |
Role of 5-HT1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan.
Topics: Animals; Arteriovenous Anastomosis; Blood Flow Velocity; Carotid Arteries; Cerebrovascular Circulati | 1991 |
[What is new in the treatment of migraine?].
Topics: Administration, Cutaneous; Estradiol; Humans; Indoles; Migraine Disorders; Serotonin; Sulfonamides; | 1990 |
Anti-migraine drugs in development: advances in serotonin receptor pharmacology.
Topics: Animals; Cerebrovascular Circulation; Drug Evaluation; Humans; Indoles; Migraine Disorders; Receptor | 1990 |
New relief for migraine sufferers.
Topics: Humans; Indoles; Migraine Disorders; Serotonin; Sulfonamides; Sumatriptan | 1990 |
The pharmacology of the novel 5-HT1-like receptor agonist, GR43175.
Topics: Animals; Dogs; Dose-Response Relationship, Drug; Female; Humans; In Vitro Techniques; Indoles; Male; | 1989 |
Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine.
Topics: Administration, Oral; Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Ind | 1989 |
Early clinical experience with subcutaneous GR43175 in acute migraine: an overview.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Indoles; Injections, Subc | 1989 |
Initial clinical experience with the use of subcutaneous GR43175 in treating acute migraine.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Indoles; Injections, Subcutaneous; Male; Mi | 1989 |
Treatment of acute migraine with subcutaneous GR43175 in West Germany.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Indoles; Injections, Subcutaneous; Male; Mi | 1989 |
Effective improvement of symptoms in patients with acute migraine by GR43175 administered in dispersible tablets.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Middle | 1989 |
Development and validation of a liquid chromatographic-mass spectrometric assay for the determination of sumatriptan in plasma.
Topics: Chemical Phenomena; Chemistry; Chromatography, Liquid; Humans; Indoles; Mass Spectrometry; Migraine | 1989 |